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iNTroDucTioN
Percutaneous coronary interventions (PCI) are among the most frequently performed 
medical interventions worldwide reflecting the large burden of coronary atherosclerosis. 
Bare metal stents were associated with a high rate of repeat revascularization due to 
clinical instent-restenosis in up to 15-20% of patients.(1) With the introduction of early 
generation drug-eluting stents, clinical restenosis was significantly reduced to approxi-
mately 5% at one year. This effect was consistent among a wide variety of patient and 
lesion subsets(3, 4) so that the use of DES was recommended by guidelines.(5) 
Part A
Despite the overwhelming benefit in efficacy achieved with early generation DES, 
registries and randomized trials investigating long-term outcomes suggested very late 
stent thrombosis and delayed restenosis as a distinct entity complicating their use (6-9), 
something not present following BMS implantation. Animal studies comparing early 
generation DES with BMS(10) and ex-vivo histological studies of patients who died due 
to stent thrombosis(11, 12) proposed adverse arterial healing as common cause of late 
early generation DES failures. Adverse arterial healing is defined as a lack of endothe-
lialization, the presence of inflammation (e.g. granulomatous eosinophilic cell infiltra-
tion, leucocyte infiltration or fibrin deposition), positive remodeling or late acquired 
malapposition. Several factors have been suggested to correlate with delayed healing, 
including toxicity of the applied drug (release kinetics and total dose), the polymer 
(hypersensitivity reactions), the stent strut and overall stent design and the underlying 
plaque type. 
Despite concerns about the long-term safety of early generation DES, a systematic 
clinical and serial angiographic evaluation of a large early DES-treated patient cohort 
followed over an extended time period of 5 years has not been investigated so far and 
the SIRTAX LATE study offered a unique opportunity to study the hypothesis of an on-
going risk of very late stent thrombosis and whether the angiographic late lumen loss 
further increases beyond one year, a time point where the neointimal formation was 
believed to stop (chapter 1). 
Whilst the evaluation of clinical outcomes is a key issue to determine the efficacy and 
safety of stent devices, understanding the mechanisms of eventual failures is of equal 
importance. Angiographic analyses are by definition limited to the lumen and do not 
allow for a detailed assessment of the stent and its acute and long-term interaction with 
the vessel wall. Two main intracoronary imaging technologies are available to evaluate 
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the post-procedural result and to monitor arterial healing following DES placement and 
to assess the underlying causes of failures. Intravascular ultrasound (IVUS) is a sound 
based technology with a resolution of 150-200 micrometer.(14) The strength of IVUS is 
a high tissue penetration enabling the visualization of the external elastic membrane 
and therefore the assessment of vessel wall remodeling. The drawback of IVUS is related 
to its limited resolution, which has been overcome by the introduction of optical coher-
ence tomography (OCT). OCT is a light based intravascular imaging technology with a 
resolution of approximately 10-20 mm. OCT is ideal to assess the arterial response to 
stent implantation as it allows the assessment of the stent strut coverage and malappo-
sition, the lumen including its integrity and shape (e.g. evaginations), the identification 
of tissue adjacent to stent struts and the vessel wall (e.g. fibrin, thrombus),  and finally 
the composition of the neointimal tissue ranging from peri-strut leucocyte infiltration to 
neoatherosclerosis.(15)
The use of OCT to determine arterial healing patterns over five years after early gen-
eration DES implantation is summarized in chapter 2.1. Among other findings, the OCT 
analysis led to the first systematic description of evaginations (chapter 2.1), a morpho-
logical marker of adverse healing solely visible by in-vivo intracoronary imaging and not 
detectable by means of histo-pathology. A systematic description of the frequency and 
extent of evaginations in various (early and newer generation) DES types is provided in 
chapter 2.2. 
According to histology studies, the underlying plaque impacts on arterial healing. 
Whether such differences may still be detectable after five years was unknown and is 
addressed in chapter 2.3. 
Neoatherosclerosis – a novel disease entity - is characterized by the development of 
atherosclerotic changes in the nascent neointimal tissue within previously implanted 
stents, and has been identified as the culprit for delayed instent-restenosis or stent 
thrombosis in various intracoronary imaging studies and case reports.(16, 17) Accord-
ingly, neoatherosclerosis may represent an accelerated and possibly more unstable 
manifestation of atherosclerosis. The mechanisms involved in the formation of neoath-
erosclerosis are poorly understood and it is believed to be a multifactorial process. It has 
been suggested that neoatherosclerosis occurs in the context of incompetently regener-
ated endothelium resulting in an excessive uptake of circulating lipids and leucodiape-
desis leading to an accelerated athrosclerosis formation within the neointima.(18) Little 
is known about the pathophysioloigcal mechanism underlying in the development 
of NA. The frequency and type of neoatherosclerosis following early generation DES 
implantation at 5 years is addressed in chapter 2.5. In addition, the question whether 
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patients with progression of atherosclerosis in native coronary segments would be at 
increased risk for the development of neoatherosclerosis is part of this Chapter.
The arterial healing response in the presence of multiple DES layers is of particular inter-
est as any adverse reactions may be more pronounced. DES overlap refers to overlapping 
stent edges in case multiple stents are implanted in the same lesion. The arterial healing 
response following DES overlap zones compared to non-overlapping regions by means 
of OCT is presented in chapter 3.1. The impact of early DES overlap on angiographic 
and clinical outcomes is further addressed in chapter 3.2.
Assessing the safety and efficacy of DES in patients at increased risk for adverse outcomes 
is highly relevant as particular drawbacks may only emerge in high risk populations. (13) 
Accordingly, clinical long-term outcome data on early generation DES in diabetic and 
STEMI patients represents a second focus of the first part of this thesis (Chapter 4).
Part B
With the aim to improve the design of early generation DES, stent strut thickness was re-
duced, the conformability increased and novel polymers with a higher biocompatibility 
were developed. As an alternative to durable polymer coatings, bioabsorbable polymers 
were introduced. Whether and to which degree DES modifications with durable polymer 
translate into an improved safety and efficacy during long-term follow-up represents 
one of the main focus of the second part of the thesis,  based on the clinical results of 
a large cohort of consecutively enrolled PCI patients undergoing new generation DES 
implantation (chapter 5.1 and 5.2). The translation of the observed benefits to high 
risk patient subgroups is addressed in chapter 6.1 and 6.2, mainly focusing on patients 
undergoing treatment of saphenous vein grafts and diabetic patients.
Stent selection in primary PCI represents one of the most debated controversies. (19) 
based on an increased risk for stent thrombosis which is related to specific to specific 
characteristics of STEMI lesions such as a large necrotic core and a high thrombus bur-
den, an up-regulated platelet aggregation(20) and the risk of delayed arterial healing.
(21) In addition,  patient’s history (e.g. bleeding diathesis) and future compliance to the 
required DAPT might be challenging to assess  in the setting of primary PCI. Against 
this background, a continued use of BMS in primary PCI has been advocated by interna-
tional guidelines. Whether the superiority of new generation DES observed in all comers 
populations can be translated to the specific setting of STEMI patients is addressed in 
chapter 7.1 on the basis of a large scale, international, randomized trial comparing a 
new generation DES with biodegradable polymer with a bare metal stent. To corrobo-
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rate the safety results, a pooled analysis of the two largest primary PCI studies is further 
presented in chapter 7.2. Cessation of dual antiplatelet was previously identified as 
predictor for the occurrence of stent thrombosis and the safety of devices may differ ac-
cording to the DAPT status. Accordingly, the question about the safety profile of newer 
generation DES versus BMS following primary PCI and after DAPT discontinuation is 
clinically relevant and addressed in the two year analysis of the aforementioned primary 
PCI study (chapter 7.3).
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Interventional Cardiology
Five-Year Clinical and Angiographic Outcomes of a
Randomized Comparison of Sirolimus-Eluting and
Paclitaxel-Eluting Stents
Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for
Coronary Revascularization LATE Trial
Lorenz Ra¨ber, MD; Lea Wohlwend, BA; Mathias Wigger, BA; Mario Togni, MD;
Simon Wandel, MSc, PhD; Peter Wenaweser, MD; Ste´phane Cook, MD; Aris Moschovitis, MD;
Rolf Vogel, MD, PhD; Bindu Kalesan, MSc; Christian Seiler, MD; Franz Eberli, MD;
Thomas F. Lu¨scher, MD; Bernhard Meier, MD; Peter Ju¨ni, MD; Stephan Windecker, MD
Background—Long-term comparative data of first-generation drug-eluting stents are scarce. We investigated clinical and
angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) at 5 years as part of the
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE study.
Methods and Results—A total of 1012 patients were randomly assigned to SES or PES. Repeat angiography was
completed in 444 of 1012 patients (43.8%) at 5 years. Major adverse cardiac events occurred in 19.7% of SES- and
21.4% of PES-treated patients (hazard ratio, 0.89; 95% confidence interval, 0.68 to 1.17; P0.39) at 5 years. There were
no differences between SES and PES in terms of cardiac death (5.8% versus 5.7%; P0.35), myocardial infarction
(6.6% versus 6.9%; P0.51), and target lesion revascularization (13.1% versus 15.1%; P0.29). Between 1 and 5 years,
the annual rate of target lesion revascularization was 2.0% (95% confidence interval, 1.4% to 2.6%) for SES and 1.4%
(95% confidence interval, 0.9% to 2.0%) for PES. Among patients undergoing paired angiography at 8 months and 5
years, delayed lumen loss amounted to 0.370.73 mm for SES and 0.290.59 mm for PES (P0.32). The overall rate
of definite stent thrombosis was 4.6% for SES and 4.1% for PES (P0.74), and very late definite stent thrombosis
occurred at an annual rate of 0.65% (95% confidence interval, 0.40% to 0.90%).
Conclusions—Long-term follow-up of first-generation drug-eluting stents shows no significant differences in clinical and
angiographic outcomes between SES and PES. The continuous increase in late lumen loss in conjunction with the
ongoing risk of very late stent thrombosis suggests that vascular healing remains incomplete up to 5 years after
implantation of first-generation drug-eluting stents.
Clinical Trial Registration—http://www.clinicaltrials.gov. Unique identifier: NCT00297661. (Circulation. 2011;123:2819-2828.)
Key Words: coronary angiography  coronary artery disease  restenosis  stents  stent thrombosis
First-generation drug-eluting stents (DES) releasing sirolimusor paclitaxel from durable polymers have reduced restenosis
compared with bare metal stents (BMS) in a broad spectrum of
patients and lesion subsets.1–3 The therapeutic benefit is most
pronounced during the first year because of the potent suppres-
sion of neointimal hyperplasia. Sirolimus-eluting stents (SES)
have been shown to be more effective than paclitaxel-eluting
stents (PES) in most studies with angiographic follow-up up to
1 year.4–7 Longitudinal angiographic follow-up series of patients
treated with BMS suggest late improvements in lumen diameter
beyond the early period of neointimal proliferation.8,9 Whether
these findings can be translated to first-generation DES and
whether there are meaningful differences between SES and PES
during long-term follow-up are largely unknown.
Editorial see p 2779
Clinical Perspective on p 2828
Compared with BMS, first-generation DES have not re-
duced rates of death or myocardial infarction (MI), but have
been associated with an increased risk of very late stent
thrombosis (ST). Experimental studies10 and human autopsy
reports11 have shown evidence of chronic inflammation and
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delayed healing with differences in pathological phenotypes
between SES and PES.12 However, the differential safety
profile of SES and PES during long-term follow-up has not
been established. Moreover, the phenomenon of very late ST
emerged among more complex patients,13 and long-term data
from randomized trials with the unrestricted use of DES are
not available. We therefore extended the clinical and angio-
graphic follow-up of patients included in the all-comers
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coro-
nary Revascularization (SIRTAX) trial to 5 years.
Methods
Study Design and Eligibility Criteria
The design and methods of this randomized, assessor-blind trial have
been reported previously.4 In brief, 1012 patients with 1 lesion in
a vessel with a reference diameter between 2.25 and 4.00 mm were
randomly assigned to treatment with SES or PES. There were no
limitations on the number of lesions or vessels or on the length of the
lesions. The study complied with the Declaration of Helsinki
regarding investigation in humans and was approved by the institu-
tional ethics committees at Bern University Hospital and University
Hospital Zurich in Switzerland. All patients provided written in-
formed consent.
Data Collection and Clinical and
Angiographic Follow-Up
Adverse events, angina status, and cardiovascular medication intake
were assessed in hospital, at 1, 6, and 9 months, and on an annual
basis up to 5 years. All patients were asked to return for repeat
angiography at 8 months. The results of the primary clinical end
point at 9 months and the principal angiographic end point at 8
months have been reported previously.4 For the purpose of the
present study, all patients who had at least 1 study lesion without
intervening revascularization during follow-up were invited to un-
dergo another angiographic study between 4 and 5 years of follow-up
(Figure 1). All patients were advised to take acetylsalicylic acid
indefinitely and clopidogrel for 1 year.4
Study End Points and Definitions
An independent clinical events committee unaware of the patients’
assignments adjudicated all clinical end points. The primary end
point was a composite of major adverse cardiac events (MACE)
(cardiac death, MI, and ischemia-driven target lesion revasculariza-
tion [TLR]) at 9 months.4 Secondary end points included ischemia-
driven TLR, target vessel revascularization or target vessel failure,
and MI. Post hoc, all stent thromboses were assessed according to the
Academic Research Consortium criteria. Late loss (LL) was defined
as the difference between the minimal luminal diameter (MLD) after
the procedure and MLD at follow-up. Delayed LL was defined as the
difference between MLD at 8 months and MLD at 5 years. The
principal secondary end point of the angiographic substudy was
delayed LL between 8 months and 5 years among patients undergo-
ing paired angiography.
Quantitative Coronary Angiography
Coronary angiograms were recorded at baseline immediately after
the procedure, at 8 months, and at 5 years, and were assessed at the
Randomized: n=1,012
All d i li l i 03 (694 l i ) All d li l l i 09 ( 1 l i )ocate  to s ro mus-e ut ng stent n=5 es ons
Received sirolimus-eluting stent: n=496 (685 lesions) 
Received other drug-eluting stent: n=  7   (    8 lesions) 
Received bare-metal stent: n=  0     (    0 lesions) 
Had PCI, but received no stent: n=  1     (    1 lesions)
ocate  to pac taxe -e ut ng stent n=5 7 5 es ons
Received paclitaxel-eluting stent: n= 507 (712 lesions)
Received other drug-eluting stent: n=     1  (    2 lesions)
Received bare-metal stent: n=     0 (    0 lesions)
Had PCI, but received no stent n=     1 (    1 lesions)
Had long-term angiography n=229 (298 lesions*)
Had planned angiographic FUP 4-5y n=205  (264 lesions)
Had unplanned angiographic FUP 4-5y  n=10 (15 lesions )
Had clinical angiographic FUP 1-4y n=  14   (  19 lesions)
Had long-term angiography n=215 (269 lesions*)
Had planned angiographic FUP 4-5y n=181  (221 lesions)
Had unplanned angiographic FUP 4-5y n=10 (13 lesions)
Had clinical angiographic FUP 1-4y n=  24     (  35 lesions)
Refused planned angiography n=117      (186 lesions)
Did not qualify for planned long-term angiography
)snoisel 85  (     63  =ndeiD
Severe renal impairment n=    6 (    7 lesions)
Undergone TLR in all study lesions n=  67 (  68 lesions)
Refused planned angiography n=119      (180 lesions)
Did not qualify for planned long-term angiography
)snoisel 26 (       04  =ndeiD
Severe renal impairment n=  13 (  20 lesions)
Undergone TLR in all study lesions: n=  70 (  74 lesions)
Zurich patients, alive and not lost n=  48       (  74 lesions)
Lost to follow-up n=   6    (   7 lesions)
*9 patients had 10 additional study lesions which underwent TLR earlier than 
8 months and those lesions were not qualifying for angiographic 5year analysis.
Zurich patients, alive and not lost n=  44        (  69 lesions)
Lost to follow-up n=    2      (    2 lesions)
*15 patients had 17 additional study lesions which underwent TLR earlier than 
8 months and those lesions were not qualifying for angiographic 5year analysis.
Clinical long-term follow-up available up to 5 years 
Followed up and alive n= 436 (595 lesions)
)snoisel 08  (     55   =ndeiD
)snoisel 91  (      21   =npu-wollof ot tsoL
Clinical long-term follow-up available up to 5 years
Followed up and alive n=441 (612 lesions)
)snoisel 47  (     84  =ndeiD
)snoisel 92  (     02  =npu-wollof ot tsoL
Analysed on angiographic outcomes n=215 (269 lesions) 
Analysis of paired angiography n=142 (179 lesions)
Analysis of 5 year angiography only n=  73 (  90 lesions)
Analysed on primary clinical endpoint n=503 (693 lesions)
Analysed on angiographic outcomes n=229 (298 lesions) 
Analysis of paired angiography n=151 (203 lesions)
Analysis of 5 year angiography only n=  78 (  95 lesions)
Analysed on primary clinical endpoint n=509 (708 lesions)
Figure 1. Flow of patients according to consolidated standards of reporting trials (CONSORT) statement. PCI indicates percutaneous
coronary intervention; FUP, follow-up; and TLR, target lesion revascularization.
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core laboratory of Bern University Hospital. Patients received
nitroglycerin before angiography, and measurements were per-
formed on cineangiograms. The contrast-filled, untapered tip of the
catheter was used for calibration. Quantitative measurements in-
cluded reference vessel diameter, MLD, and percent diameter
stenosis. Digital angiograms were analyzed with the use of an
automated edge-detection system (CAAS II, Pie Medical Imaging).
Angiographic readers were unaware of the type of stent implanted.
Quantitative coronary angiograms from patients returning for repeat
angiography in the setting of stent thrombosis were not included
during the first 30 days. However, events beyond 30 days were part
of the angiographic analysis because the need for repeat revascular-
ization could no longer be attributed to an acute response of the
lesion to the procedure.
Statistical Analyses
All patients were included in the analysis of primary and secondary
clinical outcomes. We used the Mantel-Cox method to estimate
hazard ratios and 95% confidence intervals for comparisons of
clinical outcomes between groups and the log-rank test to calculate
corresponding P values. Analyses of outcomes of the angiographic
substudy were restricted to patients who returned for 5-year angio-
graphic follow-up. Angiographic data were analyzed for all patients
undergoing paired angiography at baseline, 8 months, and 5 years, as
well as for all patients undergoing angiography at baseline and 5
years. Study lesions requiring revascularization by either percutane-
ous coronary intervention or coronary artery bypass grafting between
8 months and 5 years were assessed by quantitative coronary
angiography and contributed to the 5-year angiographic analysis. A
patient could have had 1 lesion in which a stent was implanted.
Therefore, in the analysis of the quantitative angiographic data, we
used maximum-likelihood logistic and linear regression models,
crude and adjusted for MLD at baseline, which were based on robust
standard errors that allowed for the correlation of multiple lesions
within a patient to compare the characteristics of lesion between
groups at baseline and follow-up. Trial data were held by the Clinical
Trials Unit in Bern. Analyses were performed with the use of Stata
software by an analyst who was unaware of the type of stent
implanted. No adjustments were made for multiple comparisons in
secondary analysis. All P values are 2 sided.
Results
Between April 2003 and May 2004, 1012 patients with 1401
lesions were randomly assigned to treatment with SES or
PES. At 5 years, clinical follow-up was available for 491 SES
patients (97.6%) and 489 PES patients (96.1%) (Figure 1).
Baseline clinical, angiographic, and procedural characteris-
tics were balanced between both groups (Table 1). Cardio-
vascular medications at 1 and 5 years are shown in Table I in
the online-only Data Supplement.
Clinical Outcomes
Clinical outcomes are summarized in Table 2. At 1 year, the
primary outcome of MACE was lower among SES- (8.3%)
than PES-treated patients (13.6%; P0.01). The early differ-
ence in favor of SES was driven by a 45% reduction of
ischemia-driven TLR (SES 5.8% versus PES 10.2%;
P0.01). In contrast, SES was no longer superior to PES in
terms of MACE (SES 19.7% versus PES 21.4%; P0.39)
and TLR (SES 13.1% versus PES 15.1%; P0.29) at 5 years
(Table 2). All-cause and cardiac mortality rates were similar
among patients treated with SES and PES at 1 and 5 years, as
were rates of MI (Figure 2). Landmark analysis beyond 1 year
indicated numerically higher event rates of MACE and TLR
among patients treated with SES than among patients treated
with PES (Figure 2). Differences between SES and PES in
terms of MACE and its components stratified for the time
period up to 1 year, between 1 and 5 years, and up to 5 years
are shown in Figure 3. Academic Research Consortium
definite, probable, and possible stent thrombosis occurred
with comparable frequency for both stent types during the
early, late, and very late time periods (Table 3 and Figure 4).
Beyond 1 year, the annual rate of Academic Research
Consortium definite ST was 0.67% (95% confidence interval,
0.31% to 1.03%) for SES and 0.62% (95% confidence
interval, 0.27% to 0.97%) for PES.
Angiographic Outcomes
Long-term angiographic follow-up was performed in 444
patients with 567 lesions at a median of 4.8 years for SES
(interquartile range, 4.5 to 5.1) and 4.8 years for PES
(interquartile range, 4.6 to 5.1) (Figure 1). Serial angio-
graphic follow-up at baseline, 8 months, and 5 years was
available in 293 patients with 382 lesions. Baseline clinical
and procedural characteristics in patients undergoing paired
angiography were balanced except for a lower preprocedural
MLD and higher percent diameter stenosis in SES- compared
with PES-treated patients (Tables II and III in the online-only
Data Supplement). Patients undergoing paired angiography
were younger (P0.01), more frequently male (P0.01), and
less frequently diabetic (P0.01) or hypertensive (P0.03)
than patients not undergoing paired angiography. Angiographic
findings in patients undergoing paired angiography are presented
in Table 4. In-stent MLD decreased from 2.690.39 mm after
the procedure to 2.580.43 mm at 8 months (P0.001) and to
2.250.77 mm at 5 years (P0.001) in the overall population
(Figure 5). In-stent LL at 8 months among TLR-free patients
amounted to 0.090.18 mm for SES and to 0.130.22 mm for
PES (P0.03). At 5 years, in-stent loss increased to
Table 1. Baseline Clinical Characteristics
Sirolimus-Eluting
Stent
Paclitaxel-Eluting
Stent
Total No. of patients 503 509
Age, meanSD, y 6211 6212
Male sex, n (%) 382 (76) 399 (78)
Diabetes mellitus, n (%) 108 (22) 93 (18)
Hypertension, n (%) 302 (60) 317 (57)
Hyperlipidemia, n (%) 305 (60) 290 (57)
Current smoking, n (%) 184 (37) 181 (36)
Previous MI, n (%) 145 (29) 151 (30)
Stable angina pectoris, n (%) 246 (49) 246 (48)
Acute coronary syndromes, n (%) 257 (51) 263 (52)
Unstable angina, n (%) 28 (6) 30 (6)
Non–ST-segment elevation MI, n (%) 112 (22) 123 (24)
ST-segment elevation MI, n (%) 117 (23) 110 (22)
Glycoprotein IIb/IIIa antagonists, n (%) 171 (34) 147 (29)
Multivessel disease, n (%) 300 (60) 301 (59)
Left ventricular ejection fraction,
meanSD, %
5712 5712
MI indicates myocardial infarction.
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Table 2. Clinical Outcomes at 1 Year, 5 Years, and 1 to 5 Years
Overall
Sirolimus-Eluting
Stent
Paclitaxel-Eluting
Stent
Hazard Ratio
(95% CI)* P
All events at 1 y
Total No. of patients 1012 503 509
Death 26 (2.6) 11 (2.2) 15 (2.9) 0.73 (0.34–1.60) 0.43
Cardiac death 18 (1.8) 7 (1.4) 11 (2.2) 0.64 (0.25–1.65) 0.35
MI 36 (3.9) 16 (3.2) 20 (3.9) 0.80 (0.42–1.55) 0.51
Q wave 13 (1.3) 7 (1.4) 6 (1.2) 1.18 (0.40–3.51) 0.77
Non–Q wave 23 (2.3) 9 (1.8) 14 (2.8) 0.64 (0.28–1.49) 0.30
Death or MI 60 (5.9) 26 (5.2) 34 (6.7) 0.76 (0.46–1.28) 0.30
Cardiac death or MI 52 (5.1) 22 (4.4) 30 (5.9) 0.73 (0.42–1.28) 0.27
Ischemia-driven TLR 81 (8.0) 29 (5.8) 52 (10.2) 0.55 (0.35–0.86) 0.01
Any TLR 82 (8.1) 29 (5.8) 53 (10.4) 0.54 (0.34–0.85) 0.01
Ischemia-driven TVR 93 (9.2) 35 (7.0) 58 (11.4) 0.59 (0.39–0.90) 0.01
Any TVR 95 (9.4) 36 (7.2) 59 (11.6) 0.60 (0.40–0.91) 0.01
MACE 111 (11.0) 42 (8.3) 69 (13.6) 0.60 (0.41–0.88) 0.01
Target vessel failure† 120 (11.9) 46 (9.1) 74 (14.5) 0.61 (0.42–0.88) 0.01
All events at 5 y
Death 103 (10.2) 55 (10.9) 48 (9.4) 1.15 (0.78–1.69) 0.48
Cardiac death 58 (5.7) 29 (5.8) 29 (5.7) 1.00 (0.60–1.68) 0.99
MI 68 (6.7) 33 (6.6) 35 (6.9) 0.95 (0.59–1.53) 0.82
Q wave 24 (2.4) 14 (2.8) 10 (2.0) 1.42 (0.63–3.19) 0.40
Non–Q wave 47 (4.6) 21 (4.2) 26 (5.1) 0.81 (0.45–1.44) 0.47
Death or MI 161 (15.9) 85 (16.9) 76 (14.9) 1.12 (0.82–1.53) 0.46
Cardiac death or MI 118 (11.7) 59 (11.7) 59 (11.6) 1.00 (0.70–1.44) 0.98
Ischemia-driven TLR 143 (14.1) 66 (13.1) 77 (15.1) 0.84 (0.60–1.16) 0.29
Any TLR 166 (16.4) 75 (14.9) 91 (17.9) 0.80 (0.59–1.09) 0.16
Ischemia-driven TVR 174 (17.2) 78 (15.5) 96 (18.9) 0.79 (0.59–1.07) 0.13
Any TVR 208 (20.6) 91 (18.1) 117 (23.0) 0.75 (0.57–0.99) 0.04
MACE 208 (20.6) 99 (19.7) 109 (21.4) 0.89 (0.68–1.17) 0.39
Target vessel failure† 232 (22.9) 108 (21.5) 124 (24.4) 0.85 (0.65–1.10) 0.21
All events between 1 and 5 y
Death 77 (7.8) 44 (8.7) 33 (6.5) 1.34 (0.85–2.10) 0.20
Cardiac death 40 (4.1) 22 (4.4) 18 (3.5) 1.23 (0.66–2.29) 0.52
MI 32 (3.4) 17 (3.4) 15 (2.9) 1.14 (0.57–2.28) 0.71
Q wave 11 (1.1) 7 (1.4) 4 (0.8) 1.78 (0.52–6.07) 0.35
Non–Q wave 24 (2.5) 12 (2.4) 12 (2.4) 1.00 (0.45–2.22) 1.00
Death or MI 101 (10.6) 59 (11.7) 42 (8.3) 1.41 (0.95–2.10) 0.09
Cardiac death or MI 66 (7.0) 37 (7.4) 29 (5.7) 1.28 (0.79–2.09) 0.32
Ischemia-driven TLR 62 (6.9) 37 (7.4) 25 (4.9) 1.43 (0.86–2.38) 0.16
Any TLR 84 (9.3) 46 (9.1) 38 (7.5) 1.17 (0.76–1.80) 0.47
Ischemia-driven TVR 81 (9.1) 43 (8.5) 38 (7.5) 1.09 (0.71–1.69) 0.69
Any TVR 113 (12.7) 55 (10.9) 58 (11.4) 0.91 (0.63–1.31) 0.61
MACE 97 (10.9) 57 (11.3) 40 (7.9) 1.38 (0.92–2.07) 0.11
Target vessel failure† 112 (12.7) 62 (12.3) 50 (9.8) 1.20 (0.82–1.74) 0.34
Values are expressed in number of patients (%). MI indicates myocardial infarction; TLR, target lesion revascularization; TVR, target
vessel revascularization; and MACE, major adverse cardiac event.
*Mantel-Cox models were used to calculate hazard ratio estimates and P values (log-rank test).
†Target vessel failure is composed of cardiac death, MI, or clinically indicated TVR.
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0.450.73 mm for SES and to 0.420.62 mm for PES
(P0.71). Delayed LL between 8 months and 5 years was
0.3773 mm for SES compared with 0.290.59 mm with PES
(P0.32). Differences between stent types remained much the
same after adjustment for preprocedural MLD (Table 4). Angio-
graphic analysis of all patients undergoing angiography at 5
years (n444, paired and unpaired) yielded similar results and is
summarized in Table IV in the online-only Data Supplement.
Figure 2. Cumulative event curves for the primary end point of major adverse cardiac event (MACE) (A, B), ischemia-driven target
lesion revascularization (TLR) (C, D), and cardiac death and myocardial infarction (MI) (E, F) up to 5 years with (B, D, F) and without
(A, C, E) landmark analysis at 1 year. Sirolimus-eluting stents are shown in blue and paclitaxel-eluting stents in red.
Figure 3. Hazard ratios (HR) of the primary end
point of major adverse cardiac event (MACE) and
its components stratified according to time period
(0 to 1 vs 1 to 5 years) and overall (0 to 5 years).
The P values for interaction are for differences in
hazard ratios between 0 to 1 and 1 to 5 years. CI
indicates confidence interval; MI, myocardial
infarction; TLR, target lesion revascularization;
SES, sirolimus-eluting stents; and PES, paclitaxel-
eluting stents.
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Discussion
The clinical and angiographic outcome of the 2 first-
generation DES (SES and PES) in the context of an all-
comers randomized trial during long-term follow-up to 5
years has the following findings: (1) The superiority of SES
over PES in terms of MACE and TLR at 1 year was no longer
apparent at 5 years of follow-up; (2) revascularization of the
target lesion beyond 1 year occurred at a low and stable rate
of 1.7% per year; (3) luminal LL continued to increase over
time and was similar for both stent types at 5-year angio-
graphic follow-up; and (4) very late definite ST occurred at a
steady rate of 0.65% per year, with no difference between
stent types.
Therapeutic differences between the 2 first-generation
DES have been addressed in numerous randomized trials.
Angiographic studies have consistently shown superior re-
duction of neointimal hyperplasia afforded by SES. In con-
trast, individual clinical trials comparing SES and PES have
reported mixed results, although the synthesis of the available
evidence as summarized in several meta-analyses suggests a
lower risk of TLR with SES.3 The superior suppression of
neointimal hyperplasia and lower risk of restenosis associated
with SES have been attributed to differences in the mode of
action of the therapeutic agent,14 and have been confirmed
more recently with other limus analogues.15 However, previ-
ous studies comparing SES with PES reported angiographic
outcomes at 6 to 8 months, and the longest available clinical
follow-up is limited to 2 years.16 The present study provides
additional information by extending the follow-up to 5 years
in a randomized trial investigating the unrestricted use of SES
and PES. We observed a time-by-treatment interaction for
MACE and TLR, with hazard ratios 1 during the first year
after randomization, but hazard ratios 1 in subsequent
years. The differential catch-up led to a decrease of the
advantage of SES over PES over time. Therefore, conven-
tional levels of statistical significance were no longer reached
at 5 years for the primary outcome, even though some
Table 3. Stent Thrombosis
Overall
Sirolimus-Eluting
Stent (n503)
Paclitaxel-Eluting
Stent (n509)
Hazard Ratio
(95% CI)* P
Definite stent thrombosis
Early 16 (1.6) 9 (1.8) 7 (1.4) 1.30 (0.48–3.50) 0.60
Late 3 (0.3) 1 (0.2) 2 (0.4) 0.50 (0.05–5.53) 0.57
Very late 25 (2.6) 13 (2.6) 12 (2.4) 1.09 (0.50–2.39) 0.83
Overall 44 (4.4) 23 (4.6) 21 (4.1) 1.11 (0.61–2.00) 0.74
Probable stent thrombosis
Early 4 (0.4) 0 (0.0) 4 (0.8) 0.11 (0.01–2.07) 0.12
Late 0 (0) 0 (0.0) 0 (0.0) N/A N/A
Very late† 1 (0.1) 1 (0.2) 0 (0.0) 1.01 (0.11–9.70) 1.00
Overall 5 (0.5) 1 (0.2) 4 (0.8) 0.25 (0.03–2.26) 0.18
Possible stent thrombosis
Early 0 (0) 0 (0.0) 0 (0.0) N/A N/A
Late 14 (1.4) 7 (1.4) 7 (1.4) 1.00 (0.35–2.86) 1.00
Very late 40 (4.1) 22 (4.4) 18 (3.5) 1.23 (0.66–2.30) 0.51
Overall 54 (5.4) 29 (5.8) 25 (4.9) 1.17 (0.68–1.99) 0.57
Definite or probable
stent thrombosis
Early 20 (2.0) 9 (1.8) 11 (2.2) 0.83 (0.34–2.00) 0.67
Late 3 (0.3) 1 (0.2) 2 (0.4) 0.50 (0.05–5.35) 0.57
Very late 26 (2.7) 14 (2.8) 12 (2.4) 1.18 (0.54–2.54) 0.68
Overall 49 (4.8) 24 (4.8) 25 (4.9) 0.97 (0.55–1.70) 0.91
Values are expressed in n (%). CI indicates confidence interval; N/A, not available.
*Mantel-Cox models were used to calculate hazard ratio estimates and P values (log-rank test).
†Relative risk and 95% confidence intervals were calculated with continuity correction. P-value is from Fishers-exact test.
Figure 4. Cumulative event curves for Academic Research Con-
sortium definite stent thrombosis up to 5 years with a landmark
analysis at 1 year. Sirolimus-eluting stents are shown in blue
and paclitaxel-eluting stents in red. HR indicates hazard ratio.
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Table 4. Angiographic Results of Patients With Paired Angiography
Overall
Sirolimus-
Eluting
Stent
Paclitaxel-
Eluting
Stent Difference (95% CI) P
Adjusted Difference
(95% CI) P
No. of patients 293 142 151
No. of lesions 382 179 203
Preprocedural
Reference vessel diameter, mm 2.840.44 2.800.40 2.870.47 0.07 (0.16 to 0.02) 0.13
Minimal luminal diameter, mm 0.500.44 0.440.38 0.560.48 0.12 (0.20 to0.04) 0.01
Diameter stenosis, % 82.014.9 83.813.6 80.315.8 3.56 (0.71 to 6.42) 0.01
Postprocedural
Reference vessel diameter, mm 2.880.43 2.830.40 2.920.44 0.08 (0.17 to 0.01) 0.07 0.07 (0.16 to 0.02) 0.12
Minimal luminal diameter, mm
In stent 2.690.39 2.630.35 2.740.41 0.10 (0.18 to0.02) 0.01 0.09 (0.17 to0.01) 0.03
In segment 2.600.43 2.550.39 2.650.45 0.09 (0.18 to0.01) 0.04 0.08 (0.17 to 0.01) 0.07
Diameter stenosis, %
In stent 6.85.3 7.15.3 6.65.3 0.54 (0.57 to 1.65) 0.34 0.47 (0.1 to 0.05) 0.41
In segment 8.66.6 8.76.9 8.56.4 0.15 (1.23 to 1.53) 0.83 0.08 (1.32 to 1.48) 0.91
8 Months
Reference vessel diameter, mm 2.820.45 2.780.43 2.850.47 0.07 (0.16 to 0.03) 0.16 0.06 (0.16 to 0.04) 0.22
Minimal luminal diameter, mm
In stent 2.580.43 2.550.39 2.60.47 0.05 (0.15 to 0.04) 0.25 0.04 (0.13 to 0.05) 0.38
In segment 2.470.46 2.450.43 2.50.49 0.04 (0.14 to 0.06) 0.39 0.03 (0.13 to 0.07) 0.55
Diameter stenosis, %
In stent 9.78.7 9.37.8 10.09.4 0.77 (2.62 to 1.09) 0.42 0.93 (2.76 to 0.90) 0.32
In segment 12.110.2 11.710.2 12.510.2 0.86 (3.01 to 1.28) 0.43 1.10 (3.25 to 1.05) 0.32
Binary stenosis, %
In stent 2 (0.52) 1 (0.56) 1 (0.49) 0.07 (1.38 to 1.51) 0.93 0.07 (0.51 to 0.65) 0.82
In segment 2 (0.52) 1 (0.56) 1 (0.49) 0.07 (1.38 to 1.51) 0.93 0.07 (0.51 to 0.65) 0.82
Late loss, mm 0.110.2 0.090.18 0.130.22 0.05 (0.09 to 0) 0.03 0.05 (0.09 to0.01) 0.03
5 Years
Reference vessel diameter, mm 2.830.46 2.790.44 2.860.47 0.07 (0.17 to 0.02) 0.14 0.07 (0.16 to 0.03) 0.17
Minimal luminal diameter, mm
In stent 2.250.77 2.180.79 2.310.76 0.13 (0.3 to 0.03) 0.12 0.11 (0.28 to 0.03) 0.21
In segment 2.100.79 2.030.83 2.160.76 0.13 (0.31 to 0.04) 0.13 0.11 (0.29 to 0.06) 0.20
Diameter stenosis, %
In stent 20.924.6 21.926.3 20.023.0 1.92 (3.55 to 7.4) 0.49 1.36 (4.19 to 6.91) 0.63
In segment 25.325.5 26.227.7 24.523.4 1.73 (4.01 to 7.47) 0.56 1.29 (4.52 to 7.11) 0.66
Binary stenosis, %
In stent 41 (10.7) 23 (12.9) 18 (8.87) 3.98 (3.04 to 11.0) 0.27 3.98 (3.83 to 11.8) 0.32
In segment 54 (14.1) 29 (16.2) 25 (12.3) 3.89 (3.85 to 11.6) 0.33 3.89 (4.02 to 11.8) 0.34
Late loss, mm
In stent 0.440.67 0.450.73 0.420.62 0.03 (0.12 to 0.18) 0.71 0.02 (0.13 to 0.17) 0.82
In segment 0.500.70 0.520.76 0.480.64 0.04 (0.11 to 0.20) 0.58 0.04 (0.12 to 0.19) 0.64
Delayed late loss, mm
In stent 0.330.66 0.370.73 0.290.59 0.08 (0.07 to 0.22) 0.32 0.06 (0.09 to 0.22) 0.40
In segment 0.370.70 0.420.77 0.330.63 0.09 (0.07 to 0.25) 0.27 0.09 (0.07 to 0.24) 0.29
Plus-minus values are meanSD. CI indicates confidence interval. Late luminal loss at 5-year follow-up was defined as the difference between the minimal luminal diameter
after the procedure and the minimal luminal diameter at 5-year follow-up. Delayed late loss was defined as the difference between the minimal luminal diameter after 8-month
follow-up and the minimal luminal diameter at 5-year follow-up. Adjusted differences were adjusted for preprocedural minimal luminal diameter.
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advantages of SES over PES in terms of target vessel
revascularization continued to be apparent up to 5 years.
The clinical findings are supported by the analysis of
patients undergoing paired angiography at 8 months and 5
years. Although SES showed lower LL than PES at 8 months,
a similar suppression of neointimal hyperplasia with both
stent types was noted at 5 years. SES appear to lose the initial
advantage in suppression of neointimal hyperplasia over PES,
which may be related to differences in drug release kinetics,
differential recovery of the cell cycle of quiescent smooth
muscle cells, and differences in vascular healing. SES release
80% of the drug during the first 30 days, with nearly all drug
eluted at 3 months, whereas PES release only 10% of the drug
during the early phase, with the remainder permanently
sequestered within the durable polymer. Previous serial
angiographic studies of nonrandomized cohorts support the
notion that luminal LL continues to accrue with first-
generation DES and that delayed LL of SES numerically
exceeds that observed with PES.17 However, the risk of TLR
in the present study of patients with percutaneous coronary
intervention of multiple lesions amounted to only 1.7% per
year, which is well in agreement with previous studies
comparing DES with BMS in lower-risk patient populations.
The risk of TLR was even lower (1.2% per year) when
revascularization events related to the treatment of ST were
subtracted.
We observed no difference in rates of death and MI
between SES and PES throughout 5 years. These event rates
are comparable to the long-term results of the treatment of de
novo coronary disease using a single paclitaxel-eluting stent
(TAXUS IV),18 sirolimus-eluting stent in coronary lesions
(SIRIUS),19 and randomized comparison of a sirolimus-
eluting stent with a standard stent for coronary revasculariza-
tion (RAVEL)20 studies, suggesting similar outcomes be-
tween early-generation DES and BMS. Randomized,
controlled trials with extended follow-up to 5 years compar-
ing early-generation DES with BMS reported a cumulative
incidence of very late definite ST of up to 0.8% during the
time period between 1 and 5 years.19–21 Similar low event rates
of very late definite ST have been observed in the drug-eluting
stents in the real world-LATE registry (DESIRE-LATE)22 and
Japanese Cypher23 registries. In contrast, we report a 3-fold
higher cumulative incidence of very late definite ST. The higher
incidence in the present study is likely related to the unre-
stricted use of DES in an all-comers population with inclu-
sion of patients with acute coronary syndromes as well as
multivessel disease. Three-year follow-up data from the
all-comers biolimus-eluting stent with biodegradable polymer
versus sirolimus-eluting stent with durable polymer for cor-
onary revascularisation (LEADERS) trial comparing SES
with a new-generation biolimus-eluting stent24 as well as
from the percutaneous coronary intervention versus coronary-
artery bypass grafting for severe coronary artery disease
(SYNTAX) trial comparing PES with surgical revasculariza-
tion25 suggest a cumulative incidence of very late ST of 0.9%
for SES (0.45% annual rate) and 0.6% for PES (annual rate)
between 1 and 3 years. Moreover, acute MI has been
identified as independent predictor of very late ST,26 results
in an increased incidence of late acquired stent malapposi-
tion,27 and has been associated with more extensive inflam-
mation and a higher proportion of uncovered struts compared
with stable lesions after DES implantation.11 Human autopsy
studies28 and recent clinical investigations of thrombosed
DES specimens29 imply delayed healing and vessel remodel-
ing owing to chronic inflammation as potential mechanisms
leading to this adverse event. Delayed healing has been
characterized by lack of endothelialization and persistent
fibrin deposition and has been identified as the principal
pathological finding distinguishing early-generation DES
with late thrombosis from patent DES.28 Findings of delayed
healing in early-generation DES have been complemented by
in vivo imaging studies with the use of angioscopy30 and
optical coherence tomography.31 The angiographic results of
the present study may contribute to a mechanistic explanation
of the ongoing risk of very late ST. The increase in luminal
LL between 8 months and 5 years may be an expression of the
ongoing healing process owing to chronic inflammation that
clinically can manifest as very late ST.
The clinical implications of our study are as follows: First,
the risk of repeat revascularization with first-generation DES
is low despite evidence of an angiographic catch-up phenom-
enon. Second, very late ST remains an important limitation of
first-generation DES and accounts for more than half of all
MIs between 1 and 5 years. Finally, the continuous increase
in LL in conjunction with the ongoing risk of very late ST
suggests that vascular healing remains incomplete up to 5
years after implantation of first-generation DES. This may
have important implications for the duration of dual antiplate-
let therapy in patients treated with first-generation DES.
Limitations
The study has the following limitations. The implementation
of protocol-mandated angiography at 2 time points may
inflate rates of repeat revascularization. We attempted to
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Figure 5. Box plot showing the evolution of minimal luminal diam-
eter (MLD) in patients undergoing paired angiography at baseline,
8 months, and 5 years. Bars indicate median and 25th and 75th
percentiles; lines indicate median1.5 times interquartile range;
dots indicate values outside median1.5 times interquartile range.
At 5 years, 11 patients presented with a total occlusion. Seven
occlusions were related to stent thrombosis (all symptomatic), and
4 occlusions presented as chronic total occlusions (all asymptom-
atic). RVD indicates reference vessel diameter.
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address this by reporting rates of both ischemia-driven TLR
and overall TLR. In addition, estimates of hazard ratios
comparing stent types in patients without 5-year follow-up
angiography were compatible with estimates calculated in
patients with follow-up angiography. Revascularization pro-
cedures remote from the target vessel were not part of the
present analysis, although they may be an important part of
the overall need for revascularization in routine clinical
practice because of disease progression. Because the angio-
graphic evaluation was performed at 2 distinct time points
rather than on an annual basis, we cannot determine the
dynamics of temporal changes in lumen remodeling.
Conclusions
Long-term follow-up of first-generation DES shows no sig-
nificant differences in clinical and angiographic outcomes
between SES and PES. The continuous increase in luminal
LL in conjunction with the ongoing risk of very late ST
suggests that vascular healing remains incomplete up to 5
years after implantation of first-generation DES.
Sources of Funding
This study was supported by research grants from Bern University
Hospital and the Swiss National Science Foundation. Dr Ra¨ber is the
recipient of a research fellowship (SPUM) funded by the Swiss
National Science Foundation (Grant 33CM30-124112).
Disclosures
Dr Eberli has received lecture fees from Bristol-Myers Squibb,
Cordis, Pfizer, and Boehringer, and is a consultant for Cordis. Dr
Meier has received educational and research support from Abbott,
Cordis, Boston Scientific, and Medtronic. Dr Windecker has re-
ceived consulting and lecture fees from Abbott, Boston Scientific,
Biosensors, Cordis, and Medtronic. The other authors report no
conflicts.
References
1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R.
A randomized comparison of a sirolimus-eluting stent with a standard
stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT,
Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A
polymer-based, paclitaxel-eluting stent in patients with coronary artery
disease. N Engl J Med. 2004;350:221–231.
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A,
Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate
M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P,
Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B,
Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes
associated with drug-eluting and bare-metal stents: a collaborative
network meta-analysis. Lancet. 2007;370:937–948.
4. Windecker S, Remondino A, Eberli FR, Juni P, Ra¨ber L, Wenaweser P,
Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G,
Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and
paclitaxel-eluting stents for coronary revascularization. N Engl J Med.
2005;353:653–662.
5. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi
G, Sousa E, Stoll HP. Sirolimus- vs paclitaxel-eluting stents in de novo
coronary artery lesions: the REALITY trial. Jama. 2006;295:895–904.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N,
Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or
sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl
J Med. 2005;353:663–670.
7. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK,
Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee
NH, Kim JH, Chun KJ, Park SJ. Sirolimus-eluting stent versus paclitaxel-
eluting stent for patients with long coronary artery disease. Circulation.
2006;114:2148–2153.
8. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y,
Sato Y, Yokoi H, Hamasaki N, Nosaka H, Nobuyoshi M. Three-year
follow-up after implantation of metallic coronary-artery stents. N Engl
J Med. 1996;334:561–566.
9. Asakura M, Ueda Y, Nanto S, Hirayama A, Adachi T, Kitakaze M, Hori
M, Kodama K. Remodeling of in-stent neointima, which became thinner
and transparent over 3 years. Circulation. 1998;97:2003–2006.
10. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC,
Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based,
slow-release, sirolimus-eluting stents in a porcine coronary model. Car-
diovasc Res. 2004;63:617–624.
11. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK,
Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and
increased late stent thrombosis at culprit sites after drug-eluting stent
placement for acute myocardial infarction patients. Circulation. 2008;
118:1138–1145.
12. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ,
Baim DS, Virmani R. Comparison of inflammatory response after
implantation of sirolimus- and paclitaxel-eluting stents in porcine
coronary arteries. Circulation. 2009;120:141–149.
13. Daemen J, Wenaweser P, Tsuchida K, Vaina S, Morger C, Kukreja N,
Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E,
Meier B, Windecker S, Serruys PW. Early and late coronary stent
thrombosis of sirolimus-eluting and paclitaxel-eluting stents. Lancet.
2007;369:667–678.
14. Wessely R, Schomig A, Kastrati A. Sirolimus and paclitaxel on
polymer-based drug-eluting stents: similar but different. J Am Coll
Cardiol. 2006;47:708–714.
15. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R,
Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE,
Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in
coronary artery disease. N Engl J Med. 2010;362:1663–1674.
16. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A
meta-analysis of 17 randomized trials of a percutaneous coronary
intervention-based strategy in patients with stable coronary artery disease.
J Am Coll Cardiol. 2008;52:894–904.
17. Park KW, Kim CH, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim
HS. Does “late catch-up” exist in drug-eluting stents: insights from a
serial quantitative coronary angiography analysis of sirolimus versus
paclitaxel-eluting stents. Am Heart J. 2010;159:446–453.
18. Ellis SG, Stone GW, Cox DA, Hermiller J, O’Shaughnessy C, Mann T,
Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS. Long-term safety
and efficacy with paclitaxel-eluting stents: 5-year final results of the
TAXUS IV clinical trial. J Am Coll Cardiol Cardiovasc Interv. 2009;2:
1248–1259.
19. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein
PS, Cohen SA, Wang H, Cutlip DE, Moses JW. Five-year follow-up after
sirolimus-eluting stent implantation results of the SIRIUS. J Am Coll
Cardiol. 2009;53:1488–1497.
20. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP,
Snead D, Mauri L, Cutlip DE, Sousa E. Long-term clinical outcomes with
sirolimus-eluting coronary stents. J Am Coll Cardiol. 2007;50:
1299–1304.
21. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube
E, Dudek D, Baim DS. Final 5-year results of the TAXUS II trial.
Circulation. 2009;120:1498–1504.
22. Costa JR Jr, Sousa A, Moreira AC, Costa RA, Cano M, Maldonado G,
Campos C, Carballo M, Pavanello R, Sousa JE. Incidence and predictors
of very late major cardiac adverse events in the DESIRE. J Am Coll
Cardiol Cardiovasc Interv. 2010;3:12–18.
23. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H,
Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H,
Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone
T, Nobuyoshi M, Kita T, Mitsudo K. Antiplatelet therapy and stent
thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;
119:987–995.
24. Serruys PW. Three year follow up from a prospective randomized trial of
biolimus A9 eluting stents with a bioabsorbable polymer vs. sirolimus-
eluting stents with a durable polymer. J Am Coll Cardiol. 2010;56;B9.
25. Kappetein P. Optimal revascularization strategy in patients with three-
vessel disease and/or left main disease: the 3-year outcomes of the
SNYTAX trial. Paper presented at: 24th Annual Meeting of the European
Ra¨ber et al SIRTAX LATE 2827
34  Chapter 1
Association for Cardio-Thoracic Surgery; September 12, 2010; Geneva,
Switzerland.
26. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S,
Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B,
Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent
thrombosis in routine clinical practice: 4-year results from a large
2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–1140.
27. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH,
Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism,
predictors, and long-term prognosis of late stent malapposition after
bare-metal stent implantation. Circulation. 2004;109:881–886.
28. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold
HK, Virmani R. Pathological correlates of late drug-eluting stent throm-
bosis: strut coverage as a marker of endothelialization. Circulation. 2007;
115:2435–2441.
29. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni
M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P,
Virmani R, Windecker S. Correlation of intravascular ultrasound findings
with histopathological analysis of thrombus aspirates in patients with very
late drug-eluting stent thrombosis. Circulation. 2009;120:391–399.
30. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H,
Mintz GS, Nagata S. Incomplete neointimal coverage of sirolimus-eluting
stents. J Am Coll Cardiol. 2006;47:2108–2111.
31. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa
M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of
incomplete stent apposition with drug-eluting stents. Eur Heart J.
2010;31:1470–1476.
CLINICAL PERSPECTIVE
First-generation drug-eluting stents releasing sirolimus or paclitaxel from durable polymers have reduced restenosis
compared with bare metal stents in a broad spectrum of patients and lesion subsets. Sirolimus-eluting stents (SES) have
been shown to be more effective than paclitaxel-eluting stents (PES) in most studies with angiographic follow-up up to 1
year. However, the differential safety profile of SES and PES during long-term follow-up has not been established.
Moreover, the phenomenon of very late stent thrombosis emerged among more complex patients, and long-term data from
randomized trials with the unrestricted use of drug-eluting stents are not available. A total of 1012 patients were randomly
assigned to SES or PES and followed for up to 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents
for Coronary Revascularization (SIRTAX) LATE trial. Initial advantages of SES over PES in major adverse cardiac events
and target lesion revascularization were partially canceled out by subsequent advantages of PES over SES (P for interaction
0.001). Major adverse cardiac events occurred in 19.7% of SES- and 21.4% of PES-treated patients (P0.39) at 5 years.
Similarly, there were no differences in terms of cardiac death, myocardial infarction, target lesion revascularization, and
stent thrombosis. Repeat angiography was completed in 43.8% at 5 years. The delayed lumen loss amounted to
0.370.73 mm among SES-treated patients and 0.2959 mm among PES-treated patients (P0.32). The increase in late
loss and the ongoing risk of very late stent thrombosis (annual rate of 0.65%) suggest incomplete vascular healing up to
5 years in patients with first-generation drug-eluting stents.
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2 HiGH rESoluTioN iNTrAVASculAr imAGiNG EVAluATioN oF ADVErSE HEAliNG rESPoNSES FollowiNG 
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2.1 Long-term healing response to sirolimus-eluting and paclitaxel-eluting stents: an optical coherence 
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CLINICAL RESEARCH
Long-Term Vascular Healing in Response to
Sirolimus- and Paclitaxel-Eluting Stents
An Optical Coherence Tomography Study
Lorenz Räber, MD,*† Sandro Baumgartner, MS,* Hector M. Garcia Garcia, MD, PHD,†
Bindu Kalesan, MSC,‡ Jörn Justiz, MSC, PHD,§ Thomas Pilgrim, MD,*
Aris Moschovitis, MD,* Ahmed A. Khattab, MD,* Lutz Buellesfeld, MD,*
Peter Wenaweser, MD,* Bernhard Meier, MD,* Patrick W. Serruys, MD, PHD,†
Peter Jüni, MD,‡ Stephan Windecker, MD*
Bern and Biel, Switzerland; and Rotterdam, the Netherlands
Objectives This study sought to assess stent strut coverage, malapposition, protrusion, and coro-
nary evaginations as markers of healing 5 years after implantation of sirolimus-eluting stents (SES)
and paclitaxel-eluting stents (PES), by optical coherence tomography (OCT).
Background Early-generation drug-eluting stents have been shown to delay vascular healing.
Methods A total of 88 event-free patients with 1 randomly selected lesion were suitable for final
OCT analysis 5 years after drug-eluting stent implantation. The analytical approach was based on a
hierarchical Bayesian random-effects model.
Results OCT analysis was performed at 5 years in 41 SES lesions with 6,380 struts, and in 47 PES
lesions with 6,782 struts. A total of 196 struts were uncovered in SES (1.5%) compared with 185
struts in PES lesions (1.0%, 95% credibility interval [CrI]: 0.5 to 1.6; p  0.32). Malapposed struts
were present in 1.2% of SES compared with 0.7% of PES struts (0.7%, 95% CrI: 0.03 to 1.6; p  0.23).
Protruding struts were more frequent among SES (n  114; 0.8%) than PES lesions (n  24; 0.1%,
95% CrI: 0.3 to 1.3; p  0.01). Coronary evaginations were more common among SES- than PES-
treated lesions (17 vs. 7 per 100 cross sections, p  0.003). During extended clinical follow-up, 2
patients suffered from very late stent thrombosis showing a high degree of malapposition, protru-
sion, and coronary evaginations at the time of OCT investigation.
Conclusions Early-generation drug-eluting stents show a similar degree of strut coverage and
malapposition at 5 years of follow-up. Despite an overall low degree of uncovered and malapposed
struts in event-free patients, some lesions show a clustering of these characteristics, indicating a het-
erogeneous healing response, which may be the source for very late adverse events. (J Am Coll
Cardiol Intv 2012;5:946–57) © 2012 by the American College of Cardiology Foundation
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Although early-generation drug-eluting stents (DES)
have a similar safety profile as bare-metal stents do, the
phenomenon of late stent thrombosis (ST) emerged as a
distinct entity complicating their use (1,2). Experimental
studies and autopsy reports identified delayed endotheli-
alization, chronic inflammation, and neoatherosclerosis
as morphological features differentiating early generation
DES from bare-metal stents (3–6). Incomplete endothe-
lial coverage was identified as the most important pre-
dictor of late ST in an autopsy study with a risk
continuum that increased with the numbers of uncovered
struts (7). In addition, a high incidence of late acquired
stent malapposition and positive vessel remodeling cor-
relating with the extent of inflammatory cell infiltration
was observed in intravascular ultrasound studies of pa-
tients suffering from late ST (8). Recently, differences in
the vascular healing response as well as differential
mechanisms leading to late ST have been reported for
lesions treated with either sirolimus-eluting stents (SES)
or paclitaxel-eluting stents (PES) (9).
Optical coherence tomography (OCT) allows for high-
resolution intracoronary imaging and has been validated for
assessment of stent strut coverage and apposition with an
accuracy resembling that of histological examinations
(10,11). Using OCT, early generation DES have been
associated with a higher frequency of uncovered, malap-
posed, and protruding struts than bare-metal stents have
(12,13). The use of this technology among event-free
patients may contribute to the understanding of mecha-
nisms underlying the continuous risk of late ST, may
potentially identify patients at risk, and may offer guidance
in the need for long-term dual antiplatelet therapy. Most
OCT studies to date assessed strut coverage and apposition
within the first year of DES implantation (12,14–17).
However, autopsy studies indicate that arterial healing after
DES implantation is delayed, warranting longer-term im-
aging follow-up. The present study provides quantitative
OCT findings at 5 years after DES implantation comple-
mented by geographic maps integrating the pattern of strut
coverage, apposition, and protrusion and describes differ-
ences in the vascular healing response between SES and
PES.
Methods
Patient population. The design and results of SIRTAX
(Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting
Stent for Coronary Revascularization) and SIRTAX LATE
(Sirolimus-Eluting Stent Compared With Paclitaxel-
Eluting Stent for Coronary Revascularization-Late) have
been reported previously (18,19). For the purpose of the
present study, all consecutive patients undergoing angio-
graphic follow-up at 5 years during the period between
December 2008 and July 2009 (n  145) were eligible for
OCT imaging (Fig. 1). The inclusion period commenced
with the availability of the OCT console at Bern University
Hospital in December 2008. The present study was limited
to 1 lesion to ensure optimal image quality and minimize
patient discomfort. Among patients scheduled for repeat
angiography between December 2008 and July 2009, who
had more than 1 study lesion (n  19), all lesions were
randomly allocated a numerical code of 1, 2, or 3 by an
independent statistician. OCT was routinely performed in
the lesion with the lowest number. In 4 patients with
multiple lesions, OCT was technically not feasible. In none
of these patients, the second or third lesion underwent
OCT to respect the random selection. Thus, in 15 of 88
patients suitable for final analysis, lesion selection was
random. The study complied with the Declaration of
Helsinki regarding investigation in humans and was ap-
proved by the institutional ethics committees at Bern
University Hospital, Switzerland. All patients provided
written informed consent.
OCT imaging and analysis. OCT was performed with a time
domain M2 system (Lightlab
Imaging, Westford, Massachu-
setts) using a pullback speed of 2
mm/s and the nonocclusive
flushing technique. After the di-
agnostic angiography and admin-
istration of 5,000 IU unfractionated
heparin, the ImageWire (Lightlab
Imaging) was carefully advanced
distal to the study lesion. Fol-
lowing administration of 200 g
of nitroglycerin intracoronary,
the target vessel was flushed via
the guiding catheter with non-
ionic, isosmolar contrast liquid (Iodixanol 320, Visipaque,
GE Healthcare, Cork, Ireland) using a power injector with
flush rates between 3 and 4 ml/s. OCT pullbacks were
assessed offline using a proprietary software (Lightlab Im-
aging). Lesions were analyzed performing OCT cross sec-
tions at 1-mm intervals and assessed for strut coverage,
apposition, and protrusion by a single analyst blinded. All
frames were reviewed by a second analyst who in case of
disagreement consulted with a third referee, and final
decision was based on consensus. Pullbacks were excluded in
case 30% of the total stent length was not analyzable.
Frames were considered not analyzable when more than
one-quarter of the circumference was not visible due to
insufficient flush or out of zoom. A strut was defined as a
signal-intense bright spot with a typical dorsal shadowing.
Thickness of strut coverage was measured as the distance
between the endoluminal side of the strut in the midpoint of
its long axis and the intersection of the lumen contour with
the straight line between the endoluminal side of the strut
and the gravitational center of the vessel. Struts were
Abbreviations
and Acronyms
CrI  credibility interval
DES  drug-eluting stent(s)
OCT  optical coherence
tomography
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
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Figure 2. Qualitative and Quantitative Assessment of Stent Strut Coverage, Protrusion, and Malapposition
A cross section illustrating all 3 categories is shown on the left. The strut at position 1 is apposed to the vessel wall and covered by a layer (130 m), whereas
the strut in position 2 is uncovered but apposed to the vessel. The strut at position 3 was classified as protruding because the measured protrusion into the
lumen relative to an imaginary lumen line (yellow) was 160 m. Two malapposed struts are shown at position 4 with a separation of 160 m from the
lumen and with absence of tissue between strut and lumen.
Figure 1. Flow Chart Showing Study Design and Patient Flow
OCT  optical coherence tomography; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).
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considered uncovered in case of a partial or complete
absence of tissue coverage. Strut protrusion was defined as
strut extension into the lumen for more than 160 m but
with no obvious separation from the vessel wall (Fig. 2).
Apposition was assessed by measuring the distance between
the center of the endoluminal strut surface and the inter-
section between lumen contour and the line connecting the
center of the endoluminal strut side and the gravitational
center of the vessel. Strut malapposition was defined as a
distance 160 m based on the consensus derived from the
strut thickness of SES (153 m) and PES (148 m) plus
the minimal axial resolution of OCT (10 m). This
consensus allowed a blinded assessment. Geographic maps
were created displaying struts using color codes for strut
characteristics, including strut coverage, apposition, and
protrusion. The resultant map represented the stented vessel
cut longitudinally along the reference angle 0° (correspond-
ing to the 12 o’clock position in the respective OCT cross
section) and spread out on an area (Fig. 3A).
Evaginations were suspected whenever the luminal vessel
contour extended in a pouchlike fashion beyond the line
connecting all stent struts (stent contour). Under these
circumstances, the maximal radial distance between the
circular line connecting all struts and the luminal vessel wall
was evaluated using the thickness ruler function. When the
maximal depth exceeded 160 m (similar cutoff as for the
presence of malapposition), we considered the outward
bulging as evagination (Fig. 4). By definition, the evagina-
tion is limited laterally by stent struts. In addition to the
maximal depth of the evagination, the interstrut evagination
area was assessed. The interstrut evagination area was
defined as the area limited by the stent contour luminally
and the lumen contour abluminally.
Statistical analysis. We used a Bayesian hierarchical random-
effects model based on Markov chain Monte Carlo simulation
methods with vague priors to estimate differences between
SES and PES (18). For analyses at the cross-section and strut
level, the model included random-effects at the level of pa-
tients, fully accounting for the correlation of characteristics
of cross-sectional areas or struts within patients and implic-
itly assigning analytical weights to each lesion depending on
the number of cross sections or on the number of struts
observed per lesion. For continuous outcomes, we assumed
a log normal distribution; for counts, we used a Poisson
distribution; and we used appropriate transformations to
derive arithmetic means and rates, respectively. Differences
in the percentage of lesions with any struts with unfavorable
outcome, with at least 5%, and with at least 10% of struts
with unfavorable outcome were calculated using a Bayesian
hierarchical random-effects model assuming a Bernoulli
distribution. For all other analyses at the lesion level, we
used conventional linear and Poisson regression models,
depending on the nature of the outcome (continuous or
counts). We derived 95% credibility intervals (CrI) from the
2.5th and 97.5th percentiles of the posterior distribution,
also calculating 2-sided p values from the posterior distri-
bution. Statistical analyses were performed using Win-
BUGS (version 1.4.3, Imperial College and Medical Re-
search Council, London, United Kingdom) and Stata
(version 11.0, StataCorp, College Station, Texas).
Results
Patients. The flow of patients included into the OCT study
5 years after DES implantation is shown in Figure 1. Of 95
patients undergoing OCT at 5.3 years (interquartile range:
5.1 to 5.5 years), 46 patients had been treated with SES and
Figure 3. Geographic Stent Strut Maps
(A) The concept of the creation of geographic stent strut maps is illus-
trated. Lesions are presented as areas assuming a cylindrical geometry of
the stent. Struts are color coded according to coverage, apposition, and
protrusion. The x axis represents the length of the stent (mm), whereas the
y axis indicates the position of the strut in the individual cross section
ranging from 0° to 360°.
Continued on the next page
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49 patients with PES. Five SES patients and 2 PES patients
were excluded (Fig. 1), resulting in 41 SES and 47 PES
patients included into the final analysis. Baseline clinical and
angiographic characteristics among patients undergoing OCT
at 5 years were well balanced for both groups (Table 1).
Baseline angiographic and procedural characteristics at the
Figure 3. Continued
(B) Strut coverage is presented using green for covered struts and red for uncovered struts. (C) Strut apposition is presented. Apposed struts are shown in
green; protruding struts in yellow; and malapposed struts in red. The x-axis represents the length of the stent (mm), whereas the y-axis indicates the position
of the strut in the individual cross section ranging from 0° to 360°. Zones of stent overlap are marked with blue lines. Abbreviations as in Figure 1.
Figure 4. Coronary Evaginations
(A) Illustration of a cross-section showing 3 coronary evaginations. (B) The quantitative assessment of coronary evagination depth and area is shown. A1 to A3
relates to evagination areas; d1 to d3 relates to evagination depth.
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time of DES implantation were similar for both groups,
including lesion length; vessel size; and the number, diam-
eter, and length of implanted stents (Table 2). Angiographic
follow-up at 5 years showed similar results in terms of
minimal lumen diameter, percentage of diameter stenosis,
late loss, and restenosis for both stent types (Table 3).
OCT data. Quantitative analysis of luminal, stent, and neo-
intimal volume and percentage of volume obstruction
showed no differences between SES and PES at 5 years of
follow-up (Table 4).
Results of strut-level and lesion-level OCT analyses
stratified according to stent type are presented in Table 5. A
total of 6,380 struts in 41 SES lesions and 6,782 struts in 46
PES lesions were analyzed. Uncovered struts were observed
among 1.5% (95% CrI: 0.8% to 2.6%) of all SES struts
compared with 1.0% (95% CrI: 0.5% to 1.7%) of all PES
struts (weighted difference: 0.5%, 95% CrI: 0.5% to 1.6%;
p  0.32). Lesion-level analysis showed no difference in the
proportion of lesions with 5% (10.7% vs. 7.2%, 95% CrI:
9.6% to 18.7%; p  0.60) as well as 10% uncovered struts
(2.4% vs. PES 2.0%, 95% CrI: 4.8% to 7.9%; p  0.81)
between SES and PES (Table 5, Fig. 5A). A geographic
map with the spatial distribution of uncovered and covered
struts is provided in Figure 3B. A high density of uncovered
struts is noted in Lesions #10 and #13 of SES-treated
patients and Lesion #35 of PES-treated patients.
Overall, malapposed struts were observed in 1.2% (95%
CrI: 0.6% to 2.2%) of all SES struts compared with 0.7%
(95% CrI: 0.3% to 1.3%) of all PES struts (weighted
difference: 0.5%, 95% CrI: 0.03 to 1.6; p 0.23). The mean
area of stent malapposition showed no difference between
SES and PES (SES: 0.70 mm2 [95% CrI: 0.5% to 0.96%]
vs. PES: 0.68 mm2 [95% CrI: 0.49 to 0.94]; p  0.88).
Lesion-level analysis of malapposition showed more lesions
with 5% (24.0% vs. 5.7%, weighted difference: 17.5%,
95% CrI: 1.9% to 39.3%; p  0.03), as well as 10%
Table 1. Baseline Clinical Characteristics
SES
(n  41)
PES
(n  47) p Value
Age 60 yrs 16 (39) 28 (59.3) 0.10
Male 34 (82.9) 36 (76.6) 0.46
Diabetes mellitus 8 (19.5) 8 (17.0) 0.76
Insulin dependence 2 (4.9) 3 (6.4) 0.76
Hypertension 21 (51.2) 30 (63.8) 0.23
Hyperlipidemia 25 (61.0) 25 (53.2) 0.46
Current smoking 19 (46.3) 16 (34.0) 0.24
Previous myocardial infarction 11 (26.8) 14 (29.89) 0.76
Stable angina pectoris 15 (36.6) 21 (44.7) 0.45
Acute coronary syndromes
Unstable angina 4 (9.8) 1 (2.1) 0.45
Non–STEMI 9 (22.0) 11 (23.4)
STEMI 13 (31.7) 14 (29.8)
Multivessel disease 30 (73.8) 30 (63.8) 0.35
Lesion(s) per patient
1 35 (85.4) 37 (78.7) 0.71
2 5 (12.2) 8 (17.0)
3 1 (2.4) 2 (4.3)
Left ventricular ejection fraction, % 56.7 58.6 0.40
Values are n (%) or %.
PES paclitaxel-eluting stent(s); SES sirolimus-eluting stent(s); STEMI ST-segment eleva-
tion myocardial infarction.
Table 2. Baseline Characteristics of Lesions Undergoing OCT Analysis
SES PES p Value
Lesions, n 41 47
Target lesion coronary artery
Left main 1 (2.4) 1 (2.1) 0.31
Left anterior descending 17 (41.5) 25 (53.2)
Left circumflex 13 (31.7) 7 (14.9)
Right 10 (24.4) 14 (29.8)
ACC-AHA lesion class
A 4 (9.8) 9 (19.1) 0.53
B1 17 (41.5) 20 (42.6)
B2 13 (31.7) 10 (21.3)
C 7 (17.1) 8 (17.0)
Angiographic measurements
Lesion length 16.95 7.84 15.70 7.23 0.44
Reference vessel diameter 2.87 0.40 2.89 0.41 0.82
Minimal lumen diameter 0.40 0.37 0.48 0.38 0.36
Stenosis, % lumen diameter 85.95 12.6 83.38 13.0 0.35
Pre-procedure TIMI flow grade
0 13 (31.7) 8 (17.0) 0.44
1 2 (4.9) 2 (4.3)
2 3 (7.3) 4 (8.5)
3 23 (56.1) 33 (70.2)
Post-procedure TIMI flow grade 1.0
0 0 (0) 0 (0)
1 0 (0) 0 (0)
2 1 (2.4) 1 (2.1)
3 40 (97.6) 46 (97.9)
Thrombus present 13 (32.5) 16 (34.0) 0.88
Procedures
Study stents per lesion 1.17 0.4 1.15 0.4 0.80
Stent diameter, mm 2.88 0.39 2.96 0.37 0.34
Total stent length per lesion, mm 20.59 9.05 18.47 7.67 0.24
Maximal pressure, atm 15.32 3.6 14.43 3.2 0.22
Direct stenting 0.22 0.4 0.30 0.5 0.41
Angiographic results
Reference vessel diameter, mm 2.89 0.50 2.89 0.44 1.00
Final minimal lumen diameter, mm
In-stent 2.68 0.41 2.75 0.41 0.42
In-segment 2.60 0.43 2.75 0.52 0.25
Final stenosis, % of lumen diameter
In-stent 7.73 4.5 5.55 4.3 0.03
In-segment 9.80 6.4 6.12 6.6 0.04
Acute gain, mm
In-stent 2.28 0.50 2.28 0.51 1.00
In-segment 2.22 0.49 2.32 0.66 0.54
Values are n, n (%), or mean SD.
ACC  American College of Cardiology; AHA  American Heart Association; OCT  optical
coherence tomography; TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in
Table 1.
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malapposed struts among SES- than PES-treated patients
(5.4% vs. 0.4%, weighted difference: 4.6, 95% CrI: 0.0% to
16.3%; p  0.05) (Table 5, Fig. 5B), indicating an accu-
mulation of malapposed struts in some SES lesions. Geo-
graphic stent strut maps are confirmatory in this regard and
allow a visual assessment of the distribution of malapposed
struts within a lesion.
Protruding struts were more frequent among SES (0.8%,
95% CrI: 0.4% to 1.4%) than PES in the strut-level analysis
(0.1%, 95% CrI: 0.0% to 0.3%; weighted difference: 0.7%,
95% CrI: 0.3% to 1.3%; p 0.01). Similarly, the number of
lesions with 5% (3.7% vs. 0.3%, weighted difference:
3.1%, 95% CrI: 0.2% to 13%; p  0.07), as well as 10%
protruding struts (0.6% vs. 0.0%, weighted difference: 0.5%,
Table 3. Angiographic Follow-Up Results at 5 Years of Lesions Undergoing OCT Analysis
SES PES Difference (95% CrI) p Value
Lesions, n 41 47
Reference vessel diameter, mm 2.83 0.44 2.86 0.38 0.03 (0.21 to 0.14) 0.69
Minimal lumen diameter, mm
In-stent 2.39 0.71 2.45 0.76 0.06 (0.28 to 0.16) 0.57
In-segment 2.31 0.72 2.33 0.77 0.02 (0.24 to 0.20) 0.86
% diameter stenosis
In-stent 15.82 17.2 14.78 18.4 1.04 (4.22 to 6.31) 0.70
In-segment 18.23 17.9 18.41 19.2 0.19 (5.67 to 5.30) 0.95
Late loss, mm
In-stent 0.28 0.43 0.28 0.46 0.00 (0.13 to 0.13) 1.00
In-segment 0.26 0.39 0.28 0.42 0.02 (0.14 to 0.10) 0.72
Binary restenosis
In-stent 2 (4.9) 2 (4.3) 0.62 (8.52 to 9.76) 0.89
In-segment 2 (4.9) 3 (6.4) 1.50 (12.6 to 9.56) 0.79
Values are n,mean SD, or n (%). Rowpercentages are predicted probabilities derived frommixedmaximum logistic regressionmodels.Mean SD
are predicted values derived from mixed maximum likelihood regression models. Mixed maximum likelihood regression models were used for
continuous and mixed maximum logistic regression models for binary outcomes to derive the differences between women and men. The p values
relate to the difference between 2 stent types.
CrI credibility intervals; other abbreviations as in Tables 1 and 2.
Table 4. Results of OCT Analysis—Continuous Outcomes
SES (95% CrI) PES (95% CrI) Difference (95% CI) p Value
Analysis at lesion level
Lesions analyzed, n 41 47
Cross sections analyzed per lesion 19.1 (17.9 to 20.5) 16.8 (15.7 to 18.0) 1.13 (1.03 to 1.26) 0.01
Struts analyzed per lesion 155.6 (151.8 to 159.5) 144.3 (140.9 to 147.8) 1.08 (1.04 to 1.11) 0.001
Minimal luminal area, mm2 4.66 (3.95 to 5.38) 5.08 (4.49 to 5.67) 0.42 (0.48 to 1.32) 0.36
Minimal stent area, mm2 5.37 (4.81 to 5.94) 6.22 (5.62 to 6.81) 0.84 (0.02 to 1.66) 0.04
Percentage of volume obstruction 12.2 (8.58 to 14.9) 13.7 (11.6 to 15.8) 1.53 (2.43 to 5.48) 0.45
Analysis at cross-section level
Cross sections analyzed, n 785 790
Struts per cross section 7.98 (7.52 to 8.45) 8.36 (7.90 to 8.82) 0.38 (1.00 to 0.28) 0.25
Luminal area, mm2 5.67 (5.05 to 6.32) 6.33 (5.72 to 7.04) 0.66 (1.62 to 0.19) 0.15
Stent area, mm2 6.50 (3.62 to 7.17) 7.35 (6.72 to 12.3) 0.85 (8.83 to 0.14) 0.09
Neointimal thickness, mm 0.11 (0.09 to 0.12) 0.11 (0.10 to 0.13) 0.01 (0.03 to 0.02) 0.64
Neointimal area, mm2 0.97 (0.86 to 1.10) 1.03 (0.91 to 1.16) 0.06 (0.24 to 0.12) 0.46
Mean area ISA, mm2 0.70 (0.50 to 0.96) 0.68 (0.49 to 0.94) 0.02 (0.31 to 0.34) 0.88
Mean malapposition distance, mm 0.27 (0.24 to 0.31) 0.29 (0.26 to 0.34) 0.02 (0.07 to 0.03) 0.47
Number of evaginations 0.17 (0.10 to 0.26) 0.07 (0.04 to 0.10) 0.10 (0.03 to 0.20) 0.003
Mean evagination area, mm2 0.20 (0.17 to 0.24) 0.23 (0.19 to 0.28) 0.03 (0.08 to 0.02) 0.24
Mean evagination depth, mm 0.25 (0.24 to 0.28) 0.24 (0.22 to 0.27) 0.01 (0.02 to 0.04) 0.47
Values are n or mean/% (95% CrI).
ISA incomplete stent apposition; other abbreviations as in Tables 1 to 3.
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95% CrI: 0.0% to 16.3%; p  0.12) tended to be higher
among SES than PES (Table 5) in the lesion-level analysis.
In a total of 5 SES lesions and 2 PES lesions, overlapping
stents were observed. The overlapping zones were delin-
eated in the strut maps in Figures 3B and 3C. Visual
inspection shows that neither uncovered nor malapposed
struts were more frequent in overlapping zones.
The number of coronary evaginations was higher among
SES- than PES-treated lesions (0.17 vs. 0.07 per cross sec-
tions; p  0.003), with no difference in mean area and depth
of individual evaginations. A geographic map showing the
spatial distribution of apposed, malapposed, and protruding
struts is provided in Figure 3C. A high density of strut
malapposition or protrusion (20%) is visible in Lesions #7,
#13, #21, and #40 of SES-treated patients. Of these 4 SES
patients, 2 (#7 and #40) suffered very late ST at 6 months and
1 year after acquisition of OCT imaging, respectively.
Discussion
The present OCT analysis performed among event-free
patients 5 years after the intervention focused on the
vascular healing response to early-generation SES and PES
implanted in the framework of an all-comers randomized
trial and has the following principal findings:
1. Neointimal thickness and volume are low and of
similar magnitude for SES and PES at 5 years.
2. Strut-level analysis shows an overall low frequency of
uncovered, malapposed, or protruding struts at 5 years.
3. Geographic maps identified a few patients with a high
degree of uncovered, malapposed, or protruding struts
suggesting a heterogeneous healing pattern 5 years
after early-generation DES implantation.
Figure 5. Frequency Distribution of Uncovered and Malapposed Struts
Cumulative distribution of the proportion of uncovered struts (A)
and strut malapposition (B). Abbreviations as in Figure 1.
Table 5. Results of OCT Analysis—Counts
SES (95% CrI) PES (95% CrI) Difference (95% CrI) p Value
Analysis at strut level
Struts analyzed, n 6,380 6,782
Uncovered struts, % 1.5 (0.8 to 2.6) 1.0 (0.5 to 1.7) 0.5 (0.5 to 1.6) 0.32
Protruding struts, % 0.8 (0.4 to 1.4) 0.1 (0.0 to 0.3) 0.7 (0.3 to 1.3) 0.01
Malapposed struts, % 1.2 (0.6 to 2.2) 0.7 (0.3 to 1.3) 0.5 (0.3 to 1.6) 0.23
Analysis at lesion level
Uncovered struts, lesions with
At least 10% uncovered struts 2.4 (0.3 to 10.8) 2.0 (0.2 to 7.6) 0.4 (4.8 to 7.9) 0.81
At least 5% uncovered struts 10.7 (2.9 to 26.7) 7.2 (1.7 to 20.6) 3.1 (9.6 to 18.7) 0.60
Protruding struts, lesions with
At least 10% protruding struts 0.6 (0.0 to 5.0) 0.0 (0.0 to 0.8) 0.5 (0.3 to 5.0) 0.12
At least 5% protruding struts 3.7 (0.6 to 13.8) 0.3 (0.0 to 3.6) 3.1 (0.2 to 13.0) 0.07
Malapposed struts, lesions with
At least 10% malapposed struts 5.4 (1.0 to 17.6) 0.4 (0.0 to 6.9) 4.6 (0.0 to 16.3) 0.05
At least 5% malapposed struts 24.0 (8.9 to 45.2) 5.7 (1.3 to 15.9) 17.5 (1.9 to 39.3) 0.03
Values are n, mean/% (95% CrI).
Abbreviations as in Tables 1 to 3.
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4. Lesion-level analysis and geographic maps demon-
strate a clustering of malapposition and protrusion in
SES- versus PES-treated lesions, and coronary evagi-
nations were more frequently observed in SES, sug-
gesting a potential difference in the healing response
of the 2 devices at 5 years of follow-up.
Neointimal thickness, neointimal volume, and percentage
of volume obstruction were low and of similar magnitude
for SES and PES at 5 years. Although these data were
obtained in selected, nonrandomized patients, the OCT
findings of the present study confirm similar observations in
a recent autopsy study as well as an angiographic study (19)
with late follow-up indicating the absence of significant
differences in neointimal hyperplasia between SES and PES
during long-term follow-up (9). Figure 6 illustrates the
spectrum of neointimal phenotypes encountered 5 years
after implantation of SES and PES.
Strut coverage. A number of OCT studies have investi-
gated strut coverage among SES-treated lesions at various
time points, but only very few are available for PES-treated
lesions. The rate of uncovered struts in SES-treated lesions
amounted to 15% at 3 months (20), 11% at 6 months (15),
and 2.1% at 9 months (16). Although a direct comparison
between the present study and previous reports is limited
due to patient and lesion heterogeneity as well as differences
in the analytical approach, there is a consistent increase in
strut coverage, which is most pronounced during the first
year but continues to accrue over time, resulting in a rate of
uncovered struts of only 1% to 2% at 5 years. This
observation is corroborated in a recent autopsy study report-
ing a decrease in the incidence of uncovered struts over time
particularly among DES implanted in on-label indications
(9). The same study also observed no difference in the
proportion of uncovered struts between SES and PES in
analogy to our OCT findings. To date, only 1 autopsy study
showed a correlation between uncovered struts and the risk
of stent thrombosis, suggesting delayed endothelialization
and incomplete healing as potential mechanisms of late ST
after DES implantation. Specifically, the odds for late ST
were 9-fold increased among stents with more than 30% of
uncovered struts per cross section compared with stents in
control subjects (7). This observation has not been validated
among living DES-treated patients using intracoronary
imaging so far. Moreover, most available OCT studies only
addressed overall strut coverage using strut-level (cross-
sectional) analyses without accounting for a potential clus-
tering of uncovered struts within lesions (patients). To
address this limitation, we performed both a strut-level and
lesion-level analysis and provide geographic maps of strut
coverage for individual lesions. Whereas overall strut cov-
erage was found to be nearly complete, lesion-level analysis
indicated that 10.7% of SES- and 7.2% of PES-treated
lesions had at least 5% uncovered struts. Accordingly,
clustering (10%) with a higher density of uncovered struts
was limited to few lesion numbers (SES #10, SES #13, PES
#35, and PES #40) (Fig. 5A), whereas most geographic
maps revealed only isolated single uncovered struts, suggest-
ing an individual healing response after DES implantation.
Strut apposition. Stent malapposition 5 years after DES
implantation may be related to persistent or late acquired
Figure 6. Spectrum of Neointimal Phenotypes Observed at 5 Years After Implantation of SES and PES
(A1 to A3) SES. (B1 to B3) PES. Panels A1 and B1 show absence of coverage, whereas in A2 and B2, minimal coverage with a thickness 100 m can be
observed. In A3 and B3, a more pronounced coverage is present with a maximal thickness of 820 m in SES (A3) and 600 m in PES (B3). Abbreviations as in
Figure 1.
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malapposition after resolution of thrombus or due to a
dynamic process with positive vessel remodeling over time
related to DES-induced inflammation and toxicity (8).
The assessment of malapposition in this study has to be
interpreted in the light of 1 important limitation: In the
absence of a baseline investigation, it is not possible to
differentiate whether malapposed struts at 5 years were
present at the time of the index procedure (persistent) or
whether malapposition developed during follow-up (late
acquired).
Overall, malapposed struts were rare and occurred with
similar frequency among SES- and PES-treated lesions in the
strut-level analysis. However, lesion-level analysis of strut
malapposition revealed clustering, with a higher density of
malapposed struts among SES- than PES-treated lesions.
Protruding struts according to our definition did protrude
at least 160 m into the lumen and were always in contact
with the vessel wall. Protruding struts may represent a stage
of healed, formerly malapposed struts related to incomplete
stent apposition at the time of DES implantation or may be
the result of an outward remodeling of the vessel wall giving
the appearance of coronary evaginations between the struts.
Although protruding struts were rare overall, they occurred
more frequently among SES- than PES-treated lesions.
Taken together with the more pronounced clustering of
malapposed struts in SES lesions, this observation suggests
Table 6. VLST Cases
Case #1 Case #2
Baseline findings
Age, yrs 28 56
cvRF Smoking
Arterial hypertension obesity
Family history
Smoking
Family history
Indication for PCI at baseline STEMI STEMI
Target lesion Proximal LAD Proximal RCA
Treatment at baseline Rescue PCI following failed thrombolysis
Implantation of a single SES 3.5  8 mm
Primary PCI
Implantation of 2 SES 2.75  13
and 2.75  8 mm without overlap
TIMI flow grade before 0 0
TIMI flow grade after 3 3
LVEF, % 50 50
Maximum CK, U/l 5,640 2,922
DAPT duration, yrs 1 1
OCT findings at 5 yrs
Uncovered struts, % 1.4 2.9
Malapposed struts,% 31 23
Protruding struts, % 35 8
Coronary evagination
Depth, mm 0.62 0.42
Area, mm2 0.58 0.37
Per cross section, n 1.75 1.75
Map # #40 #7
Findings at time point of VLST
Time point of VLST, yrs after index
procedure
6 5.5
Time between OCT and VLST, yrs 1 0.5
Antiplatelet therapy before VLST Only aspirin Only aspirin
Clinical presentation Anterior STEMI Inferior STEMI
OCT performed No Yes (Fig. 7)
Interventional treatment Thrombus aspiration and stent implantation
(zotarolimus-eluting stent, 3.5  30 mm)
Thrombus aspiration and balloon dilation
without stent implantation
TIMI flow grade before 0 2
TIMI flow grade after 3 3
LVEF, % 40 50
Maximal CK, U/l 900 Troponin T 0.2 ng/ml
CK  creatine kinase; cvRF  cardiovascular risk factors; DAPT  dual antiplatelet therapy; LAD  left anterior descending artery; LVEF  left
ventricular ejection function; PCI  percutaneous coronary intervention; RCA  right coronary artery; VLST  very late stent thrombosis; other
abbreviations as in Tables 1 and 2.
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a differential healing response following implantation of
SES and PES during long-term follow-up. A differential
healing response of the 2 stent types has also been reported
in a recent autopsy study. Histologically, an increased
inflammatory response resulting in positive remodeling and
malapposition has been associated with SES, whereas an
excessive para-strut fibrin deposition was observed in PES-
treated lesions (9).
Although this study did not intend to investigate the
impact of stent strut-related findings on clinical outcome, it
is noteworthy that 2 patients with a high density of both
protruding and malapposed struts as documented 5 years
after DES implantation developed late ST 6 months (SES
#7) and 1 year (SES #40) (Fig. 3C) after completion of this
OCT investigation. Table 6 summarizes the findings in
both patients at baseline, follow-up, and at the time of the
very late ST. An OCT cross section of the first patient
(SES #40) obtained at 5 years is shown in Figure 4, where
excessive coronary evaginations are noted (no OCT avail-
able at the time of very late ST), whereas serial OCT
findings (at 5 years and the time of very late ST) are shown
in Figure 7 for lesion SES #7. The 2 cases illustrate that
OCT may play a role in identifying patients at risk for
future adverse ischemic events. With respect to patho-
mechanisms leading to very late ST, the 2 cases provide
evidence that very late ST beyond 5 years after DES
implantation is not solely related to neoatheroslerosis and
late restenosis, as both findings were not present.
Coronary evaginations. Coronary evaginations reflect a dis-
tinct vessel wall morphology, which is characterized by an
outward bulging of the lumen between stent struts
(pouches) (Fig. 4). In case of 1 evagination per cross
section, the involved stent struts may appear as protruding.
Whereas the phenomenon has been reported in case reports,
no single study has described the incidence and underlying
mechanism to date. Histological evaluations of coronary
evaginations have not been reported so far, which may be
related to the fact that the outward ballooning is more
apparent in vivo in a pressurized vessel than after histolog-
ical processing. We describe, for the first time, systemati-
cally the incidence and the extent of this OCT finding and
show that coronary evaginations are more common in SES-
than PES-treated lesions but with similar cross-sectional
areas and depth. The clinical significance of coronary evagi-
nations remains unclear. Hypothetically, coronary evaginations
may represent an early stage of positive remodeling. Advanced
coronary evaginations may appear angiographically as peristent
contrast staining, an entity that has been recently correlated
with late adverse clinical outcome (21).
Study limitations. The presented data have to be interpreted
in light of several limitations. First, the data were obtained
in a highly selected patient population of event-free indi-
viduals 5 years after DES implantation. Second, the present
study provides OCT findings only at 5 years without a
baseline examination. This has implications regarding the
analysis of malapposed struts as it cannot be excluded that
differences in malapposed struts were already present at
baseline (persistent rather than late acquired). However,
intravascular ultrasound studies have shown that an impor-
tant proportion of malapposed struts at follow-up is related to
acquired rather than persistent malapposed struts (22). The
dynamic changes in the interaction of stent struts with the
arterial wall remain hypothetical and will require confirmation
in prospectively designed, serial OCT investigations. As it
relates to both strut protrusion and coronary evaginations,
matched histological evaluations are not available; therefore,
careful interpretations of these OCT findings are required.
The clinical impact of protruding struts and coronary
Figure 7. Paired OCT Investigation at 5 Years (Routine per Protocol)
and 5.5 Years (at the Time of Very Late ST)
The serial cross sections in A1 to A4 show protruding struts with coronary
evaginations of the vessel wall (A1) and malapposition in subsequent
frames (A2 to A4). The vicinity of protrusion and malapposition suggests
that coronary evaginations with protruding struts may precede a detach-
ment of the vessel wall from the stent struts, leaving behind the visual
appearance of (late acquired) malapposed struts (A2 to A4). The potential
clinical relevance of these findings by optical coherence tomography (OCT)
are supported by the occurrence of a very late stent thrombosis (ST) 6
months after the 5-year OCT investigation (B1 to B4). In B1 to B4, the
zones of malapposition are filled with material suggestive of thrombus.
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evaginations is not known and requires further evaluation in
prospective studies.
Conclusions
Early-generation DES show a similar degree of strut cov-
erage and malapposition at 5-year follow-up. Despite over-
all low rates of uncovered, malapposed, and protruding
struts, some lesions show a clustering of these characteris-
tics, indicating a heterogeneous healing pattern among
patients treated with early-generation DES. Two very late
ST cases in patients with a high number of malapposed or
protruding struts illustrate that OCT may play a role in
identifying patients at risk for future adverse ischemic
events.
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Coronaryevaginations areassociatedwithpositive
vessel remodelling and are nearly absent following
implantation of newer-generation drug-eluting
stents: an optical coherence tomography and
intravascular ultrasound study
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Objectives The purpose of this study was to assess the occurrence, predictors, and mechanisms of optical coherence tomography
(OCT)-detected coronary evaginations following drug-eluting stent (DES) implantation.
Background Angiographic ectasias and aneurysms in stented segments have been associatedwith a risk of late stent thrombosis. Using
OCT, some stented segments show coronary evaginations reminiscent of ectasias.
Methods Evaginations were defined as outward bulges in the luminal contour between struts. They were considered major eva-
ginations (MEs) when extending≥3 mm along the vessel length, with a depth ≥10% of the stent diameter. A total of 228
patientswhohad sirolimus (SES)-, paclitaxel-, biolimus-, everolimus (EES)-, or zotarolimus (ZES)-eluting stents implanted
in 254 lesions, were analysed after 1, 2, or 5 years; and serial assessment using OCT and intravascular ultrasound (IVUS)
was performed post-intervention and after 1 year in 42 patients.
Results Major evaginations occurred frequently at all time points in SES (�26%) and were rarely seen in EES (3%) and ZES (2%,
P ¼ 0.003). Sirolimus-eluting stent implantation was the strongest independent predictor of ME [adjusted OR (95% CI)
9.1 (1.1–77.4), P ¼ 0.008]. Malapposed and uncovered struts weremore common in lesions with vs. without ME (77 vs.
25%, P, 0.001 and 95 vs. 20%, P, 0.001, respectively) as was thrombus [49 vs. 14%, OR 7.3 (95% CI: 1.7–31.2),
P ¼ 0.007]. Post-intervention intra-stent dissection and protrusion of the vessel wall into the lumen were associated
with an increased risk of evagination at follow-up [OR (95% CI): 2.9 (1.8–4.9), P, 0.001 and 3.3 (1.6–6.9),
P ¼ 0.001, respectively]. In paired IVUS analyses, lesions with ME showed a larger increase in the external elastic
membrane area (20% area change) compared with lesions without ME (5% area change, P, 0.001).
Conclusion Optical coherence tomography-detected MEs are a specific morphological footprint of early-generation SES and are
nearly absent in newer-generation ZES and EES. Evaginations appear to be related to vessel injury at baseline; are asso-
ciated with positive vessel remodelling; and correlate with uncoverage, malapposition, and thrombus at follow-up.
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Keywords Optical coherence tomography † Intravascular ultrasound † Coronary evaginations † Early-generation drug-eluting
stents † Newer-generation drug-eluting stents † Positive remodelling † Malapposition † Uncovered stent struts
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Introduction
Early-generation drug-eluting stents (DESs) have been associated
with an increased risk of very late stent thrombosis (ST) due to
delayed arterial healing with evidence of prolonged inflammation,
resulting in incomplete endothelialization and acquired malapposi-
tion.1,2 Owing to an ultrahigh resolution (10 mm), optical coherence
tomography (OCT) allows an in vivo histology-like evaluation of
coronary arteries and implanted devices, including the identification
of uncovered and malapposed struts.3,4 Using OCT, it has been
observed that some stented segments show outward vessel
bulging—‘coronary evaginations’—of the luminal contour between
struts during the follow-up.5,6 Three-dimensional (3D) visualization of
these segments suggests an ectatic appearance of the vessel wall rem-
iniscent of that seen in angiographic ectasias and aneurysms, which
were previously shown to be associated with cardiovascular adverse
events.7,8 Although both drugs and polymers of DES have been sus-
pected as culprits for these changes, the specific mechanisms of the
luminal enlargement remain unknown and can only be determined
with serial invasive assessment. At present, there are no data on the
occurrence, predictors, and mechanisms of OCT-detected coronary
evaginations following implantation of early- and newer-generation
DES. The objectives of the present study were therefore to assess
evaginations using OCT at follow-up in a large cohort of patients; and
to investigate the underlying mechanism by serial investigations with
OCT and intravascular ultrasound (IVUS) in a subset of patients.
Methods
Study population
The pooled analysis included OCT acquisitions from the LEADERS-,
RESOLUTE-, and SIRTAX-LATE OCT substudies, and from the Copen-
hagen OCT registry, employing the following stents: Cypher Selectw
(Cordis, Johnson and Johnson, Warren, NJ, USA); Taxus Expressw
(Boston Scientific, Natick, MA, USA); Endeavor Resolutew (Medtronic,
Inc., Santa Rosa, CA, USA); Xience Vw (Abbott Vascular, Santa Clara,
CA, USA); and Biomatrixw (Biosensors, Inc., Newport Beach, CA, USA).
Thedesign andeligibility criteria forLEADERS-, RESOLUTE-, andSIRTAX-
LATEOCT substudies are described in detail elsewhere.6,9,10 TheCopen-
hagen OCT registry was a single-centre prospective non-randomized
evaluation of strut coverage and apposition at 12-month follow-up in rela-
tion to apposition at baseline, using the Cypher Selectw, Taxus Expressw,
and Endeavor Resolutew stents. Patients were eligible if they had ≥1
lesionwith.50% diameter stenosis in a native coronary artery, with a ref-
erence vessel diameter between 2.25 and 4.0 mm. Exclusion criteria were
ST-segment elevation myocardial infarction (MI), left ventricular ejection
fraction ,30%, renal insufficiency (creatinine .133 mmol/L), and lesion
location in the left main stem or bypass graft. Optical coherence tomog-
raphy and IVUS were performed after a satisfactory angiographic result,
defined as a residual diameter stenosis ,20% and thrombus in MI flow
grade3, and imagingwithbothmodalitieswas repeatedat 1-year follow-up.
A total of 56 consecutive patients were included at baseline out of which
eight withdrew consent for follow-up, and two were excluded due to
system failure or insufficient quality for analysis. Figure 1 shows an overview
of the number of patients, lesions, and stent types included in each cohort,
and the time point of OCT acquisition.
Out of the 46 patients with 48 lesions from the Copenhagen OCT
registry, 43 patients with 45 lesions were available with complete serial
OCT assessment at baseline and follow-up. Out of these, 40 patients
with 42 lesions had a serial IVUS assessment. All studies were conducted
in accordance with the Declaration of Helsinki and approved by the
ethical committees of the involved centres. All patients provided
written informed consent prior to the enrolment.
Optical coherence tomography and
intravascular ultrasound acquisitions
Optical coherence tomography-images were acquired with commercially
available time-domainM2andM3 systems; and the frequency-domainC7
system from LightLab/St Jude (Westford, MA, USA) at a frame rate of
15.6, 20, and 100 frames/s; and a pullback speed of 1, 3, and 10 mm/s;
with the M2, M3, and C7, respectively. Acquisition with occlusive (M2)
and non-occlusive (M3 and C7) techniques was described previously.11
Intravascular ultrasound images were acquired with the Atlantis SR Pro
40 MHz catheter and iLab system (Boston Scientific, Natick, MA, USA)
at a frame rate of 30 frames/s and pullback speed of 0.5 mm/s, according
Figure 1 Overview of the optical coherence tomography data used for the pooled analysis. FUP, follow-up; SES, sirolimus-eluting stent; PES,
paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent.
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to accepted standards. As for serial investigations, the same imaging
systems were used at baseline and follow-up.
Optical coherence tomography image analysis
The region of interest included the stented segments which were ana-
lysed systematically at 1 mm intervals according to corelab standards
(Cardialysis, BV, Rotterdam, The Netherlands). The methodology is
shown in Figure2A. The lumen- and stent areawere assessed aspreviously
reported.12 Malapposition was considered to be present when the
distance from the endoluminal strut border to the lumen contour
was larger than the sum of strut metal + polymer thickness, resulting
in cut-offs of ≥160 mm for Cypher, ≥160 mm for Taxus Express, ≥100
mm for Endeavor Resolute, ≥90 mm for Xience V, and ≥130 mm for
the Biomatrix stent.10,12,13 In case of malapposition, the incomplete
Figure 2 Overview of optical coherence tomography image analysis. (A) Frame-level analysis included the assessment of the stent area (blue-
broken trace) and lumen area (white trace). Evaginations were defined as bulges in the luminal contour between struts with a maximum depth
(white double-headed arrow) exceeding the actual strut thickness. Evagination areas were delineated by the stent contour towards the centre
of the lumen and the lumen contour in the opposite direction (broken trace along the luminal contour at 11 o’clock). Struts projecting into the
lumen without separation from the vessel wall were defined as protruding when the distance (yellow double-headed arrow) from the stent area
trace to a ‘lumen help line’ (yellow trace extrapolated between deepest point of evaginations and lumen contour) exceeded the actual strut thick-
ness. (B) A three-dimensional reconstruction of an evagination. Evaginations were considered major when extending ≥3 mm longitudinally, with a
depth≥10%of the stent diameter. Prolapse (C )wasdefined as convex-shaped tissue projecting into the lumenbetween strutswithout disruptionof
the luminal continuity, and registered only when the distance from the stent area trace (white-dotted line) to the maximum point of prolapse was
≥150 mm. Intra-stent dissections (D) were defined as disruptions of the luminal vessel contour within the stented segment, whereas tissue protru-
sion (E)wasdefinedas amasswith an irregular surface attached to the vesselwall or struts andprotruding into the lumen.Various features at baseline
(i.e. prolapse, intra-stent dissection, tissue protrusion, and malapposed struts) were cross-correlated with the presence of evaginations in matched
cross-sections at follow-up (F ).
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stent apposition (ISA) area was measured. Struts projecting into the
lumenwithout obvious separation from the vesselwall were labelled pro-
truding when the distance from the strut marker to a ‘lumen help line’
exceeded that of the actual strut thickness, using the same cut-offs as
for malapposition.5,6 The ‘lumen help line’ was drawn by extrapolating
a trace line between the deepest points in evagination/s and the luminal
vessel contour laterally. Struts within overlapped segments and those
overlying side branch ostia were excluded from the analysis. Struts
were considered uncovered if any part of the strut was visibly exposed
to the lumen, and covered if a layer of tissue was identified above the
struts.3
A coronary evagination (Figure 2A) was defined as the presence of an
outward bulge in the luminal vessel contour between apposed struts
with a maximum depth of the bulge exceeding that of the actual strut
thickness, as measured semi-automatically from the deepest point in
the bulge to the stent area trace using the thickness-ruler function.6
The same cut-offs as for malapposition were used. For each evagin-
ation, we assessed the evagination area defined as the area limited by
the stent contour towards the centre of the lumen and the lumen
contour in the opposite direction. Imaging of evaginations with both
time- and Fourier-domain OCT systems was performed in a few
cases, excluding any influence of OCT system on the appearance of
evaginations.
Evaginationsmay extend over several consecutive cross-sections, giving
the vessel an ectatic appearance by 3D reconstruction (Figure 2B). Thus,
evaginations can be characterized both at the 2D cross-sectional level,
and along the length of the stented segment. We assessed the presence
ofmajor evagination (ME), defined as theoccurrenceof cross-sectional eva-
gination in ≥3 adjacent frames (i.e. minimum 3 mm of length) with a
minimal evagination depth of 10% of the nominal stent diameter. Evagin-
ation areasof the various cross-sections belonging to aMEwere assumed
to be constant 0.5 mm proximal and distal to the analysed cross-section
in order to calculate evagination volumes for each 1 mm segment. If
evaginations were present in adjacent cross-sections, they were assumed
to be in a continuum, and their volumes were summed up to calculate
the totalevagination volume. In addition,weassessed thepresenceof throm-
bus defined as a mass ≥100 mm in diameter with an irregular surface
attached to the vessel wall or struts and protruding into the lumen.
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Table1 Baselinedemographics andbaselinepatient and lesion level predictorsofmajorevaginationsadjusted for time to
follow-up
Characteristics Entire cohort Major evagination at
follow-up
Crude OR (95% CI) P-value Adj OR (95% CI) P-value
n (%) Yes, n (%) No, n (%)
No. of patients 228 31 197
Age 60.0+10.4 59.2+11.0 60.2+10.3 1.00 (0.96–1.04) 1.00 1.00 (0.96–1.05) 0.89
Male gender 179 (78.5) 24 (77.2) 155 (78.7) 0.88 (0.35–2.26) 0.78 0.89 (0.33–2.41) 0.82
Hypertension 127 (55.7) 15 (48.4) 112 (56.9) 0.77 (0.35–1.69) 0.52
Hyperlipidaemia 153 (67.1) 20 (64.5) 133 (67.5) 0.87 (0.38–2.00) 0.74
Diabetes mellitus 44 (19.3) 4 (12.9) 40 (20.3) 0.58 (0.19–1.80) 0.35
Current/previous smoker 87 (38.2) 11 (35.5) 76 (38.6) 0.75 (0.33–1.71) 0.49
Previous MI 58 (25.7) 6 (19.4) 52 (26.7) 0.68 (0.26–1.82) 0.45
LVEF ≤50 42 (18.4) 12 (38.7) 30 (15.2) 3.20 (1.32–7.72) 0.01 2.71 (1.03–7.16) 0.044
STEMI 48 (21.1) 9 (29.0) 39 (19.8) 1.89 (0.74–4.82) 0.19 1.48 (0.49–4.44) 0.48
Stent type 0.0055 0.0084
EES (reference) 27 (11.8) 1 (3.2) 26 (13.2) Reference Reference
PES 55 (24.1) 4 (12.9) 51 (25.9) 2.06 (0.19–22.48) 1.96 (0.17–22.53)
BES 18 (7.9) 2 (6.5) 16 (8.1) 3.26 (0.27–39.38) 3.80 (0.31–46.61)
ZES 37 (16.2) 1 (3.2) 36 (18.3) 0.72 (0.04–12.08) 0.83 (0.05–14.01)
SES 91 (40.0) 23 (74.2) 68 (34.5) 8.84 (1.07–72.97) 9.05 (1.06–77.35)
Multivessel disease 23 (13.4) 3 (10.3) 20 (14.0) 0.61 (0.15–2.57) 0.51
No. of lesions 254 33 221
Target vessel 0.15
Left main (reference) 3 (1.2) 1 (3.1) 2 (0.9) Reference
LAD 101 (40.0) 7 (21.9) 94 (43.1) 0.16 (0.01–2.45) 0.19
Circumflex 57 (22.8) 7 (21.9) 50 (22.9) 0.20 (0.01–3.26) 0.26
RCA 88 (35.2) 17 (53.1) 71 (32.6) 0.47 (0.03–6.93) 0.58
Graft 1 (0.4) 0 (0) 1 (0.5) 0.16 (0.01–2.45) 0.19
Stent diametera 3.0+0.4 3.1+0.4 3.0+0.4 7.05 (0.42–119.3) 0.18
Total stented lengtha 21.6+13.9 22.6+10.4 21.4+14.3 1.00 (0.91–1.11) 0.96
Stents per lesiona 1.4+0.7 1.4+0.8 1.4+0.7 0.91 (0.07–11.12) 0.94
aExpressed as means+ SD.
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The Copenhagen OCT registry included OCT examinations at base-
line and 1-year follow-up. Cross-sections at baseline and follow-up
were matched on the basis of distance from stent borders and the pres-
ence of anatomical landmarks such as side branches. This allowed the fol-
lowing serial assessments at the cross-sectional level (Figure 2C–E):
At baseline, we assessed the presence of tissue prolapse, intra-stent
dissection and tissue protrusion. Tissue prolapse was defined as convex-
shaped tissue with a regular surface protruding into the lumen
between adjacent struts without disruption of the continuity of the
luminal vessel surface.14 The tissue was considered prolapsing only
when thedistance fromthe stent area trace to themaximumpointof pro-
lapse was ≥150 mm, chosen arbitrarily since some degree of prolapse
can be seen in most cross-sections. Intra-stent dissections were defined
as disruptions of the luminal vessel contour within the stented
segment, whereas tissue protrusionwas defined as amass with an irregular
surface attached to the vessel wall or struts and protruding into the
lumen. These features as well as the presence of ≥1 malapposed strut
were then correlated with the presence of evagination at the time of
serial follow-up, in matched cross-sections (Figure 2F).
Intravascular ultrasound image analysis
Intravascular ultrasoundpullbackswere analysedoff-line using theQCU-
CMS software (Medis, Leiden, TheNetherlands) at standard 1 mm inter-
vals, in the same region of interest as forOCT, following the international
consensus.15 Accordingly, we measured the lumen-, stent-, and external
elastic membrane area, the latter referred to as vessel area. The plaque
and media (P&M) area was calculated as (vessel area – stent area –
lumen area outside the stent), and the plaque burden as (P&M area/
vessel area) × 100. Positive vessel remodellingwasdefined as an increase
in the vessel area from baseline to follow-up.
Statistical analysis
We used Bayesian hierarchical random-effects model based on Markov
chain Monte–Carlo simulation methods16 with non-informative priors,
to compare OCT features such as strut malapposition, protrusion, and
coverage between lesions with ME and lesions without. The model
included random-effects at the level of cross-sections and lesions,
accounting for the correlation of characteristics of cross-sections
within lesions, and assigning analytical weights to each lesion depending
on the number of struts or cross-sections observed per lesion. Continu-
ous characteristicsof lesions suchas lumenareaand stent areawerecom-
pared between lesions with vs. without ME using frequentist mixed
maximum-likelihood regression models with study cohort, type of
stent, patient, and/or lesion as random intercepts. Means and standard
deviations were estimated from predicted values. To determine the
association of characteristics of lesions and patients at baseline with the
presence or absence of ME at follow-up, we usedmixedmaximum logis-
tic regressionmodels adjusted for time to follow-up (1, 2, or 5 years)with
study cohort, type of stent and lesion specified as random intercepts. The
same model was used to analyse stent and lumen area over time as
assessed with OCT and IVUS in the Copenhagen OCT registry. Mixed
maximum logistic regression models with type of stent, patient, and
lesion as random intercepts were used to assess the association of the
baseline cross-sectionalOCT features intra-stentdissection, strutmalap-
position, tissue protrusion, and prolapsewith cross-sectional evagination
at follow-up,with univariable andmultivariablemutual adjustments for all
four features. Statistical analyses were performed using WinBUGS
version 1.4.3 (Imperial College and MRC, UK) and Stata, version 11.0
(StataCorp, College Station, TX, USA).
Results
Incidence and extent of evaginations
A total of 228 patients with 254 lesions containing 5843 frames with
58 967 struts were included in the analysis (Figure 1). Overall, 75.8%
of patients were male and 19.3% had diabetes (Table 1). The clinical
setting at stent implantation was STEMI in 21.1% of cases, and 40.0%
ofpatients receivedaSES.Overall, amedian (IQR)of19(15–26)cross-
sections and 183 (140–273) struts were analysed per lesion. Out of
254 lesions, 152 (59.8%) had at least one cross-section with evagin-
ation, and 33 (13.0%) lesions contained at least one ME. Out of the
33 lesions with ME, 23 had a SES implanted, four a PES, four a BES,
one a ZES, and one an EES. The frequency of cross-sectional and ME
according to stent type and time point of implantation are shown in
Table 2. Both ‘any’ cross-sectional and ME were more frequent in
the SES group when compared with the PES-, ZES-, and EES-groups.
The frequency of MEwas low for lesions treated with ZES and EES at
1 year, and PES at 5 years.
Table 3 shows themean evagination- and ISAvolumes per lesion in
lesions with any cross-sectional evagination and lesions with ME
according to stent type and time since implantation. Evagination
volumes were consistently larger for the SES group when compared
with the other stents. Incomplete stent apposition volumes were
similarly larger in SES at 2 and 5 years. Evaluating SES alone, there
was a trend for an increase in ISA volumes from 1 to 2 to 5 years
(all lesions: P ¼ 0.024; lesions with any cross-sectional evagination:
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Table 2 Occurrence of cross-sectional and major evaginations stratified by stent type and time to follow-up
Lesions SES PES BES ZES EES P-value
No. of lesions with any evagination/total no. of lesions (%)
Year 1 22 /31 (71) 4 /8 (50) 25 /43 (58) 13 /35 (37) 0.045
Year 2 16/22 (73) 15 /27 (56) 0.25
Year 5 29 /41 (71) 28/47 (60) 0.37
No. of lesions with major evagination/total no. of lesions (%)
Year 1 8/31 (26) 1 /8 (13) 1 /43 (2) 1 /35 (3) 0.003
Year 2 4/22 (18) 4 /27 (15) 1.00
Year 5 11/41 (27) 3/47 (6) 0.02
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P ¼ 0.016; lesions with ME: P ¼ 0.14). The average depths and
lengths of cross-sectional and ME are presented in the appendix.
Predictors of major evaginations
Table 1 presents patient and lesion characteristics and their associ-
ation with ME. The indication for stent implantation was STEMI in
29.0% of patients with and 19.8% of patients without ME (P ¼
0.19). Left ventricular ejection fraction ≤50% was more frequent in
patients with compared with those without ME, and the use of SES
emerged as an independent predictor for the presence of ME.
Pooled optical coherence tomography
analysis
The quantitative results of the OCT analysis at the time of follow-up
are shown inTable 4.Minimal and average lumen and stent areaswere
larger in lesions with when compared with those without ME.
Malapposed, protruding, and uncovered struts were more
common in lesions with than without ME, and found in 77.2 vs.
24.9% (P, 0.001), 97.0 vs. 82.1% (P, 0.001), and 94.6 vs. 20.1%
(P, 0.001) lesions, respectively. Similarly, the proportion of
lesionswith≥10%malapposed and uncovered strutswas significant-
ly larger in the ME group. The average (means+ SD) thickness of
strut coverage was smaller in lesions with MEs compared with
those without this feature [0.11+0.29 vs. 0.14+ 0.23 mm; differ-
ence (95%CI):20.03 (20.06 to20.004)mm,P ¼ 0.022].At follow-
up, thrombus was more frequent in lesions with ‘any’ evagination
[28.0 vs. 5.9%, OR (95% CI): 6.1 (2.0–17.1), P ¼ 0.001] as well as
ME [48.5 vs. 14.0%, OR (95% CI): 7.3 (1.7–31.5), P ¼ 0.007].
Serial optical coherence tomography
and intravascular ultrasound analyses
Quantitative serial OCT results are shown in Table 5. All lesions with
ME were implanted with SES. The stent and lumen areas were larger
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Table3 Evaginationand incomplete stentapposition volumes at the lesion level in lesionwith anyandmajorevaginations
by stent type and time to follow-up
SES PES BES ZES EES P-value
At Year 1
Lesions with any evagination
EV 2.24+1.68 (22) 0.50+0.72 (4) 0.38+1.79 (25) 0.42+1.29 (13) 0.002
ISAV 0.20+2.12 (22) 3.00+0.90 (4) 0.76+2.25 (25) 2.20+1.63 (13) 0.30
Lesions with ME
EV 24.20+1.77 (8) 5.31+0.59 (1) 4.42+0.59 (1) 10.28+0.59 (1) 0.39
ISAV 0.54+1.64 (8) 12.10+0.58 (1) 0.26+0.58 (1) 6.23+0.58 (1) ,0.001
All lesions
ISAV 0.14+1.80 (31) 1.51+0.92 (8) 0.57+2.12 (43) 0.92+1.92 (35) 0.17
At Year 2
Lesions with any evagination
EV 2.47+2.52 (16) 0.57+2.44 (15) 0.03
ISAV 1.54+3.32 (16) 0.19+3.21 (15) 0.24
Lesions with ME
EV 30.40+1.30 (4) 4.08+1.19 (4) 0.01
ISAV 5.22+5.15 (4) 0.79+5.15 (4) 0.21
All lesions
ISAV 1.34+2.69 (22) 0.12+2.98 (27) 0.12
At Year 5
Lesions with any evagination
EV 2.54+1.58 (29) 0.72+1.55 (28) ,0.001
ISAV 3.81+6.69 (29) 1.42+6.57 (28) 0.10
Lesions with ME
EV 11.80+0.59 (11) 4.40+0.25 (3) 0.008
ISAV 7.47+13.52 (11) 1.91+7.06 (3) 0.41
All lesions
ISAV 2.72+5.49 (41) 1.04+5.88 (47) 0.09
ME, major evagination; EV, evagination volume; ISAV, incomplete stent apposition volume. Volumes are expressed as means+ SD (no. of lesions) mm3 and predicted from
maximum-likelihood models.
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in lesions with when compared with those without ME at both
baseline and follow-up, with a significant change in the lumen area
at follow-up in both groups [increase in the lumen area in lesions
with ME (P ¼ 0.01), and decrease in the lumen area in lesions
without ME (P, 0.001)]. The change in the stent area from baseline
to follow-up within the ME group was not significant (P ¼ 0.15).
Table 6 shows the association of OCT characteristics recorded at
baseline with cross-sectional evagination at follow-up in matched
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Table 4 Results of follow-up optical coherence tomography analysis
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Lesions analysed, n 33 221
Frames analysed, n 804 5039
Struts analysed, n 8385 50,582
Lumen area, mm2a 8.34+5.90 6.44+2.50 1.90 (1.08–2.72) ,0.001
Minimal lumen area, mm2a 5.99+5.60 4.88+2.20 1.12 (0.34–1.89) 0.005
Stent area, mm2a 8.50+6.10 7.37+3.00 1.13 (0.33–1.93) 0.006
Minimal stent area, mm2a 6.71+6.40 5.88+3.70 0.83 (0.03–1.62) 0.04
Strut type, % (95% CrI)
Malapposed strutsb
Malapposed struts per lesion 1.07 (0.41–2.62) 0.11 (0.06–0.17) 0.96 (0.31–2.52) ,0.001
Lesions with ≥1 77.20 (52.80–92.80) 24.9 (15.40–34.90) 51.80 (25.40–72.60) ,0.001
Lesions with ≥10% 5.53 (0.86–19.30) 0.18 (0.02–1.19) 5.24 (0.70–18.90) 0.001
Protruding strutsb
Protruding struts per lesion 3.04 (1.52–5.87) 0.11 (0.06–0.17) 2.92 (1.42–5.77) ,0.001
Lesions with ≥1 97.00 (86.70–99.60) 82.1 (72.30–89.60) 14.30 (4.04–23.80) 0.01
Lesions with ≥10% 9.34 (2.03–27.10) 4.93 (1.93–10.80) 4.09 (-3.42–21.20) 0.37
Uncovered strutsb
Uncovered struts per lesion 3.82 (2.12–6.82) 1.39 (1.06–1.79) 2.43 (0.70–5.46) 0.002
Lesions with ≥1 94.60 (81.00–99.10) 20.10 (11.40–30.00) 74.00 (56.00–85.80) ,0.001
Lesions with ≥10% 5.59 (0.85–19.30) ,0.01 (,0.01–0.16) 5.57 (0.84–19.30) ,0.001
Lumen and stent areas are expressed as means+ SD.
CrI, credibility interval.
aUsing traditional mixed maximum-likelihood model.
bUsing Bayesian hierarchical 2-level logistic regression model.
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Table 5 Quantitative serial optical coherence tomography results of the stented segment
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Patients analysed, n 8 35
Lesions analysed, n 8 37
Frames analysed, n 154 705
SA BL, mm2 8.60+1.42 7.14+1.22 1.84 (0.32–3.37) 0.02
SA FUP, mm2 9.21+1.59 7.33+1.36 2.28 (0.57–3.98) 0.009
SA change, mm2 0.61+0.29 0.20+0.24 0.43 (-0.02–0.88) 0.06
LA BL, mm2 8.85+1.11 7.30+0.92 1.89 (0.45–3.33) 0.01
LA FUP, mm2 9.03+1.22 6.29+1.01 2.89 (1.27–4.52) ,0.001
LA change, mm2 0.17+0.66 21.00+0.59 0.99 (0.29–1.69) 0.006
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; BL, baseline; FUP, follow-up.
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cross-sections. In both uni- andmultivariable analyses, intra-stent dis-
sections, and tissue protrusions at baseline were associated with
cross-sectional evagination at follow-up: the odds of evagination at
follow-up were increased by about three in the presence of either
dissection or tissue protrusion at baseline.
The corresponding serial IVUS analyses are summarized in Table 7.
At baseline, the vessel area was larger among lesions with ME. Serial
IVUS analysis showed a larger increase in the vessel area and positive
remodelling in lesions with ME when compared with those without
(21.1 vs. 4.6%, P, 0.001), mainly driven by an increase in the P&M
area and accompanied by an increase in the lumen area. Again, the
stent area appeared to increase between baseline and follow-up in
lesions with ME (P ¼ 0.84), but not in lesions without [difference in
change between groups (95% CI): 0.43 (0.01–0.85) mm2, P ¼ 0.04].
Discussion
The present study shows that OCT-detected MEs are specifically
related to early-generation SES, and much smaller and in general
less frequent in newer-generation DES. The mechanism underlying
the pathogenesis of ME was suggestively a positive remodelling.
Signs of injury documented immediately after stent implantation
were associated with an increased risk of evagination at follow-up.
Positive remodelling as acauseof coronary
evagination
Coronary artery ectasias and aneurysms following DES implantation
have generated great interest owing to their associationwith ST.7,8,17
These vessel distensions have often been accompanied by ISA, sug-
gesting positive remodelling as the underlying pathomechanism,
since regional vessel remodelling was previously identified as a cause
of late acquired stent malapposition (LASM).7,17,18 In the present
study, we took advantage of information obtained by OCT on depth,
cross-sectional area, and longitudinal extent, to assess evaginations in
three dimensions. The association between positive remodelling and
ME suggests that positive remodelling is the mechanism underlying
the pathogenesis of evaginations.
We observed that ME in general occurred more frequently and
appeared to be larger in SES, suggesting these to be a specific
morphological footprint of these early-generation DES. Conversely,
MEs were less frequent in PES compared with SES at 5 years—a dif-
ferencewhich is confirmatory of the SIRTAX-LATEOCT study. At 1
year, MEs were less frequent in PES compared with SES but were
almost absent in newer-generation ZES and EES. No difference,
however, was observed between SES and BES at 2 years—something
that needs to be interpreted in light of a relatively low sample size of
only 18 SES and 18 BES patients at 2 years of follow-up. (Accordingly,
it cannot be excluded that this finding could bedue to chance.Never-
theless, assessment of evagination volumes showed that these were
significantly larger for SES compared with BES, thus being in line with
the findings in the other subgroups, particularly the SES vs. ZES and
EES, where the sample size was also relatively low.) In a meta-analysis,
Hassan et al.19 reported similar findings in terms of IVUS-detected
LASM, which were also accompanied by positive vessel remodelling,
with the highest incidence in SES followed by PES, and newer-
generationZESandEES.These similarities, togetherwith theobserved
association of MEwith malapposed, protruding, and uncovered struts,
suggest that these features may be part of the same disease entity.
Pre-clinical and human autopsy studies previously demonstrated
that the inflammatory response following DES implantation strongly
relates to the type of stent: SES typically induces granulomatous
inflammation with macrophages, giant cells, lymphocytes, and eosi-
nophils; PES exhibits extensive fibrin deposition and medial smooth
muscle cell necrosis; ZES and EES show only low levels of inflam-
mation and fibrin deposition.1,20–22 In addition, SES has been asso-
ciated with marked adventitial inflammation and fibrosis—findings
associated with positive remodelling.20,23 These results are in line
with observations of aneurysmal vessel dilation, stent malapposition,
and generalized eosinophilic vasculitis in a case of late ST in a patient
with SES.24 Similarly, the extent of vascular remodelling predomin-
antly after SES implantation correlated with the number of eosino-
phils harvested from thrombus aspirates in patients with very late
ST,25 supporting the notion that OCT-detected ME represent a
pathological vascular reaction particularly related to this stent.
If evaginations and protruding struts are precursors of ISA, a
stretch in the P&M may occur during the vessel expansion before
complete detachment from the stent. Interestingly, we observed a
trend towards a decrease in the size of ME from 1 and 2 to 5-year
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Table 6 Assessment of the correlation of baseline optical coherence tomography features and evaginations, inmatched
cross-sections
Evagination at
follow-up
Crude OR (95% CI) P-value Multivariable OR (95% CI) P-value
Yes No
No. of frames at follow-up 128 713
Characteristics of cross-section at baseline
Intra-stent dissection, n (%) 60 (46.9) 159 (21.8) 3.01 (1.81–5.00) ,0.001 2.93 (1.75–4.89) ,0.001
Malapposed strut, n (%) 12 (9.4) 35 (4.8) 1.76 (0.77–4.03) 0.18 1.69 (0.72–3.99) 0.23
Tissue protrusions, n (%) 27 (21.1) 73 (10.0) 3.27 (1.59–6.70) 0.001 3.34 (1.61–6.93) 0.001
Prolapse, n (%) 26 (20.3) 162 (22.2) 1.04 (0.57–1.90) 0.90 1.06 (0.57–1.99) 0.85
Using mixed logistic regression with stent type, patient, and lesion as random intercept.
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follow-up among SES-stented segments, while there was a trend
towards an increase in ISA volume, suggesting that evaginations
may transition into ISA. Regarding the large ISA volumes at 1 year
in the two cases of PES and ZES with ME; the ISA in the PES repre-
sented persistent malapposition, whereas the ISA in ZES was
located in the proximity of a large bifurcation and thus likely
present at baseline.
The unexpected finding of a larger stent area only in lesions with
ME, which was consistent across the pooled analysis as well as
the serial independent evaluation with OCT and IVUS, may either
be related to the vessel expansion before detachment or due to
chance. It is unlikely that a more intense use of nitroglycerine or po-
tentially higher flush rate during OCT acquisition at follow-up when
compared with baseline could have induced these findings only in
lesions with ME.
Mechanisms of vessel remodelling
The SES-specific remodelling pattern may be triggered by the
polymer rather than the drug. Evidence in favour of this hypothesis
is thepresenceof a focal giant cell reaction surroundingpolymer rem-
nants separated from the stent struts,24 together with observations
that durable-polymer SES when compared with polymer-free SES
and bare-metal stents are associated with a larger external elastic
membrane area.23 Considering that 80% of sirolimus is released
from durable-polymer SES within the first 4 weeks, it seems unlikely
that sirolimus itself induces long-term alterations of the vessel wall
such as the ME detected up to 5 years in the present study.
The specific mechanisms by which polymers may induce positive
remodelling in casesof coronaryaneurysms andLASMremain specu-
lative. In relation to SES, it is known that methacrylate may exert a
toxic effect on endothelial cells and leucocytes, and can modulate
pro-coagulant activities of monocytes.26 Exposure to the poly-n-
butyl-methacrylate polymer can furthermore cause delayed (type
IV) hypersensitivity reactions mediated at least in part by accumu-
lated CD4 T-helper cells secreting interleukin (IL)-4 and IL-13.24
Ofnote, IL-13wasassociatedwith increased smoothmuscle cell con-
tractility in asthma,27 andcan inducealveolar remodelling andemphy-
sema inmice via induction of matrixmetalloproteinase (MMP)-9 and
MMP-12.28 Both these MMPs were identified as important factors in
the development of abdominal aortic aneurysms in humans by deg-
radation of elastin.29 At the same time, MMP-12 has been found to
be amediatorof the accumulationofmacrophages and eosinophils.28
Similar pathwaysmay be responsible for the remodelling and eosino-
philia observed in SES-treated coronary arteries. However, then
remains the question why not all patients develop this finding.
To further address this, we compared OCT findings following
stent implantation with the presence of evaginations at follow-up in
corresponding cross-sections. Accordingly, our study demonstrated
that cross-sections exhibiting intra-stent dissections and tissue pro-
trusions at baseline—both representing markers of injury—were
associated with an increased risk of evagination at the time of OCT
follow-up. (Of note, tissue protrusionswere defined as tissue projec-
tions with irregular lumen contour and thereby suggestive of either
thrombus or tissue disruptions other than intra-stent dissections,
whereas tissue prolapses were characterized by an intact lumen
contour, suggestive of prolapsing plaque.) This relationship is sup-
ported by previous observations relating OCT-detected evagina-
tions and coronary artery aneurysms with vessel wall dissections
and deep arterial injury caused by oversized balloons, stents,
and atherectomy.5,30,31 Nevertheless, considering that intra-stent
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Table 7 Quantitative serial intravascular ultrasound results of the stented segment
Major evagination at follow-up Diff (95% CI) P-value
Yes No
SA BL, mm2 8.67+1.94 7.61+1.62 1.31 (20.43 to 3.05) 0.14
SA FUP, mm2 9.18+2.03 7.67+1.68 1.76 (20.09 to 3.60) 0.06
SA change, mm2 0.50+0.31 0.06+0.24 0.43 (0.01 to 0.85) 0.04
LA BL, mm2 8.67+1.92 7.59+1.61 1.33 (20.39 to 3.06) 0.13
LA FUP, mm2 9.28+2.00 7.37+1.63 2.10 (0.24 to 3.97) 0.03
LA change, mm2 0.59+0.40 20.22+0.33 0.75 (0.22 to 1.28) 0.006
VA BL, mm2 16.53+2.63 13.78+1.99 3.44 (0.62 to 6.25) 0.02
VA FUP, mm2 20.06+3.44 14.41+2.76 6.29 (3.00 to 9.59) ,0.001
VA change, mm2 3.51+1.19 0.63+1.00 2.84 (1.71 to 3.98) ,0.001
P&M area BL, mm2 7.86+1.79 6.14+1.56 2.11 (0.52 to 3.70) 0.009
P&M area FUP, mm2 10.78+2.36 7.02+2.06 4.17 (2.08 to 6.27) ,0.001
P&M area change, mm2 2.89+0.92 0.87+0.76 2.06 (1.11 to 3.00) ,0.001
PB BL, % 46.82+4.02 44.36+2.95 3.02 (22.65 to 8.70) 0.30
PB FUP, % 52.78+4.36 48.46+3.15 5.26 (20.93 to 11.46) 0.10
PB change, % 5.90+1.98 3.95+1.72 2.21 (20.08 to 4.49) 0.06
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; VA, vessel area; P&M, plaque and media; PB, plaque burden; BL, baseline; FUP, follow-up.
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dissections were present in 27%, 15%, and 31% of cross-sections in
SES, PES and ZES, respectively, it may be argued that the influence
of stent type, as compared to that of vessel injury, is relatively
greater on the development of ME, which in the serially studied
lesions were all present in segments implanted with SES. Although
the depth of intra-stent dissections could not be systematically
assessed due to the limited tissue penetration of OCT, we did
observe 12 cases of evaginations following intra-stent dissections
extending into the media and adventitia (Figure 3).
Potential clinical relevance of coronary
evaginations
Features associated with very late ST include uncovered struts, late
malapposition, positive remodelling, chronic inflammation as well
as ectasias and aneurysms.1,2,7,8,17,25,32We found nearly all these fea-
tures to bemore common in lesionswithME, suggesting thatMEmay
be part of the same pathophysiological entity commonly recognized
as inappropriatehealing followingDES implantation, proposing apos-
sible linkwith late ST.Moreover, our finding of a greater frequency of
thrombus in lesions with ‘any’ andMEsmay be an expression of a po-
tential thrombogenicity of these lesions compared with those
without evaginations. Although our pooled study sample included
one of the largest OCT cohorts to date, it was too small for a mean-
ingful evaluation of such a relationship, however, two of the patients
withME fromtheSIRTAX-LATEcohort experiencedvery lateSTat5
and 12 months following 5-year OCT follow-up. Both of these oc-
curred in SES which had some of the most extensive evagination-
and ISA volumes in the entire cohort.6 Along the same line,
Alfonso et al.7 described that among patients with angiographic
Figure 3 Co-location of intra-stent dissections post-PCI and evaginations at follow-up. (A–C) Three cross-sections obtained at corresponding
sites before (A1–C1), immediately after (A2–C2), and at 1 year (A3–C3) following stent implantation. The large side-branch (*) in (A1)–(A3) confirms
a goodmatching, as does the pericardial space (†) and evidence of trilaminar vessel structure (i, intima;m,media; a, adventitia) in (B1)–(B3) and (C1)–
(C3). In (B2) and (C2), a large intra-stent dissection extends from 10 to 1 o’clock (white arrows), exposing the underlying adventitia, and a small dis-
section is seen at 6 o’clock (white arrow). Of note, evaginations (e) are clearly seen at the corresponding sites at follow-up in (B3) and (C3). The upper
middlepanel showsa schematicoverviewof the locationof intra-stentdissectionatbaselineandevaginationat follow-upwithinmatched frames. (D)An
endoscopic three-dimensional view of the vessel in question, where evaginations (e) create an irregular luminal surface. The optical coherence tom-
ography-catheter (Cx) is located to the leftof the ‘pointof view’. (E)Aperpendicular viewof theevagination in (B3) and (C3) at 10o’clock (whitee in (E)),
which in the three-dimensional reconstruction is separated fromanother evagination (black e in (E)) along the vessel segment by a strut (white arrow).
The evagination at 12 o’clock in (C3) is hidden behind the optical coherence tomography-catheter (Cx) in (E).
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coronary artery aneurysms, subsequent ST correlated with a larger
vessel and lumen volume by IVUS at the time of imaging. Similarly,
Imai et al.8 observed an increased risk of ST and target lesion revascu-
larization in SES with ectasias measuring ≥20% of the stent diameter
and extending longitudinally at least the length of the stent diameter,
corresponding to an ectasia depth and length of 0.6 mm and 3 mm in
a 3 mm stent, respectively—a similar length but twice the depth of
the ME definition used in our study. These data suggest that the
extent of evagination matters and that clarification of the natural
history of evaginations as well as the relationship between the
degree of evagination and clinical events merits consideration.
Although first-generation SES are no longer manufactured, they
have been implanted in a considerable number of patients world-
wide. Recent data from a registry of .12 000 patients, and a
meta-analysis including 49 trials, suggest that treatment with newer-
generation EES is associated with a lower risk of very late ST when
compared with early-generation SES and PES,33,34 which are add-
itionally associated with a continued risk of very late ST when com-
pared with EES. In this context, it is interesting that the occurrence
of evaginations, malapposition, and uncoverage by OCT in the
present study, aswell as the incidenceof IVUS-detectedLASM inpre-
vious studies,19 follow a similar pattern. Our findings therefore
suggest that evaginations detected with high-resolution OCT may
be predictors of late ST particularly in SES, and alongside malapposi-
tion and uncoverage provide a possible explanation for differences
in late adverse ischaemic events in early- compared with newer-
generation DES. Conversely, PES when compared with SES
showed fewer ME and only a modest increase when compared
with newer-generation DES. Although clinical rates of ST have
been comparable between SES and PES, the trigger leading to throm-
bosis appears to differ21 in view of substantial differences in the fre-
quency of evaginations. Studies assessing clinical outcomes with
OCT and IVUS—particularly with serial imaging—are demanding
to perform due to the relatively complex and costly set-ups and
the large number of patients required. In view of this, the present
study, although relatively small with the 254 imaged lesions, provides
important new insights into the utility of OCT for assessing vascular
reactions following stent implantation, and suggests that this technol-
ogy can identify features specific for different stents, which may be
useful for improving the prediction of events in the future.
Limitations
The following shortcomings must be considered when interpreting
the results of the present study. First, we pooled data from four sep-
arate cohortswith different time to follow-up, outofwhichone came
from a non-randomized registry. Efforts were made to adjust for
these issuesby using frequentist andBayesianmixedmodels account-
ing for the clustered nature of data. Secondly, we did not assess the
type of malapposition at follow-up primarily as our focus was on eva-
ginations, and since the relationship between acquiredmalapposition
and positive remodelling has already been shown.18 Considering that
positive remodelling is a common denominator of evaginations and
LASM, it seems reasonable to assume that the majority of malap-
posed struts at follow-up within lesions with ME were late acquired,
particularly since there was no correlation between malapposed
struts at baseline and ME at follow-up. Thirdly, we extrapolated
cross-sectional evagination areas 0.5 mm proximal and distal to the
frame of interest to estimate the volume of ME, which may both
over- and underestimate the size. Separate evaluation of cross-
sectional and ME does however not affect the results of the relative
occurrence and predictors of evaginations. Whether this is also
true for the mechanisms is unknown since serial IVUSwas only avail-
able for one of the cohorts. In this regard, it cannot be discarded that
evaginations at 2 and 5 years may be caused by mechanisms other
than remodelling as observed at 1 year. Furthermore, OCT cross-
sections were analysed at 1 mm intervals, although the highest sam-
pling density with commercially available new-generation OCT is
0.2 mm. This could potentially give inaccurate estimates of the occur-
rence and size of cross-sectional and ME. Considering that gold-
standard histology typically evaluates entire lesions based on three to
five cross-sections—remarkably lower compared with the average
19 cross-sections per lesion assessed in our study—we chose to
accept this level of accuracy, as well as the potential imprecision in
the selection of corresponding cross-sections at baseline and
follow-up, which is inevitably present whenever serial evaluations are
performed. Also, although care was taken to obtain as accurate mea-
surements of evagination- and ISA-volumes as possible, the inherent
risk of multiplication of small measurement errors cannot be excluded.
Finally, even though this study is one of the largest OCT studies
to date, the small number of lesions with MEs, especially in the
ZES and EES groups at 1 year, nonetheless limits the power of
the study.
Conclusion
Optical coherence tomography-detected MEs are a specific mor-
phological footprint of early-generation SES and are nearly absent
in newer-generation ZES and EES. Optical coherence tomography
detected intra-stent dissections and tissue protrusions at baseline
are associated with an increased risk of evaginations at follow-up.
The mechanism underlying the pathogenesis of ME is suggestively a
positive remodelling.
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Appendix
Addendum to the methodology
and results
Optical coherence tomography and
intravascular ultrasound image analysis
The lumen area (LA) was measured using the automatic area trace
function. Stent struts were defined as signal-intense spots with
dorsal shadowing and a marker was placed at the endoluminal
leading edge of the strut, in the mid-point of its axis. The stent area
(SA) was measured by connecting the strut markers with a trace
line. Strut appositionwas assessed for each strut by measuring the dis-
tance fromthe strutmarker to the lumencontour semi-automatically
using the thickness-ruler function.
For the LEADERS and RESOLUTE trials, lumen and stent area
measurements, strut apposition, and strut coverage were assessed
by corelab analysts (Cardialysis) blinded to stent type andclinical out-
comes. The OCT analyses of the SIRTAX-LATE OCT substudy, the
Copenhagen OCT registry, and the assessment of evaginations and
protruding struts in all studies were performed by two observers.
In case of disagreement, a referee was consulted to a final decision.
The time-consuming assessment of evaginations in the LEADERS,
RESOLUTE, and Copenhagen cohorts were performed un-blinded,
as blinding would have implied a detailed assessment of evaginations
using the cut-off of the thinnest stent (Xience, 90 mm or Resolute,
100 mm), and thus the assessment of a large number of bulges in
the thicker stents which would, following un-blinding, not fulfil the
definition of evagination. Assessments of OCT cross-sections at
baseline and follow-up were performed independently, without
knowledge of the characteristics of matched cross-sections. The
same methodology was used throughout all four OCT studies.
Intravascular ultrasound analyses were performed by two obser-
vers, and in case of disagreement a referee was consulted to reach
a final decision. Baseline IVUS assessment was performed independ-
ently of the follow-up evaluation, and without knowledge of the
results of the OCT analysis.
Details of the Bayesian approach
The proportions of malapposed, protruding, and uncovered struts
per lesion were analysed using a model with Bernoulli distribution,
while the proportions of lesions with ≥1 and ≥10% malapposed,
protruding, and uncovered struts were analysed using Bayesian hier-
archical random-effectsmodelwith logit distribution. Estimateswere
derived fromthemedianof theposterior distributionof the50 001 to
150 000 iteration, with the initial 50 000 iterations discarded as
‘burn-in’. We derived 95% credibility intervals (95% CrI) from the
2.5th and 97.5th percentiles of the posterior distribution, also calcu-
lating two-sidedP-values fromtheposteriordistribution. 95%CrI and
P-values from posterior distributions can be interpreted similarly to
conventional 95% confidence intervals and P-values.
Additional details on the evagination size
The average depths and lengths of cross-sectional and ME are pre-
sented in the appendix table 1 and 2.
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Appendix table 1 Specification of the volume, depth and number of cross-sections spanned for “any” cross-sectional
evaginations, by stent type and time to FUP
SES PES BES ZES EES p
At Year 1
Lesions with any evagination N 22 4 25 13
EV 2.24+1.68 0.50+0.72 0.38+1.79 0.42+1.29 0.002
Max depth 0.36+0.45 0.33+0.19 0.23+0.48 0.25+0.34 0.005
N CS/lesion* 4.02 (2.90–6.68) 2.56 (2.09–3.67) 3.01 (2.34–4.16) 2.26 (1.94–2.88) 0.46
At Year 2
Lesions with any evagination N 16 15
EV 2.47+2.52 0.57+2.44 0.03
Max depth 0.32+0.63 0.26+0.61 0.15
N CS/lesion* 4.41 (3.57–10.96) 2.32 (1.74–8.49) 0.13
At Year 5
Lesions with any evagination N 29 28
EV 2.54+1.58 0.72+1.55 ,0.001
Max depth 0.36+0.80 0.30+0.56 0.13
N CS/lesion* 4.44 (3.99–5.92) 2.25 (1.96–2.73) ,0.001
N CS/lesions refers to the number of CSs per lesion with any evagination. Values are presented as means+ SD unless otherwise specified.
EV, evagination volume; CS, cross-section.
*Expressed as median (IQR). Volumes are expressed in mm3, and depths in mm.
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Background: Pathology studies have shown delayed arterial healing in culprit lesions of patients with acute cor-
onary syndrome (ACS) compared with stable coronary artery disease (CAD) after placement of drug-eluting
stents (DES). It is unknown whether similar differences exist in-vivo during long-term follow-up. Using optical
coherence tomography (OCT), we assessed differences in arterial healing between patients with ACS and stable
CAD five years after DES implantation.
Methods and results:A total of 88 patients comprised of 53 ACS lesionswith 7864 struts and 35 stable lesionswith
5298 struts were suitable for final OCT analysis five years after DES implantation. The analytical approach was
based on a hierarchical Bayesian random-effects model. OCT endpoints were strut coverage, malapposition,
protrusion, evaginations and cluster formation. Uncovered (1.7% vs. 0.7%, adjusted p = 0.041) or protruding
struts (0.50% vs. 0.13%, adjusted p = 0.038) were more frequent among ACS compared with stable CAD lesions.
A similar trend was observed for malapposed struts (1.33% vs. 0.45%, adj. p = 0.072). Clusters of uncovered
or malapposed/protruding struts were present in 34.0% of ACS and 14.1% of stable patients (adj. p = 0.041).
Coronary evaginations were more frequent in patients with ST-elevation myocardial infarction compared with
stable CAD patients (0.16 vs. 0.13 per cross section, p = 0.027).
Conclusion: Uncovered, malapposed, and protruding stent struts as well as clusters of delayed healing may be
more frequent in culprit lesions of ACS compared with stable CAD patients late after DES implantation. Our ob-
servational findings suggest a differential healing response attributable to lesion characteristics of patients
with ACS compared with stable CAD in-vivo.
© 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The long-term risk for recurrent events is higher among patients
with acute coronary syndromes (ACS) compared to those with stable
coronary artery disease (CAD) after placement of drug-eluting stent
(DES). Aside from non-device related factors, differences in arterial
healing have been suggested as a potential explanation with a higher
frequency of uncovered struts, fibrin deposition and inflammation
observed in autopsy specimen [1]. Few studies using intravascular opti-
cal coherence tomography imaging also observed a higher rate of un-
covered and malapposed stent struts among ACS patients but were
limited to one year follow-up after DES implantation [2–4]. Owing to a
possible association of uncovered and malapposed struts with the risk
of late stent thrombosis [5] and the prevailing uncertainty with respect
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to the optimal duration of dual antiplatelet therapy, differences in arte-
rial healing between patients with ACS and stable CAD after placement
of DES remain clinically relevant. We therefore compared markers of
arterial healing including strut coverage, protrusion, malapposition,
and coronary evaginations among patients with ACS and stable CAD
using OCT five years after implantation of early generation DES.
2. Methods
2.1. Patient population and lesion selection
The design and results of SIRTAX (Sirolimus-Eluting Stent ComparedWith Paclitaxel-
Eluting Stent for Coronary Revascularization) and SIRTAX LATE (Sirolimus-Eluting Stent
Compared With Paclitaxel-Eluting Stent for Coronary Revascularization—Late) have
been previously reported [6]. For the purpose of the present study, all consecutive pa-
tients undergoing angiographic follow-up at five years between December 2009 and
July 2010 (n = 145) were eligible for OCT imaging. The flow of patients and reasons for
exclusion are reported in the diagram (Fig. 1). In patients withmore than one study lesion
(n= 19), all lesions were randomly allocated a numerical code of 1, 2 or 3 by an indepen-
dent statistician. OCT was routinely performed in the lesion with the lowest number. In
none of these patients, the second or third lesion underwent OCT to respect the random
selection. In four patients with multiple lesions, OCT was technically not feasible. Thus,
in 15 patients suitable for final analysis, lesion selection was performed in a random
manner. Among these patients, a total of 8wereACS patients and only in twoACS patients,
the imaging was done in the non-culprit lesion at baseline (culprit lesion defined ac-
cording to ECG and ventriculography findings).
The study complied with the Declaration of Helsinki regarding investigation in
humans and was approved by the institutional ethics committees at Bern University
Hospital, Switzerland. All patients provided written informed consent.
2.2. OCT imaging and analysis
OCT was performed with a time domain M2 system (Lightlab Imaging, Westford,
Massachusetts) using a pullback speed of 2 mm/s and the non-occlusive flushing
technique. After the diagnostic angiography and administration of 5000 IU unfractionated
heparin, the ImageWire (Lightlab Imaging) was carefully advanced distal to the study
lesion. Following administration of 200 μg of i.c. nitroglycerin, the target vessel was
flushed through the guiding catheter with non-ionic, isosmolar contrast agent (Iodixanol
320, Visipaque, GE Healthcare, Cork, Ireland) using a power injector with flush rates be-
tween 3 and 4 ml/s. OCT pullbacks were assessed offline using a proprietary software
(Lightlab Imaging, St. Jude Medical). Lesions were analyzed at cross sectional level with
an interval of at 1 mm and assessed for strut coverage, malapposition, and protrusion by
a single analyst blinded to patient and lesion presentation. All frames were reviewed by
a second analyst, who in case of disagreement consultedwith a third referee,withfinal de-
cision based on consensus. Pullbacks were excluded in case N30% of the total stent length
was not analyzable. Frames were considered not analyzable when N25% of the circumfer-
ence was not visible due to insufficient flush or out of zoom. A strut was defined as a
signal-intense bright spot with a typical dorsal shadowing. Thickness of strut coverage
was measured as the distance between the endoluminal side of the strut in the midpoint
of its long axis and the intersection of the lumen contour with the straight line between
the endoluminal side of the strut and the gravitational center of the vessel. Struts
were considered uncovered in case of a partial or complete absence of tissue coverage.
Protrusion was defined as strut extension into the lumen for more than 160 μm but
with no obvious separation from the vessel wall [7]. Apposition was assessed by mea-
suring the distance between the center of the endoluminal strut surface and the inter-
section between lumen contour and the line connecting the center of the endoluminal
strut side and the gravitational center of the vessel. Strut malapposition was defined
as a distance ≥160 μm based on the consensus derived from the strut thickness of
SES (153 μm) and PES (148 μm) plus the minimal axial resolution of OCT (10 μm).
This consensus allowed a blinded assessment. Representative examples of uncovered,
protruding or malapposed stent struts are presented in Fig. 2. Geographic maps
were created displaying struts using color codes for strut characteristics, including
strut coverage, apposition, and protrusion (Fig. 3). The resultant map represented the
stented vessel cut longitudinally along the reference angle 0° (corresponding to the 12
o'clock position in the respective OCT cross section) and spread out on an area [7].
The stent maps of all lesions are depicted in Fig. 4.
Coronary evaginations (Fig. 2, example E) were suspected whenever the luminal
vessel contour extended in a pouchlike fashion beyond the line connecting all stent struts
(stent contour). Under these circumstances, the maximal radial distance between the
circular line connecting all struts and the luminal vessel wall was evaluated using the
Fig. 1. Flow chart showing study design and patient flow.
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thickness ruler function.When themaximal depth exceeded 160 μm(similar cut off as for
the presence of malapposition), we considered the outward bulging as evagination [7].
By definition, the evagination is limited laterally by stent struts. In addition to themaximal
depth of the evagination, the interstrut evagination area was assessed. The interstrut
evagination area was defined as the area limited by the stent contour luminally and the
lumen contour abluminally.
We analyzed clusters of uncovered and malapposed/protruding struts separately.
A cluster of either uncovered (or malapposed/protruding) stent struts requires the
presence of at least 6 adjacent uncovered (ormalapposed or protruding) stent strutswith-
in an area defined bymultiple lines connecting all uncovered (ormalapposed/protruding)
struts without including a covered (or apposed) strut. All outmoster blue lines determine
the final cluster area (tracked red in Fig. 5), in which no covered (or apposed) strut can be
found. As an additional precondition, a longitudinal extension of at least 1.5 mm and a
lateral extension of at least 90° were required (Fig. 5).
2.3. Statistical analysis
Weused a Bayesian hierarchical random-effects model based onMarkov chainMonte
Carlo simulation methods with vague priors to estimate differences between ACS and
stable CAD patients. The analysis was adjusted for differences in baseline characteristics
(hypertension, hyperlipidemia, left ventricular function). For analyses at the cross-section
and strut level, themodel included random-effects at the level of patients, fully accounting
for the correlation of characteristics of cross-sectional areas or struts within patients and
implicitly assigning analytical weights to each lesion depending on the number of cross
sections or on the number of struts observed per lesion. For continuous outcomes, we as-
sumed a log normal distribution; for counts, we used a Poisson distribution; we used ap-
propriate transformations to derive arithmetic means and rates, respectively. Differences
in the percentage of lesions with any struts with unfavorable outcome, with at least 5%,
andwith at least 10% of struts with unfavorable outcomewere calculated using a Bayesian
hierarchical random-effects model assuming a Bernoulli distribution. For all other analyses
at the lesion level, we used conventional linear and Poisson regression models, depending
on the nature of the outcome (continuous or counts). We derived 95% credibility intervals
(CrI) from the 2.5th and 97.5th percentiles of the posterior distribution, also calculating 2-
sided p values from the posterior distribution. Statistical analyses were performed using
Win-BUGS (version 1.4.3, Imperial College and Medical Research Council, London, United
Kingdom) and Stata (version 11.0, StataCorp, College Station, Texas).
3. Results
3.1. Patients
The flow of patients included into the OCT study five years after
DES implantation is shown in Fig. 1. Of the 95 patients undergoing
OCT at 5.3 years (interquartile range: 5.1 to 5.5 years), 57 patients
had presented with ACS and 38 patients with stable CAD at the
time of DES placement. A total of 4 ACS patients and 3 stable CAD pa-
tients were excluded, resulting in 53 ACS and 35 stable CAD patients
included into the final OCT analysis. Baseline clinical and angiographic
characteristics of patients undergoing OCT at 5 years are shown in
Table 1. ACS compared with stable CAD patients were less frequently
hypertensive and dyslipidemic and had a lower left ventricular ejection
fraction. Baseline lesion characteristics are summarized in Table 2.
Lesions of ACS patients had smaller minimal lumen diameter, reduced
TIMI flow, and more thrombus within the target lesion compared with
stable CAD patients. Results of quantitative coronary angiography
(QCA) at five years showed similar results in terms of reference vessel
diameter, minimal lumen diameter, % diameter stenosis, late lumen
loss and binary restenosis (Table 3).
3.2. OCT data
The quantitative analysis of lumen, stent, neointimal area and %
volume obstruction showed no differences between ACS and stable
CAD patients (Table 4). Neointimal thickness tended to be lower
in ACS compared with stable CAD lesions (77 μm vs. 95 μm, weighted
difference:−0.014 mm, 95% CrI−0.04 mm–0.003 mm, p = 0.10).
Results of strut- and lesion-level OCT analyses stratified according to
clinical presentation are presented in Table 5. A total of 7864 struts in 53
ACS lesions and 5298 struts in stable CAD lesions were analyzed.
3.2.1. Stent strut coverage
Adjusted analyses showed a higher number of uncovered struts in
ACS (1.73%, 95% CrI: 1.03 to 2.74) compared with stable CAD patients
(0.70%, 95% CrI: 0.32 to 1.31, weighted difference: 0.15%, 95% CrI 0.01
to 1.05, adj. p= 0.041). Lesion-based analyses showed a higher propor-
tion of lesions with any uncovered strut (83.9% vs. 52%, adj. p = 0.048)
and ≥10% uncovered struts (5.24% vs. 0.03%, adj. p = 0.018). A two-
dimensional map of stent strut coverage is provided in Fig. 2A. Clusters
Fig. 2. Spectrum of healing response observed at five years after DES implantation is shown in this figure. Panel A depicts a normal vessel healing with a thin neointimal layer, panel B
shows the absence of stent strut coverage and some thrombus formation, panel C presents malapposition, panel D depicts protruding struts, and evaginations are observed on panel E.
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of uncovered struts were documented in 6 (17%) ACS lesions (#14, #18,
#19, #42, #46, #49) and 2 (#1) stable CAD lesions (5.7%, adj. p= 0.24).
3.2.2. Malapposition
Among the ACS lesions, there was a trend towards a higher rate
of malapposed struts (1.33%, 95% CrI 0.72%–2.30 vs. 0.45%, 95 CrI
0.18–1.02, weighted difference: 0.20%, 95% CrI −0.02%–1.81%, adj.
p = 0.072). Neither the mean ISA area (0.55 mm2 vs. 0.50 mm2, adj.
p = 0.80), nor the mean ISA distance (0.27 mm vs. 0.26 mm, adj.
p = 0.72) differed between ACS and stable CAD lesions.
Lesion-level analysis of malapposition showed a trend towards
more lesions with at least one malapposed strut among the ACS
lesions compared with stable CAD lesions (77.7% vs. 39.5%, adj.
p = 0.066), no difference however was found in the proportion of
lesions with at least ≥10% malapposed struts (2.75% vs. 1.80%, adj.
p = 0.89) (Table 5).
Clusters of malapposed or protruding stent struts were found in 15
(28.3%) ACS lesions (#1, #4, #5, #8, #14, #16, #17, #19, #23, #24,
#29, #37, #45, #52) and 4 (#6, #7, #15, #17) non-ACS lesions (11.4%,
adj. p = 0.069) (Fig. 4A). Clusters of uncovered or malapposed/
protruding stent struts were found in 18 (34%) ACS lesions (#1, #4,
#5, #8, #14, #16, #17, #18, #19, #23, #24, #29, #37, #42, #45, #46,
#49, #52) and 5 (#1, #6, #7, #15, #17) non-ACS lesions (14.3%, adj.
p = 0.049).
3.2.3. Protrusion
Protruding struts were more frequent in ACS (0.50%, 95% CrI: 0.25–
0.91) compared with stable CAD lesions (0.13%, 95% CrI: 0.04–0.32;
weighted difference: 0.06%, 95% CrI: 0.001%–0.56%; adj. p = 0.038).
The percentage of lesions with at least one protruding strut was higher
among the ACS lesions (54.3% vs. 13.9%, adj. p = 0.012), whereas the
proportion of lesions with ≥10% protruding struts (0.40% vs. 0.01%;
adj. p = 0.98) was not different.
3.2.4. Coronary evaginations
The number of coronary evaginations tended to be higher in ACS
lesions (0.16 vs. 0.13 per cross sections; adj. p = 0.10) in the absence
of differences in mean area and depth of individual evaginations
(Table 4). While no difference was observed between NSTEMI and sta-
ble patients (0.14 vs. 0.13 per cross section, adj. p = 0.70), a significant
difference was noted between STEMI and stable patients (0.16 vs. 0.13,
adj. p = 0.027) (Table 6, Fig. 6).
3.2.5. Type of ACS
The results of OCT analyses according to ACS type – STEMI and
NSTEMI – are presented in Table 6 and Fig. 6. Uncovered (1.68% vs.
0.76%, weighted difference 0.89 (−0.09–2.25), p = 0.077), protruding
(0.52% vs. 0.14%, weighted difference 0.38 (0.08–0.93), p = 0.012)
and malapposed struts (1.46% vs. 0.48%, weighted difference 0.95
Fig. 3. The concept of the creation of geographic stent strut maps is illustrated. Lesions are presented as areas assuming a cylindrical geometry of the stent. Struts are color coded according
to coverage, apposition, andprotrusion. The x axis represents the length of the stent (mm),whereas the y axis indicates the position of the strut in the individual cross section ranging from
0° to 360°.
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(0.12–2.28), adj. p = 0.022) were more prevalent in STEMI compared
with stable CAD lesions. Similarly, all three characteristics were more
frequent among NSTEMI than stable CAD lesions, although less pro-
nouncedwithout reaching conventional levels of statistical significance.
STEMI lesions had a significantly higher number of coronary evagi-
nations compared with stable CAD lesions (0.16% vs. 0.13%, weighted
difference 0.03%, 95% CrI 0.004%–0.06%, adj. p = 0.027) with a larger
mean evagination area (0.21 mm2 vs. 0.16 mm2, weighted difference
0.06 mm2, 95% CrI 0.01 mm2–0.10 mm2, adj. p = 0.024) and depth
(0.25 mm vs. 0.22 mm, weighted difference 0.03 mm, 95% CrI
0.003 mm–0.07 mm, adj. p = 0.035). Conversely, no significant differ-
ences were observed between NSTEMI and stable CAD lesions.
4. Discussion
This is the first in-vivo OCT study, which compares the arterial
healing response during long-term follow-up between ACS and
stable CAD patients after DES placement with the following princi-
pal findings:
1. Uncovered (adj. p = 0.041, adj. difference 0.15, 95% CI 0.01–1.05)
and protruding struts (adj. p = 0.038, adj. difference 0.06, 95%
CI 0.001–0.56) were more frequent in ACS than stable CAD pa-
tients, with the highest incidence among STEMI patients. Similarly,
there was a trend towards a higher frequency of malapposed
stent struts in ACS lesions (adj. p = 0.072, adj. difference 0.20,
95% CI −0.02–1.81).
2. Clusters of adverse strut characteristics (uncovered, malapposed
or protruding stent struts) are more common among ACS patients
(adj. p = 0.049)
3. Coronary evaginations are most frequently observed in lesions
of STEMI (adj. p = 0.027) compared to stable CAD lesions. No
difference, however, was observed between NSTEMI and stable
CAD patients (adj. p = 0.70).
Fig. 4. Geographical stent strut maps of all 53 ACS (upper panel) and 35 non-ACS lesions (lower) are shown. Each lesion is assigned with a lesion number (e.g. #1–#53 in ACS lesion,
#1–#35 in non-ACS lesions). Lesions are presented as areas assuming a cylindrical geometry of the stent. Struts are color coded according to coverage, apposition and protrusion. Strut
coverage is presented in panel A using a green color for covered struts and red color for uncovered struts. In panel B, strut apposition is presented. Apposed struts are shown in green,
protruding struts in yellow, and malapposed struts in red. The x-axis represents the length of the stent (mm) whereas the y-axis indicates the position of the strut in the individual
cross section ranging from 0 to 360°. Zones of stent overlap are marked with blue lines. The cluster analysis indicates that clusters of uncovered or malapposed/protruding stent struts
were found in 18 (34%) ACS lesions (#1, #4, #5, #8, #14, #16, #17, #18, #19, #23, #24, #29, #37, #42, #45, #46, #49, #52) and 5 (#1, #6, #7, #15, #17) non-ACS lesions (14.3%, adj.
p = 0.049).
5L. Räber et al. / International Journal of Cardiology xxx (2014) xxx–xxx
Please cite this article as: Räber L, et al, Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and
stable coronary artery a..., Int J Cardiol (2014), http://dx.doi.org/10.1016/j.ijcard.2014.02.036
74  Chapter 2.3
Previous investigations of arterial healing in response to stent im-
plantation have largely focused on differences between DES and BMS.
Only few intravascular imaging studies addressed differences in vessel
wall healing between ACS and stable CAD patients. Gonzalo et al. [2]
found a higher rate of incomplete stent apposition and uncovered
stent struts in STEMI compared with stable CAD patients 6 months
after DES implantation. Similarly, Kubo et al. [3] reported a higher rate
of malapposed and uncovered struts among patients with unstable an-
gina at 9 months. None of these studies addressed thequestionwhether
differences in healing persist or continue to accrue over time depending
on lesion type. We observed a higher proportion of uncovered struts
(adj. p = 0.041, adj. difference 0.15, 95% CI 0.01–1.05) and protruding
struts (adj. p = 0.038, adj. difference 0.06, 95% CI 0.001–0.56) and a
trend towards more malapposed struts (adj. p = 0.072, adj. difference
0.20, 95% CI−0.02–1.81) among event-free ACS patients. Differences
were observed both on a strut and lesion level and further substantiated
by two-dimensional analysis of clusters of adverse characteristics.
The latter observation is of importance as a spatial accumulation of
uncovered or malapposed/protruding struts may be clinically more
relevant than isolated stent strut findings. Clusters of uncovered and
malapposed/protruding struts were more common in ACS lesions (adj.
p= 0.049) and require further analysis with respect to recurrent ische-
mic events. To test whether the type of ACS influences the healing
pattern, we stratified our analysis according to STEMI, NSTEMI and sta-
ble CAD and observed a gradient of risk with the highest frequency
of uncovered, malapposed and protruding struts among the STEMI pa-
tients followed by NSTEMI and stable CAD patients (Fig. 6).
The present analysis was not limited to stent strut characteristics
but also incorporated the vessel wall between and behind struts,
namely the assessment of coronary evaginations [7]. Evaginations
were more frequent among STEMI as compared to stable CAD patients
(adj. p = 0.027), notably after adjustment for stent type. Coronary
Fig. 5. Two examples of lesions with clusters according to the definition outlined in the
Methods section are shown. The red line reflects the border within which no single
covered or malapposed/protruding strut can be seen.
Table 1
Baseline clinical characteristics.
ACS No ACS p-Value
Number of patients (n) 53 35
Age N60 years (%) 11 (20.8) 12 (34.3) 0.22
Males (n [%]) 44 (83.0) 26 (74.3) 0.42
Diabetes mellitus (n [%]) 9 (17.0) 28 (80.0) 0.78
Insulin dependent 3 (5.7) 2 (5.7) 1.00
Hypertension (n [%]) 26 (49.1) 25 (71.4) 0.048
Hyperlipidemia (n [%]) 25 (47.2) 25 (71.4) 0.029
Current smoking (n [%]) 25 (47.2) 10 (28.6) 0.12
Previous myocardial infarction (n [%]) 16 (30.2) 9 (25.7) 0.81
Multivessel disease (n [%]) 35 (66.0) 25 (71.4) 0.65
SYNTAX score 14.0 ± 9.0 10.4 ± 5.5 0.64
Lesion per patient
One 43 (81.1) 29 (82.9) 0.65
Two 9 (17.0) 4 (11.4)
Three 1 (1.9) 2 (5.7)
Left ventricular ejection fraction (%), mean (SD) 55.9 (9.9) 60.5 (10.9) 0.04
Stent type
SES 27 (50.9) 14 (40.0) 0.38
PES 26 (49.1) 21 (60.0)
p value based on Fishers' exact test for categorical variables and student t test for
continuous variables
Table 2
Baseline characteristics of lesions undergoing OCT analysis.
ACS No ACS p-Value
Number of lesions 53 35
Target lesion coronary artery (n [%])
Left main 0 (0) 2 (5.7) 0.24
Left anterior descending 25 (47.2) 17 (48.6)
Left circumflex 11 (20.7) 9 (25.7)
Right 17 (32.1) 7 (20.0)
ACC-AHA lesion class (n [%])
A 5 (9.4) 8 (22.9) 0.20
B1 23 (43.4) 14 (40.0)
B2 17 (32.1) 6 (17.1)
C 8 (15.1) 7 (20.0)
Angiographic measurements
Lesion length (mm ± SD) 16.4 (5.9) 16.2 (9.5) 0.93
Reference vessel diameter (mm ± SD) 2.9 (0.4) 2.8 (0.4) 0.73
Minimal lumen diameter (mm ± SD) 0.35 (0.4) 0.59 (0.3) 0.003
Stenosis (% lumen diameter ± SD) 87.9 (12.8) 79.3 (10.8) 0.002
Pre-procedure TIMI flow b .001
Grade 0 21 (39.6) 0 (0)
Grade I 3 (5.7) 0 (0)
Grade II 6 (11.3) 2 (5.7)
Grade III 23 (43.4) 33 (94.3)
Thrombus not present 25 (48.1) 35 (100) b .001
Calcification 17 (32.1) 14 (40.0) 0.50
Procedures
No. of study stents per lesion (n ± SD) 1.2 (0.4) 1.1 (0.4) 0.76
Stent diameter (mm ± SD) 3.0 (0.4) 2.9 (0.4) 0.37
Total stent length per lesion (mm ± SD) 19.6 (7.6) 19.3 (9.4) 0.88
Maximal pressure (atm ± SD) 15.3 (3.5) 14.1 (3.1) 0.10
Direct stenting (n ± SD) 0.26 (0.4) 0.26 (0.4) 0.94
Angiographic results
Reference vessel diameter (mm ± SD) 2.9 (0.4) 2.8 (0.5) 0.23
Final minimal lumen diameter (mm ± SD)
In-stent 2.7 (0.4) 2.7 (0.4) 0.42
In-segment 2.7 (0.4) 2.6 (0.5) 0.47
Final stenosis (% of lumen diameter ± SD)
In-stent 6.9 (4.8) 5.9 (4.1) 0.32
In-segment 8.4 (6.9) 7.5 (6.5) 0.63
Acute gain (mm ± SD)
In-stent 2.4 (0.5) 2.1 (0.5) 0.004
In-segment 2.4 (0.5) 2.1 (0.6) 0.031
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evaginations refer to an outward bulging of the vessel wall between
stent struts and are a phenomenon, which has been described system-
atically for the first time in the SIRTAX LATE OCT study [8]. In a
large pooled database, we observed a higher frequency of evaginations
in early generation DES (with preference of SES over PES) as compared
to newer generation DES. In a serial imaging substudy using OCT
and IVUS, intra-stent dissections, protrusion, and thrombus were iden-
tified as a potential cause of evaginations [9]. Both protrusion and
thrombus have been shown to be more frequent in STEMI patients
[10], explaining our findings of a higher frequency of evaginations in
STEMI compared with stable angina patients. Similar to uncovered
and malapposed stent struts, the clinical relevance of evaginations has
not been determined in a prospective study. However, lesions with
very late stent thrombosis share morphological features observed in
lesions with evaginations [11,12], suggesting a potential link between
the two entities.
ACS lesions substantially differ from those of stable CAD in terms
of the underlying tissue composition. While plaques underlying ACS
are frequently characterized by large lipid pools with necrotic cores
and thrombus, stable CAD lesions often consist of fibrous or calcific tis-
sue [13]. Although it remains unknown how and to which degree the
underlying plaque morphology affects arterial healing after DES place-
ment, several hypotheses have been put forward. Limus derivatives
and paclitaxel are lipophilic drugs with high affinity for lipid-rich/
necrotic core plaques, residing for extended periods of time compared
with fibrous tissue, which is more frequent in stable CAD lesions [14].
Similarly, an increased thrombus load may reduce systemic washout
and preserve drug in the arterial wall [15]. Both observationsmay result
in higher drug content and may influence healing by slowing smooth
muscle cell proliferation and endothelial regrowth, thus preventing
endothelial coverage of stent struts. In addition, necrotic cores are
avascular compared to fibrous tissue of stable CAD plaques with a
lower density of smooth muscle and endothelial cells. In-vivo studies
correlating tissue composition with the arterial healing response are
relatively scarce. Recently, Hong and coworkers found the extent of ne-
crotic core to be related to late acquired malapposition at one year [16].
Likewise, intravascular ultrasound studies of patients undergoing treat-
ment for STEMI found late acquired vessel wall malapposition to be
more common in DES treated attenuated than non-attenuated plaques
[17]. Both studies suggest that the presence of necrotic core is associated
with an adverse healing pattern. Also thrombus is more prevalent in
ACS lesions. Thrombus may undergo maturation or is being dissolved/
embolized. The latter has been suspected to result in late acquired
malapposition. However, to date, no single serial intravascular imaging
study has proven a solid association between thrombus and the occur-
rence of late acquired malapposition [18,19].
Table 3
Angiographic follow-up results at five years of lesions undergoing OCT analysis.
ACS No ACS Difference (95% CI) p-Value
Number of lesions 53 35
Reference vessel diameter (mm ± SD) 2.90 (0.57) 2.75 (0.61) 0.15 (−0.02 to 0.32) 0.09
Minimal lumen diameter (mm ± SD)
In-stent 2.48 (0.72) 2.33 (0.77) 0.15 (−0.07 to 0.37) 0.19
In-segment 2.39 (0.73) 2.22 (0.78) 0.17 (−0.05 to 0.39) 0.13
% diameter stenosis
In-stent 15.02 (17.56) 15.65 (18.80) −0.63 (−6.00 to 4.75) 0.82
In-segment 17.73 (18.25) 19.24 (19.54) −1.50 (−7.09 to 4.08) 0.6
Late loss (mm ± SD)
In-stent 0.27 (0.44) 0.30 (0.47) −0.03 (−0.16 to 0.10) 0.66
In-segment 0.25 (0.40) 0.31 (0.43) −0.07 (−0.19 to 0.06) 0.28
Binary restenosis (n [%])
In-stent 2.00 (3.77) 2.00 (5.71) −1.94 (−19.19 to 15.30) 0.83
In-segment 3.00 (5.66) 2.00 (5.71) −0.05 (−9.85 to 9.74) 0.99
Row percent (%) values are predicted probabilities derived frommixed maximum logistic regression models. Mean and standard deviation (SD) are predicted values derived frommixed
maximum likelihood regressionmodels. Mixedmaximum likelihood regressionmodels were used for continuous andmixedmaximum logistic regressionmodels for binary outcomes to
derive the differences between females and males. p-Values relate to the difference between two stent types.
Table 4
Results of OCT analysis— continuous outcomes.
ACS (95% CI) No ACS (95% CI) Crude difference (95% CI) p-Value Adj. difference (95% CI) p-Value
Analysis at lesion level
Number of lesions analyzed 53 35
Cross sections analyzed per lesion 17.1 (15.5–18.8) 16.5 (14.7–18.6) 0.52 (−2.11–3.15) 0.68 0.20 (−1.97–2.66) 0.87
Struts analyzed per lesion 136.7 (121.1–154.2) 137.2 (118.0–161.7) −0.70 (28.7–25.4) 0.96 −1.99 (−30.7–27.0) 0.89
Minimal luminal area (mm2) 6.21 (5.57–6.91) 5.26 (4.63–6.00) 0.94 (0.002–1.89) 0.049 0.52 (−0.14–1.36) 0.12
Minimal stent area (mm2) 7.08 (6.47–7.75) 6.29 (5.62–7.01) 0.80 (−0.16–1.74) 0.10 0.43 (−0.22–1.19) 0.19
Percent volume obstruction (%) 7.50 (5.02–12.5) 8.47 (5.05–16.8) −0.95 (−9.43–5.01) 0.75 −0.77 (−66.4–47.8) 0.75
Analysis at cross section level
Number of cross section analyzed 955 620
Number of struts per cross section 7.51 (7.10–7.94) 7.76 (7.24–8.32) −0.25 (−0.96–0.44) 0.46 −0.19 (−1.06–0.70) 0.65
Luminal area (mm2) 6.34 (5.76–6.97) 5.35 (4.76–6.05) 0.99 (0.07–1.84) 0.031 0.50 (−0.04–1.20) 0.07
Stent area (mm2) 7.18 (6.60–7.77) 6.47 (5.89–7.21) 0.72 (−0.31–1.49) 0.14 0.40 (−0.17–1.12) 0.18
Neointimal thickness (mm) 0.077 (0.069–0.087) 0.095 (0.082–0.109) −0.018 (−0.034–0.002) 0.029 −0.014 (−0.04–0.003) 0.10
Neointimal area (mm2) 0.82 (0.73–0.91) 0.91 (0.80–1.05) −0.10 (−0.25–0.07) 0.23 −0.07 (−0.23–0.09) 0.38
Mean area ISA (mm2) 0.55 (0.42–0.71) 0.50 (0.33–0.75) 0.05 (−0.23–0.28) 0.71 0.03 (−0.32–0.48) 0.80
Mean malapposition distance (mm) 0.27 (0.24–0.30) 0.26 (0.22–0.31) 0.004 (−0.05–0.06) 0.88 0.014 (−0.06–0.10) 0.72
Number of evaginations 0.16 (0.14–0.17) 0.13 (0.11–0.15) 0.02 (−0.01–0.05) 0.063 0.02 (−0.004–0.053) 0.10
Mean evagination area (mm2) 0.20 (0.17–0.23) 0.16 (0.3–0.20) 0.04 (−0.003–0.08) 0.07 0.02 (−0.01–0.06) 0.19
Mean evagination depth (mm) 0.25 (0.23–0.27) 0.22 (0.20–0.25) 0.03 (−0.001–0.06) 0.06 0.02 (−0.01–0.05) 0.17
Presented are means or percentages with 95% confidence intervals or 95% credible intervals. Adjusted for stent type, hypertension, hyperlipidemia, LVEF, and maximal pressure.
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Observational studies identified ACS as an independent predictor
for the occurrence of stent thrombosis for up to 4 years [20,21]. Rates
of definite or probable very late ST (between years 1 and 3) were 50%
higher in the STEMI population of HORIZONS-AMI [22] compared with
stable CAD in the SPIRIT II/III pooled analysis treated with PES [23].
While a higher thrombus load [24] may explain early differences in
clinical outcomes, differences in long-term clinical events are not fully
understood. Interestingly, our findings in ACS lesions were identified
as pathological substrate underlying cases of late ST, offering a potential
explanation for the increased rate of ST during long-term follow-up [1].
Despite the lack of a prospective evaluation of the impact of uncovered
andmalapposed/protruding struts on stent thrombosis, Guagliumi et al.
[5] observed in a case control study using OCT that patients suffering
late ST had a higher proportion of uncovered and malapposed stent
struts as compared to control patients.
5. Limitations
Results need to be carefully interpreted in light of several limita-
tions. First, this is a post-hoc subanalysis of an OCT study designed to
evaluate long-term healing differences between a sirolimus-eluting
and a paclitaxel-eluting stent, thus the presented results can only be
considered as hypothesis generating. Second, the absence of a post-
procedural baseline OCT imaging prevents the differentiation between
persistent and late acquired malapposition. As a consequence, we
cannot precisely determine whether malapposition at follow-up is
caused by inadequate stent expansion or due to differences of the
underlying plaque, therefore relating to true healing differences. Of
note, Gutierrez-Chico et al. [25] have previously demonstrated that
malapposed struts with a distance of less than 270 μm undergo healing
in 100% of cases. We measured a median malapposition distance of
Table 6
Stratification according to STEMI, NSTEMI/unstable angina and stable CAD.
STEMI (95% CI) NSTEMI (95% CI) Stable (95% CI) Diff. (95% CI)
STEMI vs. stable
p-Value Diff. (95% CI)
NSTEMI vs. stable
p-Value p-Trend
Results of OCT analysis— counts
Analysis at strut level
Total number of struts analyzed 4784 3102 5298
Uncovered struts (%) 1.68 (0.91–2.97) 1.48 (0.57–3.45) 0.76 (0.37–1.45) 0.89 (−0.09–2.25) 0.077 0.69 (−0.37–2.69) 0.23 0.18
Protruding struts (%) 0.52 (0.23–1.08) 0.41 (0.12–1.18) 0.14 (0.04–0.31) 0.38 (0.08–0.93) 0.012 0.26 (−0.05–1.04) 0.12 0.07
Malapposed struts (%) 1.46 (0.70–2.78) 0.91 (0.28–2.55) 0.48 (0.22–1.02) 0.95 (0.12–2.28) 0.022 0.41 (−0.39–2.08) 0.33 0.17
Analysis at lesion level
Uncovered struts, lesions with
Any uncovered struts 86.9 (68.1–96.6) 77.2 (42.1–95.5) 54.1 (29.7–77.5) 31.6 (4.49–60.1) 0.023 21.9 (−18.2–55.1) 0.26 0.11
Protruding struts, lesions with
Any protruding struts 54.1 (29.8–77.3) 49.7 (17.2–82.6) 16.3 (4.91–36.2) 36.7 (7.50–65.1) 0.014 32.0 (−3.44–69.4) 0.08 0.03
Malapposed struts, lesions with
Any malapposed struts 87.1 (68.4–96.6) 59.6 (23.9–88.3) 37.8 (16.4–62.3) 48.1 (18.8–74.2) 0.001 20.9 (−20.7–59.5) 0.33 0.09
Results of OCT analysis— continuous outcomes
Analysis at cross section level
Number of evaginations 0.16 (0.14–0.19) 0.14 (0.11–0.17) 0.13 (0.11–0.15) 0.03 (0.004–0.06) 0.027 0.01 (−0.03–0.04) 0.70 0.35
Mean evagination area (mm2) 0.21 (0.18–0.25) 0.17 (0.13–0.22) 0.16 (0.13–0.20) 0.06 (0.01–0.10) 0.024 0.01 (−0.04–0.06) 0.75 0.44
Mean evagination depth (mm) 0.25 (0.23–0.28) 0.24 (0.21–0.28) 0.22 (0.20–0.24) 0.03 (0.003–0.07) 0.035 0.02 (−0.2–0.06) 0.26 0.17
Table 5
Results of OCT analysis— counts.
ACS (95% CI) No ACS (95% CI) Crude difference (95% CI) p-Value Adj. difference (95% CI) p-Value
Analysis at strut level
Total number of struts analyzed 7864 5298
Uncovered struts (%) 1.73 (1.03–2.74) 0.70 (0.32–1.31) 1.01 (0.16–2.07) 0.020 0.15 (0.01–1.05) 0.041
Protruding struts (%) 0.50 (0.25–0.91) 0.13 (0.04–0.32) 0.36 (0.09–0.77) 0.011 0.06 (0.001–0.56) 0.038
Malapposed struts (%) 1.33 (0.72–2.30) 0.45 (0.18–1.02) 0.85 (0.06–1.86) 0.035 0.20 (−0.02–1.81) 0.072
Analysis at lesion level
Uncovered struts, lesions with
Any uncovered struts 83.9 (67.7–94.3) 52.0 (28.4–75.5) 30.9 (4.89–58.6) 0.019 20.4 (0.06–59.7) 0.048
At least 10% uncovered struts 5.24 (1.08–15.6) 0.03 (0.0002–1.97) 5.02 (0.87–15.3) 0.006 0.99 (0.001–82.5) 0.018
Protruding struts, lesions with
Any protruding struts 54.3 (34.1–73.7) 13.9 (3.71–32.8) 39.3 (13.6–63.8) 0.004 4.01 (0.04–48.6) 0.0196
At least 10% protruding struts 0.40 (0.01–3.75) 0.01 (0.0001–1.65) 0.31 (−0.92–3.56) 0.27 −0.16 (−31.3–60.3) 0.98
Malapposed struts, lesions with
Any malapposed struts 77.7 (59.8–91.0) 39.5 (17.5–64.4) 37.3 (8.01–65.6) 0.012 20.3 (0.96–58.5) 0.066
At least 10% malapposed struts 2.75 (0.43–10.7) 1.80 (0.15–9.89) 0.75 (−5.88–7.71) 0.70 −0.003 (−3.96–3.42) 0.89
Presented are means or percentages with 95% confidence intervals or 95% credible intervals. Adjusted for stent type, hypertension, hyperlipidemia, LVEF, and maximal pressure.
Fig. 6. Frequency of adverse stent strut characteristics and evaginations as assessed
5 years after DES implantation and stratified according to the clinical presentation is
presented in this bar graph.
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270 μm, suggesting that a certain proportion of malapposed struts
were indeed late acquired and reflect differences in healing pattern ac-
cording to clinical presentation. Third, patients undergoing follow-up
imaging at five years were free of any study lesion related events and
thus present a highly selected subcohort of patients at a relatively
low risk for adverse events, explaining why the absolute difference in
numbers between groups was relatively low. Along the same line, rel-
atively low neointimal thickness values were measured, which is a di-
rect consequence of the exclusion of all patients who underwent target
lesion revascularization within 5 years.
The present results are based on findings with early generation
drug-eluting stents. Whether they are applicable to newer generation
DES remains unclear and needs further investigation.
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Neoatherosclerosis as reason for stent failures beyond 5 years after
drug-eluting stent implantation
Masanori Taniwaki, StephanWindecker, and Lorenz Ra¨ber*
Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern 3010, Switzerland
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A 69-year-oldmale (case 1)was admitted due to acute non-
ST-segmentelevationmyocardial infarction(NSTEMI).Eight
years earlier, he had previously undergone treatmentwith a
sirolimus-eluting stent (SES). Four years after stent implant-
ation, a follow-up angiography was obtained showing a
patent stent without obstructive in-stent restenosis (Panel
A).Angiogramsobtainedat the timeofNSTEMI (PanelB)dis-
closed subtotal occlusion in the middle of the SES (arrow-
heads). Optical coherence tomography revealed a signal
intense luminal layer with an underlying, highly attenuating,
diffusely demarcated area, suggestive for an instent
fibroatheroma (Panel D) with a minimal cap thickness of
80 mm. Accordingly, ischaemia was caused by the high
degree of stenosis (Panel E). Similarly, a 59-year-old male
(case 2) was admitted due to STEMI. Nine years before, he
had received a paclitaxel-eluting stent (PES). Five years
after stent implantation, a follow-upangiographyrevealedapatent stent (Panel F).Angiogramsobtainedat the timeofSTEMI (PanelG)disclosed
total occlusion in the proximal of PES (arrowheads). Optical coherence tomography showed a rupture of thin cap fibroatheromawithin the
stented segment (Panel I). The thin cap fibroatheroma caused a severe stenosis with superimposed thrombus (Panel J).
Neoatherosclerosishasbeen recently describedasparticulardiseaseentitybeing responsible for very late stent failures.These twocases
illustrate that the presence of a favourable long-term angiographic result years after DES implantation does not exclude a future
neoatherosclerosis-related event (restenosis or stent thrombosis). Large observational and long-term intracoronary imaging studies
are required to fully elucidate the dynamics and clinical relevance of neoatherosclerosis.
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ABSTrAcT
Background: The mechanisms underlying in-stent neoatherosclerosis (NA) are poorly 
understood. The purpose of the present study was to investigate the relationship be-
tween in-stent NA and native atherosclerosis progression of untreated coronary seg-
ments.
methods and results: In-stent NA was assessed by OCT among patients included in 
the SIRTAX-LATE OCT study five years after DES (sirolimus-eluting and paclitaxel-eluting 
stents) implantation. NA was defined as the presence of fibroatheroma or fibrocalcific 
plaques within the neointima of stented segments with a longitudinal extension >1.0 
mm. Atherosclerosis progression in untreated native coronary segments was evalu-
ated by serial quantitative coronary angiography (QCA). The change in minimal lumen 
diameter (MLD) was serially assessed within matched segments at baseline and five-
year angiographic follow-up. The key clinical endpoint was non-target lesion (non-TL) 
revascularization throughout 5 years. A total of 88 patients with 88 lesions were avail-
able for OCT analysis five years after DES implantation. In-stent NA was observed in 
16% of lesions with the majority of plaques being fibroatheromas (11.4%) followed by 
fibrocalcific plaques (5.7%). A total of 704 non-TL segments were serially evaluated by 
QCA. Between baseline and five-year follow-up, the reduction in MLD was significantly 
more pronounced in patients with NA (-0.25mm, 95%-CI -0.36 to -0.17mm) as compared 
to patients without NA (-0.13mm, 95%-CI -0.17 to -0.10mm, p=0.002). Similarly, non-
TL revascularization was more frequent in patients with NA (78.6%) as compared with 
patients without NA (44.6%, p=0.006) throughout five years. 
conclusions: In-stent neoatherosclerosis is more common among patients with angio-
graphic and clinical evidence of native atherosclerosis progression suggesting similar 
pathophysiological mechanisms. 
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ABBrEViATioNS AND AcroNymS
ARC = Academic Research Consortium
CI = Confidence interval
DES = Drug-eluting stent
MI = Myocardial infarction
NA = Neoatherosclerosis 
PES = Paclitaxel eluting stents
SES = Sirolimus-eluting stents
ST = Stent thrombosis
TLR = Target lesion revascularization
KEyworD
Keywords: drug-eluting stent, DES, Sirolimus-eluting stent, SES, Paclitaxel-eluting stent, 
PES, neoatherosclerosis, target lesion revascularization, long-term outcomes
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iNTroDucTioN
Drug-eluting stents (DES) reduce the risk of repeat revascularization compared with bare 
metal stents, but late stent failure may still occur due to restenosis or stent thrombosis 
.1 In-stent neoatherosclerosis (NA) - a novel disease entity- is characterized by the devel-
opment of atherosclerotic changes in the nascent neointimal tissue within previously 
implanted stents. Although there is no large scale prospective study assessing the im-
pact of NA on late stent failure and associated clinical outcomes, NA has been identified 
as the culprit for delayed instent-restenosis or stent thrombosis in various intracoronary 
imaging studies and case reports. 2-4 Accordingly, NA may represent an accelerated and 
possibly more unstable manifestation of atherosclerosis.2,5 While histological analyses 
were performed for the documentation of NA in human ex-vivo pathology studies, opti-
cal coherence tomography (OCT) is able to accurately characterize the in-vivo vascular 
response after stent implantation including the development of in-stent NA.2, 4
Despite the potential clinical impact of NA during the long-term course following DES 
implantation, little is known about the pathophysiological mechanisms underlying the 
development of NA. Based on histological similarities between NA and native athero-
sclerosis, we hypothesized that patients with progression of atherosclerosis in native 
coronary segments would be at increased risk for the development of NA within stented 
segments. 5 We therefore investigated the type and frequency of in-stent NA as assessed 
by OCT and native atherosclerosis progression in the entire untreated coronary artery 
tree assessed by quantitative coronary angiography (QCA) among patients included in 
the SIRTAX-LATE OCT cohort study five years after DES implantation. 6
mETHoDS
Patient population
The design and results of the SIRTAX and SIRTAX LATE study (Sirolimus-Eluting Stent 
Compared With Paclitaxel-Eluting Stent for Coronary Revascularization) have been 
previously reported. 7 8 For the purpose of the present study, we analyzed all patients 
included in the SIRTAX LATE OCT study. Among 145 patients who underwent angio-
graphic follow-up five years after DES implantation between December 2008 and July 
2009, 88 patients with 88 lesions were included in the OCT study. 6 The study complied 
with the Declaration of Helsinki regarding investigation in humans and was approved by 
the institutional ethics committees at Bern University Hospital, Switzerland. All patients 
provided written informed consent. 
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ocT imaging and analysis 
OCT was performed with a time domain M2 system (Lightlab Imaging, Westford, Mas-
sachusetts) using a pullback speed of 2mm/s and the non-occlusive flushing technique. 
After the diagnostic angiography and administration of 5,000 IU unfractionated heparin, 
the ImageWire (Lightlab Imaging) was carefully advanced distal to the study lesion. Fol-
lowing administration of 200 µg of intracoronary nitroglycerin, the target vessel was 
flushed via the guiding catheter with nonionic, isosmolar contrast liquid (Iodixanol 320, 
Visipaque, GE Healthcare, Cork, Ireland) using a power injector with flush rates between 
3 and 4 ml/s. OCT pullbacks were assessed offline using a proprietary software (Lightlab 
Imaging). Stented segments were analyzed for strut coverage, apposition, and protru-
sion at frames with 1-mm intervals by two independent analysts blinded (LR, SB) for 
stent type. For in-stent NA assessment, frames were analyzed at 0.125-mm intervals by 
two independent investigators (LR, MT). In case of disagreement a third referee was con-
sulted and final decision was based on consensus. Pullbacks were excluded in case >30% 
of the total stent length was not analyzable. Frames were considered not analyzable 
when more than one-quarter of the circumference was not visible due to insufficient 
flush or out of zoom. Definitions used for stent strut analyses (coverage, malapposition, 
protrusion) were previously reported. 6
Neointima was defined as the tissue between the luminal border and the inner border 
of the struts. NA lesion was defined as the presence of a fibroatheroma or fibrocalcific 
plaques within the neointima of a stented segment with a longitudinal extension of 
≥1mm. A gap of at least 0.5 mm was used to define the boundary between two NA 
lesions.
Fibroatheromas (FA) were characterized as a signal-poor region displaying a high at-
tenuation (to differentiate from layered neointima) with diffuse borders with an angle 
over 90 degree. Thin-cap fibroatheroma (TCFA) were defined as FA with a fibrous cap 
≤65 µm and thick cap fibroatheroma (ThCFA) with a fibrous cap >65 µm. Fibrocalcific 
plaques were defined as signal-poor region with low backscatter and clear borderlines 
extending with an angel over 90 degrees. Whenever the calcific pool extended into the 
region behind the stent, we disregarded the presence of neoatherosclerosis.
Additional characteristics which potentially reflect neoatherosclerotic changes 
were investigated. Signal rich bands were defined as lines or dots with strong signal 
attenuation producing a shadow with a sharply delineated lateral border. Microvessels 
were defined as a small vesicular or tubular structure with a diameter of 50 to 300 µm 
without a connection to a side branch. Intimal tear was defined as the discontinuity in 
true luminal surface without cavity regardless of the presence of a plaque. Intraluminal 
thrombus was defined as an irregular mass discontinuous from the surface of the vessel 
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wall and with a dimension over 250 µm. Erosion was defined as intraluminal irregular 
mass connected to the luminal surface and without evidence of cap rupture evaluated 
in multiple adjacent frames. A signal poor region surrounding stent struts without sig-
nificant signal attenuation and with a lateral extension over 90 degree was defined as 
peri-strut low intensity. Layered appearance of the neointima was not considered to be 
neoatherosclerosis. To determine the reproducibility of neoatherosclerosis, 20 random 
OCT pullbacks were chosen and repeatedly analyzed to calculate intra-observer and 
inter-observer reproducibility. 
qcA analysis
After administration of intracoronary nitroglycerin (100 to 300 µg), standard biplane 
angiographic images were obtained so that each coronary segment was recorded in at 
least two orthogonal views. All angiographies were analyzed by the angiographic core 
laboratory at Bern University Hospital. Assessors were blinded to the OCT analysis and 
clinical outcomes. Methods for the serial assessment of the target lesions (stent) were 
previously reported. 8 All three major epicardial vessels including all side branches with a 
RVD of >1.5 mm in diameter (with the exception of the treated vessel segment) were as-
sessed by QCA at baseline and at follow-up using similar projections whenever possible. 
For this purpose, segments were divided in subsegments according to the modified 
American College of Cardiology/American Heart Association (AHA/ACC) classification 
using the Quantitative Coronary Angiogram- CMS software version 7.3 (Medis Medical 
Imaging Systems, Leiden, the Netherlands) (Figure 1). 9, 10 Minimal lumen diameter 
(MLD), reference vessel diameter, segment length, and diameter stenosis ([1 – minimal 
luminal diameter/reference vessel diameter] x 100) were assessed. In case a segment 
was revascularized prior to the five year follow-up examination, the latest available 
angiography prior to revascularization was used for analysis. The change of all variables 
was derived for each segment as outcome (follow-up) – outcome (baseline), except 
the change in MLD was defined as MLD (baseline) – MLD (follow-up). The angiographic 
endpoint of interest was mean change in MLD. (Figure 1) 
clinical follow-up 
An independent clinical events committee adjudicated all data on case-report forms. On 
the basis of follow-up angiography, major adverse cardiovascular events were further 
classified into occurring at initially treated sites (target lesion segments) or at previously 
untreated native coronary segments (non-target lesion segments). 
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All adverse events of target and non-target lesion segments were assessed in hospital, 
at 1, 6, and 9 months, and on an annual basis up to 5 years. All patients were advised 
to take acetylsalicylic acid indefinitely and clopidogrel for 1 year after the procedure. 
Medication status and lipid profiles were also obtained on an annual basis up to 5 
years. The definition of cardiac death included any death due to immediate cardiac 
cause, procedure-related deaths, unwitnessed death, and death of unknown cause. The 
diagnosis of MI was based on an elevation in creatine kinase (CK) to more than twice 
Figure 1. Serial qcA analysis. This figure shows the serial QCA analysis within matched regions of all 
untreated coronary artery segments at baseline (Panel A and B) and at 5 year follow-up (Panel C and D). 
Untreated coronary artery segments were classified according to the modified AHA/ACC classification. The 
treated lesion is shown in the proximal LAD.
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the upper limit of normal (ULN) and an elevation of CK-MB to more than three times 
ULN in the presence of ischemic symptoms or ischemic ECG changes. Target vessel 
revascularization (TVR) was defined as any repeat percutaneous intervention or surgical 
bypass of any segment within the entire major coronary vessel proximal and distal to 
the target lesion, including upstream and downstream branches and the target lesion 
itself. Target lesion revascularization (TLR) was defined as a repeated revascularization 
due to a stenosis within the stent or within the 5mm borders proximal or distal to the 
stent. Any revascularization included all TLR, all target vessel revascularization, and any 
non-target vessel revascularization. Non-target lesion revascularization was defined as 
any revascularization except for TLR and non-previous stented segments. The clinical 
endpoint of this study was the occurrence of any non-target lesion revascularization 
within the five year angiographic follow-up window. To further investigate the clinical 
impact of neoatherosclerotic findings, we extended the clinical follow-up to 9 years 
from index procedure. 
Statistical Analysis
Comparison of baseline characteristics, medication, lipid profiles, and stents were 
performed with Wilcoxon rank-sum or Fisher’s exact tests. Stratification: Patients were 
stratified in two groups according to the presence of at least one NA plaque detected 
by OCT at five year follow-up in the target lesion (Based on criterion that a NA plaque is 
>= 1.0 mm). ocT: Frame-level OCT outcomes were analyzed with linear mixed models 
with patient as random intercept and lesion-level OCT outcomes with linear models. 
qcA: QCA outcomes were recorded for several segments per patient at baseline and at 
angiographic follow-up. The absolute change from baseline to follow-up was computed 
for each segment. Patient-level outcomes and their changes were then derived by taking 
the arithmetic mean over several segment. To compare the strata, medians taken over 
the patients are reported with 95%-confidence intervals from non-parametric bootstrap 
with p-values from Wilcoxon rank sum tests. As sensitivity analyses, the same was per-
formed with (1) only 47 PES-implanted patients and (2) patients were stratified based on 
the criterion that a NA plaque is >= 1.5 mm (Appendix). clinical events: The incidence 
of revascularization events up to and including the five year angiographic follow-up was 
compared between the strata. Analyses were based on the first event per patient. Crude 
percentages are reported, hazard ratios and p-values are from Cox proportional hazard 
models. Statistical analyses were done with the computing environment R (The R Foun-
dation for Statistical Computing17) and with Stata (StataCorp, College Station, Texas).
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rESulTS
Frequency, type, and distribution of neoatherosclerosis
NA formation was observed in 14 (15.9%) of 88 lesions with the majority of plaques ful-
filling the diagnostic criteria of fibroatheromas (11.4%) and less frequently fibrocalcific 
plaques (5.7%) (Table 1, Figure 2). Multiple NA lesions in the same stent were observed 
in 4 lesions (4.5%). The qualitative assessment of in-stent NA findings (frame level analy-
sis of the presence or absence of NA) was highly reproducible. The intra-observer and 
inter-observer reproducibility (R2) were 0.886 and 0.857, respectively. Only in one patient 
the criteria of a FA were observed in the absence of a longitudinal extension fulfilling 
Table 1. Neoatherosclerosis related findings of lesions undergoing ocT analysis. 
overall
(N=88)
SES
(N=41)
PES
(N=47)
P-value
Plaque type
Neoatherosclerosis (lesions with at least one plaque) 14 (15.9) 2 (4.9) 12 (25.5) 0.009
Fibrocalcific plaque 5 (5.7) 0 (0) 5 (10.6) 0.058
Fibroatheroma 10 (11.4) 2 (4.9) 8 (17.0) 0.10
Thick cap FA 8 (9.1) 1 (2.4) 7 (14.9) 0.06
Thin cap CFA 3 (4.3) 1 (2.4) 2 (4.3) 1.00
Incidence of multiple fibrocalcific plaques 1 (1.1) 0 (0) 1 (2.1) 1.00
Incidence of multiple thick cap FA 1 (1.1) 0 (0) 1 (2.1) 1.00
Incidence of multiple thin cap FA 0 (0) 0 (0) 0 (0)
Multiple neoatherosclerotic plaque 4 (4.5) 0 (0) 4 (8.5) 0.12
Non-plaque related neoatherosclerotic findings 
Signal rich band 28 (31.8) 6 (14.6) 22 (46.8) 0.001
Microvessels 2 (2.3) 0 (0) 2 (4.3) 0.50
Intimal tear 1 (1.1) 0 (0) 1 (2.1) 1.00
Intraluminal thrombus 10 (11.4) 4 (9.8) 6 (12.8) 0.75
Erosion 3 (3.4) 3 (7.3) 0 (0) 0.10
Plaque rupture 0 (0) 0(0) 0(0)
other findings
Peri-strut signal poor layer 15 (17.1) 2 (4.9) 13 (27.7) 0.005
Lesions with any potentiall NA findings 36 (40.9) 10 (24.4) 26 (55.3) 0.005
Values are the number of patients (%), one stented lesion per patient underwent OCT analysis.  P-values 
from Fisher’s exact test. Plaque defined as at least 8 consecutive frames (>= 1mm) with fibrocalcific, thick or 
thin cap fibroatheroma. Non-plaque findings  defined as at least 3 consecutive frames with the same find-
ing.  FA, fibroatheroma; OCT, optical coherence tomography; SES, sirolimus-eluting stent; PES, paclitaxel-
eluting stent.
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the criteria of a NA lesion (≥1mm). The most frequently observed findings potentially 
related to NA were signal rich bands, which were observed in 31.8% of stents. Other find-
ings potentially related to NA were infrequent (microvessels:2.3%, surface erosion:3.4%). 
NA was more common among lesions treated with PES (25.5%) compared with SES 
(4.9%; p=0.009) and differences between stent types applied to both the frequency of 
fibrocalcific plaques (SES 0% vs. PES 10.6%, p=0.058) as well as fibroatheromas (SES 4.9% 
vs. PES 17.0%, p=0.10). Similarly, signal rich bands were more frequent among lesions 
treated with PES than SES (46.8% vs. 14.6%, p=0.001).
Baseline characteristics of patients with and without NA
Baseline clinical, angiographic and procedural characteristics of patients with and with-
out NA are summarized in Table 2. No significant differences were recorded in terms of 
age, cardiovascular risk factors, clinical presentation and angiographic findings with the 
exception of type of implanted stent as mentioned above. We assessed the adherence 
to cardiovascular medications including acetylsalicylic acid, betablocker, angiotensin 
converting enzyme (ACE) inhibitor/angiotensin receptor (AR) blocker, statin, or their 
combination throughout five years. There was no difference in the intake of any of these 
medications (or combinations of 1,2 or 3 medications) between patients with compared 
to those without NA throughout five years (Table 3). In addition, no difference in lipid 
levels at baseline or at five years was noted and no difference in the reduction of low-
density lipoprotein-cholesterol (LDL-C) over 5 years (NA: -25.9 vs. no-NA: -9.1 mg/dL, 
Figure 2. longitudinal NA lesion map. 
The stented vessel regions are represented by black lines with indication of the location of NA laque types 
(coloured) and non-analyzable frames (gray). The longitudinal resolution is 0.125 mm. Stents with NA 
plaques (i.e. ≥ 1 mm longitudinal extension) are shown in the upper part of the figure and stents without in 
the lower part. Stents are stratified according to SES and PES.
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p=0.62) or change in high-density lipoprotein-cholesterol (HDL-C) over five years (NA 
-1.4 vs. no-NA -2.6 mg/dL, p=0.85) was observed. 
Table 2 Baseline clinical, procedural, stented-lesion, and angiographic characteristics
Patients with 
neoatherosclerosis
(N=14)
Patients without 
neoatherosclerosis 
(N=74)
P-value
Age (years) 56 (49.0 to 71.5) 60 (53.0 to 64.0) 0.89
Male 10 (71.4) 60 (81.1) 0.47
BMI, kg/m2 27.4 (24.9 to 28.9) 27.8 (24.7 to 30.8) 0.75
Cardiac risk factors
Diabetes mellitus 3 (23.1) 13 (18.8) 0.71
Hyperlipidemia 8 (61.5) 42 (60.9) 0.47
Hypertension 10 (76.9) 41 (59.4) 0.35
Current smoker 6 (46.2) 29 (42.0) 1.00
Previous PCI  4 (28.6) 15 (20.3) 0.49
Previous MI 3 (21.4) 22 (29.7) 0.75
Left ventricular ejection fraction (%) 62.5 (52.5 to 65.0) 60 (50.0 to 65.0) 0.97
Clinical presentation
Stable CAD 6 (42.9) 30 (40.5) 1.00
Acute coronary syndrome 8 (57.1) 44 (59.5) 1.00
Unstable angina 0 5 (6.7) 1.00
NSTEMI 6 (42.9) 14 (18.9) 0.08
STEMI 2 (14.3) 25 (33.8) 0.21
Target lesion coronary artery
LAD 7 (50.0) 35 (47.3) 1.00
LCX 3 (21.4) 17 (23.0) 1.00
LMCA 0 (0.0) 2 (2.7) 1.00
RCA 4 (28.6) 20 (27.0) 1.00
Pre-procedure angiographic 
measurements
MLD (mm) 0.35 (0.09 to 0.54) 0.41 (0.16 to 0.76) 0.61
RVD (mm) 2.91 (2.48 to 3.00) 2.86 (2.54 to 3.14) 0.78
Diameter stenosis (%) 86.5 (82.0 to 96.8) 86.0 (75.0 to 95.0) 0.59
Calcification
None or mild 10 (71.4) 47 (63.5) 0.76
Moderate or severe 4 (28.6) 27 (36.5) 0.76
Multivessel disease 9 (64.3) 29 (42.3) 1.00
SYNTAX score 13.3 (6.5 to 15.5) 11 (7.0 to 17.0) 0.78
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ocT analysis 
OCT findings at five years in lesions with and without NA are summarized in Table 4. 
Lesions with NA  showed an increase in neointimal thickness (0.15 vs. 0.11mm, p=0.001), 
neointimal area (1.27 vs. 0.96 mm2, p=0.003) and percent volume obstruction (19.6% vs. 
13.0%, p=0.001). Lesions with any protruding struts were less frequent among lesions 
with NA than lesions without NA (14.3% vs. 46.0%, p=0.037). 
qcA analysis
A total of 704 untreated, native coronary artery segments at baseline were matched with 
the corresponding segments at five years follow-up, allowing the assessment of longi-
tudinal changes over time (Table 5). A reduction in MLD was observed in both groups 
(with and without NA). The mean reduction in MLD of untreated, native coronary artery 
Table 2 Baseline clinical, procedural, stented-lesion, and angiographic characteristics (continued)
Patients with 
neoatherosclerosis
(N=14)
Patients without 
neoatherosclerosis 
(N=74)
P-value
Procedures
Lesion length (mm) 14.5 (10 to 20) 15 (10 to 20) 0.98
No. of stents per lesion
One stent per lesion 10 (71.4) 65 (87.8) 0.21
Two stents per lesion 4 (28.6) 8 (10.8) 0.09
Three stents per lesion 0 (0) 1 (1.4) 1.00
Multiple stent per lesion 2 (14.3) 8 (10.8) 0.66
SES implantation 2 (14.3) 39 (52.7) 0.009
PES implantation 12 (85.7) 35 (47.3) 0.009
Post-procedure angiographic 
measurements 
MLD in segment (mm) 2.73 (2.62 to 3.20) 2.63 (2.28 to 3.00) 0.77
MLD in stent (mm) 2.68 (2.48 to 2.93) 2.64 (2.38 to 3.00) 0.88
RVD in segment (mm) 2.83 (2.77 to 3.17) 2.94 (2.50 to 3.24) 0.93
RVD in stent (mm) 2.94 (2.53 to 3.04) 2.85 (2.54 to 3.06) 0.99
Diameter stenosis (%) 
In-segment 4.0 (4.0 to 6.0) 7.0 (4.0 to 12.0) 0.38
In-stent 6.0 (1.8 to 7.0) 7.0 (3.0 to 9.0) 0.28
Values shown are median (lower to upper quartile) or number (%). P-values from Wilcoxon rank sum test or 
Fisher’s exact test. BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary interven-
tion; CABG, coronary artery bypass graft; CAD, coronary artery disease; NSTEMI, Non-ST segment elevation 
myocardial infarction; STEMI, ST-segment elevation myocardial infarction; MLD, minimal lumen diameter; 
RVD, reference vessel diameter; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent.
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segments between baseline and five year follow-up was more pronounced in lesions 
of patients with NA (-0.25mm, 95%CI -0.36 to -0.17) compared to lesions of patients 
without NA (-0.13mm, 95%CI -0.17 to -0.10, p=0.002) (Figure 3). Similarly, the change 
of % diameter stenosis was higher in lesions of patients with NA (6.0%, 95%CI 5.3 to 
11.1) compared to those without NA (4.3%, 95%CI 2.5 to 6.2, p=0.048). We performed 
a sensitivity analysis applying a more strict definition of NA lesions requiring a longi-
tudinal extension of 1.5mm. With this criteria, the difference in mean change in MLD 
(-0.32 vs. -0.13 mm, p=0.0005) and % diameter stenosis of non-TL segments (6.1 vs. 4.3%, 
p=0.037) remained unchanged (Supplemental Table S1). No significant difference in 
terms of the angiographic SYNTAX score at index procedure was observed (NA: 13.3 vs. 
no-NA: 11.0, p=0.78). 
Table 3 medication and lipid profile at baseline and 5 years follow-up
 
Patients with 
neoatherosclerosis 
(N=14) 
Patients without 
neoatherosclerosis 
(N=74) p-value
Medication throughout 5 years
Statin 11 (78.57 %) 56 (75.68 %) 1.00
ACE-i/AT2-B 1 (7.14 %) 14 (18.92 %) 0.45
β blocker 6 (42.86 %) 35 (47.3 %) 1.00
Aspirin 11 (78.57 %) 63 (85.14 %) 0.69
At least 1 CV 12 (85.71 %) 68 (91.89 %) 0.61
At least 2 CV 11 (78.57 %) 58 (78.38 %) 1.00
At least 3 CV 6 (42.86 %) 35 (47.3 %) 1.00
Lipid profile (mg/dL)
Cholesterol at baseline (mg/dL) 196.2 (168.7 to 217.5) 194.1 (166.6 to 224.3) 0.87
cholesterol at follow-up (mg/dL) 163.0 (146.0 to 197.9) 170.0 (147.7 to 193.2) 0.96
∆ cholesterol (mg/dL) -8.5 (-54.9 to 5.0) -22.45 (-45.5 to 0.0) 0.96
LDL-C at baseline (mg/dL) 122.5 (88.6 to 174.7) 118.6 (94.6 to 144.0) 0.47
LDL-C at follow-up (mg/dL) 102.7 (87.5 to 140.6) 109.1 (92.7 to 129.2) 0.88
∆ LDL-C (mg/dL) -25.9 (-58.7 to 24.1) -9.1 (-28.5 to 16.4) 0.62
HDL-C at baseline (mg/dL) 51.4 (43.9 to 67.5) 47.6 (42.5 to 58.7) 0.60
HDL-C at follow-up (mg/ dL) 51.1 (44.1 to 56.6) 46.4 (38.3 to 57.8) 0.30
∆ HDL-C (mg/dL) -1.4 (-9.4 to 2.5) -2.6 (-8.2 to 2.3) 0.85
Values shown are median (lower to upper quartile) or number (%). P-values from Wilcoxon rank sum test 
or Fisher’s exact test. 
CV = cardiovascular medication (Statin, ACE-inhibitor, β blocker, or Aspirin)
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clinical events
Clinical events throughout five years are summarized in Table 6. Non-TL revasculariza-
tions occurred more frequently in patient with NA (78.6%) as compared to patients 
without NA (44.6%, HR=2.95 (95%-CI: 1.47 to 5.93), p=0.006). Similarly, non-TVR (71.4% 
vs. 43.2%, HR= 2.25 (1.1 to 4.58), p=0.04) and any revascularization (78.6% vs. 50.0%, 
HR=2.68 (1.35 to 5.35), p=0.01) were more frequently observed in the NA lesion group. 
Results remained essentially unchanged when censoring immediately before the an-
giographic follow-up (non-TL revascularization: 57.1% vs. 32.4%, HR=2.34, 95% CI 1.05 
to 5.22, p=0.05). We further assessed clinical events over an additional 4 years after OCT 
and did not record any differences between patients with versus without NA. (Supple-
mental Table S2).
Table 4 ocT analysis of stent and neointimal characteristics 
 
lesions with 
neoatherosclerosis 
(N=14 patients) 
lesions without 
neoatherosclerosis 
(N=74 patients) P-value
Analysis at lesion level
Number of analyzed lesions N=14 N=74
Analyzed region length (mm) 16.5 (13.0 to 19.9) 17.0 (15.5 to 18.5) 0.803
Number of struts per lesion 151 (117 to 185) 149 (134 to 164) 0.913
Lesions with uncovered struts 9 (64.29%) 49 (66.22%) 1.000
Lesions with any protruding struts 2 (14.29%) 34 (45.95%) 0.037
Lesions with any malapposed struts 5 (35.71%) 47 (63.51%) 0.075
Percent Volume Obstruction (%) 19.6 (16.1 to 23.0) 13.0 (11.6 to 14.6) 0.001
Analysis at frame level
Number of analyzed frames N=245 N=1330
Number of struts per frame 8.6 (7.8 to 9.4) 8.2 (7.9 to 8.6) 0.410
Neoint. thickness, mean per frame (mm) 0.15 (0.13 to 0.18) 0.11 (0.1 to 0.12) 0.001
Stent area (mm2) 6.86 (5.76 to 7.96) 7.31 (6.83 to 7.79) 0.464
Lumen area (mm2) 5.63 (4.47 to 6.79) 6.52 (6.02 to 7.03) 0.172
Neointimal area (mm2) 1.27 (1.09 to 1.46) 0.96 (0.88 to 1.04) 0.003
Reported values are mean (95% CI) or count (%). Lesion-level analysis with linear models or with Fisher’s 
exact test. Frame-level analysis with linear mixed models with patient as random intercept.
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DiScuSSioN
This cohort study of patients with coronary artery disease previously treated with DES 
allowed to correlate the process of in-stent NA with native atherosclerosis progression, 
due to its design including serial angiographic surveillance, annual clinical follow-up, 
and intracoronary imaging using OCT at five years. 
Table 5 qcA analysis of non-Tl segments
 
Patients with 
neoatherosclerosis 
median (95% ci) 
Patients without 
neoatherosclerosis 
median (95% ci) p-value
Nb. patients N=14 N=73
Nb. segment N=120 N=584
Nb. of segments per patient 8.6 8.0
Segment localization§ 0.31
LAD 38 (32%) 194 (33%) 0.82
LCX 34 (28%) 197 (34%) 0.30
RCA 48 (40%) 193 (33%) 0.18
Reference diameter (mm)
Baseline 2.32 (2.23 to 2.67) 2.36 (2.28 to 2.47) 0.94
Follow-up 2.38 (2.12 to 2.5) 2.38 (2.28 to 2.44) 0.50
Mean segment length per pat. (mm)
Baseline 30.76 (29.53 to 33.21) 30.94 (29.57 to 31.98) 0.68
Follow-up 31.37 (29.5 to 32.66) 31.34 (29.48 to 32.5) 0.99
Total segment length per pat. (mm)
Baseline 278 (249 to 302) 256 (237 to 274) 0.15
Follow-up 280 (251 to 293) 255 (236 to 281) 0.34
Minimal Lumen diameter (mm)
Baseline 1.9 (1.66 to 2.16) 1.9 (1.84 to 2.01) 0.62
Follow-up 1.54 (1.41 to 1.88) 1.78 (1.72 to 1.88) 0.072
Change* in MLD (FUP-BL) -0.25 (-0.36 to -0.17) -0.13 (-0.17 to -0.10) 0.002
Diameter stenosis (%)
Baseline 20.94 (19.15 to 22.55) 20.03 (18.45 to 21.92) 0.32
Follow-up 27.67 (25.21 to 35.9) 23.61 (21.49 to 28.79) 0.063
Change* in %DS (FUP-BL) 6.03 (5.28 to 11.06) 4.31 (2.47 to 6.24) 0.048
Values are medians over several patients (95% CIs from non-parametric bootstrap). P-values from Wilcoxon 
rank sum test. Patient-level outcomes derived as the mean from several segments. § Reported as count (%), 
p-values from Pearson Chi square test. *Change was derived at the level of segments. QCA, quantitative 
coronary angiogram; FUP, follow-up; BL, baseline.
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Association between NA and native coronary atherosclerosis progression
The principal finding of this cohort study is a significant association between in-stent NA 
and the progression of native coronary atherosclerosis.
The mechanism underlying in-stent NA are poorly understood and it is believed to be 
a multifactorial process. It has been suggested that NA occurs in the context of incom-
Figure 3. Angiographic analysis. Box-plot representation of the per-patient mean angiographic change 
in MLD (MLD follow-up minus MLD baseline) from untreated coronary artery segments that were serially 
assessed and matched. Analysis is stratified according to presence (N=14 patients) or absence (N=74 pa-
tients) of NA plaques in the stented vessel that underwent OCT analysis. Lower and upper box edges are 
the quartiles and thick line is the median. A horizontal reference line at change=0 is drawn.
Table 6 clinical events up to 5 years angiographic follow-up
  Patients with 
neoatherosclerosis 
(N=14)
Patients without  
neoatherosclerosis  
(N=74)
Hazard ratio (95% ci) p-value
Non-TVR 10 (71.4 %) 32 (43.2 %) 2.25 (1.1 to 4.58) 0.038
Non-TLR1 11 (78.6 %) 33 (44.6 %) 2.95 (1.47 to 5.93) 0.006
Any revascularization.2 11 (78.6 %) 37 (50.0 %) 2.68 (1.35 to 5.35) 0.010
Any MI 0 (0 %) 2 (2.70 %) 1.000
All cause death 0 (0 %) 0 (0 %)
Nr. of events (%) are reported. Analysis censored for each patient the day after 5y imaging follow-up. Medi-
an follow-up time was 1933 days (IQR: 1847 to 2012). Hazard ratios and p-values from Cox proportional haz-
ards model. If <5 events, p-values from Fisher’s exact test. TLR, target lesion revascularization; TVR, target 
vessel revascularization; MI, myocardial infarction. TLR was not reported, as the study population consisted 
of patients free from target lesion events.  1Non-TVR or TVR excluding TLR; 2Non-TVR or TVR including TLR.
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petently regenerated endothelium, which results in an excessive uptake of circulating 
lipids and leucodiapedesis leading to an accelerated atherosclerosis formation within 
the neointima.11 Of note, in a recent ex-vivo histological analysis NA was observed at a 
similar frequency following implantation of new generation everolimus-eluting stents 
compared with early generation DES despite evidence of other signs of improved arte-
rial healing . These findings suggest that small alterations of the endothelium within 
the neointima may be sufficient to determine an accelerated in-stent NA formation. As 
NA is less frequent and occurs later in BMS compared with DES, the antiproliferative 
agent released from DES may be suspected as a causative factor. Our findings indicate 
that NA is more likely to develop in patients with a progressive native atherosclerosis 
phenotype during long-term follow-up. Therefore, pathogenetic factors contributing to 
Figure 4. Association between NA lesion formation and atherosclerosis progression in untreated 
coronary artery segments.
This figure shows a representative example of a patient with a thin cap fibroatheroma within the neointima 
(Panel F) displaying a strong attenuation which prevents the visualization of the stent struts behind the 
lipid pool/necrotic core. In the distal RCA, a non-significant stenosis of 35% at baseline (Panel D) progressed 
over the duration of 5 years to a significant stenosis of 90
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the progression of native atherosclerosis appear to be similar to those involved in NA 
formation. Of note, coronary artery disease complexity as assessed by the angiographic 
SYNTAX score at baseline was comparable in patients with and without evidence of 
in-stent NA, suggesting that the observed association between NA and native athero-
sclerosis progression is independent from the initial disease severity. A recent analysis 
of the RESOLUTE All Comers trial showed a considerable overlap between clinical and 
angiographic factors associated with in-stent restenosis requiring revascularization 
and those associated with atherosclerosis progression leading to revascularization of 
previously untreated coronary segments during 4 years follow-up. 12 Assuming that 
restenosis is at least in part caused by NA formation, these clinical findings support the 
results of our cohort study. Based on our findings, it could be hypothesized that thera-
peutic strategies known to attenuate atherosclerosis progression – such as high-dose 
statin therapy – may be also effective to suppress the development or progression of 
NA. In this context, we investigated whether patients with in-stent NA were less adher-
ent to evidence based cardiovascular medications including statins, but did not observe 
any differences between groups. Similarly, the reduction in LDL-C and the increase in 
HDL-C, both known to be associated with atherosclerosis progression, were not different 
between patients with compared to those without NA lesions. Based on the relatively 
small sample size and of this cohort, we consider these observations the latter results as 
indefinite. Adequately designed clinical trials are warranted to further substantiate this 
hypothesis. 
Frequency of NA
The reported frequency of in-stent NA substantially differs from previous studies. This 
is explained at least in part by the variety of NA definitions applied and the substantial 
differences in patient selection. In a human pathology study, Nakazawa and colleagues 
reported a frequency of 31% in 209 DES lesions at a mean of 1.2 years after stent implan-
tation by defining NA as the presence of either peri-strut foamy macrophage clusters, 
fibroatheromas, thin-cap fibroatheromas, or plaque ruptures with thrombosis.5 More 
recently, the same group of investigators observed a similar frequency of NA among 
patients treated with everolimus-eluting stents (29%), SES (35%) and PES (19%) 30 days 
to 3 years after stent implantation.13 The overall frequency of any NA related findings in 
our OCT investigation (40.9%) was comparable to these two pathology studies with the 
exception that NA was more frequently observed after PES implantation – which might 
be related to a different selection of patients and a longer follow-up time. In-vivo studies 
using OCT to describe the frequency of in-stent NA are scarce. Yonetsu and colleagues 
defined NA as the presence of lipid-laden neointima in the absence of a longitudinal 
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criteria and reported a frequency of 75% at four years of follow-up. We found a consider-
ably lower frequency, even when considering a wider definition under the inclusion of 
any potential in-stent NA related findings. A possible explanation for this discrepancy 
is the higher proportion of symptomatic patients with a clinical indication for repeat 
angiography in the study by Yonetsu and colleagues compared with our study. Another 
explanation is the risk of overestimation of NA using OCT, as suggested by Nakano and 
colleagues.14 To overcome this risk, we applied a conservative definition of NA requiring 
a longitudinal extension of at least 1.0 mm in length, and we carefully excluded potential 
macrophage accumulation and fibrin deposition by identifying signal rich bands and 
peri-strut low intensity area. This strategy may have led to a more accurate assessment 
of advanced in-stent NA, as indicated by a frequency of NA closely resembling human 
pathology studies.
Predictors of NA lesion formation
With the exception of device type, we have not observed any differences in baseline 
clinical, procedural or angiographic variables between patients with NA as compared to 
those without NA at 5 years. In a histology study, younger age, longer implant duration, 
SES and PES usage, and underlying unstable plaque were identified as independent 
predictors of NA formation. 5 Moreover, in an in-vivo OCT study Yonetsu and colleagues 
identified time from stent implantation, active smoking, chronic kidney disease, and use 
of ACE-AR-II as independent predictors of NA. 15 Our study results may assist in under-
standing why active smoking and chronic kidney disease emerged as predictors for NA 
formation, both established risk factors for native atherosclerosis. 
Stent related differences
Several reports from autopsy and animal models showed device-specific vascular 
responses after SES and PES implantation. 16,17 In an ex-vivo histological study, the inci-
dence of any NA findings was more frequent in SES compared with PES less than 2 years 
after stent implantation (SES 37% vs. PES 21%, p=0.021). However, the frequency of any 
NA findings did not differ between SES and PES after 2 years until 6 year (SES 44% vs. PES 
38%, p=0.72) suggesting time-dependent differences in NA development between the 
two devices. 5 In contrast with these findings, we observed a higher frequency of NA in 
PES as compared with SES at 5 years. In the absence of serial OCT assessment we were 
unable to evaluate time-dependent differences in NA formation. Moreover, considering 
that patients were not randomly selected and that only event-free patients were eligible 
for OCT at 5 years follow-up, our findings with regards to stent related differences in NA 
have to be interpreted with caution.
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clinical impact of NA 
The impact of NA on clinical outcomes has not been prospectively investigated at this 
point in time. Observational studies and case reports, however, suggest an association 
between NA lesions and late stent failures. 2, 4 We observed no significant differences in 
target-lesion related outcomes between patients with and without NA during 4 years 
follow-up after the assessment of NA by OCT.  However, in view of the relatively small 
number of patients with NA in our study, further prospective investigations are required 
for definitive conclusions on the clinical impact of NA. 
Study limitations
Our study needs to be interpreted in light of some limitations. First, only selected pa-
tients free from target lesion related events were considered eligible for angiographic 
and OCT long-term evaluation. Thus, the generalizability of our findings may be limited. 
Second, the sample size was relatively small. This limits secondary analyses focusing on 
predictors of NA as well as the evaluation of the clinical impact of NA. However, the 
findings related to our primary hypothesis are statistically robust and mechanistically 
plausible. Third, we investigated the occurrence of NA in early generation DES that are 
no longer used in clinical practice. It remains to be shown if our findings apply to 
new generation DES, although new generation everolimus-eluting stents have been 
reported to have a similar propensity to develop NA as early generation DES in a recent 
ex-vivo histological analysis. Although OCT has been validated against histology for the 
assessment of atherosclerotic plaque composition and phenotype, we are unaware of a 
dedicated validation study for the diagnosis of in-stent NA. However, there is no reason 
to assume that the assessment of NA would substantially differ from the one of native 
atherosclerosis. Whilst the assessment of calcifications is not expected to be the be the 
cause of misinterpretations, the differentiation between in-stent fibroatheroma and 
macrophage accumulations, fibrin accumulations surrounding stent struts, or the pen-
etration of necrotic core from the original plaque might be the source of misdiagnosis 
appears more challenging. 
The virtual inexistence of ruptured plaques after balloon angioplasty ushered in the 
term coronary plaque sealing by balloon angioplasty.18 Initial stents had a risk of late 
thrombotic occlusion exceeding the risk of spontaneous plaque rupture and were not 
to be considered for plaque sealing. The fact that NA mimicking unstable plaques is rare 
(particularly with SES) and no MI or death occurred from NA (Table 6) is noteworthy. 
Plaque sealing by stenting may become appealing with ever improving DES.
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coNcluSioNS
The formation of in-stent NA is closely associated with progression of native coronary 
atherosclerosis, suggesting similarities in the pathophysiologic mechanisms of these 
two entities. These findings may have important clinical implications for the develop-
ment and implementation of strategies to prevent NA among patients undergoing PCI.
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DATA SuPPlEmENT
Table S1 qcA analysis of non-Tl segments: patient stratification based on plaques with longitudinal 
extension >= 1.5 mm.
 
Patients with 
neoatherosclerosis§ 
median (95% ci)
Patients without 
neoatherosclerosis§ 
median (95% ci) p-value
Nb. patients 11 76
Nb. segment 93 611
Nb. of segments per patient 8.5 8.0
Segment localization(1) 0.616
LAD 29 (31%) 203 (33%) 0.786
LCX 28 (30%) 203 (33%) 0.633
RCA 36 (39%) 205 (34%) 0.390
Reference diameter (mm)
Baseline 2.28 (2.13 to 2.65) 2.37 (2.29 to 2.50) 0.451
Follow-up 2.23 (2.04 to 2.43) 2.39 (2.28 to 2.46) 0.094
Mean segment length per pat. (mm)
Baseline 30.72 (29.45 to 32.52) 31.00 (29.57 to 32.21) 0.939
Follow-up 30.97 (29.29 to 32.94) 31.54 (29.48 to 32.5) 0.868
Total segment length per pat. (mm)
Baseline 277 (244 to 295) 259 (236 to 275) 0.358
Follow-up 280 (244 to 292) 255 (238 to 281) 0.523
Minimal Lumen diameter (mm)
Baseline 1.71 (1.65 to 2.15) 1.92 (1.84 to 2.03) 0.197
Follow-up 1.47 (1.36 to 1.71) 1.81 (1.72 to 1.88) 0.007
Change* in MLD (FUP-BL) -0.32 (-0.40 to -0.20) -0.13 (-0.17 to -0.10) 0.0005
Diameter stenosis (%)
Baseline 21.10 (19.25 to 25.31) 19.84 (18.52 to 21.61) 0.156
Follow-up 28.41 (26.32 to 38.70) 24.00 (21.77 to 27.48) 0.032
Change* in %DS (FUP-BL) 6.09 (5.28 to 13.40) 4.32 (2.55 to 6.14) 0.037
Values are medians over several patients (95% CIs from non-parametric bootstrap). P-values from Wilcoxon 
rank sum test. Patient-level outcomes derived as the mean from several segments. (1) Reported as count 
(%), p-values from Pearson Chi square test. *Change derived at the level of segments. QCA, quantitative 
coronary angiogram. § Lesions with neoatherosclerosis is defined over 1.5mm in length.
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Table S2 clinical events from 5 to 9 years
Patients with
neoatherosclerosis
(N=14)
Patients without 
neoatherosclerosis 
(N=74)
P-value
   TVR 2 (14.3) 12 (16.2) 1.00
   TLR 2 (14.3) 8 (10.8) 0.66
   Non-TVR 2 (14.3) 12 (16.2) 1.00
   Non-target lesion revascularization 2 (14.3) 16 (21.6) 0.73
   Any revascularization 2 (14.3) 20 (27.0) 0.50
   Any MI 0 (0) 7 (9.5) 0.59
   All cause death 1 (7.1) 2 (2.7) 0.41
   Stent thrombosis 0 (0) 3 (4.1) 1.00
Values are n(%), p-values from Fisher’s exact test. TLR, target lesion revascularization; TVR, target vessel 
revascularization, MI, myocardial infarction. Clinical events were considered from 1 day after the 5 years 
imaging follow-up and until the 9 years clinical follow-up.  Median analysis time was 1448 days (IQR: 1408 
to 1478).
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Table S3 qcA analysis of non-Tl segments restricted to PES implanted patients
 
Patients with 
neoatherosclerosis 
median (95% ci) 
Patients without 
neoatherosclerosis median 
(95% ci) p-value
Nb. patients 12 34
Nb. segment 103 282
Nb. of segments per patient 8.6 8.3
Segment localization§ 0.35
LAD 34 (33%) 93 (33%) 1.00
LCX 28 (27%) 96 (34%) 0.25
RCA 41 (40%) 93 (33%) 0.26
Reference diameter (mm)
Baseline 2.32 (2.25 to 2.71) 2.37 (2.28 to 2.53) 0.97
Follow-up 2.38 (2.08 to 2.59) 2.36 (2.27 to 2.5) 0.61
Mean segment length per pat. (mm)
Baseline 30.76 (29.3 to 34.15) 31.51 (29.03 to 33.52) 0.99
Follow-up 30.76 (29.27 to 32.54) 32.03 (29.92 to 34.34) 0.34
Total segment length per pat. (mm)
Baseline 278 (257 to 308) 260 (236 to 280) 0.30
Follow-up 280 (254 to 293) 268 (236 to 286) 0.67
Minimal Lumen diameter (mm)
Baseline 1.9 (1.66 to 2.16) 1.92 (1.8 to 2.03) 0.60
Follow-up 1.48 (1.37 to 1.94) 1.78 (1.6 to 1.94) 0.069
Change* in MLD (FUP-BL) -0.27 (-0.38 to -0.18) -0.11 (-0.18 to -0.08) 0.004
Diameter stenosis (%)
Baseline 20.97 (18.6 to 24.46) 20.41 (18.58 to 22.17) 0.54
Follow-up 28.27 (24.93 to 37.91) 24.85 (21.96 to 30.77) 0.10
Change* in %DS (FUP-BL) 7.25 (4.92 to 12.23) 4.61 (2.55 to 7.98) 0.12
Values are medians over several patients (95% CIs from non-parametric bootstrap). P-values from Wilcoxon 
rank sum test. Patient-level outcomes derived as the mean from several segments. § Reported as count 
(%), p-values from Pearson Chi square test. *Change derived at the level of segments. QCA, quantitative 
coronary angiogram.
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EDITORIAL COMMENT
Late Vascular Response
Following Drug-Eluting
Stent Implantation*
Lorenz Räber, MD,†‡ Patrick W. Serruys, MD, PHD‡
Bern, Switzerland; and Rotterdam, the Netherlands
The therapeutic effect of drug-eluting stents (DES) as
compared with bare-metal stents (BMS) is most pro-
nounced during the first year as a result of the potent
inhibition of neointimal hyperplasia in the presence of
the antiproliferative drug. Whereas healing with BMS,
and in parallel, neointimal proliferation, has been shown
to be complete after 3 to 6 months (1), potentially
followed by a late lumen enlargement beyond 1 year, a
different pattern emerged with early generation DES,
characterized by delayed healing with an ongoing neoin-
timal growth beyond 6 months in both experimental and
clinical studies (2,3). However, the long-term course of
neointimal growth has not been well investigated in early
generation DES, and it remains unclear whether newer
generation DES show a similar response despite im-
provements in design.
See page 1067
In this issue of JACC: Cardiovascular Interventions,
Collet et al. (4) report long-term intravascular ultrasound
(IVUS) data from patients included in the first-in-man
evaluation of sirolimus-eluting stent (SES) slow-release
cohort and the first-in-man evaluation of biolimus-
eluting stent using a biodegradable polymer (BES). All
patients underwent serial IVUS investigation post-
procedure, between 6 and 12 months and at 4 to 5 years.
Neointimal growth was not halted after the first
follow-up at 6 (BES) and 12 months (SES), respectively,
but continued to increase with a similar magnitude for
both BES and SES during long-term follow-up. These
results indicate that neointimal growth continues with
durable (SES) as well as with biodegradable (BES)
polymer-based DES beyond the time point, at which
healing is complete with BMS.
The different time point at which the first follow-up was
performed (6 months in BES vs. 12 months in SES) makes
any comparison of the dynamics in neointimal response
between the 2 stent types questionable. SES release 80% of
the drug during the first 30 days, with nearly all drug eluted
at 3 months, whereas BES is characterized by a bioabsorb-
able abluminal polymer, namely polylactide, which is pre-
dictably degraded by surface hydrolysis to lactide during a
period of 6 to 12 months (5). It remains uncertain whether
the increase in neointimal tissue from 6 months to 5 years
observed with BES is solely related to the decrease of drug
dose, or whether it reflects a true increase beyond 1 year as
the result of impaired healing as has been described in early
generation DES. Since the bioabsorption of the polymer has
been correlated with a transient inflammatory response, it
would be interesting to evaluate the intimal thickness after
completion of biodegradation (12 to 18 months) and during
long-term follow-up (4 to 5 years). Only this design would
allow the investigation of whether BES is associated with an
increasing neointimal proliferation during long-term
follow-up after completion of the bioabsorption process.
BMS Versus Early-Generation DES
In BMS, longitudinal angiographic and angioscopic
follow-up series observed late improvements in lumen
diameter, suggesting fibrotic maturation and regression of
the neointima, and a similar pattern with absence of delayed
late loss beyond 8 months was noted with a polymer-free
DES (6–8). Caution, however, should be exercised because
limited data are available with BMS beyond 3 years. An
optical coherence tomography study reported on a transfor-
mation of the neointima into lipid-laden tissue, reflecting
atherosclerotic progression (9) and very late erosion of the
minimal lumen diameter between 4 and 10 years and
beyond 10 years have been observed in a small angiographic
study. In contrast to BMS, angiographic and IVUS studies
of early generation DES documented a continued increase
in neointimal formation. Recently, the 5-year angiographic
follow-up results of the SIRTAX LATE (Sirolimus-
Eluting versus Paclitaxel-Eluting Stents for Coronary
Revascularization-Late) trial have shown a catch-up of 0.33
 0.66 in delayed late loss between 8 months and 5 years for
both SES and paclitaxel-eluting stents (PES). The study of
Collet et al. (4), not only is confirmatory, but further
improves our understanding in terms of late stent vessel wall
interactions using IVUS. A limitation of this study is that
patients presenting for repeat revascularization of the target
lesion did not undergo IVUS and are not part of the present
analysis. This inherently leads to a much lower absolute
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
From the †Department of Cardiology, Bern University Hospital, Bern, Switzer-
land; and the ‡Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
Dr. Räber is the recipient of a research fellowship (SPUM) funded by the Swiss
National Science Foundation (grant 33CM30-124112). Dr. Serruys has reported that
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increase in neointimal tissue growth than observed in
reality.
Mechanisms of Late Intimal Growth
in Early-Generation DES
What are the mechanisms responsible for the ongoing
growth of neointima, and how might these be mitigated,
and perhaps most important, are these observations clini-
cally relevant (Fig. 1)? As a first mechanism, the antipro-
liferative drug concentration diminishes over time according
to the individual elution profile of the devices, and with
decreasing dose, the inhibiting effect declines. As a second
mechanism, the presence of fibrin—which has been de-
scribed in the vicinity of stent struts in experimental and
autopsy studies—is an initiator of smooth muscle cell
migration and proliferation (10). Porcine coronary models
have revealed an increasing amount of fibrin in the long-
term course (90 days) following implantation of early
generation DES, and in analogy to prolonged wound
healing that may result in an exaggerated scar formation,
delayed fibrinolysis is a stimulus to smooth muscle cell
proliferation and excessive collagenous matrix formation
(11). Third, chronic inflammation is a trigger for late
neointimal growth, and histological animal studies suggest
that the inflammatory response among different DES ap-
pears clearly distinct in terms of the proportion of giant
cells, granulomas, eosinophils, lymphocytes, and fibrin de-
position (11). Whereas SES may cause a granulomatous and
eosinophilic reaction starting at 28 days that continues to
increase over time, PES is characterized by lower levels of
inflammation, but higher amounts of fibrin deposition (2).
Information about newer generation DES, such as BES, is
currently still lacking. Fourth, the formation of neoathero-
sclerosis, mainly characterized by in-stent thin-cap
fibroatheroma-containing neointima and neocalcifications,
may reflect a contributing factor that arises later in the time
course and is not yet sufficiently described (12,13).
Clinical Significance of Late Catch-Up
The most relevant question emerging from the observation
by Collet et al. (4) is whether the late “catch up” translates
into a clinically meaningful need for target lesion revascu-
larization (TLR) during long-term follow-up, reducing the
early efficacy benefit of DES. Long-term results from
randomized controlled trials of early and newer generation
DES consistently show a yearly TLR rate of 2% beyond 1
year without any differences as compared with BMS (Table 1).
After subtraction of stent thrombosis–related TLRs (as they
are often not restenosis related), the annual TLR rate is as
low as 1% to 1.5%. Against this background, it is reasonable
Figure 1. The Different Time Course of the Neointimal Growth (Indicated by Late Loss) for BMS and for Early- and Newer-Generation DES Is Shown
Throughout 5 Years
Different mechanisms contributing to the late neointimal growth in drug-eluting stents (DES) are presented. SMC M  smooth muscle cell migration into neoin-
tima. D and E  D and E domains of fibrinogen. Schematic drawing of fibrinogen is referring to Naito et al. (10). Arrow in histological cross section depicts peri-
strut inflammatory cell infiltrates. In addition, a case example of a sirolimus-eluting stent showing delayed neointimal growth is depicted (kindly provided by
Juan Luis Gutiérrez Chico, MD, Vigo, Spain).
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to conclude that early generation DES delay intimal forma-
tion and healing during the long-term course, yet without
significantly compromising the early benefit in efficacy.
Prolonged neointimal proliferation, however, may be a
useful marker to assess the delay in healing. Of note, delayed
healing has been characterized histologically by lack of
endothelialization and persistent fibrin deposition, and both
were identified as the principal pathological finding in an
autopsy study distinguishing late thrombosed from patent
early generation DES.
Glimpse Into the Future
Newer generation DES were designed to overcome the
limitations of early generation DES. The biocompatibility
of the durable polymers was improved, and the concept of
completely bioabsorbable polymers was introduced. The
strut thickness was further reduced, the drug dose was
adapted, and the release kinetics optimized. Animal studies
revealed a lower rate of uncoverage (marker of healing), and
similar observations were observed using optical coherence
tomography in vivo with both BES and everolimus-eluting
stents as compared with SES (14,15). As these findings
were paralleled by improved clinical outcomes (16), it is
tempting to hypothesize that newer generation DES will
translate into a less pronounced neointimal growth beyond
1 year as a result of less fibrin deposition and less inflam-
mation in nonrandomized studies, and, therefore, may
result in less very late stent thrombosis during long-term
follow-up. A common limitation of both early and newer
generation DES is the presence of a permanent metallic
scaffold that serves as the nidus for late adverse stent vessel
wall interactions. Recently, the use of fully bioabsorbable
everolimus-eluting scaffolds have demonstrated their poten-
tial ability to treat coronary artery stenoses, and other fully
absorbable technologies are currently under investigation
(17). Whether these “new kids on the block” will overcome
the aforementioned limitations of conventional metallic
DES has yet to be shown.
Reprint requests and correspondence: Dr. Lorenz Räber, De-
partment of Cardiology, Bern University Hospital, 3010 Bern,
Switzerland. E-mail: lorenz.raeber@insel.ch.
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Tissue coverage and neointimal hyperplasia in overlap
versus nonoverlap segments of drug-eluting stents 9 to
13 months after implantation: In vivo assessment with
optical coherence tomography
Juan Luis Gutiérrez-Chico, MD, PhD, FESC, FACC, a Lorenz Räber, MD, b Evelyn Regar, MD, PhD, FESC, a
Takayuki Okamura, MD, PhD, a Carlo di Mario, MD, PhD, FESC, FACC, c Gerrit-Anne van Es, MSc, PhD, d
Stephan Windecker, MD, PhD, FESC, b and Patrick W. Serruys, MD, PhD, FESC, FACC a Rotterdam,
The Netherlands; Bern, Switzerland; and London, United Kingdom
Background Histologic experimental studies have reported incomplete neointimal healing in overlapping with respect
to nonoverlapping segments in drug-eluting stents (DESs), but these observations have not been confirmed in human coronary
arteries hitherto. On the contrary, angiographic and optical coherence tomography studies suggest that DES overlap elicits
rather an exaggerated than an incomplete neointimal reaction.
Methods Optical coherence tomography studies from 2 randomized trials including sirolimus-eluting, biolimus-eluting,
everolimus-eluting, and zotarolimus-eluting stents were analyzed at 9- to 13-month follow-up. Coverage in overlapping segments
was compared versus the corresponding nonoverlapping segments of the same stents, using statistical pooled analysis.
Results Forty-two overlaps were found in 31 patients: 11 in sirolimus-eluting stents, 3 in biolimus-eluting stents, 17 in
everolimus-eluting stents, and 11 in zotarolimus-eluting stents. The risk ratio of incomplete coverage was 2.35 (95% CI 1.86-
2.98) in overlapping versus nonoverlapping segments. Thickness of coverage in overlaps was only 85% (95% CI 81%-90%) of
the thickness in nonoverlaps. Significant heterogeneity of the effect was observed, especially pronounced in the comparison of
thickness of coverage (I2 = 90.31).
Conclusions The effect of overlapping DES on neointimal inhibition is markedly heterogeneous: on average, DES
overlap is associated with more incomplete and thinner coverage, but in some cases, the overlap elicits an exaggerated
neointimal reaction, thicker than in the corresponding nonoverlapping segments. These results might help to understand why
overlapping DES is associated with worse clinical outcomes, both in terms of thrombotic phenomena and in terms of restenosis
and revascularization. (Am Heart J 2013;166:83-94.e3.)
The reduction of restenosis rates achieved by drug-
eluting stents (DESs)1 has been obscured by concerns
about late and very late stent thrombosis.2,3 Pathology
studies have described delayed neointimal healing with
incomplete endothelialization of the struts4 as the
common morphologic finding in fatal cases of late and
very late stent thrombosis.
The effect of DES overlap on the neointimal healing
process is still poorly understood. Experimental studies
on animal models have reported incomplete neointimal
healing in overlap compared with nonoverlap segments
in first-generation DES, with more incomplete endothe-
lialization, greater fibrin deposition, and greater cellular
inflammatory infiltrates.5 Drug overdose, larger amounts
of polymer, and the double-metallic layer often altering
the structural geometry of the stent might explain the
suboptimal neointimal coverage in overlaps. Neverthe-
less, these observations have not been confirmed in
human coronary arteries hitherto. On the contrary,
several angiographic studies have associated DES overlap
with greater late loss and binary restenosis,6,7 most
frequently involving the overlap segment,7 thus suggest-
ing that DES overlap elicits rather an exaggerated than an
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incomplete neointimal reaction. Likewise, a randomized
single-center clinical trial addressed specifically the
neointimal coverage of overlap versus nonoverlap
segments in different types of DES, as estimated by
optical coherence tomography (OCT)8: the percent of
covered struts was not significantly different between
overlap and nonoverlap segments; the thickness of
coverage was either not different or even thicker in
overlaps; and the percent neointimal volume obstruction
was larger. A higher metal-to-artery surface ratio or more
severe strut-imposed vessel injury could be advocated to
explain a hyperproliferative neointimal reaction in the
overlaps.9,10 Understanding how overlapping DES affects
the neointimal healing process after stenting is relevant
because it is a widespread practice, required in approx-
imately one-third of the coronary interventions caused by
excessive lesion length or suboptimal results,11-13 and is
associated with worse long-term clinical outcomes, both
in terms of repeated revascularization and in terms of
death/myocardial infarction.7
We hypothesize that the neointimal reaction at over-
lapping segments might be heterogeneous, hence with
marked variations between patients and lesions, thus
explaining the inconsistency between different histolo-
gy, angiography, and OCT studies. The aim of this study
is to compare the OCT tissue coverage of overlap versus
nonoverlap segments in different types of DES, using a
method that accounts for a potential heterogeneity of
the effect.
Methods
Study sample
Data at follow-up from OCT substudies of 2 different
randomized trials were analyzed: LEADERS (NCT00389220),14-16
comparing a biolimus-eluting stent (BES) with bioresorbable
polymer in abluminal coating (BioMatrix Flex; Biosensors
International, Morges, Switzerland) versus a sirolimus-eluting
stent (SES) with durable polymer (Cypher SELECT; Cordis, Miami
Lakes, FL), and the RESOLUTE-All comers (NCT00617084),17,18
comparing a zotarolimus-eluting stent (ZES) with hydrophilic-
polymer coating (Resolute; Medtronic Inc, Santa Rosa, CA) versus
an everolimus-eluting stent (EES) with fluoropolymer (Xience V;
Abbott Vascular, Santa Clara, CA). The design and results of these
trials have been published elsewhere.14-18 Both trials followed an
all-comer design,withminimal exclusion criteria. In LEADERS, the
OCT follow-upwas scheduled at 9months,whereas in RESOLUTE-
III, it was at 13 months.
Optical coherence tomography study and analysis
Optical coherence tomography pullbacks were obtained at
follow-up with M3 or C7 systems (Lightlab Imaging, Westford,
MA), according to the availability at the participating sites,
using occlusive or nonocclusive technique, as appropriate.19
Table I summarizes the technical specifications of each OCT
system and optical catheters.
Optical coherence tomography pullbacks were analyzed
offline in a core laboratory (Cardialysis BV, Rotterdam, The
Netherlands) by independent staff blinded to stent-type
allocation and to other clinical or procedural variables, using
proprietary software (Lightlab Imaging). Cross sections at 1-mm
longitudinal intervals within the stented segment were analyzed.
Overlapping segments were delimited by their most distal and
most proximal cross sections. Lumen and stent areas were
drawn in each cross section, and neointimal hyperplasia (NIH)
area was derived. Stent and NIH volumes were calculated for
each segment by multiplying the mean corresponding area by
the segment length. In-stent percent neointimal volume
obstruction was calculated as follows: (NIH volume/stent
volume) * 100.
A metallic strut typically appears as a bright signal-intense
structure with dorsal shadowing. In the overlapping segments in
which a double-strut layer could be clearly identified, those
struts clearly pertaining to the outer layer were labeled as such (
Figure 1). Apposition was assessed by measuring the distance
between each strut marker and the lumen contour, placing the
marker at the adluminal leading edge, in the midpoint of the
strut long axis. Distance was measured after a straight line
connecting this marker with the center of gravity of the vessel.20
Struts were classified as incomplete stent apposition (ISA) if the
distance between the strut marker and the lumen contour was
bigger than the specific strut thickness plus the axial resolution
of OCT (14 μm).16,21,22 This resulted in ISA thresholds of N168
μm for SES, N131 μm for BES, N99 μm for EES, and 111 μm for
ZES. Struts located at the ostium of side branches, with no
vessel wall behind, were labeled as nonapposed side-branch
(NASB) struts and considered an independent category of
apposition.16,18,21-23
Struts were classified as uncovered if any part of the strut was
visibly exposed to the lumen, or covered if a layer of tissue was
visible over all the reflecting surfaces. In covered struts,
thickness of coverage was measured from the strut marker to
the adluminal edge of the tissue coverage, following a straight
line connecting the strut marker with the center of gravity of the
vessel (Figure 2).8,15,16,18,20-22,24
Statistical analysis. Reproducibility of the total strut count
and the outer-layer strut count was tested with nonparametric
correlation in all overlapping cross sections (Kendall tau-b). For
each overlap, the risk ratio (RR) for uncoverage in the
overlapping segment versus the corresponding proximal and
Table I. Technical specifications of the different OCT systems in
the study
M3 C7
Technique Nonocclusive Nonocclusive
Domain Time Fourier
Catheter ImageWire Dragonfly
Rotation speed (frames/s) 20 100
Pullback speed (mm/s) 3 10-20
Axial resolution (μm) 10-20 10-20
Lateral resolution (μm) 20-90 20-40
Patients/overlaps with SES 9/11 0/0
Patients/overlaps with BES 3/3 0/0
Patients/overlaps with EES 3/5 8/12
Patients/overlaps with ZES 3/3 5/8
Total nr of patients/overlaps 18/22 13/20
All systems and catheters from Lightlab Imaging.
84 Gutiérrez-Chico et al
American Heart Journal
July 2013
Progress with DES technology 121
distal nonoverlapping segments was calculated. Individual RR
was pooled using an inverse variance random-effects model,
taking into account between-cluster and within-cluster variabil-
ity.22,23,25 Stents with no overlap (no exposition) or zero
uncovered struts (no events) were not informative to evaluate
the RR for uncoverage and discarded from the analysis.22,23,25 A
proportional continuity correction was applied to stents with
zero uncovered struts (zero events) in only one of the compared
segments (either overlap or nonoverlap segments).26
Given the extremely skewed nonnormal distribution of the
thickness of coverage in the struts, comparison of this variable
was performed using the log transformation of the thickness of
coverage,21 calculating the standardized difference of means for
each overlap through the method of Hedges.27 Individual
differences of means were pooled using an inverse variance
random-effects model.
Analysis of heterogeneity of the effect was reported as I2
(proportion of the effect attributable to heterogeneity) and the
P value of the Q test, considering statistically significant a P
value ≤0.1. In case of significant heterogeneity of the effect, the
influence of the type of stent would be explored by random-
effects meta-regression and by stratified analysis. Calculations
were done with PASW 17.0 (Chicago, IL) and CMA version 2
(Biostat Inc, Englewood, NJ) software packages.
Figure 1
Examples of cross sections in overlapping segments in which a double-strut layer can be clearly identified. Struts in the outer layer (red dots) are
covered more completely (B) and by thicker neointimal (C) than struts in the inner or indeterminate layer (white dots).
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This study has been sponsored by Medtronic Cardio Vascular,
Santa Rosa, CA, and Biosensors International, Morges, Switzer-
land. The core laboratory and Clinical Research Organization
responsible for the analysis (Cardialysis BV) and the participat-
ing centers have received grants to run the trials. The authors are
solely responsible for the design and conduct of this study, all
study analyses, and drafting and editing of the manuscript.
Results
Forty-two overlaps were found in 31 of 104 patients
screened in the study population (online Appendix
Supplementary Figure 1): 11 SES, 3 BES, 17 EES, and 11
ZES (16,928 struts).
Baseline clinical and procedural characteristics of the
patients with overlaps are shown in Table II. Angiographic
characteristics of the lesions are available as supplementary
material (online Appendix Supplementary Table I). Table
III summarizes OCT-derived areas and volumes of the
overlapping segments compared with the control non-
overlapping segments of the same stents. No significant
difference in percent neointimal volume obstruction was
found, although tended to be slightly lower in overlaps.
Areas and volumetric analysis stratified by type of stent can
be found in the supplementary material section (online
Appendix Supplementary Table II). Total struts count and
outer-layer struts count showed optimal interobserverse
reproducibility (Kendall tau-b 0.864 and 0.951, respective-
ly), with no significant bias in any of the analysts.
Descriptives of coverage in the global sample
Table IV shows the total count of struts in overlapping
and nonoverlapping segments and the raw proportions of
coverage stratified by apposition category. There was a
5.1% uncoverage rate in all visible struts in overlaps at
follow-up, raising to 6.2% if the struts of the outer layers
were excluded. Only 2.3% of the struts in nonoverlapping
segments of the corresponding stents were uncovered.
The thickness of coverage had a mean of 109 μm (median
80 μm, interquartile range 40-150 μm) in the overlaps and
of 150 μm (median 120 μm, interquartile range 60-210
μm) in nonoverlaps.
Risk ratio for noncoverage in overlapping versus
nonoverlapping segments
Six overlapping DESs were totally covered and hence
not suitable for RR estimation. Excluding the struts in
the outer layers, the pooled RR of incomplete coverage
in overlaps versus nonoverlaps was 2.35 (95% CI 1.86-
2.98) for the whole DES sample (Table V; Figure 3A).
There was moderate heterogeneity of the effect (I2 =
48.58), which was not explained by the type of stent
(meta-regression adjusted r2 = 0.029, P = .234) The
magnitude of the effect was only minimally softened if
all visible struts in the overlapping segments were
considered in the analysis (Table V; Figure 3B), with
no influence of the type of stent (adjusted r2 = 0.035,
P = .212).
Figure 2
Examples of covered (white arrows) and uncovered struts (red arrows) in overlapping (left) and nonoverlapping regions (right) at follow-up.
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Difference in thickness of coverage between overlapping
versus nonoverlapping segments
The distribution of the thickness of coverage was
normalized by logarithmic transform (Figure 4). Exclud-
ing the struts in the outer layers, the pooled ratio
(thickness in overlap/thickness in nonoverlap) was 0.85
(0.81-0.89) for the whole DES sample (Table VI;
Figure 5A). There was extreme heterogeneity of the
effect (I2 N 89.00), not attributable to the type of stent
(meta-regression adjusted r2 = −0.010, P = .441). The
magnitude of the effect changed dramatically if all
visible struts in the overlapping segments were
Table II. Patients' and procedural baseline characteristics in the subgroup with overlapping stents, grouped by type of stent
SES (n = 9) BES (n = 3) EES (n = 11) ZES (n = 8) P
Age (y) 58.2 (8.7) 59.3 (7.0) 60.5 (6.9) 57.4 (12.4) .887
Male 6 (66.7%) 3 (100.0%) 8 (72.7%) 7 (87.5%) .557
Cardiovascular risk factors
Hypertension 7 (77.8%) 2 (66.7%) 4 (36.4%) 6 (75.0%) .205
DM 2 (22.2%) 1 (33.3%) 2 (18.2%) 3 (37.5%) .788
Insulin requiring 0 (0.0%) 1 (33.3%) 1 (9.1%) 0 (0.0%) .180
Hypercholesterolemia 7 (77.8%) 3 (100.0%) 8 (72.7%) 6 (75.0%) .791
Smoking 4 (44.4%) 0 (0.0%) 6 (54.5%) 3 (37.5%) .396
Current smoker (b30 d) 4 (44.4%) 0 (0.0%) 5 (45.5%) 2 (25.0%) .419
Family history of CHD 8 (88.9%) 2 (66.7%) 4 (50.0%) 3 (75.0%) .368
Antecedents
Previous MI 3 (33.3%) 3 (100.0%) 4 (36.4%) 2 (25.0%) .138
Previous PCI 2 (22.2%) 1 (33.3%) 1 (9.1%) 4 (50.0%) .241
Previous CABG 0 (0.0%) 1 (33.3%) 2 (18.2%) 0 (0.0%) .199
Clinical presentation .374
Stable angina 6 (66.7%) 3 (100.0%) 4 (36.4%) 5 (62.5%) .201
Unstable angina 2 (22.2%) 0 (0.0%) 2 (18.2%) 1 (12.5%) .817
Myocardial infarction 1 (11.1%) 0 (0.0%) 5 (45.5%) 1 (12.5%) .150
STEMI 0 (0.0%) 0 (0.0%) 3 (27.3%) 1 (12.5%) .284
Silent ischemia 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) .396
Procedural characteristics
No. of vessels treated 1.11 (0.33) 1.33 (0.58) 1.27 (0.47) 1.63 (0.74) .272
No. of lesions treated 2.22 (1.09) 1.67 (1.15) 1.55 (0.82) 1.63 (0.74) .398
No. of stents implanted 2.3 (0.73) 2.00 (1.00) 3.09 (1.22) 3.00 (2.56) .144
Total stented length (mm) 48.9 (22.2) 54.7 (24.1) 64.1 (25.5) 60.4 (61.1) .829
Small vessel (b2.5-mm diameter) 4 (44.4%) 2 (66.7%) 6 (75.0%) 2 (25.0%) .217
Continuous variables are reported as mean (SD) and categorical variables as n (%); stent groups are compared with 1-way analysis of variance and Pearson χ2, respectively.
DM, Diabetes mellitus; CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass graft; STEMI, ST-elevation myocardial infarction.
Table III. Areas and volumetric analysis of overlap segments compared with nonoverlap segments of the same stents
All DES: 31 patients, 33
lesions, 42 overlaps Overlap
Nonoverlap
PDistal Proximal Combined
Stent length (mm) 3.8 (4.8) 16.2 (7.3) 16.2 (7.9) 32.0 (12.5) b.0001⁎
MLA (mm2) 6.22 (2.43) 4.58 (2.58) 5.72 (2.47) 4.34 (2.45) b.0001⁎
Mean lumen area (mm2) 6.70 (2.57) 5.86 (2.63) 7.19 (2.56) 7.00 (2.42) .045⁎
Lumen volume (mm3) 27.9 (42.2) 91.64 (58.98) 114.3 (67.8) 203.2 (110.0) b.0001⁎
Minimum stent area (mm2) 7.03 (2.44) 5.68 (2.52) 6.81 (2.45) 5.43 (2.31) b.0001⁎
Mean stent area (mm2) 7.60 (2.50) 6.87 (2.53) 8.11 (2.42) 7.45 (2.35) .315
Stent volume (mm3) 30.6 (44.0) 107.7 (61.8) 129.3 (71.5) 233.9 (114.4) b.0001
% Frames with ISA 2.68 (9.62) 1.16 (3.46) 3.50 (10.34) 2.29 (5.24) .822
Maximum ISA area (mm2) 0.02 (0.08) 0.16 (0.53) 0.33 (1.18) 0.48 (1.24) .023⁎
ISA volume (mm3) 0.02 (0.06) 0.28 (1.03) 1.12 (5.28) 1.38 (5.26) .102
Corrected by stent volume (%) 0.13 (0.50) 0.17 (0.63) 0.78 (3.93) 0.56 (2.38) .268
Maximum NIH area (mm2) 1.28 (0.86) 1.84 (0.87) 1.87 (0.88) 2.19 (0.88) b.0001⁎
NIH volume (mm3) 2.8 (2.9) 16.4 (11.1) 16.1 (12.0) 32.1 (19.5) b.0001⁎
In-stent NIH volume obstruction (%) 13.3 (10.9) 17.1 (11.2) 13.4 (9.3) 15.0 (9.6) .065
MLA, Minimal lumen area.
⁎ P ≤ .05.
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considered in the analysis (Table VI; Figure 5B), being
close to reach statistical significance in the opposite
direction to the one obtained in the analysis of just the
inner layer, irrespective of the type of stent (adjusted r2
= −0.019, P = .640).
Discussion
The main findings of this analysis are as follows: (1) the
neointimal inhibition in DES overlapping segments is
markedly heterogeneous: in some cases, the overlap
shows signs of delayed healing as compared with the
corresponding nonoverlapping segments, but in other
cases, the overlap elicits a more exaggerated and thicker
neointimal reaction; (2) on average, DES overlaps tend to
be at higher risk for delayed coverage than nonoverlap-
ping segments; (3) the neointimal layer covering the
struts in DES overlaps tends to be, on average, thinner
than in nonoverlapping segments; and (4) this extremely
heterogeneous effect of overlaps on the neointimal
reaction does not depend on the type of DES.
Table IV. Cross-tab showing the raw counts (%) of covered and uncovered struts in the overlapping and nonoverlapping segments within the
stents, stratified by apposition category, without clustering by patient or lesion
Coverage
TotalCovered Uncovered
Overlaps (excluding outer layer) 2177 (93.8%) 143 (6.2%) 2320
WA 2168 (94.1%) 135 (5.9%) 2303
ISA 2 (27.4%) 7 (77.8%) 9
NASB 7 (87.5%) 1 (12.5%) 8
Overlaps (all struts) 2674 (94.9%) 145 (5.1%) 2819
WA 2664 (95.1%) 137 (4.9%) 2801
ISA 2 (22.2%) 7 (77.8%) 9
NASB 8 (88.9%) 1 (11.1%) 9
nonoverlaps 13,788 (97.7%) 321 (2.3%) 14,109
WA 13,672 (98.2%) 256 (1.8%) 13,928
ISA 42 (47.2%) 47 (52.8 %) 89
NASB 74 (80.4%) 18 (19.6%) 92
Total no. of struts (excluding outer layer) 15,965 (97.2%) 464 (2.8%) 16,429
Total no. of struts (all struts) 16,462 (97.2%) 466 (2.8%) 16,928
The overlapping segments are presented according to the 2 different analysis performed: excluding or including the struts of the outer layer. WA, well apposed (struts).
Table V. Pooled analysis of the RR of incomplete coverage in overlap versus nonoverlap segments, stratified by type of stent
n
Magnitude of effect
RR
95% CI Heterogeneity of the effect
Lower Upper I2 P
Excl outer layer DES 36 2.39 1.57 3.63 48.58 .001
SES 11 1.59 0.78 3.21 59.60 .006
BES 3 0.97 0.48 1.96 0.00 .689
EES 14 3.51 1.63 7.57 21.98 .215
ZES 8 4.63 2.12 10.13 39.45 .116
All struts DES 36 2.00 1.32 3.02 47.78 .001
SES 11 1.33 0.68 2.60 55.71 .012
BES 3 0.78 0.39 1.58 0.00 .686
EES 14 2.98 1.38 6.41 22.25 .212
ZES 8 3.96 1.81 8.63 39.65 .115
The overlapping segments are presented according to the 2 different analysis performed: excluding or including the struts of the outer layer. RR N 1, higher risk of uncoverage in
overlaps; RR b 1, higher risk of uncoverage in nonoverlaps.
A: RR of incomplete coverage, excluding the outer layer. Forest plot showing the RR of incomplete coverage in overlapping versus nonoverlapping
segments at 9 to 13 months in the whole sample and stratified by type of stent. Lines represent the 95% CI for the RR in each overlap, with the pooled
RR at the bottom. B: RR of incomplete coverage, all visible struts analyzed. Forest plot showing the RR of incomplete coverage in overlapping versus
nonoverlapping segments at 9 to 13 months in the whole sample and stratified by type of stent. Lines represent the 95% CI for the RR in each overlap,
with the pooled RR at the bottom.
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These results may be interpreted as suggestive of
incomplete neointimal healing in DES overlapping re-
gions, with respect to nonoverlapping segments in
human coronary arteries. This observation in vivo is
consistent with the results of experimental histologic
studies on rabbit iliac arteries, which had reported more
incomplete endothelialisation, greater fibrin deposition,
and greater cellular inflammatory infiltrates in first-
generation DES overlapping regions.5 Although these
studies do not report any formal comparison of the
neointimal thickness between overlapping versus non-
overlapping regions, indirect qualitative assessment
Figure 4
Distribution of the variable thickness of coverage. The variable follows an extremely skewed distribution, fitting within an exponential curve (left
panel). After logarithmic transformation, the variable approximates a normal distribution (right panel).
Table VI. Pooled analysis of the thickness of coverage in overlap versus nonoverlap segments, stratified by type of stent
n
Magnitude of effect
Overlap/Nonoverlap ratio
95% CI Heterogeneity of the effect
Lower Upper I2 P
Excl outer layer DES 42 0.85 0.81 0.89 90.31 b.0001
SES 11 0.71 0.64 0.77 92.69 b.0001
BES 3 0.93 0.80 1.10 56.19 .102
EES 17 0.97 0.89 1.05 89.95 b.0001
ZES 11 0.85 0.78 0.93 89.34 b.0001
All struts DES 42 1.03 0.99 1.08 90.70 b.0001
SES 11 0.92 0.85 1.00 93.91 b.0001
BES 3 1.16 1.00 1.35 64.68 .059
EES 17 1.10 1.02 1.19 89.56 b.0001
ZES 11 1.05 0.97 1.14 90.50 b.0001
Results presented as ratio “thickness in overlap/thickness in nonoverlap,” derived from the comparison of standardised differences of means (Hedges g) after log transformation.
Overlapping segments are presented according to the 2 different analysis performed: excluding or including the struts of the outer layer.
A: Thickness of coverage, excluding the outer layer. Forest plot showing standardized difference of means (Hedges' g) of the log-transformed
thickness of coverage in overlapping versus nonoverlapping segments in the whole sample and stratified by type of stent. Lines represent the 95% CI
in each overlap, with the pooled difference of means at the bottom. B: Thickness of coverage, all visible struts analyzed. Forest plot showing
standardized difference of means (Hedges g) of the log-transformed thickness of coverage in overlapping versus nonoverlapping segments in the
whole sample and stratified by type of stent. Lines represent the 95% CI in each overlap, with the pooled difference of means at the bottom.
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seems to suggest that the neointimal layer might be
thinner in the overlaps.5
The coverage of overlaps has been specifically analyzed
by previous OCT studies. The ODESSA trial randomized
77 patients to an intervention with overlapping bare-
metal stent, first-generation SES, first-generation paclitax-
el-eluting stents, or a phosphorylcholine polymer–coated
ZES.8 However, the percent of covered struts was similar
in overlap and nonoverlap segments, the thickness of
coverage was either similar or even thicker in the
overlaps, and the percent neointimal volume obstruction
was consistently larger. No single parameter suggested
incomplete neointimal healing in overlaps, as reported in
preclinical studies, or even seemed to point to the
opposite direction: a neointimal reaction rather exagger-
ated than tamed. Our results might explain this apparent
discrepancy on the basis of methodological consider-
ations. One of them is the “layer effect”: it could be
postulated that the outer layer of struts is covered more
completely and by a thicker neointimal layer than the
inner layer. If the outer struts are excluded from the
analysis, the coverage of the remaining (inner and
indeterminate) struts is less complete and thinner in
overlaps than in nonoverlaps, as hereby demonstrated.
Mixing together outer and inner struts increases artifi-
cially the thickness of coverage and reduces the
proportion of uncovered struts, resulting in an unpre-
dictable average. This is especially relevant for the
neointimal thickness, whose results can be utterly
reversed depending on the choice for one method or
the other. Neither histology nor invasive imaging has
taken into account the layer effect so far. This could
partially explain some inconsistency within histologic
studies: although signs of incomplete coverage are
generally reported in overlaps,5,28,29 some studies did
not find impaired endothelialization,29 and sometimes,
the thickness of coverage was found similar28 or even
thicker than in nonoverlaps.28,29 Interestingly, the studies
reporting thicker coverage in the overlaps performed the
measurement from the outer layer of struts.29 Likewise,
our results for the all-strut analysis are similar to the ones
reported by OCT in the ODESSA trial.8 Nonetheless,
factors other than the layer effect, such as differences
in overlap length or in the stent-to-artery ratio between
experimental and clinical procedures, could also
contribute to the discrepancy between histology and
OCT studies.
Another important methodological detail is the
skewed distribution of the thickness of coverage.
Summarizing this variable by a mean can be totally
misleading, as previously demonstrated.21 Normalization
of the variable is mandatory if the statistical method
requires normal distribution.
Although the average results show significantly greater
neointimal inhibition in overlapping regions, it is to
notice that the neointimal reaction is subjected to large
variability between the different individual cases ana-
lyzed. This hypothesis led to a prespecified analysis taking
into account an eventually heterogeneous effect. The
results confirm the hypothesis, demonstrating and
quantifying this heterogeneity. Heterogeneity might
explain the discrepancy between histology and some
angiographic studies: overlaps are subjected to more
intense neointimal inhibition, as suggested by histology
and indirectly by some angiographic studies,30 but this
effect is not homogeneous, and in some cases, the
neointimal proliferation is rather exaggerated. Angio-
graphic studies usually reflect these hyperproliferative
cases because they lack the resolution to detect subtle
changes in the neointimal layer. This would explain the
greater angiographic late loss and binary restenosis in
overlaps found in most angiographic studies,6,7 despite
an average more intense neointimal inhibition, and why
clinical studies show worse outcomes both in terms of
repeated revascularization and of death/myocardial
infarction.7 The characteristics of the underlying lesion/
vessel at the site of overlap could explain partly this
heterogeneous response.31
To our knowledge, this is the first OCT study assessing
the coverage of overlaps in second-generation DES. A
similar trend was observed in all types of DES analyzed,
with no significant deviation in meta-regression. The lack
of significance in the BES subgroup is likely attributable to
the small number of overlaps in this subgroup (n = 3)
rather than to a true biological effect. These results will
deserve further clarification in the future.
Limitations
This is a post hoc analysis of data prospectively
collected in randomized trials15,18; the level of evidence
generated by this kind of design is weaker than in a
properly randomized study.8
Considering OCT, tissue coverage as surrogate for
neointimal healing is biologically plausible and intuitively
accepted by the scientific community, but still, caution is
required. Optical coherence tomography tissue coverage
correlates with histologic neointimal healing and
endothelialization after stenting in animal models,32,33
but its sensitivity and specificity in human atherosclerotic
vessels are still unknown. Optical coherence tomography
cannot detect thin endothelial layers below 14-μm axial
resolution and cannot discern between neointima and
other material such as fibrin or thrombus. The analysis of
optical density might help in the future.24
The lack of prestenting and immediately poststenting
OCT pullbacks prevented to explore the role played in
the outcome by the underlying plaque characteristics and
the postprocedural intervention results, respectively.
These factors might partially explain the heterogeneity
of the effect described. This study was underpowered to
explore all possible sources of heterogeneity, comprising
patient-, vessel-, procedure-, and device-related factors.
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Only the influence of the type of stent was explored by
means of a stratified analysis. This kind of subgroup
analysis must be considered exploratory and hypothesis
generating; it cannot be interpreted as a comparison
between the different types of stents.
This analysis included OCT studies performed with
different OCT systems, at different follow-up periods
and, using the highest pullback speed available, to
improve the acquisition with the nonocclusive tech-
nique. Although these are potential limitations, the axial
resolution in all the systems and pullback speeds remains
the same,19,20,34 and in each case, the follow-up was
scheduled after healing was estimated to be maximal.
Pullback speed may affect the longitudinal resolution
and the distortion induced by cardiac motion artefact,
but it does not seem to affect the axial resolution of the
images, which is the most relevant feature for assess-
ment of coverage.34 The statistical analysis compared
the coverage in overlaps versus nonoverlapping seg-
ments of the same stents, thus minimizing the impact of
the aforementioned limitations in the final results.
Although currently there is no compelling evidence
about the optimal longitudinal segmentation for strut
analysis in OCT studies, analysis at b1-mm intervals
might have improved the sensitivity to detect small
regions of uncoverage or malapposition.
Our results correspond to a routine clinical scenario in
which the length of the overlapping segments was much
shorter than that of the nonoverlapping segments. The
conclusion might be different in a scenario in which the
length of the overlap was relatively longer, similarly to
some experimental studies.28 Likewise, this analysis
corresponds to those patients who required overlapping
stents during the intervention, a relatively small sub-
group, eventually reflecting a more adverse clinical
scenario than the average patient undergoing percutane-
ous coronary intervention. This might have introduced
some bias in the results and explain partially the
differences with previous studies.
Conclusion
The effect of overlapping DES on neointimal inhibition
is markedly heterogeneous: on average, DES overlap is
associated with more incomplete and thinner coverage,
but in some cases, the overlap elicits an exaggerated
neointimal reaction, thicker than in the corresponding
nonoverlapping segments. These results might help to
understand why overlapping DES is associated with
worse clinical outcomes, both in terms of thrombotic
phenomena and in terms of restenosis revascularization.
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Appendix
Supplementary Table I. Angiographic characteristics of the lesions grouped by type of stent
SES (n = 9) BES (n = 3) EES (n = 12) ZES (n = 9) P
Target vessel .182
LM 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
LAD 4 (44.4%) 2 (66.7%) 1 (8.3%) 5 (55.6%) .073
LCX 0 (0.0%) 0 (0.0%) 3 (25.0%) 1 (11.1%) .317
RCA 5 (55.6%) 1 (33.3%) 8 (66.7%) 3 (33.3%) .432
TO 1 (11.1%) 1 (33.3%) 2 (16.7%) 1 (11.1%) .796
Ostial lesion 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (11.1%) .432
Bifurcation 0 (0.0%) 0 (0.0%) 4 (33.3%) 3 (33.3%) .166
Mod or severe calcific 2 (22.2%) 0 (0.0%) 0 (0.0%) 2 (22.2%) .285
QCA characteristics
Lesion length (mm) 16.7 (10.8) 10.9 (10.0) 18.3 (14.5) 13.6 (11.7) .681
Prestenting
RVD (mm) 2.51 (0.60) 3.25 (0.60) 2.37 (0.49) 2.82 (0.41) .184
MLD (mm) 0.74 (0.63) 0.78 (1.10) 0.66 (0.48) 0.91 (0.48) .794
% Diameter stenosis 71 (23) 76 (34) 73 (18) 68 (14) .945
Poststenting
In-stent
RVD (mm) 2.85 (0.60) 2.49 (0.78) 2.89 (0.46) 2.89 (0.46) .691
MLD (mm) 2.30 (0.49) 2.08 (0.89) 2.39 (0.52) 2.43 (0.38) .765
% Diameter stenosis 19 (6) 17 (14) 18 (8) 16 (8) .857
In-segment
RVD (mm) 2.76 (0.60) 2.37 (0.84) 2.68 (0.52) 2.73 (0.33) .721
MLD (mm) 2.02 (0.56) 1.57 (0.56) 1.95 (0.39) 2.14 (0.34) .292
% Diameter stenosis 27 (9) 34 (2) 27 (8) 21 (11) .188
Continuous variables are reported as mean (SD) and categorical variables as n (%); stent groups are compared with 1-way analysis of variance and Pearson χ2, respectively. LM, Left
main stem; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; TO, total occlusion; QCA, quantitative coronary angiography; RVD, reference vessel
diameter; MLD, minimal lumen diameter.
Supplementary Table II. Areas and volumetric analysis of the overlap segments compared with the proximal and distal nonoverlap segments
of the same stents, stratified by stent type
31 patients,
33 lesions,
42 overlaps
SES: 9 patients,
9 lesions,
11 overlaps
BES: 3 patients,
3 lesions,
3 overlaps
EES: 11 patients,
12 lesions,
17 overlaps
ZES: 8 patients,
9 lesions,
11 overlaps
Overlap Nonoverlap P Overlap Nonoverlap P Overlap Nonoverlap P Overlap Nonoverlap P
Stent length (mm) 4.3 (2.5) 27.1 (11.0) .003⁎ 11.5 (15.8) 32.0 (21.2) .285 2.8 (2.6) 33.4 (11.6) b.0001⁎ 2.8 (2.4) 34.7 (13.4) .003⁎
MLA (mm2) 6.64 (1.80) 4.35 (2.21) .003⁎ 6.24 (2.80) 3.80 (4.15) .285 6.54 (2.92) 4.77 (2.80) b.0001⁎ 5.32 (2.12) 3.83 (1.73) .003⁎
Mean lumen area (mm2) 7.37 (2.28) 7.25 (2.08) .722 6.68 (3.03) 6.21 (2.97) 1.000 6.91 (2.94) 7.50 (2.90) .007⁎ 5.68 (2.11) 6.18 (1.76) .041
Lumen volume (mm3) 33.1 (22.5) 178.3 (82.1) .003⁎ 92.2 (144.5) 153.7 (48.7) .593 20.5 (23.1) 228.6 (129.8) b.0001⁎ 16.4 (15.9) 202.5 (113.5) .003⁎
Minimum stent area (mm2) 7.04 (1.84) 5.25 (1.92) .003⁎ 6.69 (2.66) 4.44 (3.78) .285 7.65 (3.07) 6.06 (2.62) .001⁎ 6.13 (1.70) 4.89 (1.74) .004⁎
Mean stent area (mm2) 7.83 (2.30) 7.40 (1.91) .155 7.19 (2.90) 6.40 (2.93) 1.000 8.19 (2.95) 8.16 (2.81) .758 6.56 (1.70) 6.68 (1.69) .213
Stent volume (mm3) 34.7 (22.3) 190.9 (84.2) .003⁎ 96.7 (149.8) 176.5 (77.4) .593 24.0 (26.2) 269.3 (126.3) b.0001⁎ 18.7 (16.9) 237.9 (121.0) .003⁎
% Frames with ISA 5.37 (15.05) 4.01 (9.14) .917 0.00 (0.00) 0.00 (0.00) 1.000 1.96 (8.08) 2.14 (3.11) .236 1.82 (6.03) 1.42 (2.82) 1.000
Maximum ISA area (mm2) 0.04 (0.10) 0.99 (2.12) .116 0.00 (0.00) 0.00 (0.00) 1.000 0.02 (0.07) 0.47 (0.88) .028⁎ 0.02 (0.08) 0.11 (0.21) .109
ISA volume (mm3) 0.03 (0.09) 3.48 (9.98) .116 0.00 (0.00) 0.00 (0.00) 1.000 0.01 (0.05) 1.03 (1.99) .028⁎ 0.01 (0.04) 0.18 (0.41) .109
Corrected by stent
volume (%)
0.23 (0.65) 1.65 (4.58) .345 0.00 (0.00) 0.00 (0.00) 1.000 0.14 (0.59) 0.27 (0.52) .237 0.06 (0.19) 0.06 (0.14) 1.000
Maximum NIH area (mm2) 0.73 (0.59) 1.70 (0.92) .006⁎ 0.90 (0.39) 1.44 (0.79) .285 1.68 (1.01) 2.70 (0.82) .001⁎ 1.31 (0.62) 2.08 (0.49) .003⁎
NIH volume (mm3) 1.6 (1.5) 16.2 (12.4) .003⁎ 4.6 (5.4) 22.8 (29.6) .285 3.5 (3.5) 41.8 (18.5) b.0001⁎ 2.2 (1.6) 35.6 (14.2) .003⁎
In-stent NIH
volume obstruction (%)
6.2 (6.0) 8.8 (6.4) .091 9.0 (7.1) 10.1 (10.0) 1.000 17.3 (12.0) 18.8 (10.8) .309 15.5 (10.6) 16.5 (7.1) .594
Continuous variables are reported as mean (SD) and categorical variables as n (%); stent groups are compared with 1-way analysis of variance and Pearson χ2, respectively. DCB,
Drug-coated balloon; MLA, minimal lumen area.
⁎ P ≤ .05.
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Supplemental methods: detailed
explanation of the statistical analysis
Pooled analysis is particularly suitable for the statistical
analysis of an effect by combining data from different
groups of subjects, each group submitted to slightly
different environmental conditions. In this situation, it is
not acceptable to merge all the individuals together and
apply conventional statistics, because one of the re-
quirements for this approach is not accomplished: the
individual measurements are not independent from each
other, but strongly interdependent within the groups.
The biomedical community is actually very familiar
with the methodology of pooled analysis because it is
used in the following:
• Meta-analysis35
• Epidemiology36
In this study, we apply a pooled statistical method for
the analysis of OCT data because the clustering of data is
an analogous methodological problem to the one faced
by meta-analysis or by epidemiologic studies in commu-
nities. Pooled analysis has been previously applied to
OCT studies,37-39 offering the advantage of presenting
the data on a format the biomedical community is more
familiar with.
Pooled statistics can be used in meta-analysis (com-
bining different trials or studies), in interventional
epidemiology (combining different communities), or in
OCT studies (combining the results from different
stents, or in this specific case from different overlaps)
(Supplementary Figure 2). A detailed explanation of the
principles of pooled analysis applied to OCT studies can
be found in Gutiérrez-Chico et al (Circulation 2011) as
supplementary material.38
Number of stents analyzed
The number of stents analyzed depends on the research
question because not all the stents in the sample might be
informative for all possible research questions.
In a meta-analysis, we search for the trials (or studies)
addressing our research question, and then we select
those which are truly informative to answer the question.
To be informative, a trial must have the following:
• Exposition to the study factor
• Events (at least in one of the arms)
In a trial, the “exposition” is guaranteed (randomiza-
tion), but if we performed a meta-analysis of observa-
tional studies and we found studies with no exposition,
they would be discarded (they are not informative for our
research question).
Likewise, trials with no events (0 events in both arms)
should be discarded (they are not informative for our
research question).
Supplementary Figure 1
Flowchart summarizing the patients and stents included in this study,
pooled from 2 different OCT randomized trials.
Supplementary Figure 2
Schematic representation of the clustering of measurements in different
study designs: meta-analysis, epidemiology, and OCT studies. Pooled
analysis can be used in all these designs in which individual mea-
surements (patients, individuals, or struts) are grouped into different
units of clustering (trial, community, or stent), respectively.
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In our OCT study (Supplementary Figure 3), these
principles are applied as follows:
• Research question: comparing the coverage of over-
lapping versus nonoverlapping segments as a binary
outcome per strut
o Stents with no exposition (no overlap) are
discarded.
o Stents with no events (complete coverage of over-
lapping and nonoverlapping segments) are
discarded.
• Research question: comparing the thickness of
coverage in overlapping versus nonoverlapping
segments
o Stents with no exposition (no overlap) are
discarded.
o Stents with no events would be discarded, but in this
case, every single strut has a thickness of coverage
≥0, so all the overlaps are considered in the
comparison.
Supplementary References
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Supplementary Figure 3
Schematic representation of the parallelism between meta-analysis and
OCT studies when statistical pooled analysis is applied. If the target
variable of our OCT study is coverage, uncovered struts in a stent are
equivalent to events in a trial included in a meta-analysis. In this
specific OCT, we explore the effect of overlapping segments (exposed)
as compared with nonoverlapping segments (nonexposed) on strut
coverage (target variable, events).
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CLINICAL RESEARCH Interventional Cardiology
Impact of Stent Overlap on Angiographic
and Long-Term Clinical Outcome in Patients
Undergoing Drug-Eluting Stent Implantation
Lorenz Räber, MD,* Peter Jüni, MD,†‡ Lukas Löffel, BA,* Simon Wandel, PHD, MSC,‡
Stéphane Cook, MD,* Peter Wenaweser, MD,* Mario Togni, MD,* Rolf Vogel, MD, MSC,*
Christian Seiler, MD,* Franz Eberli, MD,§ Thomas Lüscher, MD, Bernhard Meier, MD,*
Stephan Windecker, MD*†
Bern and Zurich, Switzerland
Objectives We compared the angiographic and long-term clinical outcomes of patients with and without overlap of drug-
eluting stents (DES).
Background DES overlap has been associated with delayed healing and increased inflammation in experimental studies, but
its impact on clinical outcome is not well established.
Methods We analyzed the angiographic and clinical outcomes of 1,012 patients treated with DES in the SIRTAX (Sirolimus-
Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) trial according to the presence or absence of
stent overlap and the number of stents per vessel: 134 (13.2%) patients with multiple DES in a vessel with overlap,
199 (19.7%) patients with multiple DES in a vessel without overlap, and 679 (67.1%) patients with 1 DES per vessel.
Results Angiographic follow-up at 8 months showed an increased late loss in DES overlap patients (0.33  0.61 mm)
compared with the other groups (0.18  0.43 mm and 0.15  0.38 mm, p  0.01). The smallest minimal lu-
men diameter was located at the zone of stent overlap in 17 (68%) of 25 patients with stent overlap who under-
went target lesion revascularization. Major adverse cardiac events were more common in patients with DES
overlap (34 events, 25.4%) than in the other groups (42 events, 21.1% and 95 events, 14.0%) at 3 years (p 
0.01). Both the risk of target lesion revascularization (20.2% vs. 16.1% vs. 9.7%, p  0.01) and the composite
of death or myocardial infarction (17.2% vs. 14.1% vs. 9.1%, p  0.01) were increased in patients with DES
overlap compared with the other groups.
Conclusions DES overlap occurs in 10% of patients undergoing percutaneous coronary intervention in routine clinical practice
and is associated with impaired angiographic and long-term clinical outcome, including death or myocardial infarc-
tion. (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization; NCT00297661). (J Am Coll
Cardiol 2010;55:1178–88) © 2010 by the American College of Cardiology Foundation
Stent overlap has been reported in as many as 30% of
patients undergoing percutaneous coronary interventions
owing to excessive lesion length, edge dissections, or incom-
plete stent coverage (1–3). Clinical outcome of patients with
overlapping bare-metal stents (BMS) has been found to be
inferior to that of patients treated with a single BMS, largely
related to increased rates of target lesion revascularization
(TLR) (4–7). The potent suppression of neointimal hyper-
plasia afforded by first-generation drug-eluting stents
(DES) with a reduction in clinical and angiographic reste-
nosis raised hopes of further improvement of results in
patients with stent overlap (8–12). Yet, clinical outcomes of
overlapping DES demonstrated conflicting results. A
pooled analysis of studies assessing clinical outcomes of
overlapping sirolimus-eluting stents (SES) showed similar
rates of ischemic end points and repeat revascularization at
both 30 days and 8 months compared with a single SES,
and a significant reduction in the need for repeat revascu-
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larization compared with a BMS (13). Conversely, multiple
overlapping paclitaxel-eluting stents (PES) were associated
with improved efficacy but increased rates of periprocedural
myonecrosis compared with overlapping BMS, presumably
related to more frequent side branch compromise (14,15).
More recently, safety concerns surfaced with the use of
first-generation DES during long-term follow-up, presum-
ably related to delayed healing and impaired endotheliali-
zation (16). The latter phenomenon may be particularly
pronounced at sites of DES overlap owing to increased drug
and polymer concentrations. One experimental study spe-
cifically addressed the differential response of arterial heal-
ing at sites of DES overlap. Compared with nonoverlapping
DES and BMS sites, overlapping DES segments showed
more neutrophils, eosinophils, and fibrin deposition, sug-
gesting impaired healing and increased inflammation (17).
However, the impact of these findings on long-term clinical
outcomes is not well established. The objective of the
present study was to compare the angiographic and long-
term clinical outcomes of patients with overlapping DES
compared with those of patients with multiple DES with no
overlap, or a single DES implanted in a vessel.
Methods
Patient population and intervention. The design of the
SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting
Stents for Coronary Revascularization) trial was previously
reported (18). It was an observer-blind, randomized, con-
trolled trial comparing the safety and efficacy of SES and
PES in 1,012 patients undergoing percutaneous coronary
interventions. Eligible patients had a history of stable
angina or acute coronary syndrome and presented with at
least 1 lesion with a stenosis 50% in a vessel with a
reference vessel diameter between 2.25 and 4.0 mm suitable
for stent implantation. There were no limitations on the
number of treated lesions and vessels or lesion length.
Before or at the time of the procedure, patients received at
least 100 mg of aspirin, a loading dose of clopidogrel, and
unfractionated heparin (70 to 100 U/kg body weight). After
the procedure, all patients were prescribed lifelong aspirin
therapy and clopidogrel for 12 months. All patients were
requested at the time of randomization to undergo repeat
angiography at 8 months. Subsequently, a research nurse
contacted all patients and asked them at least once to
schedule an appointment for repeat angiography. The study
complied with the Declaration of Helsinki regarding inves-
tigations in humans and was approved by the research ethics
committees at the University Hospitals of Bern and Zurich,
Switzerland. All patients provided written informed consent.
Definition and end points. Stent overlap was defined as
the presence of 2 stents within a single treated lesion and
an overlapping stent zone of at least 1 mm, as determined by
quantitative coronary angiography. Overlapping stent zones
were identified based on the po-
sition of the stent balloon mark-
ers of the second stent relative to
the first stent. Adverse events were
assessed during the hospitaliza-
tion, at 1, 6, and 9 months and at
1, 2, and 3 years. An independent
clinical events committee unaware
of the patient’s treatment assign-
ment adjudicated all end points.
The prespecified primary end
point was a composite of major
adverse cardiac events (MACE),
defined as cardiac death, myocar-
dial infarction (MI), or ischemia-
driven TLR at 9 months. Second-
ary end points included ischemia-driven TLR, target vessel
revascularization, or target vessel failure at all scheduled
follow-up visits. Definitions of ischemia-driven TLR, MI, and
stent thrombosis were published previously (18).
Quantitative coronary angiography. Coronary angio-
grams were digitally recorded at baseline, immediately after
stent implantation, and at follow-up and were assessed at
the angiographic core laboratory of the University of Bern.
Digital angiograms were analyzed with the use of an
automated edge-detection system (CAAS II, Pie Medical
Imaging, Maastricht, the Netherlands). Quantitative mea-
surements included the reference vessel diameter, the min-
imal lumen diameter, and percentage of diameter stenosis.
Binary restenosis was defined as stenosis50% in the target
lesion at angiographic follow-up. All angiographic measure-
ments of the target lesion were obtained within the stent
and the areas 5 mm proximal and distal to the stent edge.
All lesions of patients with stent overlap who underwent
TLR at any time point up to 3 years were analyzed by
quantitative coronary angiography to determine the zone of
restenosis triggering the repeat revascularization and the site
of minimal lumen diameter. The restenosis pattern was
analyzed independently by 2 fellows in cardiology (L.R. and
L.L.). In cases of disagreement, an external cardiologist who
was not involved in the SIRTAX trial made the final
decision.
Statistical analysis. For the purpose of the present study,
we performed an analysis of clinical and angiographic
outcomes stratified according to the presence or absence of
stent overlap. Among patients without overlap, we specified
2 groups: the first group consisted of patients with multiple
DES within a vessel but no overlap, and the second group
consisted of the remaining patients who had a single DES
implanted within a vessel.
Patient characteristics at baseline were compared among
the 3 patient groups using chi-square tests for binary and
maximum-likelihood linear regression models for continu-
ous outcomes, which allowed the comparison of the 3
groups. In cases of multiple lesions in a patient, we restricted
the analysis to the lesions that led to the final classification
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
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of patients: If patients were classified as having stent
overlap, we excluded lesions without documented overlap
(n  64 lesions); if patients were classified as having
multiple DES in a vessel but no overlap, we excluded lesions
in vessels with only 1 DES implanted (n  34 lesions).
Lesion characteristics were compared using maximum-
likelihood logistic and linear regression models with robust
standard errors that accounted for the correlation of lesion
characteristics within patients. We then used Cox propor-
tional hazards models along with Wald tests to allow an
overall comparison of outcomes of all 3 groups. We per-
formed crude analyses and analyses adjusted for the presence
or absence of diabetes, lesion length, reference vessel diam-
eter, number of lesions, stent allocation, American College
of Cardiology/American Heart Association lesion classifi-
cation, and the presence of acute coronary syndrome and
plotted Kaplan-Meier survival curves of MACE, TLR, and
the composite of death or MI. The analyses of patients and
clinical outcomes were based on all 1,012 patients included
in the SIRTAX trial, with patients censored at the time of
loss to follow-up. The analysis of angiographic outcomes
was restricted to the 540 patients with available angiographic
follow-up at 8 months. We used maximum-likelihood logistic
and linear regression models based on robust standard errors
that allowed for the correlation of multiple lesions within a
patient to compare the quantitative angiographic data across
groups. Then we restricted the analysis to the 27 lesions with
stent overlap that underwent TLR and used a maximum-
likelihood logistic regression model with robust standard errors
that allowed for the correlation of stent zones within a lesion to
perform a test for trend on the pattern of restenosis across
ordered zones: zone of overlap, zone of nonoverlap, and
zone of stent border. All p values are 2 sided. Analyses were
performed using Stata version 10.1 software (StataCorp,
Inc., College Station, Texas).
Results
Baseline clinical and angiographic characteristics. A to-
tal of 1,012 patients were randomly allocated to treatment
with SES (n  503) or PES (n  509). Multiple DES in a
vessel with overlap were documented in 134 (13.2%) pa-
tients with 138 lesions, multiple DES in a vessel without
overlap in 199 (19.7%) patients with 394 lesions, and a
single DES in a vessel in 679 (67.1%) patients with 778
lesions. There were significant differences among groups in
age, the presence of multivessel disease, and the number of
lesions per patient (all p values 0.01) (Table 1). Lesion
characteristics differed significantly among groups in all
respects except reference vessel diameter (Table 2); lesions
with stent overlap were most complex. Procedural results are
summarized in Table 3. Patients with DES overlap received
more and longer stents per lesion compared with the control
groups (p  0.01) and differed in acute gain (p  0.01). The
reasons for stent overlap were, in descending order (Table 4),
excessive lesion length in relation to maximal available stent
length (43.5%), incomplete target lesion coverage (35.5%), and
dissections at the stent edges (19.6%).
Clinical outcomes. Clinical outcome data were complete
for 1,002 (99.0%) of 1,012 patients at 3 years of follow-up.
Crude and adjusted analyses of clinical events at 3 years of
follow-up are presented in Table 5. Compared with con-
trols, patients with DES overlap were more likely to
experience a MACE in crude (p  0.01) and adjusted
(p  0.04) analyses. The individual hazard ratio comparing
DES overlap patients with patients with multiple DES in a
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Multiple Stents
Single Stent‡ p Value§Overlap* No Overlap†
Total no. of patients 134 199 679
Age 65 yrs 45 (33.6) 104 (52.3) 293 (43.2) 0.01
Males 107 (79.9) 150 (75.3) 524 (77.2) 0.63
Diabetes mellitus 23 (17.2) 47 (23.6) 131 (19.3) 0.28
Hypertension 90 (67.2) 122 (61.3) 410 (60.4) 0.34
Hyperlipidemia 80 (59.7) 109 (54.8) 408 (60.1) 0.40
Current smoking 52 (38.8) 69 (34.7) 244 (35.9) 0.74
Previous MI 42 (31.3) 62 (31.2) 193 (28.4) 0.65
Stable angina pectoris 58 (43.3) 88 (44.2) 346 (51.0) 0.10
Acute coronary syndromes 76 (56.7) 111 (55.8) 333 (49.0) 0.26
Unstable angina 8 (6.0) 9 (4.5) 41 (6.0)
Non–ST-segment elevation MI 39 (29.1) 50 (25.1) 146 (21.5)
ST-segment elevation MI 29 (21.6) 52 (26.1) 146 (21.5)
Multivessel disease 95 (70.9) 143 (71.9) 364 (53.6) 0.01
No. of lesions per patient 1.5 (0.6) 2.2 (0.5) 1.1 (0.4) 0.01
Left ventricular ejection fraction 56.5 (10.6) 55.7 (11.9) 57.1 (11.9) 0.35
Values are n (%) or mean SD. *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without
overlap. ‡Patients with a single stent in a vessel. §p values are for differences among groups.
MI  myocardial infarction.
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vessel without overlap was 1.22 in crude analyses (95%
confidence interval [CI]: 0.77 to 1.91, p  0.40), but 1.99
in adjusted analyses (95% CI: 1.16 to 3.41, p  0.01).
Conversely, the hazard ratio comparing DES overlap pa-
tients with patients with a single DES in a vessel was 1.93
in crude analyses (95% CI: 1.3 to 2.85, p  0.01) and 1.50
in adjusted analyses (95% CI: 0.91 to 2.46, p  0.11). The
differences were driven by both effectiveness (crude and
adjusted analyses of TLR: p  0.01 and p  0.10,
respectively) and safety end points (composite of death or
MI: p  0.01 and p  0.02, respectively). Table 6 presents
shorter-term results at 30 days of follow-up; no clear-cut
pattern could be detected. There was little evidence of a
worse outcome in patients with stent overlap, but 95% CIs
were wide. At 9 months, the pattern of MACE, TLR, and
the composite of death or MI was similar to that at 3 years.
In adjusted analyses, the hazard ratio comparing DES
overlap patients with patients with 1 stent per vessel but
Baseline Characteristics of LesionsTable 2 Baseline Characteristics of Lesions
Multiple Stents
Single Stent‡ p Value§Overlap* No Overlap†
Total no. of lesions 138 394 778
Target lesion coronary artery
Left main 2 (1.5) 1 (0.1) 16 (2.1) 0.01
Left anterior descending 53 (38.4) 177 (44.9) 379 (48.7)
Left circumflex 27 (19.6) 63 (16.0) 159 (20.4)
Right 53 (38.4) 143 (36.3) 214 (27.5)
Bypass graft 3 (2.2) 10 (2.5) 10 (1.3)
ACC/AHA lesion class
A 19 (13.8) 74 (18.8) 167 (21.5) 0.01
B1 39 (28.3) 181 (45.9) 347 (44.6)
B2 44 (31.9) 79 (20.1) 186 (23.9)
C 36 (26.1) 60 (15.2) 78 (10.0)
Angiographic measures
Lesion length, mm 17.07 10.54 12.62 8.71 11.11 4.87 0.01
Reference vessel diameter, mm 2.83 0.40 2.80 0.41 2.84 0.41 0.28
Minimal lumen diameter, mm 0.41 0.45 0.64 0.47 0.49 0.42 0.01
Stenosis, % lumen diameter 85.37 15.39 77.40 15.24 82.91 14.05 0.01
Values are n (%) or mean SD. *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without
overlap. ‡Patients with a single stent in a vessel. §p values are for differences among groups from linear and logistic regression models using robust
sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients.
ACC/AHA  American College of Cardiology/American Heart Association.
Quantitative Procedural ResultsTable 3 Quantitative Procedural Results
Multiple Stents
Single Stent‡ p Value§Overlap* No Overlap†
Total no. of lesions 138 394 778
Procedures
No. of stents, per lesion 2.2 0.5 1.1 0.3 1.0 0.1 0.01
Stent diameter, mm 2.8 0.4 2.9 0.4 2.9 0.4 0.01
Stent length per lesion, mm 36.6 16.7 17.2 8.8 16.7 6.4 0.01
Maximal pressure, atm 14.3 2.9 14.0 3.1 14.3 3.0 0.46
Angiographic results
Final minimal lumen diameter, mm
In-stent 2.65 0.35 2.63 0.36 2.69 0.38 0.05
In-segment 2.54 0.40 2.53 0.40 2.62 0.43 0.04
Final stenosis, % of lumen diameter
In-stent 7.73 4.71 7.16 4.65 6.82 5.39 0.12
In-segment 9.24 6.85 8.63 6.82 8.50 7.12 0.68
Acute gain, mm
In-stent 2.23 0.56 1.99 0.49 2.20 0.50 0.01
In-segment 2.16 0.55 1.91 0.53 2.15 0.53 0.01
Values are mean SD. *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap.
‡Patients with a single stent in a vessel. §p values are for differences among groups from linear and logistic regression models using robust
sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients.
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no overlap was 2.34 for MACE (95% CI: 1.12 to 4.92), 2.77
for TLR (95% CI: 1.18 to 6.50), and 1.69 for the composite
of death or MI (95% CI: 0.60 to 4.75). The corresponding
Kaplan-Meier curves for MACE, TLR, and the composite
of death or MI are presented in Figure 1. Cumulative event
curves of patients with DES overlap and patients with a
single stent in a vessel started to diverge immediately after
randomization for all end points; curves for patients with
overlap and for patients with multiple stents in a vessel but
no overlap started to diverge only at 12 to 24 months.
Angiographic results. The angiographic follow-up was
performed at a median of 8.3 months (interquartile range
7.2 to 10.3 months) after randomization. A total of 540
(53.4%) patients underwent angiography, 167 (16.5%) pa-
tients refused, 287 (28.4%) patients consented and were
invited but did not attend angiography, 16 (1.6%) patients
died, and 2 (0.2%) patients were lost to follow-up before
follow-up angiography could be performed. Angiographic
follow-up data were available for 77 patients with overlap
(81 lesions), 101 patients with multiple DES in a vessel
without overlap (177 lesions), and 362 patients with a single
DES per vessel (413 lesions) (Table 7). Patients undergoing
angiographic follow-up were younger (p  0.01), more
likely to be male (p  0.01), and less likely to have diabetes
(p  0.04), hypertension (p  0.04), or chest pain (p 
0.01) (18). In 18 of the 77 patients with stent overlap, the
minimal lumen diameter measured immediately after the
index procedure was located at the zone of overlap (23.4%),
and the subgroup of patients undergoing TLR (n  27)
showed the same pattern. The in-stent percentage diameter
stenosis was more pronounced among patients with overlap
compared with control groups (18.8% vs. 12.2% and 10.4%,
p  0.01), as were in-stent late loss (0.33 mm vs. 0.18 and
0.15 mm, p  0.04) and binary in-stent restenosis (12.4%
vs. 5.1% and 3.6%, p 0.01). Stent fractures were observed in
1 of the 77 patients with overlap at angiographic follow-up.
Pattern of restenosis. Twenty-seven patients with 27 le-
sions with DES overlap underwent TLR during the
follow-up up to 3 years. Angiograms obtained before TLR
were available for 25 of the 27 patients. Figure 2 presents
the distribution of restenoses across the different zones of
the treated lesions. Of 25 lesions, 17 (68%) had documented
binary restenosis at the zone of stent overlap as opposed to
6 (24%) at the proximal stent zones without overlap, 4
(16%) at the distal stent zones without overlap, 4 (16%)
within the proximal edge, and 1 (4%) within the distal edge
(p for trend 0.01). The minimal lumen diameter within a
treated lesion, corresponding to the area of maximal reste-
nosis, was located at the zone of DES overlap in 17 of the
25 (68%) lesions, within the proximal or distal stent area in
4 (16%) lesions, and within 5 mm of the proximal or distal
stent edges in another 4 (16%) lesions (p for trend 0.01).
In 18 lesions, restenoses were classified as focal (72%), as
multifocal in 3 (12.0%), and as diffuse in the remaining 4
(16.0%). Among lesions classified as having a focal resteno-
sis, 6 had total occlusion. Focal restenoses predominantly
occurred in the overlapping stent zone; 3 (50%) of 6 cases
with total occlusion and 9 (75%) of 12 cases without total
occlusion were found at the zone of stent overlap. Figure 3
shows a representative example of focal restenosis associated
with stent overlap, and Figure 4 shows an example of a
lesion with stent overlap and subsequent total occlusion.
Discussion
In this analysis of the 3 years of follow-up of the SIRTAX
trial, we found patients with DES overlap at increased risk
of MACE, including repeat revascularization and ischemic
adverse events. At 1 month, there was little evidence of
increased rates of MACE associated with DES overlap, but
95% CIs were wide and we cannot exclude substantial
differences among groups. Clinical findings at 9 months and
3 years of worse outcomes in patients with overlap were
echoed by inferior angiographic outcomes at 8 months.
Twenty-five patients with DES overlap and available an-
giographic data underwent TLR of a lesion. Among these,
12 (48%) had focal restenosis or total occlusion at the site of
overlap and an additional 5 (20%) had diffuse restenosis
with the minimal lumen diameter located at the site of
overlap. The most frequent reasons for DES overlap were
an excessive lesion length in relation to maximal available
stent length and insufficient lesion coverage, whereas peris-
tent or guiding catheter dissections were rare.
Study strengths and limitations. Our analysis is based on
the nearly complete follow-up of the SIRTAX trial, a
randomized superiority trial in an unselected all-comer
population seen at 2 major cardiovascular centers in Swit-
zerland. Allocation of patients was concealed, treatment
protocols were standardized, there was active follow-up of
patients with blinded adjudication of clinical events, and the
analysis was according to the intention-to-treat principle
(18). A major limitation of this and any other study
comparing outcomes in patients with and without overlap is
the selection of control individuals, which is inherently
related to prognosis. Patients with stent overlap tend to have
more, longer, and more complex lesions than controls, and
statistical attempts to control the resulting confounding may
only be partially successful. We therefore opted for compar-
ing patients with stent overlap with 2 different groups: 1
group of patients with multiple DES within a vessel but no
Overlapping Stents: Reason forImpl ntation per LesionTable 4 Ov rlapping Stents: Reason forOverlapping Stent Implantation per Lesion
Total no. of lesions 138 (100)
Excessive lesion length 60 (43.5)
Incomplete lesion coverage 49 (35.5)
Dissection proximal 12 (8.7)
Dissection distal 15 (10.9)
Guiding catheter dissection 1 (0.7)
Residual thrombus 1 (0.7)
Values are n (%).
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overlap and 1 group with implantation of a single DES only
within a vessel. To ensure full transparency, we present
results from both unadjusted analyses and analyses adjusted
for the most important confounding factors. It is the
consistency of the different comparisons and of the crude
and adjusted analyses that supports our conclusion that
patients with DES overlap are at increased risk of MACECl
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Figure 1 Time to Event Curves for Various Clinical End Points
Kaplan-Meier cumulative event curves for major adverse cardiac events (MACE)
(A) (composite of cardiac death, myocardial infarction [MI], or ischemia-driven
revascularization of the target lesion), target lesion revascularization (TLR) (B), and
the composite of overall death or MI (C). p values are for differences in hazards
among groups in crude and adjusted analyses. DES  drug-eluting stent(s).
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Figure 2 Pattern of Restenosis in Patients With Overlapping Stents
The lesions of 25 patients with overlapping stents who underwent target lesion revascularization within the 3-year follow-up period are shown. This figure provides an
example of the different zones of a lesion (middle), a schematic representation of all 25 lesions, and the locations of binary restenosis represented by a blue-colored
bar (bottom) and a summary histogram of the distribution of zones affected by binary restenosis (top). The p value is for trend across ordered zones and derived from a
logistic regression model with robust sirolimus-eluting stents (see Methods section). p  0.01.
Angiographic ResultsTable 7 Angiographic Results
Multiple Stents
Single Stent (C)
Difference (95% CI)
p Value*Overlap (A) No Overlap (B) A vs. B A vs. C
Total no. of lesions 81 177 413
Minimal lumen
diameter, mm
In-stent 2.30 0.71 2.44 0.55 2.57 0.54 0.14 (0.32 to 0.03) 0.27 (0.42 to0.11) 0.01
In-segment 2.18 0.73 2.31 0.61 2.39 0.64 0.12 (0.30 to 0.06) 0.20 (0.37 to0.04) 0.04
% diameter stenosis
In-stent 18.8 22.65 12.2 15.83 10.40 13.87 6.62 (1.18 to 12.05) 8.36 (3.45 to 13.28) 0.01
In-segment 21.2 23.90 16.0 18.02 16.28 18.34 5.21 (0.67 to 11.08) 4.95 (0.40 to 10.30) 0.17
Late loss, mm
In-stent 0.33 0.61 0.18 0.43 0.15 0.38 0.15 (0.00 to 0.30) 0.17 (0.04 to 0.31) 0.04
In-segment 0.36 0.63 0.22 0.45 0.24 0.49 0.14 (0.01 to 0.29) 0.12 (0.02 to 0.26) 0.18
Binary restenosis
In-stent 10 (12.4) 9 (5.1) 15 (3.6) 7.2 (0.1 to 14.6) 8.7 (1.8 to 12.7) 0.01
In-segment 12 (14.8) 14 (7.9) 33 (8.0) 6.9 (1.4 to 15.3) 6.8 (0.0 to 13.8) 0.13
Values aremean SD or n (%). All analyses are based on regressionmodels using robust sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients. Italics indicate
pairwise comparisons that are statistically significant at the conventional 2-sided p 0.05 and corresponding 95% confidence intervals not overlapping the line of no difference at 0. *p values for differences
among groups.
CI  confidence interval.
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compared with any other group of patients. Ours is the only
study with a follow-up duration as long as 3 years and the
only analysis to use multiple control groups and statistical
adjustments to ensure optimal control of confounding.
Stent overlap and outcome with BMS. Ellis et al. (19)
reported the outcome of 206 patients undergoing angio-
graphic follow-up at 6 months after Palmaz-Schatz BMS
implantation. Stent overlap was associated with a higher
rate of restenosis than single stents (64% overlap vs. 30% no
overlap, p  0.001). These findings were corroborated in
several subsequent studies with multiple overlapping BMS
emerging as independent predictor of restenosis (20,21).
More recently, Kereiakes et al. (13) reported on the out-
comes of 703 patients with or without overlapping BMS. At
Figure 3 Coronary Angiography of a Restenotic, Nonocclusive Lesion Associated With DES Overlap
Angiograms before (A) and after (B) percutaneous coronary intervention in a patient treated with overlapping drug-eluting stents (DES) (2 DES each, 33 mm in length),
with a zone of overlap of 5.9 mm in length. (C) The patient presented 24 months after the index procedure with a troponin-positive non–ST-segment elevation myocardial
infarction and underwent urgent repeat angiography revealing a subtotal in-stent restenosis at the site of DES overlap.
Figure 4 Coronary Angiography of a Restenotic, Total Occlusive Lesion Associated With DES Overlap
(A) Subtotal occlusion of the right coronary artery was treated with a 28-mm drug-eluting stent (DES). (B) Due to excessive lesion length, an 8-mm DES was implanted
distally with an overlapping zone of 3 mm. (C) The post-procedural result. (D) After 3 years, the patient underwent angiography due to clinical symptoms of unstable
angina. Total occlusion was documented, and the site of occlusion was located within the previously determined site of overlap (OL).
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1-year follow-up, overlapping BMS were associated with a
higher rate of MACE, mainly driven by a greater need for
TLR (28.2% with overlapping BMS vs. 16.8% without
overlapping BMS, p  0.01). BMS overlap also resulted in
a higher rate of periprocedural MI (3.4% vs. 0.9%, p 0.03)
in this study. Similarly, Kornowski et al. (22) observed a
higher incidence of non–Q-wave MIs in patients with
(22.8%) as compared to patients without (13.4%) BMS
overlap (p  0.005).
Stent overlap and outcome with DES. Although DES
compared with BMS have significantly reduced the risk of
restenosis, knowledge regarding the early and late safety and
efficacy of DES in the presence of stent overlap is incom-
plete. Data from the subgroup of 379 patients receiving
multiple overlapping stents included in TAXUS V showed
higher rates of periprocedural MIs with PES (8.3%) than
with BMS (3.3%, p  0.047) (15). Detailed angiographic
analysis revealed a greater degree of side-branch compro-
mise with PES compared with BMS during the procedure,
potentially related to the thicker polymer-coated struts of
PES. In contrast, repeat revascularization (12.6% vs. 28.2%,
p  0.001) and MACE (20.4% vs. 32.0%, p  0.01) at 9
months were less frequent with overlapping PES than
BMS. Dawkins et al. (23) noted a trend towards higher
rates of periprocedural MIs in patients with overlapping
PES (7.6%) than BMS (1.6%) (p  0.21) included in
TAXUS VI. During a follow-up of 9 months, the difference
in MIs decreased, whereas rates of repeat revascularization
were significantly lower with PES (1.6%) than with BMS
(25.0%) (p  0.001) (23). Similarly, Ruchin et al. (24)
observed a high rate of periprocedural MIs (12.9%) in a
series of 318 patients treated with overlapping SES (24). In
contrast, Kereiakes et al. (13) reported a similar incidence of
periprocedural MIs and MACE in a pooled analysis of 5
clinical trials in 1,034 patients. At 1-year follow-up, there
were no significant differences among overlapping and
single SES with respect to MACE (p  0.70) and TLR
(p  0.30). However, these analyses were typically based on
follow-up durations of only 1 year. Our analysis is based on
3 years of follow-up. When visually exploring patterns of
cumulative event curves (Fig. 1), it becomes obvious that
differences become more pronounced after termination of
the follow-up at 1-year.
Our findings are biologically plausible. Analysis of the
pattern of restenosis in patients with DES overlap who
underwent TLR during the follow-up period revealed that
the maximal lumen narrowing occurred at sites of DES
overlap in the majority of patients, which in turn suggests a
causal link between overlap and risk of restenosis. We can
only speculate as to the mechanism of the increased risk of
death or MI found in our study. Experimental studies raised
concerns regarding both the safety and efficacy of overlap-
ping DES because of the increased density of polymer, drug,
and stent material. Decreasing efficacy of overlapping PES
has been observed, for example, with increasing follow-up
time in a porcine coronary artery model (25). Finn et al. (17)
reported signs of incomplete and delayed endothelialization,
greater accumulated fibrin deposition as markers of delayed
healing, and increased inflammation at sites of overlapping
DES in rabbit iliac arteries. Incomplete endothelialization
and increased inflammation at sites of overlapping DES
have also been found in a porcine restenosis model (26). Our
findings are also corroborated by a recent cohort study in
patients who had undergone DES implantation. During a
mean follow-up period of 399 days, Alfonso et al. (27)
reported a coronary artery aneurysm rate of 1.3% after DES
implantation. In 4 of 15 patients with a documented
aneurysm, the aneurysm was found at the zone of stent
overlap, which suggests excessive vessel remodeling as a
result of the high density of drug or polymer. Another
recent clinical investigation with angioscopy demonstrated
incomplete neointimal coverage after SES, but not BMS,
implantation at 2 years of follow-up. This phenomenon was
particularly pronounced in 4 patients with DES overlap
(28). Using optical coherence tomography 6 months after
SES implantation, Matsumoto et al. (29) observed incom-
plete stent strut coverage in the majority of patients (84%)
and overlapping SES showed a higher rate of strut malap-
position than nonoverlapping SES (8% vs. 0.8%, respec-
tively; p  0.0001). Although the findings from these
imaging studies were not associated with adverse clinical
outcomes, they may contribute to ischemic adverse events
during longer term follow-up, particularly after dual anti-
platelet therapy was terminated. Although we observed
similar rates of stent thrombosis among DES with and
without overlap in the present study, much larger patient
populations would be required to statistically establish
differences between both groups.
Conclusions
DES overlap occurs in a considerable proportion of patients
undergoing percutaneous coronary intervention in routine
clinical practice. The most common reasons for DES
overlap are excessive lesion length and incomplete lesion
coverage. DES overlap does not seem to be associated with
an increased risk of periprocedural MI, but is associated
with impaired clinical and angiographic outcomes during
long-term follow-up.
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Long-term clinical and angiographic outcomes of
diabetic patients after revascularization with early
generation drug-eluting stents
Michael Billinger, MD, a,f Lorenz Räber, MD, a,f Sarah Hitz, MS, a Giulio G. Stefanini, MD, a Thomas Pilgrim, MD, a
Christoph Stettler, MD, b Thomas Zanchin, MS, a Cedric Pulver, MS, a Nico Pfäffli, MS, a Franz Eberli, MD, c
Bernhard Meier, MD, a Bindu Kalesan, MSc, d,e Peter Jüni, MD, d,e and Stephan Windecker, MD a,e Bern, and
Zurich, Switzerland
Background Early generation drug-eluting stents (DESs) reduce restenosis and repeat revascularization procedures.
However, the long-term safety and efficacy of early generation DES according to diabetic status are poorly established.
Methods A total of 1,012 patients were randomly assigned to treatment with sirolimus-eluting (n = 503) or paclitaxel-
eluting stents (n = 509). Serial angiographic follow-up at baseline, 8 months, and 5 years was available in 293 patients with
382 lesions. The primary end point was a composite of major adverse cardiac events (cardiac death, myocardial infarction,
and ischemia-driven target lesion revascularization). Clinical and angiographic outcomes through 5-year follow-up were
compared between diabetic and nondiabetic patients.
Results Major adverse cardiac events were more common among diabetic than nondiabetic patients at 5 years (25.9% vs
19.2%, hazard ratio [HR] 1.45, 95% CI 1.06-1.99, P = .02). The difference in disfavor of diabetic patients was largely
determined by a higher rate of cardiac mortality (11.4% vs 4.3%, HR 2.86, 95% CI 1.69-4.84, P b .0001), whereas the risk of
myocardial infarction (6.5% vs 6.8%, HR 1.00, 95% CI 0.55-1.84, P = .99) and ischemia-driven target lesion
revascularization (14.4% vs 14.1%, HR 1.09, 95% CI 0.73-1.64, P = .67) was comparable. The risk of stent thrombosis
was similar among diabetic and nondiabetic patients (definite or probable: 6.0% vs 4.6%, HR 1.36, 95% CI 0.71-2.67, P =
.35). Among 293 patients undergoing serial angiography, very-late lumen loss amounted to 0.42 ± 0.63 mm in diabetic
patients and 0.44 ± 0.68 mm in nondiabetic patients (P = .79).
Conclusions Diabetic patients remain at increased risk for mortality after revascularization with early generation DES
during long-term follow-up. Conversely, diabetes is no longer associated with an increased risk of clinical and angiographic
restenosis after revascularization with early generation DES. (Am Heart J 2012;163:876-886.e2.)
Early generation drug-eluting stents (DESs) have
reduced restenosis compared with bare-metal stents with-
out apparent impact on mortality and myocardial infarc-
tion (MI) in both diabetic and nondiabetic patients.1,2
However, little is known regarding the relative safety
and efficacy of early generation DES in diabetic
compared with nondiabetic patients during long-term
follow-up. We therefore investigated the clinical and
angiographic outcomes of the unrestricted use of early
generation DES among diabetic and nondiabetic pa-
tients included into the SIRTAX LATE study during
follow-up through 5 years.3
Methods
Study design and eligibility criteria
The design and methods of the SIRTAX LATE study have been
reported previously.4 A total of 1,012 patients with ≥1 lesion
in a vessel with a reference diameter between 2.25 and
4.00 mm were randomly assigned to treatment with sirolimus-
eluting stent (SES) (Cypher; Cordis, Johnson & Johnson, Miami
Lakes, FL) or paclitaxel-eluting stent (PES) (Taxus; Boston
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Scientific, Natick, MA) without limitations on the number of
lesions or vessels. The study complied with the Declaration of
Helsinki and was approved by the institutional ethics commit-
tees at the University Hospital Bern in Zurich, Switzerland. All
patients provided written, informed consent.
Data collection and clinical and
angiographic follow-up
Adverse events were assessed in-hospital at 1, 6, and 9 months
and on an annual basis up to 5 years. All patients were asked to
return for repeat angiography at 8 months. The results of the
primary clinical end point at 9 months and the principal
angiographic end point at 8 months have been previously
reported.4 All patients who had at least 1 study lesion without
intervening revascularization were invited to undergo an
angiographic study between 4 and 5 years of follow-up.
All patients who had at least 1 lesion without intervening
revascularization during long-term follow-up were invited to
undergo repeat angiography at 5 years of follow-up. Patients
undergoing clinically indicated revascularization of the target
lesion beyond 8 months (time point of the first angiographic
follow-up) were included into the angiographic long-term
cohort and contributed to the assessment of delayed late loss
at 5 years.
All patients were advised to take acetylsalicylic acid indefi-
nitely and clopidogrel for the duration of 1 year.
Study end points and definitions
Diabetes was defined by the presence of antidiabetic medical
therapy at baseline.
An independent clinical events committee unaware of the
patients' assignments adjudicated all clinical end points. The
primary end point was a composite of major adverse cardiac
events (MACEs): cardiac death, MI, and ischemia-driven
target lesion revascularization (TLR) at 9 months.4 Secondary
end points included the individual components of MACE as
well as overall mortality, any TLR, target vessel revascular-
ization (TVR), target vessel failure (composite of cardiac
death, MI, and ischemia-driven TVR), and stent thrombosis
(ST). All STs were adjudicated post hoc according to the
Academic Research Consortium criteria.5 Definitions of
clinical end points have been previously reported.4
The principal secondary end point of the angiographic
substudy was delayed late lumen loss (LL) between 8 months
and 5 years among patients undergoing paired angiography.
Lumen loss was defined as the difference between the
minimal luminal diameter (MLD) after the procedure and
MLD at follow-up. Delayed LL was defined as the difference
between MLD at 8 months and MLD at 5 years. Secondary
angiographic end points were percent diameter stenosis and
binary restenosis. Binary restenosis was defined as stenosis
of at least 50% of the MLD in the target lesion at
angiographic follow-up.
Quantitative coronary angiography
Digital angiograms were analyzed with the use of an
automated edge detection system (CAAS II; Pie Medical
Imaging, Maastricht, The Netherlands). Angiographic readers
were unaware of the type of stent implanted. Quantitative
coronary angiography from patients returning for repeat
angiography in the setting of ST was not included during the
first 30 days. However, events beyond 30 days were part of
the angiographic analysis because the need for repeat
revascularization could no longer be attributed to a short-
term response of the lesion to the procedure.
Statistical analyses
Baseline characteristics were compared between diabetic and
nondiabetic patients using χ2 test without taking into account
the random allocation to SES or PES. We used a Cox
proportional hazards model to compare clinical outcomes
between groups. P values for differences in clinical outcomes
between diabetic and nondiabetic patients were derived from
Cox proportional hazards models adjusted for treatment
allocation. To determine whether there was an interaction
between treatment effect and diabetic status, we used
likelihood ratio tests. Angiographic data were analyzed for all
patients undergoing paired angiography at baseline, 8 months,
and 5 years. Study lesions requiring revascularization by either
percutaneous coronary intervention (PCI) or coronary artery
bypass grafting between 8 months and 5 years were assessed
by quantitative coronary angiography and contributed to the 5-
year angiographic analysis. A patient could have had N1 lesion
in which a stent was implanted. Therefore, in the analysis of
the quantitative angiographic data, we used maximum likeli-
hood logistic and linear regression models, crude and adjusted
for MLD at baseline, which were based on robust standard
errors that allowed for the correlation of multiple lesions within
a patient to compare the characteristics of lesion between
groups at baseline and follow-up. Trial data were held by CTU
Bern, University of Bern, Bern, Switzerland. Analyses were
performed with the use of Stata 11.1 (College Station, TX). No
adjustments were made for multiple comparisons in secondary
analysis. All P values are 2 sided.
Results
Between April 2003 and May 2004, 1,012 patients
with 1,401 lesions were randomly assigned to treat-
ment with SES (n = 503) or PES (n = 509). Two
hundred one patients (20%) with 292 lesions were
diabetic, and 811 patients with 1,117 lesions were
nondiabetic. Diabetic compared with nondiabetic
patients were older (P b .001), more often female (P
= .01), more commonly hypertensive (P b .001), and
had more frequently multivessel disease (P = .05).
Smokingwas less prevalent (P b .001), whereas a previous
MI tended to be more common (P = .06) among diabetic
than nondiabetic patients (Table I). Baseline angiographic
characteristics and procedural results were comparable
between diabetic and nondiabetic patients, as summa-
rized in Table I, respectively. Evaluation of the cardiovas-
cular medication profile at 30 days and 1 and 5 years
showed a lower intake of acetylsalicylic acid among
diabetic patients during long-term follow-up, which was
compensated by more frequent use of oral anticoagulants
(online Appendix Supplemental Table I).
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Clinical outcomes
At 5 years, clinical follow-up was available for 190 diabetic
(94.5%) and 790 nondiabetic (97.4%) patients (Figure 1).
Clinical events according to diabetic status at 5-year follow-
up are summarized in Table II. Major adverse cardiac event
(25.9% vs 19.2%, P = .02) and target vessel failure (27.9% vs
21.7%, P = .03) were more common among diabetic than
nondiabetic patients (Figure 1A). The difference in disfavor
of diabetic patients was determined by a higher rate of all-
cause mortality (18.9% vs 8.0%, P b .0001) and cardiac
mortality (11.4% vs 4.3%, P b .0001) (Figure 1B). In contrast,
there were no differences between diabetic and nondia-
betic patients in rates of MI (6.5% vs 6.8%, hazard ratio [HR]
1.00, P = .99), ischemia-driven TLR (14.4% vs 14.1%, P =
.67), and TVR (16.9% vs 17.3%, P = .81) through 5 years
(Figure 1C). Rates of definite ST (4.5% vs 4.3%, P = .85) and
definite or probable ST (6.0% vs 4.6%, P = .35) were
comparable between diabetic and nondiabetic patients
(Table III, Figure 1D). Hazard ratios of the primary endpoint
and its components comparing diabetic with non-diabetic
patients and stratified according to different time periods
(0-1, 1-5, 0-5 years) are shown in Figure 2. After stratification
of the diabetic patients according to individuals treated with
insulin, we observed a nonsignificant signal toward higher
event rates among individuals treated with insulin than in
those without insulin in terms of cardiac death, MI, cardiac
death or MI, and target vessel failure (Table IV). Clinical
long-term outcomes of patients according to stent type are
shown in the online Appendix Supplemental Table II. In
contrast to similar clinical safety and efficacy outcomes
among nondiabetic patients, diabetic patients treated with
SES had a lower rate of clinically indicated TLR (10.2%)
compared with PES (19.4%, P = .05) through 5 years.
Similarly, rates of MI were lower with SES (2.8%) than PES
(10.8%, P = .03), as were rates of definite and probable STs
(SES 2.8%, P = .049). However, there were no differences in
terms of all-cause and cardiac mortalities between stent
types among diabetic patients.
Angiographic outcomes
Long-term angiographic follow-up was performed in
444 patients with 567 lesions at a median of 4.8 years
Table I. Clinical, procedural and angiographic characteristics at baseline
Diabetic patients, n = 201 Nondiabetic patients, n = 811 P
Clinical characteristics
Age, y 65.9 ± 8.9 61.4 ± 11.4 b.001
Men 142 (70.7) 639 (78.8) .01
Hypertension 162 (80.6) 460 (56.7) b.001
Hyperlipidemia 123 (61.2) 474 (58.5) .48
Current smoking 41 (20.4) 324 (40.0) b.001
Previous MI 70 (34.8) 227 (28.0) .06
Allocated stent .20
SES 108 (53.7) 395 (48.7)
PES 93 (46.3) 416 (51.3)
Preprocedure angiographic measures
Lesion length, mm 12.2 ± 7.2 13.2 ± 8.0 .08
Reference vessel diameter, mm 2.80 ± 0.4 2.82 ± 0.4 .54
Minimal lumen diameter, mm 0.54 ± 0.5 0.52 ± 0.4 .52
Stenosis, % lumen diameter 81.1 ± 15.2 81.7 ± 14.6 .61
Procedural characteristics
No. of lesions 292 1117
No. of lesions treated per patient 1.5 ± 0.6 1.4 ± 0.6 .11
No. of stents per lesion 1.14 (0.4) 1.14 (0.4) 1.00
Maximal stent diameter, mm 2.85 (0.4) 2.89 (0.4) .08
Total stent length per lesion, mm 18.6 (11.3) 18.9 (10.3) .75
Maximal pressure, atm 14.1 (3.0) 14.2 (3.0) .66
Direct stenting 98 (33.6) 370 (33.1) .23
Postprocedure angiographic measures
Final minimal lumen diameter, mm
In-stent 2.64 (0.4) 2.67 (0.4) .28
In-segment 2.56 (0.4) 2.58 (0.4) .79
Final stenosis, % of lumen diameter
In-stent 7.23 (6.6) 6.98 (4.7) .39
In-segment 8.92 (7.0) 8.55 (6.9) .60
Acute gain, mm
In-stent 2.10 (0.5) 2.14 (0.5) .24
In-segment 2.03 (0.6) 2.08 (0.5) .36
Values shown are mean ± SD or n (percentage).
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for diabetic (interquartile range 4.5-5.2 years) and 4.8
years for nondiabetic patients (interquartile range 4.6-
5.1 years). Serial angiographic follow-up at baseline,
8 months, and 5 years was available in 43 diabetic
patients with 56 lesions and 205 nondiabetic patients
with 326 lesions. Patients undergoing paired angiogra-
phy were younger (P b .01), more frequently male (P
b .01), and less frequently diabetic (P = .01) or
hypertensive (P = .03) than patients not undergoing
paired angiography. Angiographic findings in patients
undergoing paired angiography are presented in Table
V. Delayed LL was comparable between diabetic and
nondiabetic patients (in-stent: 0.32 ± 0.61 mm vs 0.33
± 0.66 mm, P = .96). Moreover, in-stent LL at
8 months was 0.09 ± 0.15 mm among TLR-free
diabetic patients and 0.11 ± 0.21 mm among TLR-free
nondiabetic patients (P = not significant). Through 5
years, in-stent LL increased to 0.42 ± 0.63 mm among
TLR-free diabetic patients and to 0.44 ± 0.68 mm
among TLR-free nondiabetic patients (P = not signif-
icant). The time course of MLD at baseline, 8 months,
and 5 years in diabetic as compared with nondiabetic
patients is shown in Figure 3. Among both diabetic
and nondiabetic patients, there was an erosion of MLD
between baseline and 8 months and between 8 months
and 5 years. The online Appendix Supplemental Table
III shows angiographic results separately for both stent
types among diabetic and nondiabetic patients. In TLR-
free patients undergoing serial angiography at 8 months
and 5 years, delayed late loss was similar among
diabetic SES (0.35 ± 0.46 mm) and PES (0.30 ± 0.71
mm, P = .77) patients. Similarly, there were no
differences in late loss between the 2 stent types at
8 months likely because of the exclusion of patients
with TLR up to 8 months.
Discussion
The present study investigating the clinical and
angiographic outcomes of early generation DES among
diabetic and nondiabetic patients during follow-up
through 5 years has the following findings:
1. Diabetic as compared with nondiabetic patients
have a 2.5-fold increased risk of all-cause and
cardiac mortalities with a gradient in risk increasing
from nondiabetic over patients with type 2 diabetes
mellitus to patients with type 1 diabetes mellitus;
2. Diabetic and nondiabetic patients have a similar risk
of MI and ST;
3. Diabetic patients have no increased risk of repeat
revascularization as compared with nondiabetic
patients; and
4. Delayed LL of the target lesion was similar for
diabetic and nondiabetic patients through 5 years
without meaningful difference between diabetic
SES and PES patients.
Diabetic as compared with nondiabetic patients
undergoing PCI with early generation DES continue
to have impaired survival. In the present study,
mortality was 3-fold increased for patients treated
with insulin and 2-fold increased for individuals treated
without insulin compared with nondiabetic patients,
and two thirds of deaths was due to a cardiac cause.
Although mortality remains increased, diabetic patients
benefit from revascularization to at least the same
degree as nondiabetic patients. In the Primary
Coronary Angioplasty vs Thrombolysis-2 trial collabo-
rative analysis of 19 randomized, controlled trials with
6,315 ST-elevation myocardial infarction patients,
primary PCI reduced mortality to a similar degree in
diabetic as in nondiabetic patients.6 Among patients
with non–ST-elevation acute coronary syndromes,
diabetes is recognized as a high-risk marker, and an
early invasive strategy has been shown superior to a
conservative strategy among diabetic patients in FRISC-
II7 and TACTICS-TIMI 188—lending support to a class
IA recommendation for an early invasive strategy in
diabetic patients.9,10 Among diabetic patients with
stable coronary artery disease, PCI (88.3%) was
associated with similar survival as medical treatment
alone (87.8%, P = .97) in the recent BARI-2D trial,
although DES was used in only one third of treated
patients in this study.11
In view of the persistent risk of mortality among
diabetic patients despite revascularization therapy, partic-
ular attention should be paid to secondary preventive
measures including optimal medical treatment. The
impact of evidence-based medications on event-free
survival has been highlighted in results of the Euro-
Heart Survey. One-year mortality was lower among
diabetic patients on (3.5%) compared with those without
evidence-based medications (7.7%), and the use of
evidence-based medications was identified as an inde-
pendent protective factor for death (HR 0.37, 95% CI
0.20-0.67, P = .001).12 In this context, the intake of
evidence-based medications during long-term follow-up in
the present study is of some concern. The lower use of
acetylsalicylic acid was counterbalanced by the more
frequent use of oral anticoagulation. However, the use of
β-blockers, angiotensin-converting enzyme (ACE) inhi-
bitors, and statins declined in both groups over time.
Moreover, statins were less frequently used in diabetic
than nondiabetic patients despite their beneficial cardio-
vascular risk profile.
Despite a higher cardiac mortality among diabetic
patients, rates of MI and revascularization were not
increased when compared with that of nondiabetic
patients. Diabetic patients are affected by autonomic
neuropathy with degeneration of nerve fibers, which
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may explain, at least in part, the observed phenomenon.
Thus, myocardial ischemia or even MI may present with
atypical symptoms or silently among diabetic patients.
Results from the Framingham study13 and other cohort
studies14 demonstrated that the propensity for silent
myocardial ischemia and infarction is higher in diabetic as
compared with nondiabetic patients. In addition, an
autopsy study reported myocardial scars without known
history of MI to be more common in diabetic as
compared with nondiabetic patients.15
Figure 1
Clinical outcomes according to diabetic status through 5 years. Cumulative event curves for the primary end point MACE (A), cardiac death or
MI (B), ischemia-driven TLR (C), and definite ST (D) up to 5 years. Diabetes is shown in a black solid line; no diabetes, in a black broken line.
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In addition, autonomic neuropathy may increase the
likelihood for lethal ventricular arrhythmias by prolong-
ing the QT interval16 as another potential explanation for
an increased rate of sudden cardiac death among diabetic
patients. Finally, patients with diabetes may be more
prone to diabetes-induced cardiomyopathy and resultant
heart failure, which, in turn, is associated with an
increased risk of cardiac mortality.
The risk of TLR in the present study was not different
between diabetic and nondiabetic patients during long-
term follow-up through 5 years. This finding is notable
because diabetes mellitus used to be an independent
}
Figure 1 (continued )
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predictor of restenosis in the balloon angioplasty and
bare-metal stents era. Angiographic and ultrasonic
studies have shown more neointimal hyperplasia in
diabetic than nondiabetic patients in response to stent-
mediated arterial injury.17-22 Early generation DES
results in a profound suppression of neointimal
hyperplasia and appears to overcome the more
profound proliferative vascular response in diabetic
patients. The similar outcome in terms of revasculari-
zation efficacy is further supported by angiographic
follow-up studies. Iijima et al23 reported results of
angiographic follow-up 6 months after early generation
DES implantation in an observational study of 2,557
consecutive patients and showed similar rates of
restenosis in diabetic and nondiabetic patients. These
results are not only corroborated by the present study
but also extended to very late angiographic follow-up to
5 years, confirming similar late loss and restenosis for
both groups without relevant differences between stent
types. However, late loss continued to accrue over
Table II. Long-term clinical outcomes according to diabetic status 0 to 5 years
Diabetic, n = 201 Nondiabetic, n = 811 HR (95% CI) P
Death 38 (18.9) 65 (8.0) 2.53 (1.70-3.78) b.0001
Cardiac death 23 (11.4) 35 (4.3) 2.86 (1.69-4.84) b.0001
MI 13 (6.5) 55 (6.8) 1.00 (0.55-1.84) .99
Ischemia-driven TLR 29 (14.4) 114 (14.1) 1.09 (0.73-1.64) .67
Any TLR 31 (15.4) 135 (16.6) 1.00 (0.68-1.48) .99
Ischemia-driven TVR 34 (16.9) 140 (17.3) 1.05 (0.72-1.52) .81
Any TVR 40 (19.9) 168 (20.7) 1.05 (0.74-1.48) .78
Death or MI 49 (24.4) 112 (13.8) 1.88 (1.34-2.63) b.0001
Cardiac death or MI 34 (16.9) 84 (10.4) 1.74 (1.17-2.59) .01
MACE 52 (25.9) 156 (19.2) 1.45 (1.06-1.99) .02
Target vessel failure 56 (27.9) 176 (21.7) 1.38 (1.02-1.87) .03
Values shown are n (percentage).
Figure 2
Risk of cardiac events according to diabetic status through 5 years. Hazard ratios of the primary end point MACE and its components stratified
according to period (0-1 vs 1-5 years) and overall (0-5 years). The P values for interaction are for differences in HRs between 0 and 1 and 1 to 5 years.
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time, which may be related to ongoing vascular healing
after early generation DES implantation.
Diabetes constitutes a prothrombotic state that has
been related to increased platelet activation and
increased levels of tissue factor, fibrinogen, and
plasminogen activator inhibitor 1. Along this line,
diabetes mellitus has been identified as predictor of ST
in numerous studies with the use of both bare-metal
stents and DES.24,25 However, we did not observe an
excess risk of ST in diabetic compared with nondiabetic
patients enrolled in the present study. This finding may
be related to chance or more likely differences in
duration of dual antiplatelet therapy. Initial studies with
early generation DES prescribed thienopyridines for a
duration of 3 to 6 months, whereas more than two thirds
of patients in the present study still used thienopyridines
at 9 months of follow-up. Nevertheless, the cumulative
incidence of definite very-late ST amounted to 3.5%
among diabetic and 2.3% among nondiabetic patients
at 5 years. The relatively high incidence of very-late ST
may be related to the unrestricted use of DES with
inclusion of patients with acute coronary syndromes and
other off-label indication.
There are several clinical implications of our study.
First, diabetic patients remain at increased risk for
cardiovascular mortality after revascularization with
early generation DES. Second, the excess risk of
restenosis has been successfully abrogated by early
generation DES with durable long-term results
through 5 years. Third, continuous efforts to
improve compliance with evidence-based medications
and other secondary preventive measures remain of
pivotal importance particularly in the care of
diabetic patients.
The advantage of SES over PES in terms of repeat
revascularization procedures at 1 year as observed in
the overall SIRTAX trial population was lost during
long-term follow-up16 because of clinical and angio-
graphic erosions that were more pronounced among
SES- than PES-treated patients. Conversely, differences
Table III. Stent thrombosis in patients with and without diabetes through 5 years
Diabetic, n = 201 Nondiabetic, n = 811 HR (95% CI) P
Definite ST
Early 1 (0.5) 15 (1.8) 0.26 (0.03-2.00) .20
Late 1 (0.5) 1 (0.1) 4.10 (0.25-65.90) .32
Very late 7 (3.5) 19 (2.3) 1.60 (0.67-3.81) .29
Overall 9 (4.5) 35 (4.3) 1.07 (0.52-2.24) .85
Probable ST
Early 3 (1.5) 1 (0.1) 13.55 (1.41-130.26) .02
Late 0 (0.0) 0 (0.0) –
Very late 0 (0.0) 1 (0.1) 1.34 (0.05-32.8) 1.00
Overall 3 (1.5) 2 (0.2) 6.64 (1.11-39.80) .04
Definite or probable ST
Early 4 (2.0) 16 (2.0) 1.02 (0.34-3.04) .98
Late 1 (0.5) 1 (0.1) 4.10 (0.25-65.90) .32
Very late 7 (3.5) 20 (2.5) 1.51 (0.64-3.58) .35
Overall 12 (6.0) 37 (4.6) 1.36 (0.71-2.62) .35
Values shown are n (percentage).
Table IV. Long-term clinical outcomes according to insulin-dependent diabetic status through years
Insulin, n = 64 No insulin, n = 137 HR (95% CI) P
Death 16 (25.0) 22 (16.1) 1.61 (0.84-3.07) .15
Cardiac death 11 (17.2) 12 (8.8) 1.99 (0.88-4.54) .10
MI 7 (10.9) 6 (4.4) 2.23 (0.74-6.66) .15
Ischemia-driven TLR 12 (18.8) 17 (12.4) 1.42 (0.68-2.99) .35
Any TLR 14 (21.9) 17 (12.4) 1.68 (0.83-3.42) .15
Ischemia-driven TVR 15 (23.4) 19 (13.9) 1.64 (0.83-3.25) .15
Any TVR 17 (26.6) 23 (16.8) 1.54 (0.82-2.90) .18
Death or MI 21 (32.8) 28 (20.4) 1.62 (0.92-2.87) .10
Cardiac death or MI 16 (25.0) 18 (13.1) 1.87 (0.95-3.69) .07
MACE 22 (34.4) 30 (21.9) 1.51 (0.87-2.62) .15
Target vessel failure 24 (37.5) 32 (23.4) 1.59 (0.93-2.70) .09
Values shown are n (percentage).
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in favor of diabetic patients treated with SES as
compared with PES were sustained during longer term
follow-up in the present study. To date, only limited
data are available for the very–long-term follow-up
comparison of SES and PES among diabetic patients. A
network meta-analysis2 of 3,852 randomized diabetic
patients with maximal follow-up up to 4 years found
no differences between SES and PES in terms of
death, MI, and repeat revascularization but a trend
toward a lower rate of ST with SES as compared with
PES. More recently, a newer-generation everolimus-
eluting stent was found superior in terms of safety
and efficacy compared with PES among nondiabetic
but not diabetic patients up to 2 years. Nevertheless,
the limus analogue-based stent platform was not
associated with any clinical disadvantage compared
with PES, and it will be of interest whether
differences in favor of newer-generation DES among
diabetic patients may emerge during longer term
follow-up to 5 years.
Limitations
Although the comparison of SES and PES among diabetic
patients was a prespecified subgroup analysis, the study
population is not of sufficient magnitude to examine
significant interactions between diabetes and clinical
outcome according to randomly assigned stent type.
Revascularization procedures remote from the target vessel
were not part of the present analysis, although they may be
an important part of the overall need for revascularization in
routine clinical practice because of disease progression.
Conclusions
Diabetic patients remain at increased risk for
mortality after revascularization with early generation
Table V. Angiographic follow-up results of lesions undergoing paired angiography at baseline, 8 months, and 5 years
All (n = 382) Diabetic (n = 56) Nondiabetic (n = 326) Difference (95% CI) P
Before procedure
Diameter of reference vessel, mm 2.84 (0.44) 2.84 (0.43) 2.84 (0.44) 0.00 (−0.15 to 0.15) .98
MLD, mm 0.50 (0.44) 0.55 (0.46) 0.50 (0.43) 0.04 (−0.08 to 0.17) .51
Stenosis, % of luminal diameter 81.9 (14.91) 80.70 (15.14) 82.16 (14.88) −1.22 (−5.50 to 3.05) .57
After procedure
Diameter of reference vessel, mm 2.88 (0.43) 2.90 (0.40) 2.87 (0.43) 0.02 (−0.11 to 0.15) .78
MLD, mm
In stent 2.69 (0.39) 2.71 (0.32) 2.69 (0.40) 0.02 (−0.09 to 0.12) .75
In segment 2.60 (0.43) 2.61 (0.37) 2.60 (0.44) 0.00 (−0.13 to 0.12) .97
Stenosis , % of luminal diameter
In stent 6.83 (5.31) 6.61 (5.18) 6.87 (5.34) −0.23 (−1.85 to 1.39) .79
In segment 8.61 (6.64) 9.32 (6.20) 8.49 (6.71) 0.84 (−1.09 to 2.78) .39
8 m
Diameter of reference vessel, mm 2.82 (0.45) 2.83 (0.43) 2.81 (0.45) 0.01 (−0.14 to 0.16) .89
MLD, mm
In stent 2.58 (0.43) 2.62 (0.39) 2.57 (0.44) 0.04 (−0.08 to 0.16) .5
In segment 2.47 (0.46) 2.52 (0.39) 2.47 (0.48) 0.05 (−0.08 to 0.18) .44
Stenosis, % of luminal diameter
In stent 9.66 (8.71) 8.84 (6.59) 9.81 (9.03) −1.02 (−3.12 to 1.07) .34
In segment 12.12 (10.19) 10.79 (7.69) 12.35 (10.56) −1.63 (−4.21 0.95) .22
Late luminal loss, mm
In stent 0.11 (0.20) 0.09 (0.15) 0.11 (0.21) −0.03 (−0.07 to 0.02) .29
In segment 0.13 (0.23) 0.09 (0.12) 0.14 (0.25) −0.05 (−0.10 to −0.01) .03
5 y
Diameter of reference vessel, mm 2.83 (0.46) 2.84 (0.46) 2.82 (0.46) 0.01 (−0.14 to 0.17) .85
MLD, mm
In stent 2.25 (0.77) 2.29 (0.65) 2.24 (0.79) 0.04 (−0.14 to 0.23) .65
In segment 2.10 (0.79) 2.19 (0.63) 2.09 (0.82) 0.10 (−0.09 to 0.28) .29
Stenosis, % of luminal diameter
In stent 20.86 (24.60) 19.01 (21.37) 21.18 (25.13) −2.05 (−8.38 to 4.27) .52
In segment 25.31 (25.46) 22.19 (21.07) 25.85 (26.13) −3.56 (−10.17 to 3.06) .29
Late luminal loss, mm
In stent 0.44 (0.67) 0.42 (0.63) 0.44 (0.68) −0.02 (−0.20 to 0.16) .79
In segment 0.50 (0.70) 0.41 (0.63) 0.51 (0.71) −0.10 (−0.28 to 0.09) .31
Delayed late luminal loss, mm
In stent 0.33 (0.66) 0.32 (0.61) 0.33 (0.66) 0.00 (−0.19 to 0.18) .96
In segment 0.37 (0.70) 0.33 (0.61) 0.38 (0.72) −0.05 (−0.24 to 0.13) .56
Values shown are means (SD).
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DES during long-term follow-up. Conversely, diabetes
is no longer associated with an increased risk of
clinical and angiographic restenosis after revasculariza-
tion with early generation DES.
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Appendix
Supplemental Table I. Medications intake through 5 years
Diabetic patients Nondiabetic patients Difference (95% CI) P
At 30 d
Patients alive 197 809
Acetylsalicylic acid 186 (94.4) 783 (96.8) −2.4 (−5.8 to 1.1) .11
Thienopyridine 186 (94.4) 767 (94.8) −0.4 (−3.9 to 3.2) .83
Oral anticoagulant 12 (6.1) 26 (3.2) 2.9 (−0.7 to 6.4) .06
β-Blocker 138 (70.1) 626 (77.4) −7.3 (−14.3 to −0.3) .03
ACE inhibitor or/and ARB 108 (54.8) 435 (53.8) 1.1 (−6.7 to 8.8) .79
Statin 171 (86.8) 747 (92.3) −5.5 (−10.6 to −0.5) .01
At 1 y
Patients alive 190 785
Acetylsalicylic acid 157 (82.6) 701 (89.3) −6.7 (−12.5 to −0.9) .01
Thienopyridine 61 (32.1) 255 (32.5) −0.4 (−7.8 to 7.0) .92
Oral anticoagulant 21 (11.1) 68 (8.7) 2.4 (−2.5 to 7.3) .30
β-Blocker 135 (71.1) 515 (65.6) 5.4 (−1.8 to 12.7) .15
ACE inhibitor or/and ARB 91 (47.9) 340 (43.3) 4.6 (−3.3 to 12.5) .25
Statin 169 (88.9) 705 (89.8) −0.9 (−5.8 to 4.1) .73
At 5 y
Patients alive 163 745
Acetylsalicylic acid 123 (75.5) 626 (84.0) −8.6 (−15.7 to −1.5) .01
Thienopyridine 35 (21.5) 160 (21.5) 0.0 (−7.0 to 7.0) 1.00
Oral anticoagulant 22 (13.5) 62 (8.3) 5.2 (−0.4 to 10.8) .04
β-Blocker 98 (60.1) 472 (63.4) −3.2 (−11.5 to 5.0) .44
ACE inhibitor or/and ARB 66 (40.5) 303 (40.7) −0.2 (−8.5 to 8.1) .97
Statin 121 (74.2) 648 (87.0) −12.7 (−19.9 to −5.6) b.001
Values shown are n (percentage). ARB, Angiotensin receptor antagonist.
Supplemental Table II. Long-term clinical outcomes in diabetic patients 0 to 5 years according to stent type
SES = 108
n = 201
PES = 93
n = 811 HR (95% CI) P
Death 21 (19.4) 17 (18.3) 1.02 (0.54-1.93) .95
Cardiac death 12 (11.1) 11 (11.8) 0.90 (0.40-2.05) .81
MI 3 (2.8) 10 (10.8) 0.24 (0.07-0.88) .03
Ischemia-driven TLR 11 (10.2) 18 (19.4) 0.47 (0.22-0.98) .05
Any TLR 12 (11.1) 19 (20.4) 0.48 (0.23-0.99) .05
Ischemia-driven TVR 14 (13.0) 20 (21.5) 0.53 (0.27-1.05) .07
Any TVR 17 (15.7) 23 (24.7) 0.56 (0.30-1.04) .07
Death or MI 24 (22.2) 25 (26.9) 0.76 (0.44-1.33) .34
Cardiac death or MI 15 (13.9) 19 (20.4) 0.63 (0.32-1.24) .18
MACE 22 (20.4) 30 (32.3) 0.56 (0.32-0.98) .04
Target vessel failure 25 (23.1) 31 (33.3) 0.62 (0.37-1.05) .08
Definite ST 3 (2.8) 6 (6.5) 0.40 (0.10-1.59) .19
Definite or probable ST 3 (2.8) 9 (9.7) 0.27 (0.07-0.99) .049
Billinger et al 886.e1
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Supplemental Table III. Angiographic results of lesions undergoing angiography at baseline, 8 months, and 5 years
Diabetic patients Nondiabetic patients
SES, n = 23 PES, n = 33 P SES, n = 156 PES, n = 170 P
Before procedure
Diameter of reference vessel, mm 2.92 (0.37) 2.79 (0.47) .33 2.78 (0.41) 2.89 (0.47) .04
MLD, mm 0.36 (0.33) 0.68 (0.49) 0 0.45 (0.38) 0.54 (0.47) .05
Stenosis, % of luminal diameter 87.48 (11.67) 75.97 (15.63) 0 83.30 (13.83) 81.11 (15.76) .16
After procedure
Diameter of reference vessel, mm 2.93 (0.36) 2.87 (0.42) .6 2.82 (0.41) 2.93 (0.45) .03
MLD, mm
In stent 2.68 (0.30) 2.73 (0.34) .6 2.63 (0.36) 2.74 (0.42) .01
In segment 2.61 (0.35) 2.61 (0.40) .98 2.55 (0.40) 2.66 (0.46) .03
Stenosis , % of luminal diameter
In stent 8.57 (5.03) 5.24 (4.91) .02 6.90 (5.30) 6.84 (5.40) .91
In segment 10.35 (5.99) 8.61 (6.33) .34 8.45 (7.05) 8.53 (6.40) .91
8 m
Diameter of reference vessel, mm 2.87 (0.35) 2.80 (0.48) .61 2.77 (0.44) 2.86 (0.47) .09
MLD, mm
In stent 2.59 (0.38) 2.63 (0.40) .72 2.54 (0.39) 2.60 (0.48) .29
In segment 2.49 (0.37) 2.54 (0.40) .61 2.45 (0.44) 2.49 (0.51) .48
Stenosis, % of luminal diameter
In stent 10.61 (6.81) 7.61 (6.25) .09 9.06 (7.95) 10.49 (9.89) .18
In segment 13.04 (7.28) 9.21 (7.67) .08 11.46 (10.61) 13.17 (10.47) .16
Late luminal loss, mm
In stent 0.09 (0.16) 0.10 (0.14) .82 0.09 (0.19) 0.14 (0.23) .03
In segment 0.12 (0.14) 0.06 (0.10) .09 0.10 (0.24) 0.17 (0.25) .02
Binary restenosis, %
In stent 0.00 (0.00) 0.00 (0.00) 1.00 (0.64) 1.00 (0.59) .95
In segment 0.00 (0.00) 0.00 (0.00) 1.00 (0.64) 1.00 (0.59) .95
5 y
Diameter of reference vessel, mm 2.90 (0.42) 2.80 (0.48) .49 2.77 (0.44) 2.87 (0.47) .05
MLD, mm
In stent 2.24 (0.59) 2.33 (0.70) .61 2.17 (0.81) 2.31 (0.77) .14
In segment 2.18 (0.57) 2.20 (0.67) .91 2.01 (0.86) 2.16 (0.78) .13
Stenosis, % of luminal diameter
In stent 22.41 (19.03) 16.64 (22.85) .3 21.81 (27.29) 20.61 (23.06) .7
In segment 24.76 (17.95) 20.39 (23.10) .45 26.45 (28.91) 25.30 (23.40) .72
Late luminal loss, mm
In stent 0.44 (0.48) 0.40 (0.72) .81 0.46 (0.76) 0.43 (0.60) .76
In segment 0.42 (0.47) 0.41 (0.72) .92 0.54 (0.80) 0.49 (0.62) .61
Binary restenosis, %
In stent 2.00 (3.57) 2.00 (0.61) .71 21.00 (37.50) 16.00 (4.91) .31
In segment 2.00 (3.57) 2.00 (0.61) .71 27.00 (48.21) 23.00 (7.06) .39
Delayed late luminal loss, mm
In stent 0.35 (0.46) 0.30 (0.71) .77 0.37 (0.76) 0.29 (0.56) .34
In segment 0.30 (0.45) 0.34 (0.70) .8 0.44 (0.81) 0.33 (0.61) .22
886.e2 Billinger et al
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CLINICAL
Comparison of drug-eluting stents with bare
metal stents in patients with ST-segment
elevation myocardial infarction
Bindu Kalesan1,2,3†, Thomas Pilgrim1†, Katja Heinimann3, Lorenz Ra¨ber1,4,
Giulio G. Stefanini1, Marco Valgimigli5, Bruno R. da Costa3, Franc¸ois Mach6,
Thomas F. Lu¨scher7, Bernhard Meier1,2, Stephan Windecker1,2, and Peter Ju¨ni2,3*
1Department of Cardiology, Bern University Hospital, Bern, Switzerland; 2Clinical Trials Unit, University of Bern, Bern, Switzerland; 3Institute of Social and Preventive Medicine,
University of Bern, Switzerland; 4Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 5Department of Cardiology, University Hospital
of Ferrara, Italy; 6Department of Cardiology, University Hospital of Geneva, Switzerland; and 7Department of Cardiology, University Hospital of Zurich, Switzerland
Received 6 December 2011; revised 10 January 2012; accepted 1 February 2012; online publish-ahead-of-print 23 February 2012
Aims To evaluate safety and effectiveness of early generation drug-eluting stents (DES) compared with bare-metal stents
(BMS) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous
coronary intervention (PCI), and to determine whether benefits and risks vary over time.
Methods and
results
We performed a meta-analysis of 15 randomized controlled trials enrolling a total of 7867 patients comparing
first-generation FDA-approved DES with BMS in patients with STEMI. Random effect models were used to assess
differences in outcomes between DES and BMS among different time periods with regard to the pre-specified
primary outcomes stent thrombosis (ST) and target vessel revascularization (TVR). The overall risk of definite ST
was similar for DES and BMS [risk ratio (RR) ¼ 1.08, 95% CI 0.82–1.43]. However, there were time-dependent
effects, with a RR of 0.80 during the first year (95% CI 0.58–1.12) and 2.10 during subsequent years (95% CI
1.20–3.69), with a positive test for interaction between RR of ST and time (P for interaction ¼ 0.009). Results
were similar for definite or probable ST (P for interaction ¼ 0.015). In the overall analysis, TVR was performed
less frequently in patients with DES when compared with BMS (RR 0.51, 95% CI 0.43–0.61), with a greater
benefit in the first year (RR 0.46, 95% CI 0.38–0.55) when compared with subsequent years (RR 0.75, 95% CI
0.59–0.94; P for interaction ¼ 0.007).
Conclusion An early benefit of early generation DES in primary PCI for STEMI with a reduction in TVR and a trend towards less
definite ST is offset in subsequent years by an increased risk of very late ST.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Early generation drug-eluting stents (DES) † Bare-metal stents (BMS) † ST-segment elevation myocardial infarction
(STEMI) † Stent thrombosis (ST)
Introduction
In patients with ST-segment elevation myocardial infarction
(STEMI), primary percutaneous coronary intervention (PCI)
decreases infarct size and rates of re-infarction, and improves
survival compared with fibrinolysis.1 Bare-metal stents (BMS)
reduce the risk of re-occlusion and re-infarction after PCI,2,3
whereas early generation drug-eluting stents (DES) further
decrease the risk of restenosis and target lesion revascularization
without increasing the incidence of death or myocardial infarction
in a broad spectrum of patients, including STEMI.4,5 However,
there is a higher risk of late and very late stent thrombosis (ST)
associated with DES when compared with BMS,6 which is more
pronounced in patients with STEMI than in patients with stable
† B.K. and T.P. contributed equally to this work.
* Corresponding author: Division of Clinical Epidemiology & Biostatistics, Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland. Tel: +41 31 631 33
78, Fax: +44 31 631 35 20, Email: pjuni@ispm.unibe.ch
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170  Chapter 4.2
coronary artery disease.7,8 In autopsy specimens of lesions treated
with DES, histopathological analysis shows evidence of delayed
healing due to chronic inflammation, persistent fibrin deposition,
and a greater number of uncovered struts in patients with STEMI
when compared with stable coronary artery disease.9 Optical
Coherence Tomography in patients with STEMI also suggests an
increased risk of uncovered and malapposed struts in lesions
treated with DES when compared with BMS.10
Chronic inflammation and uncovered struts may become
particularly important after cessation of dual antiplatelet therapy
(DAPT) 6 to 12 months after stent implantation, which may cause
the risks and benefits of DES vis-a`-vis BMS to vary over time.11 Pre-
viousmeta-analyses investigating clinical outcomes of DES vs. BMS in
STEMI patients were limited to a maximum follow-up of 2 years,4
were restricted to one type of early generation DES,12,13 or did
not examine differences in relative risks of events over time.4,8 We
therefore set out to investigate the long-term safety and effective-
ness of early generationDES approved by theUS Food andDrugAd-
ministration compared with BMS and to determine whether relative
risks and benefits of DES vs. BMS varied over time.
Methods
Search strategy and selection criteria
We searched Medline, Embase, the Cochrane Central Register of
Controlled Trials (CENTRAL) (Supplementary material online,
Appendix S1), and relevant websites (www.cardiosource.com, www.
clinicaltrialresults.org, www.escardio.org, www.tctmd.com www.
theheart.org) (from the inception of each database to April 2011),
checked conference proceedings, relevant reviews, editorials, and
meta-analyses and reference lists of identified reports for randomized
or quasi-randomized trials in any language that compared sirolimus
eluting stents (SES, Cypher or Cypher Select, Cordis, Miami Lakes,
FL, USA), or paclitaxel eluting stents (PES, Taxus or Taxus Express,
Boston Scientific, Natick, MA, USA) with BMS in adults with STEMI.
Two of the authors (T.P. and G.G.S.) performed screening of
titles and abstracts, reviewed full-text articles, and determined their
eligibility in duplicate.
Data collection and quality assessment
We extracted characteristics of trials, patients, and interventions,
including study design, length of follow-up, components of methodo-
logical quality, and source of funding, gender, diabetes status, and
smoking status of included patients, stent type, reference vessel diam-
eter, number of stents implanted, length and diameter of the implanted
stents, and the recommended duration of DAPT according to the
protocol. As components of methodological quality,14,15 we assessed
concealment of allocation, blinding of investigators adjudicating clinical
events, and the inclusion of all randomized individuals in the analysis
according to the intention-to-treat principle. Concealment of alloca-
tion was considered adequate if the investigators responsible for the
selection of patients did not know before allocation which treatment
was next in line (central randomization, sealed, opaque, sequentially
numbered assignment envelopes, etc.). Any procedures based on pre-
dictable generation of allocation sequences, and potentially transparent
attempts to conceal allocation, such as assignment envelopes which
were not opaque or not sealed,16 were considered inadequate. The
analysis was considered to be according to the intention-to-treat prin-
ciple if all randomized patients were analysed in the group they were
originally allocated to, regardless of the treatment actually received.
All data were extracted by one reviewer (K.H.) and subsequently
checked by a second reviewer (B.K. or B.d.C.).
Outcomes
We pre-specified definite ST as the primary safety outcome and target
vessel revascularization (TVR) as the primary effectiveness outcome.
Definite ST was defined as a thrombosis within the stented segment,
confirmed by angiography or pathology in accordance with the criteria
of the Academic Research Consortium.17 Target vessel revasculariza-
tion was defined as repeat percutaneous intervention or bypass
surgery of the target vessel done for restenosis or other complications.
Data on TVR were unavailable in two trials,18,19 and we used data on
target lesion revascularization as a proxy measure, which was available
for one of the trials.18 We pre-specified the following secondary safety
outcomes: cardiac death, defined as any death due to a cardiac cause
(for example, myocardial infarction, low output failure, fatal arrhyth-
mia), procedure-related deaths, deaths related to concomitant treat-
ment, and death of unknown cause; myocardial infarction, including
fatal and non-fatal non-Q wave or Q wave myocardial infarction; a
composite of death or myocardial infarction. Data on the composite
of death or myocardial infarction were unavailable in eight trials,18–25
and we used data on the composite of cardiac death or myocardial in-
farction as a proxy measure, which was available in two trials.18,19 The
numbers of patients experiencing an event and the overall number of
patients at risk were recorded separately for year 1 and subsequent
years. For two trials,26,27 we obtained additional outcome data for
the follow-up period beyond 1 year. Outcomes data were extracted
by one of the authors (L.R.) and checked by another author (K.H.).
Statistical analysis
We calculated risk ratios (RR) as measures of treatment effect and
used a DerSimonian and Laird random effects model to combine esti-
mates across trials.28 Two three-arm trials had allocated patients to
SES, PES, or BMS and we combined data of SES and PES groups to
derive RRs. First, we performed overall analyses using the maximum
follow-up duration available for each trial. Then, we performed
analyses separately for the first year and for subsequent years
accompanied by tests for interaction between RR and time period
from random-effects meta-regression. We determined heterogeneity
across trials using the I2 statistic and constructed funnel plots (see
Web Supplementary material online, Appendix S2 for details of statis-
tical analysis). Then, we performed analyses stratified by the following
characteristics: adequate concealment of allocation, blind adjudication
of events, adequacy of analyses in accordance with the intention-
to-treat principle, trial size, industry-independent funding, protocol-
mandated duration of DAPT, and type of DES. We derived
numbers-needed-to-treat (NNTs) and numbers needed-to-harm
(NNHs) to prevent or cause one additional event per year when com-
pared with BMS from baseline event rates in BMS arms and the pooled
RR comparing DES and BMS.29 Assumptions for baseline event rates
were based on median annual event rates in year 1 and in subsequent
years found in BMS arms of included trials and registry studies7,30–34
comparing first generation DES with BMS in patients with STEMI
with at least 300 patients in the BMS group (Supplementary material
online, Appendix S3). Numbers-needed-to-treat and NNHs were cal-
culated separately for year 1, for years 2–5, and for the entire
period of 1–5 years. All analyses were performed using STATA 11.2.
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Figure 1 Number of patients experiencing definite ST out of the total patients DES and BMS. Risk ratios with 95% CI for definite stent
thrombosis comparing DES vs. BMS for individual trials and the pooled trials. DES, drug-eluting stent; BMS, bare-metal stent; ST, stent
thrombosis.
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Results
We identified 558 references in our literature search and consid-
ered 43 to be potentially eligible (Supplementary material online,
Appendix S2). Forty reports describing 15 trials met our inclusion
criteria and were included in the meta-analysis,18–27,35–59 13 pub-
lished as full-text journal articles, and 2 presented at scientific
meetings only. The trials had randomly allocated 7867 patients
undergoing primary PCI in the setting of STEMI to treatment
with either early generation DES or BMS. Seven trials allocated
patients to SES,20,21,23,24,26,27,35 and five to PES.18,19,22,37,38 Three
trials used both types of DES,25,39,44 two had three arms,39,44
and one had two arms, with the implantation of SES (47%), PES
(40%), or Zotarolimus-eluting stents (13%) in patients in the
DES arm remaining at the discretion of the treating physician.25
The methodological characteristics of trials are summarized in
Supplementary material online, Appendix S5. All trials were described
as randomized. Concealment of allocation was adequate in four
trials.19,24,25,37 Blind adjudication of events was described in eight
trials;18,19,21,26,27,37,39,44 in one trial,23 a clinical events committee
was described to adjudicate events, but it remained unclear whether
members of the committee were aware of the assigned stent type.
Seven trials had analysed their data according to the intention-to-treat
principle.18,20,25,27,37,38,44 The maximum length of follow-up ranged
from 7 months to 6 years with a duration of follow-up of 3 years or
more in 11 trials.18–21,23–27,37,39,44 Three trials reported funding to
be completely independent from industry.18,19,27 The clinical charac-
teristics of included patients are summarized in Table 1. The mean
age ranged from 59 to 65 years, the percentage of males from 70 to
83%, the percentage of patients with diabetes from 10 to 28%, and
the percentage of patients with multi-vessel disease from 34 to 53%.
A loading dose of clopidogrel 300 mg was administered in nine
trials18,19,23,24,26,27,38,39,44 and 300–600 mg in four trials,21,25,35,37
whereas two trials did not report the loading dose.20,56 The duration
of DAPT recommended according to protocol for patients with DES
ranged from3 to12months, with identical recommendeddurations in
DES and BMS patients in all but one trial.35 Glycoprotein IIb/IIIa inhibi-
tors were administered in .95% of the patients in 11 out of 15
trials,19–21,24–27,35,37,38,44 in 71 and 74% of the patients in two trials
use;18,23 two other trials did not report the rate of GpIIb/IIIa inhibitor
use39,56 (Supplementary material online, Appendix S3). The use of
mechanical thrombo-aspirationwas not reported, with the exception
of one trial (4% of patients),44 whereas a filterwire was reported in
another trial (41% of the patients).54 Angiographic follow-up was
performed in six trials, in 24–95% of the patients.19–21,23,37,38
All 15 trials contributed to the analysis of the primary safety end-
point of definite ST, which was reported in 151 patients treated with
DES (3.2%) and 83 patients allocated to BMS (2.7%). Nine trials
reported ST based on ARC definitions.19,23–26,37–39,44 Figure 1
(top) presents the Forest plot with RRs of individual trials scattered
around the null effect line at 1, a pooled RR of 1.08 (95% CI 0.82–
1.43) and no evidence for heterogeneity between trials (I2 ¼ 0%,
Figure 2 Contour enhanced funnel plots for definite ST and TVR with log of the RR of individual trials on the x-axis scattered against the
corresponding standard error on the y-axis. The larger a trial, the more events accumulated, the smaller the standard error as a measure of
statistical precision. In the absence of bias, the scatter of trials should have the shape of an inverted funnel, with large trials scattering little at the
top and small trials scattering considerably at the bottom. If the funnel plot is asymmetrical, this suggests the presence of small study effects,
suggesting that methodological problems, selective reporting of outcomes in small trials, and publication bias may have resulted in an overesti-
mation of effects. Red solid lines are prediction lines from univariable meta-regression models with standard error as explanatory variable and
red broken lines are corresponding 95% prediction intervals. The more the prediction line deviates from the vertical line, the more pronounced
is asymmetry. Contours distinguish between grey areas of significance at a two-sided P ≤ 0.05 and white areas of non-significance at a two-sided
P . 0.05. If trials seem to be missing in areas of non-significance, this adds to the notion of the presence of bias. The prediction lines should be
interpreted independently of contours. P-values are from the Harbord test. ST, stent thrombosis; TVR, target vessel revascularization.
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174  Chapter 4.2
P for heterogeneity ¼ 0.83). Figure 2 (left) presents the correspond-
ing funnel plot. The scatter of effect estimates and the prediction line
frommeta-regression models with standard error as an explanatory
variable indicated complete symmetry, with all trials in white areas
of non-significance at P. 0.05. The regression test was negative
(P ¼ 0.69). Stratified analyses according to the methodological
and clinical characteristics of trials (Table 2, left) showed only
minor variation across strata and corresponding tests for interaction
were negative. Figure 1 shows forest plots of definite ST occurring
during the first year (middle) and subsequent years (bottom).
During the first year after stent implantation, patients with DES
tended to be less likely than patients with BMS to experience defin-
ite ST (RR 0.80, 95% CI 0.58–1.12). Conversely, patients with DES
were more likely than patients with BMS to experience definite ST
during subsequent years (RR 2.10, 95% CI 1.20–3.69), and a test of
interaction between RR of definite ST and time was positive (P for
interaction ¼ 0.009). Results were similar for the composite of
definite or probable ST; definite or probable ST during the first
year tended to be less likely in patients with DES than with BMS
(RR 0.81, 95% CI 0.60–1.11), whereas the risk during subsequent
years was greater (RR 2.01, 95% CI 0.79–1.31), with a positive
test for interaction (P for interaction ¼ 0.015).
Fourteen trials contributed to the analysis of the primary
efficacy endpoint TVR, which was performed in 429 patients
treated with DES (9.0%) and 452 patients treated with BMS
(14.6%), with a pooled RR of 0.51 (95% CI 0.43–0.61, Figure 3,
top) and no evidence for heterogeneity between trials (I2 ¼ 24%,
P for heterogeneity ¼ 0.19). Figure 2 (right) presents the
corresponding funnel plot. The scatter of effect estimates and
the prediction line from meta-regression models with standard
error as an explanatory variable indicated asymmetry and the
contours to distinguish between areas of significance and non-
significance at P ¼ 0.05 suggested missing trials in the white area
of non-significance. The regression test for asymmetry was positive
at P ¼ 0.002. Accordingly, stratified analyses according to the
methodological and clinical characteristics indicated a greater
benefit from DES in small when compared with large trials
(Table 2, right). In the analysis stratified according to the time
(Figure 3, middle and bottom), we found a more pronounced
reduction in the relative risk of TVR for DES when compared
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Table 2 Stratified analysis by characteristics of trials and stent type for overall follow up
Definite stent thrombosis Target vessel revascularization
No. of
trials
No. of
patients
DES vs. BMS I2 P-inter No. of
trials
No. of
patients
DES vs. BMS I2 P-inter
All trials 15 7867 1.08 (0.82–1.43) 0 14 7431 0.51 (0.43–0.61) 24
Adequate concealment of allocation 0.56 0.18
Yes 4 4388 1.00 (0.69–1.46) 0 3 3952 0.58 (0.43–0.80) 50
No/unclear 11 3479 1.19 (0.78–1.82) 0 11 3479 0.47 (0.38–0.57) 0
Blind adjudication of events 0.71 0.85
Yes 9 6403 1.11 (0.81–1.51) 0 8 5967 0.50 (0.39–0.65) 51
No/unclear 6 1464 0.96 (0.49–1.88) 0 6 1464 0.48 (0.36–0.65) 0
Intention to treat analysis 0.95 0.59
Yes 7 4841 1.07 (0.75–1.53) 0 7 4841 0.51 (0.38–0.67) 50
No/unclear 8 3026 1.09 (0.69–1.73) 0 7 2590 0.48 (0.37–0.62) 0
Trial size 0.99 0.043
.300 8 6777 1.08 (0.80–1.46) 0 7 6341 0.57 (0.47–0.70) 29
,300 7 1090 1.08 (0.47–2.45) 0 7 1090 0.36 (0.26–0.51) 0
Funding independent from industry 0.59 0.58
Yes 3 1230 1.09 (0.33–3.66) 33 2 794 0.56 (0.31–1.02) 46
No/unclear 12 6637 1.05 (0.78–1.41) 0 12 6637 0.50 (0.41–0.60) 28
Type of stent 0.99 0.10
SES 9 1391 1.14 (0.72–1.81) 0 8 1035 0.45 (0.34–0.59) 0
PES 6 2998 1.15 (0.79–1.66) 0 6 2779 0.58 (0.43–0.79) 32
Protocol mandated duration of DAPT 0.40 0.58
9 or 12 months 7 2056 0.83 (0.42–1.61) 0 6 1620 0.47 (0.35–0.61) 0
3 or 6 months 8 5811 1.14 (0.84–1.56) 0 8 5811 0.51 (0.39–0.66) 47
Note that one two-arm trial did not contribute to the analysis according to stent type since different stent types were used in the DES arm, and two three-arm trials allowed both
a comparison of SES with BMS and a comparison of PES with BMS. Therefore, 16 comparisons are reported in stratified analysis according to stent type. P-inter, P for interaction
between subgroups using meta regression.
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Figure 3 Number of patients requiring TVR among all total patients in DES and BMS. Risk ratios for definite stent thrombosis comparing DES
vs. BMS for individual trials and the pooled population. DES, drug-eluting stent; BMS, bare-metal stent; ST, stent thrombosis; TVR, target vessel
revascularization.
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176  Chapter 4.2
with BMS during the first year (RR 0.46, 95% CI 0.38–0.55) as
opposed to subsequent years (RR 0.75, 95% CI 0.59–0.94), with
a positive test of interaction between RR of TVR and time (P for
interaction ¼ 0.007, Figure 4, top).
Sensitivity analyses of time-dependent effects after restriction to
trials of higher methodological quality showed similar results as the
main analysis for both primary endpoints (Table 3). Stratified ana-
lyses according to the stent type also suggested similar results
for definite ST, but more pronounced time-dependent effects for
TVR with SES than with PES, even though confidence intervals
were wide and overlapping (Table 3). A post hoc analysis of
time-dependent effects after exclusion of the largest trial,
HORIZONS-AMI,37 yielded again similar results. For definite ST,
the RR was 0.75 during the first year (95% CI 0.47–1.18) and
2.06 during subsequent years (95% CI 1.02–4.15; P for
interaction ¼ 0.028). For TVR, the RR was 0.39 during the first
year (95% CI 0.32–0.48) and 0.80 during subsequent years (95%
CI 0.54–1.19; P for interaction ¼ 0.005).
Figure 4 presents full analyses of primary and secondary outcomes
overall and stratified according to the time period. We found vari-
ation across time periods for definite ST, TVR, MI, and the
composite of definite or probable ST, all with positive tests for inter-
action between treatment effect and time (P for interaction
≤0.015). For remaining outcomes, there was no evidence to
suggest time-dependent effects. Table 4 presents estimated NNTs
to prevent one event and NNHs to cause one event during the
first year and subsequent years and for the entire duration of follow-
up for all outcomes. The NNT to prevent one definite ST compared
with BMS during the first year was 238, but the estimate did not
reach conventional levels of statistical significance (P ¼ 0.17) and
the 95% CI included infinity (95% CI 114 to 1). The NNH to
cause one additional definite ST during the subsequent 4 years
was 76 (95% CI 31–417, P ¼ 0.009). Taken together, this resulted
in a NNH to cause one additional definite ST over 5 years of 111,
with the 95% CI, including infinity (95% CI 21 to 1, P ¼ 0.46).
Numbers-needed-to-treat of 19 were reached to avoid one TVR
during the first year (95% CI 16–23), 71 during the subsequent 4
years (95% CI 44–298), and 15 for years 1–5 combined (95% CI
11–27), with all estimates reaching conventional levels of statistical
significance (P ≤ 0.015). Additional statistical trends were only
observed for MI, with a NNT of 79 to prevent one MI during the
first year (95% CI 49–355, P ¼ 0.01) and a NNH of 76 to cause
Figure 4 Risk of clinical outcomes comparing DES with BMS stratified according to time. DES, drug-eluting stent; BMS, bare-metal stent.
P-inter: P for interaction between year 1 and subsequent years using meta-regression.
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one MI compared with BMS during the subsequent 4 years (95% CI
29 to 1, P ¼ 0.10). Taken together, this resulted in a clinically
irrelevant NNH of 1961 to cause one MI during years 1–5 (95%
CI 22 to 1, P ¼ 0.98).
Discussion
This meta-analysis of 15 randomized trials in 7867 patients who
underwent primary PCI for STEMI suggests time-dependent clinical
effects of early generation FDA-approved DES compared with
BMS for definite ST, definite or probable ST, TVR, and myocardial
infarction. During the first year, there was a safety advantage of
DES over BMS in terms of lower rates of ST and MI, whereas an
opposite pattern emerged during subsequent years, with a safety
advantage of BMS over DES. This qualitative interaction between
risks and benefits was particularly robust for the endpoint definite
ST, with a trend towards a 20% relative risk reduction during the
first year, which was offset by a more than 100% relative risk
increase during subsequent years (P for interaction ¼ 0.009). For
the primary effectiveness outcome of TVR, we did not find a quali-
tative, but still an important quantitative interaction, with a more
than 50% relative risk reduction in TVR during the first year,
which decreased but was maintained at 25% during subsequent
years (P for interaction ¼ 0.007). Overall, the effectiveness of
DES in reducing the rate of TVR was maintained across the
entire duration of follow-up, with an estimated NNT to prevent
one TVR during the first 5 years after stent implantation of 15,
which is clearly clinically relevant. For none of the safety outcomes,
we found any evidence for overall risk increases associated with
DES, with risk ratios near one for death overall, cardiac death,
MI, ST, and the composite of death or MI. Conversely, there was
clear evidence of late harm with an increased risk of definite and
definite or probable ST as well as MI.
What does this meta-analysis add in comparison with previously
published systematic reviews? First, we included 15 studies with a
total of 7867 patients. Therefore, this is the largest meta-analysis of
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Table 3 Sensitivity analysis of time-dependent effects after restriction of trials of higher methodological quality and
after stratification according to stent type
Definite stent thrombosis Target vessel revascularization
No. of
trials
No. of
patients
DES vs. BMS I2 P-inter No. of
trials
No. of
patients
DES vs. BMS I2 P inter
All trials 0.009 0.007
Year 1 15 7867 0.80 (0.58–1.12) 0 14 7431 0.46 (0.38–0.55) 6
Subsequent years 11 7067 2.10 (1.20–3.69) 0 11 7067 0.75 (0.59–0.94) 0
Trials with concealed allocation 0.20 0.26
Year 1 4 4388 0.82 (0.53–1.27) 0 3 7904 0.50 (0.33–0.76) 54
Subsequent years 3 3952 1.61 (0.73–3.57) 0 3 7904 0.73 (0.56–0.95) 0
Trials with blind adjudication 0.019 0.063
Year 1 9 6403 0.82 (0.57–1.18) 0 8 5967 0.44 (0.33–0.59) 40
Subsequent years 8 5967 2.21 (1.18–4.14) 0 8 5967 0.71 (0.56–0.91) 0
Trials with ITT analysis 0.068 0.30
Year 1 7 4841 0.81 (0.53–1.23) 0 7 4841 0.49 (0.37–0.65) 28
Subsequent years 6 4761 1.95 (0.96–3.95) 0 6 4761 0.67 (0.52–0.86) 0
Large trials 0.016 0.022
Year 1 8 6777 0.79 (0.56–1.14) 0 7 6341 0.48 (0.37–0.61) 34
Subsequent years 7 6341 2.12 (1.17–3.84) 0 7 6341 0.79 (0.62–1.01) 0
Trials with industry independent funding 0.21 0.67
Year 1 3 1230 0.69 (0.23–2.07) 0 2 794 0.52 (0.26–1.04) 43
Subsequent years 2 794 3.99 (0.85–18.6) 0 2 794 0.70 (0.30–1.64) 0
SES 0.096 0.027
Year 1 9 2779 0.83 (0.47–1.47) 0 8 2064 0.35 (0.25–0.48) 0
Subsequent years 8 2567 2.18 (0.91–5.23) 0 7 1868 0.80 (0.45–1.42) 0
PES 0.053 0.42
Year 1 6 4485 0.84 (0.55–1.30) 0 6 4408 0.60 (0.47–0.76) 0
Subsequent years 3 3657 2.57 (1.15–5.72) 0 4 4008 0.70 (0.54–0.92) 0
P-inter, P for interaction between year 1 and subsequent years using meta regression.
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its kind. Secondly, we focused on long-term outcomes, and provide
the longest follow-up reported to date with a maximum length of
follow-up up to 6 years. This is important as previous large-scale
trials and meta-analyses failed to detect differences in late safety
outcomes with the use of early generation DES, prematurely con-
cluding the absence of harm among STEMI patients. Thirdly, we
examined the data for the presence of small study effects using
contour-enhanced funnel plots and regression tests. Finally and
most importantly, we systematically analysed time-dependent
effects of stent-type allocation on all clinical outcomes (Figure 4).
Our analysis indicates that the use of early generation DES is asso-
ciated with a significantly lower risk of TVR and MI as well as a
trend towards fewer definite ST during the period of up to 1
year, whereas a reverse pattern of a higher risk of definite ST
and a trend towards more MIs becomes apparent during the
period beyond 1 year. This suggests that the long-term safety of
DES needs further improvement.
Patients with STEMI are at increased risk of ST when compared
with patients with stable coronary artery disease both after DES
and after BMS implantation.7,8,60 However, the observed differen-
tial in timing of ST suggests differences in the underlying patho-
physiological pathways leading to this adverse event after DES
implantation. Thus, early ST is closely related to the acute phase
after the coronary event and procedure, with pronounced activa-
tion of platelets and the coagulation cascade. In this context,
experimental data suggest that durable polymer-based DES exert
anti-thrombogenic properties resulting in a lower degree of throm-
bus adhesion,61 which may be of particular importance among
STEMI patients. Along this line, the results of the present study
provide preliminary clinical evidence of a somewhat lower risk of
definite ST and MI after DES when compared with BMS implant-
ation among STEMI patients. Conversely, ST occurring later in
the process may be related to a chronic process with delayed
arterial healing and vessel remodelling due to chronic local inflam-
mation potentially related to the persistence of durable polymers62
and/or long-term effects of eluted drugs. Along this line, autopsy
data indicate a differential healing response of DES implanted
into plaques of patients with STEMI when compared with stable
coronary artery disease with evidence of persistent inflammation
and a higher proportion of uncovered struts among coronary seg-
ments treated with DES than BMS.9 Among patients treated with
DES, incomplete stent apposition has been recognized as an im-
portant morphological substrate associated with the occurrence
of very late ST.63 It is more frequently observed in STEMI patients
than in those who undergo DES implantation for stable angina and
may be related to incomplete stent apposition at the time of im-
plantation, presence of jailed thrombus with subsequent reso-
lution, or vessel remodelling in response to toxic effects of the
drug or polymer. In addition, optical coherence tomography10
and intravascular ultrasound studies52 among STEMI patients
provide evidence for a higher rate of uncovered stent struts as
well as incomplete stent apposition in DES compared with BMS.
All these factors may be of particular relevance upon discontinu-
ation of DAPT during long-term follow-up.
The higher risk of definite ST with early generation DES than
BMS more than 1 year after stent implantation directly translated
into an increased risk of myocardial infarction, with identical
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NNHs of 76 to cause one event for both ST and MI. Whether pro-
longation of DAPT beyond 1 year among patients with STEMI who
are at a higher risk of very late ST compared with other patient
subsets may overcome this disadvantage, which could in turn trans-
late into a lower overall relative risk of ST and MI, remains subject
to debate. In addition, the use of newer generation DES with
durable polymers of improved biocompatibility,64 biodegradable
polymers which dissolve completely once the drug is eluted,11
or even fully bioresorbable vascular scaffolds65 are currently
being investigated to address this issue in STEMI patients.66,67
This meta-analysis demonstrated a sustained benefit of DES
when compared with BMS in reducing the risk of TVR. The mag-
nitude of the relative risk reduction of approximately 50% was
comparable to what was found in randomized trials of patients
with stable coronary artery disease and is clinically important
with a NNT of only 15.5 The relative risk reduction in TVR
observed during the first year decreased considerably during
subsequent years, however (P for interaction ¼ 0.007).68 The
decrease in benefit over time was previously referred to as late
catch-up phenomenon69 and some studies found DES associated
with delayed late lumen loss beyond the first year of follow-up.68,70
Our results suggest that the increased rate in VLST requiring
repeat intervention might contribute to this phenomenon. We
were also surprised to find evidence of small study effects71,72
for TVR, suggesting that methodological problems14 and selective
reporting of outcomes73 in small trials combined with publication
bias74 may have resulted in an overestimation of the effectiveness
of first-generation DES.
Conclusions
The use of early generation DES in primary PCI for STEMI is asso-
ciated with a large reduction in TVR and a trend towards less def-
inite ST during the first year, which is offset by an increased risk of
very late ST and accompanying clinical outcomes during subse-
quent years.
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online.
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NEw GENErATioN DES
5 cliNicAl ouTcomES wiTH  THE uNrESTricTED uSE oF NEw GENErATioN EVErolimuS-
EluTiNG STENTS
5.1 Early experience in the unrestricted use of newer generation everolimus-eluting stents compared to early 
generation SES
Long-term comparison of everolimus-
eluting and sirolimus-eluting stents 
for coronary revascularization.
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CLINICAL RESEARCH Interventional Cardiology
Long-Term Comparison of Everolimus-Eluting and
Sirolimus-Eluting Stents for Coronary Revascularization
Lorenz Räber, MD,* Peter Jüni, MD,†‡ Eveline Nüesch, PHD,‡ Bindu Kalesan, MSC,‡
Peter Wenaweser, MD,* Aris Moschovitis, MD,* Ahmed A. Khattab, MD,* Maryam Bahlo, MD,*
Mario Togni, MD,* Stéphane Cook, MD,* Rolf Vogel, MD, PHD,* Christian Seiler, MD,*
Bernhard Meier, MD,* Stephan Windecker, MD*†
Bern, Switzerland
Objectives This study sought to compare the unrestricted use of everolimus-eluting stents (EES) with sirolimus-eluting
stents (SES) in patients undergoing percutaneous coronary intervention.
Background It is unclear whether there are differences in safety and efficacy between EES and SES during long-term follow-up.
Methods Using propensity score matching, clinical outcome was compared among 1,342 propensity score–matched pairs of pa-
tients treated with EES and SES. The primary outcome was a composite of death, MI, and target vessel revascularization.
Results The median follow-up was 1.5 years with a maximum of 3 years. The primary outcome occurred in 14.9% of
EES- and 18.0% of SES-treated patients up to 3 years (hazard ratio [HR]: 0.83, 95% confidence interval [CI]: 0.68
to 1.00, p  0.056). All-cause mortality (6.0% vs. 6.5%, HR: 0.92, 95% CI: 0.68 to 1.25, p  0.59) was similar,
risks of myocardial infarction (MI) (3.3% vs. 5.0%, HR: 0.62, 95% CI: 0.42 to 0.92, p  0.017), and target vessel
revascularization (7.0% vs. 9.6%, HR: 0.75, 95% CI: 0.57 to 0.99, p  0.039) were lower with EES than SES.
Definite stent thrombosis (ST) (HR: 0.30, 95% CI: 0.12 to 0.75, p  0.01) was less frequent among patients
treated with EES. The reduced rate of MI with EES was explained in part by the lower risk of definite ST and the
corresponding decrease in events associated with ST (HR: 0.25, 95% CI: 0.08 to 0.75, p  0.013).
Conclusions The unrestricted use of EES appears to be associated with improved clinical long-term outcome compared with
SES. Differences in favor of EES are driven in part by a lower risk of MI associated with ST. (J Am Coll Cardiol
2011;57:2143–51) © 2011 by the American College of Cardiology Foundation
Early generation drug-eluting stents (DES) releasing siroli-
mus (sirolimus-eluting stents [SES]) or paclitaxel
(paclitaxel-eluting stents [PES]) have reduced the need of
repeat revascularization compared with bare-metal stents
(1,2). Although the rate of mortality and myocardial infarc-
tion (MI) was similar for DES and bare-metal stents (3),
very late stent thrombosis (ST) emerged as a distinct entity
complicating the use of early generation DES (4). More-
over, restenosis still occurs after DES implantation with
evidence of an erosion of antirestenotic efficacy over time
(5). Newer generation DES have been developed with the
aim to improve the safety and efficacy of early generation
devices (6). The newer generation everolimus-eluting stent
(EES) has been shown to improve outcome compared with
PES (7–10). However, data comparing EES with SES are
limited. Since SES have been shown to be superior com-
pared with PES (3,11) as well as with a new-generation
stent eluting zotarolimus from a phosphorylcholine polymer
(12,13), it is relevant to determine whether EES provide
therapeutic benefit over SES. We therefore compared the
outcomes of the unrestricted use of EES and SES in a large,
consecutively enrolled patient population followed for up to
3 years in a propensity-matched analysis.
Methods
Study population and data collection. A total of 1,532 consec-
utive patients were treated with SES (Cypher, Cordis, Miami
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Lakes, Florida) between May 2004
and January 2006, whereas 1,601
consecutive patients underwent
treatment with EES (XIENCE V,
Abbott Vascular, Santa Clara, Cali-
fornia; or PROMUS,Boston Scien-
tific, Natick, Massachusetts) be-
tween November 2006 and March
2009. Patients included in the
SIRTAX (Sirolimus-Eluting Ver-
sus Paclitaxel-Eluting Stents for
Coronary Revascularization) trial
were not eligible in view of man-
dated angiographic follow up (14).
The study complied with the Dec-
laration of Helsinki and was ap-
proved by the institutional ethics
committee at Bern University
Hospital, Switzerland. Patients
gave written informed consent to
be prospectively followed.
All patients were followed up for major adverse cardiac
events using patient-administered postal questionnaires.
Vital status was ascertained from hospital records and
municipal civil registries. All suspected events were
independently adjudicated by a clinical event committee
whose members were unaware of the type of stent
implanted. Baseline clinical and procedural characteris-
tics and all follow-up data were entered into a dedicated
database, held at an academic clinical trials unit (CTU
Bern, Bern University Hospital, Switzerland) responsible
for central data audits and maintenance of the database.
Procedures. The treatment guidelines, including peripro-
cedural and post-procedural medication regimen, were
performed according to current practice guidelines and
did not change between the inclusion of the first patient
into the SES and inclusion of the last patient into the
EES cohort. All patients received a loading dose of
clopidogrel 300 to 600 mg during the procedure and were
prescribed aspirin once daily lifelong and clopidogrel for
12 months. The use of glycoprotein IIb/IIIa antagonists
was left to the discretion of the operator. Creatinine
kinase (CK), CK-MB, and troponin T were routinely
assessed at baseline and 12 to 24 h after percutaneous
coronary intervention as was a 12-lead electrocardiogram.
Biomarkers were sampled every 6 to 8 h in patients with
signs of ischemia until identification of peak levels.
Definitions. The primary endpoint was the composite of
death, MI, and target vessel revascularization (TVR) up
to a maximum follow-up of 3 years. The definition of
cardiac death included any death due to immediate
cardiac cause, procedure-related deaths, and death of
unknown cause. The diagnosis of Q-wave MI required
ischemic signs or symptoms and new pathological Q
waves in 2 contiguous electrocardiogram leads. In the
absence of Q waves, the diagnosis of MI was based on an
elevation in CK to 2 upper limit of normal and an
elevation of CK-MB or troponin to 3 upper limit of
normal. TVR was defined as repeat revascularization of
any segment within the entire major coronary vessel proximal
and distal to a target lesion. Target lesion revascularization
(TLR) was defined as revascularization for a stenosis within
the stent or the 5-mm borders adjacent to the stent. ST
Baseline Characteristics After PS MatchingTable 1 Baseline Characteristics After PS Matching
Before Propensity Score Matching After Propensity Score Matching
EES
(n  1,601)
SES
(n  1,532) p Value
EES
(n  1,342)
SES
(n  1,342) p Value
Age, yrs 65.3  11.8 63.3  11.4 0.001 63.7  11.6 63.9  11.4 0.62
Male 1,213 (75.8) 1,193 (77.9) 0.16 1,047 (78.0) 1,040 (77.5) 0.72
Body mass index, kg/m2 27.4  4.9 27.4  4.3 0.66 27.4  4.5 27.4  4.2 0.72
Diabetes mellitus 289 (18.1) 270 (17.6) 0.76 228 (17.0) 235 (17.5) 0.72
Insulin-requiring diabetes 84 (29.1) 63 (23.6) 0.19 70 (30.7) 55 (23.4) 0.14
Hypertension 958 (59.8) 831 (54.2) 0.002 748 (55.7) 746 (55.6) 0.94
Hypercholesterolemia 865 (54.0) 766 (50.0) 0.02 688 (51.3) 713 (53.1) 0.33
Current smoking 445 (27.8) 490 (32.0) 0.01 405 (30.2) 422 (31.5) 0.48
Family history of CAD 457 (28.5) 412 (26.9) 0.30 390 (29.1) 363 (27.1) 0.25
Impaired renal function 48 (3.0) 48 (3.1) 0.83 33 (2.5) 45 (3.4) 0.17
Type of indication 0.001 0.009
Stable angina pectoris 696 (43.5) 688 (44.9) 648 (48.3) 597 (44.5)
Unstable angina 115 (7.2) 64 (4.2) 34 (2.5) 64 (4.8)
Non–ST-segment elevation MI 527 (32.9) 455 (29.7) 405 (30.2) 419 (31.2)
ST-segment elevation MI 261 (16.3) 324 (21.2) 255 (19.0) 262 (19.5)
Cardiogenic shock 37 (2.3) 15 (1.0) 0.002 25 (1.9) 14 (1.0) 0.08
Left ventricular ejection
fraction 50%
939 (58.7) 1,012 (66.1) 0.001 871 (64.9) 842 (62.7) 0.24
Values are expressed as mean  SD or n (%). 2-sided p values were calculated using a chi-square test for categorical variables and using an unpaired t test for continuous variables.
CAD  coronary artery disease; EES  everolimus-eluting stent(s); MI  myocardial infarction; PS  propensity score; SES  sirolimus-eluting stent(s).
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
PS  propensity score
RR  relative risk
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization
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was defined according to Academic Research Consortium
definitions (15).
Statistical analysis. This was a propensity score (PS)-
matched superiority analysis. Sample size considerations
were based on an updated pooled analysis of trials compar-
ing EES with PES (16), suggesting a relative risk (RR) of
0.60 for the composite of death, MI, or TVR, and a network
analysis comparing SES with PES (3), which suggested a
RR of 0.80 in favor of SES. Taken together, these data
suggested a RR of 0.60/0.80  0.75 in favor of EES. With
an expected crude event rate of 18% at a median
follow-up of 1.5 years with SES, a sample size of 1,400
matched pairs would provide 90% power to detect a RR
of 0.75 in favor of EES. Assuming that 90% of patients
treated with EES could be matched to patients treated
with SES, 1,560 patients treated with EES were neces-
sary for this study.
We compared baseline characteristics between patients
treated with EES and SES using a chi-square test for
categorical variables and an unpaired t test for continuous
variables. Then, we used PS matching to account for
differences in baseline characteristics. PS for receiving
EES were estimated using a probit model including age,
gender, and pre-treatment variables associated with stent
selection in the multivariable model at p  0.10 as
independent variables (arterial hypertension, hypercho-
lesterolemia, clinical manifestation of coronary artery
disease at baseline, and ejection fraction below 50%). An
automated matching procedure randomly selected a pa-
tient treated with EES and a randomly selected patient
treated with SES from the pool of patients with PS
within a caliper of 0.05 on the propensity score. For
each pair, we ensured equal follow-up times. We used
Cox proportional hazards models that accounted for the
Procedural Characteristics and Discharge Medications After PS MatchingTable 2 Procedural Characteristics and Discharge Medications After PS Matching
EES
(n  1,342)
SES
(n  1,342) p Value
Procedural characteristics
Multivessel treatment 315 (23.5) 217 (16.2) 0.001
Number of vessels treated per patient 1.3 0.5 1.2 0.4 0.001
Number of lesions treated per patient 1.8 1.0 1.5 0.7 0.001
1 lesion 691 (51.5) 843 (62.8)
2 lesions 394 (29.4) 361 (26.9)
3 lesions 172 (12.8) 116 (8.6)
4 lesions 85 (6.3) 20 (1.5)
Target vessel, number of patients
Left main 58 (4.3) 31 (2.3) 0.004
Left anterior descending 661 (49.3) 659 (49.1) 0.22
Left circumflex 412 (30.7) 316 (23.6) 0.001
Right coronary artery 477 (35.5) 464 (34.6) 0.20
Arterial bypass graft 3 (0.2) 2 (0.2) 0.20
Saphenous vein graft 42 (3.1) 41 (3.1) 0.91
Number of stents per patient 2.0 1.1 1.8 0.9 0.001
Average stent diameter, mm 2.9 0.4 2.9 0.4 0.001
Total stent length per patient, mm 31.4 19.4 32.7 19.0 0.07
Maximal inflation pressure, atm 14.7 4.0 14.9 4.2 0.28
Glycoprotein IIb/IIIa antagonist 385 (28.7) 407 (30.3) 0.35
Medication at discharge
Aspirin 1,312 (97.8) 1,294 (96.6) 0.06
Clopidogrel 1,310 (97.6) 1,285 (96.4) 0.07
Oral anticoagulation 19 (1.4) 27 (2.0) 0.23
Beta-blocker 861 (64.2) 818 (61.4) 0.14
ACE inhibitor 694 (51.7) 722 (54.2) 0.20
AT II inhibitor 192 (14.3) 213 (16.0) 0.23
Calcium antagonist 118 (8.8) 132 (9.9) 0.32
Statin 1,118 (83.3) 1,145 (85.9) 0.06
Oral antidiabetic agents 139 (10.4) 135 (10.1) 0.84
Insulin 82 (6.1) 80 (6.0) 0.91
Diuretics 235 (17.5) 249 (18.7) 0.43
Proton pump inhibitor 274 (20.4) 252 (18.9) 0.33
Values are expressed as n (%) or mean SD. 2-sided p values were calculated using a chi-square test for categorical variables and using an unpaired
t test for continuous variables.
ACE  angiotensin-converting enzyme; AT  angiotensin; PS  propensity score; other abbreviations as in Table 1.
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1:1 matching to calculate hazard ratios (HR) comparing
the 2 stent types. In a sensitivity analysis, we adjusted
procedural characteristics that differed between stent
types in the PS-matched sample at p  0.10. For ST, we
performed landmark analyses according to time points
specified in Academic Research Consortium definitions
(15). Then, we compared the 2 stent types separately on
clinical outcomes associated with ST (defined as events
occurring within a 1-day time window of ST) and not
associated with ST. Finally, we used univariable Cox
models to determine whether procedural characteristics
were associated with the primary composite endpoint,
because procedural characteristics were different between
stent types. All p values and 95% confidence intervals
(CIs) are 2-sided.
Results
A total of 3,133 patients (98.7%) completed the last
follow-up (EES  98.7%, SES  98.7%). A comparison of
Clinical OutcomesTable 3 Clinical Outcomes
EES
(n  1,342)
SES
(n  1,342)
Hazard Ratio
(95% CI) p Value
30 days
Death, all 28 (2.1) 37 (2.8) 0.76 (0.46–1.24) 0.27
Cardiac death 27 (2.0) 32 (2.4) 0.84 (0.51–1.41) 0.52
MI 32 (2.4) 45 (3.4) 0.71 (0.45–1.12) 0.14
Q-wave 3 (0.2) 9 (0.7) 0.33 (0.09–1.23) 0.10
Non–Q-wave 29 (2.2) 33 (2.5) 0.88 (0.53–1.45) 0.61
TLR 8 (0.6) 16 (1.2) 0.50 (0.21–1.17) 0.11
TVR 10 (0.8) 22 (1.6) 0.45 (0.22–0.96) 0.039
Death or MI 56 (4.2) 80 (6.0) 0.70 (0.49–0.98) 0.039
Cardiac death or MI 55 (4.1) 75 (5.6) 0.73 (0.51–1.03) 0.08
Cardiac death, MI, or TLR 61 (4.6) 81 (6.0) 0.75 (0.54–1.05) 0.09
Cardiac death, MI, or TVR 62 (4.6) 85 (6.3) 0.73 (0.52–1.01) 0.06
Death, MI, or TLR 62 (4.6) 86 (6.4) 0.72 (0.52–0.99) 0.048
Death, MI, or TVR 63 (4.7) 90 (6.7) 0.70 (0.51–0.96) 0.029
1 year
Death, all 60 (4.5) 68 (5.1) 0.87 (0.61–1.23) 0.43
Cardiac death 42 (3.1) 51 (3.8) 0.82 (0.55–1.24) 0.35
MI 39 (2.9) 55 (4.1) 0.69 (0.45–1.04) 0.08
Q-wave 6 (0.5) 13 (1.0) 0.50 (0.19–1.33) 0.17
Non–Q-wave 33 (2.5) 39 (2.9) 0.79 (0.50–1.27) 0.34
TLR 48 (3.6) 59 (4.4) 0.85 (0.58–1.26) 0.43
TVR 65 (4.8) 99 (7.4) 0.68 (0.49–0.93) 0.017
Death or MI 95 (7.1) 116 (8.6) 0.80 (0.60–1.05) 0.11
Cardiac death or MI 77 (5.7) 100 (7.5) 0.74 (0.55–1.01) 0.06
Cardiac death, MI, or TLR 117 (8.7) 140 (10.4) 0.84 (0.66–1.08) 0.18
Cardiac death, MI, or TVR 131 (9.8) 174 (13.0) 0.75 (0.60–0.95) 0.017
Death, MI, or TLR 135 (10.1) 156 (11.6) 0.87 (0.69–1.10) 0.26
Death, MI, or TVR 149 (11.1) 190 (14.2) 0.78 (0.63–0.97) 0.026
Up to 3 years
Death, all 81 (6.0) 87 (6.5) 0.92 (0.68–1.25) 0.59
Cardiac death 52 (3.9) 59 (4.4) 0.88 (0.61–1.28) 0.51
MI 44 (3.3) 67 (5.0) 0.62 (0.42–0.92) 0.017
Q-wave 6 (0.5) 21 (1.6) 0.30 (0.12–0.75) 0.010
Non–Q-wave 38 (2.8) 42 (3.1) 0.83 (0.53–1.31) 0.43
TLR 62 (4.6) 81 (6.0) 0.80 (0.57–1.12) 0.20
TVR 94 (7.0) 129 (9.6) 0.75 (0.57–0.99) 0.039
Death or MI 120 (8.9) 145 (10.8) 0.80 (0.63–1.02) 0.08
Cardiac death or MI 91 (6.8) 120 (8.9) 0.74 (0.56–0.97) 0.030
Cardiac death, MI, or TLR 144 (10.7) 174 (13.0) 0.84 (0.67–1.05) 0.12
Cardiac death, MI, or TVR 171 (12.7) 217 (16.2) 0.79 (0.64–0.97) 0.025
Death, MI, or TLR 173 (12.9) 198 (14.7) 0.88 (0.71–1.09) 0.22
Death, MI, or TVR 200 (14.9) 241 (18.0) 0.83 (0.68–1.00) 0.056
Data are n (%). Hazard ratios are from Cox proportional hazard model. p values are 2-sided from superiority testing with a Wald test. *Relative risks
were calculated after a continuity correction of 0.5; p values are 2-sided from Fisher exact test.
CI  confidence interval; MI  myocardial infarction; TLR  target lesion revascularization; TVR  target vessel revascularization.
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patients before PS matching is provided in Table 1. One
thousand three hundred forty-two patients treated with
EES could be matched to 1,342 patients treated with SES.
The median follow-up duration was 1.3 years in both
groups (range 1.0 year to 2.2 years), with an accumulated
2,221 and 2,238 patient-years, respectively. Table 1 shows
pre-treatment characteristics at baseline after matching,
which were comparable between groups. Table 2 presents
procedural characteristics after matching. Implantation of
EES appeared more complex, with a higher proportion
of patients with multivessel disease and higher number of
lesions and vessels treated per patient. Discharge medi-
cations were comparable for both groups, and the median
length of clopidogrel prescription duration was 12 months
(Table 2).
Table 3 presents clinical outcomes up to 3 years. The primary
outcome occurred in 14.9% of EES- and 18.0% of SES-treated
patients up to 3 years (p 0.056) (Fig. 1). The trend in favor of
EESwas driven by a significantly lower rate ofMI (3.3% vs. 5.0%,
p  0.017) and TVR (7.0% vs. 9.6%, p  0.039). Rates of
all-cause and cardiac mortality were similar, whereas Q-wave MI
(0.5% vs. 1.6%, p 0.010) and the composite of cardiac death or
MI (6.8% vs. 8.9%, p  0.030) were less frequent with EES.
Table 4 shows associations of procedural characteristics with
the primary outcome stratified by stent type and overall. The
presence of more complex procedural characteristics was gen-
erally associated with worse outcome for both stent types and
overall. A sensitivity analysis of the primary outcome adjusted
for procedural characteristics yielded similar results: HR: 0.78,
95% CI: 0.63 to 0.97, p  0.029.
Results on Academic Research Consortium–defined ST
are summarized in Table 5. Definite ST was less frequent
with EES than SES (0.5% vs. 1.6%, HR: 0.30, 95% CI:
0.12 to 0.75, p  0.010) as was definite or probable ST
(Fig. 2). Clinical outcomes associated with definite ST (left)
and outcomes occurring in the absence of ST (right) are shown
in Figure 3. ST-associated MI (HR: 0.25, 95% CI: 0.08 to
0.75, p  0.013) and TVR (HR: 0.33, 95% CI: 0.12 to 0.92,
p  0.033) were less frequent with EES. These differences
were less pronounced for MI (HR: 0.79, 95% CI: 0.51 to 1.21,
p  0.28) and TVR (HR: 0.84, 95% CI: 0.63 to 1.12, p 
0.24) occurring in the absence of ST (Fig. 3).
Figure 1 Clinical Outcomes in a PS-Matched Cohort of Patients Who Received EES or SES
Cumulative incidence of the primary outcome (A), death (B), myocardial infarction (MI) (C), and target vessel revascularization (TVR) (D) up to 3 years.
p values are from 2-sided Wald tests. EES  everolimus-eluting stent(s); PCI  percutaneous coronary intervention; PS  propensity score; SES  sirolimus-eluting stent(s).
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Discussion
In this observational, PS-matched study, nested in a pro-
spective registry, the use of EES was associated with a trend
toward a lower risk of the patient-oriented safety and
efficacy endpoint of death, MI, and TVR as compared with
SES during follow-up to 3 years. The risk of MI was
reduced by 38%, and differences in rates of MI were driven
by a 70% reduction in the risk of Q-wave MI.
The results of the present study contribute to a mechanistic
explanation of differences in clinical outcome between EES
and SES. The lower risk ofMI with EESwas explained in part
by the lower rate of ST (Fig. 2), whereas differences in the risk
of MI occurring in the absence of ST were less pronounced
(Fig. 3). This observation is important because the unrestricted
use of early generation DES was associated with an ongoing
risk of ST during long-term follow-up and stirred a debate
regarding the need of prolonged dual antiplatelet therapy
(17–20). Our long-term data provide novel evidence that ST
beyond 1 year is less frequent with EES compared with SES
(p 0.007), circumventing an important shortcoming of early
generation DES. The mechanisms underlying the lower risk of
ST with EES remain speculative but may be related to the
lower strut thickness with less arterial injury and more rapid
and complete endothelialization, a biocompatible polymer less
prone to hypersensitivity reactions, and a lower dose of the
antiproliferative drug.
The risk of TVR was 25% lower with EES than SES, and
the majority of revascularization procedures were related to the
target lesion. Of note, the risk of TVR associated with ST was
lower with EES, whereas differences between stent types were
less pronounced for revascularization procedures performed in
the absence of ST. This suggests that differences in revascu-
larization in favor of EES were related in part to a lower
predisposition for ST rather than restenosis. One clinical
registry and 2 randomized clinical trials have compared EES
with SES. The X-SEARCH registry (21) showed similar
safety and efficacy outcomes in both EES and SES at 6 months
of follow-up after multivariate adjustment of the 2 sequential
cohorts. The ISAR-TEST 4 (Intracoronary Stenting and
Angiographic Results: Test Efficacy of 3 Limus-Eluting
Association of Procedural CharacteristicsWith Primary Outcome up to 3 Years,Overall and Stra ified by Type of Stent
Table 4
Asso iation of Procedural Characteristics
With Primary Outcome up to 3 Years,
Overall and Stratified by Type of Stent
Procedural Characteristics
Hazard Ratio
(95% CI) p Value
Multivessel treatment, yes vs. no
SES 1.67 (1.24–2.26) 0.001
EES 1.62 (1.20–2.18) 0.001
Overall 1.60 (1.30–1.97) 0.001
Number of vessels treated per patient
(per vessel)
SES 1.69 (1.30–2.21) 0.001
EES 1.55 (1.21–1.98) 0.001
Overall 1.56 (1.31–1.87) 0.001
Number of lesions treated per patient
(per lesion)
SES 1.36 (1.17–1.59) 0.001
EES 1.21 (1.07–1.36) 0.002
Overall 1.23 (1.12–1.34) 0.001
Target vessel, number of patients
Left main, yes vs. no
SES 3.01 (1.76–5.17) 0.001
EES 2.59 (1.63–4.11) 0.001
Overall 2.64 (1.86–3.74) 0.001
Left anterior descending, yes vs. no
SES 1.10 (0.85–1.42) 0.46
EES 0.99 (0.75–1.31) 0.96
Overall 1.05 (0.87–1.27) 0.61
Left circumflex, yes vs. no
SES 0.93 (0.69–1.26) 0.64
EES 1.29 (0.97–1.72) 0.09
Overall 1.08 (0.88–1.33) 0.48
Right coronary artery, yes vs. no
SES 0.89 (0.68–1.16) 0.38
EES 0.82 (0.61–1.10) 0.19
Overall 0.85 (0.70–1.04) 0.12
Arterial bypass graft, yes vs. no
SES —
EES 5.97 (1.48–24.1) 0.01
Overall 2.70 (0.67–10.8) 0.16
Saphenous vein graft, yes vs. no
SES 3.32 (2.10–5.25) 0.001
EES 1.76 (0.96–3.23) 0.07
Overall 2.52 (1.74–3.62) 0.001
Number of stents per patient, yes vs. no
SES 1.33 (1.19–1.50) 0.001
EES 1.18 (1.06–1.32) 0.002
Overall 1.23 (1.13–1.33) 0.001
Average stent diameter, per mm
SES 0.68 (0.47–0.98) 0.04
EES 0.55 (0.36–0.82) 0.004
Overall 0.60 (0.46–0.79) 0.001
Continued in next column
ContinuedTable 4 Continued
Procedural Characteristics
Hazard Ratio
(95% CI) p Value
Total stent length per patient, per mm
SES 1.02 (1.01–1.02) 0.001
EES 1.01 (1.01–1.02) 0.001
Overall 1.02 (1.01–1.02) 0.001
Glycoprotein IIb/IIIa antagonist,
yes vs. no
SES 0.89 (0.67–1.18) 0.42
EES 0.87 (0.63–1.19) 0.38
Overall 0.88 (0.72–1.09) 0.25
A value above 1 indicates that the presence of a characteristic was associated with an increased
risk of experiencing the primary composite outcome.
CI  confidence interval; EES  everolimus-eluting stent; SES  sirolimus-eluting stent.
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STents 4) trial (22) observed a trend toward lower TLR (9.9%
vs. 13.5%, p  0.06) and a significant reduction of binary
restenosis at 2 years (12.7% vs. 16.9%, p  0.03) in favor of
EES in the absence of differences for safety endpoints among
1,304 patients randomly assigned treatment with EES or SES.
The SORT OUT IV (Randomized Clinical Comparison of
the Xience V and the Cypher Coronary Stents in Non-selected
Patients With Coronary Heart Disease) trial (23) reported
noninferior outcomes of EES compared with SES in terms of
major adverse cardiac events and TLR at 9 months among
2,774 patients randomly assigned treatment with EES or SES.
The investigators noted a trend toward a lower rate of definite
ST with EES (0.1% vs. 0.7%, HR  0.22, 95% CI: 0.05 to
1.02, p  0.05).
Study limitations. This was not a randomized trial, and
results may be biased. However, we used appropriate PS
matching to ensure comparability of groups. Propensity
scores were defined as the probability to receive EES
conditional on pre-treatment covariates. These covariates
summarize what is known about that patient prior to
treatment. By definition, it is not possible to include
procedural characteristics of the compared interventions in
the PS. Procedural characteristics after PS matching were
different between groups, however. To determine whether
this could explain some of the observed differences between
stent types, we examined the association between markers of
increased procedural complexity and clinical outcome, and
performed a sensitivity analysis adjusted for procedural
characteristics. Our results indicate that, if anything, EES
was put at a disadvantage by the observed higher procedural
complexity (Table 4) and that results remained robustly in
favor of EES after adjusting for procedural characteristics
(p 0.029). Another limitation is the sequential enrollment
period. It cannot be excluded that changes in treatment may
have had a favorable impact on clinical outcome. However,
results were obtained at a single institution with similar
patient profiles during sequential enrollment periods, thus
minimizing the risk of institutional heterogeneity. Treat-
ment protocols did not change during enrollment, and we
Figure 2 Definite ST of Patients in a PS-Matched Cohort
Who Received EES or SES
Cumulative incidence for definite stent thrombosis (ST) (A), and for the composite
of definite or probable ST (B) up to 3 years. p values are from 2-sided Wald tests.
Dotted line  SES, continuous line  EES. Abbreviations as in Figure 1.
Stent ThrombosisTable 5 Stent Thrombosis
EES
(n  1,342)
SES
(n  1,342)
Hazard Ratio
(95% CI) p Value
Definite ST
Early 4 (0.3) 10 (0.8) 0.40 (0.13–1.28) 0.12
Late 2 (0.2) 5 (0.4) 0.50 (0.09–2.73) 0.42
Very late* 0 (0) 7 (0.7) 0.07 (0–1.16) 0.007
Overall 6 (0.5) 22 (1.6) 0.30 (0.12–0.75) 0.010
Definite or probable ST
Early 31 (2.3) 42 (3.1) 0.74 (0.46–1.17) 0.20
Late 2 (0.2) 5 (0.4) 0.50 (0.09–2.73) 0.42
Very late* 0 (0) 7 (0.7) 0.07 (0–1.16) 0.007
Overall 33 (2.5) 54 (4.0) 0.64 (0.41–0.98) 0.041
Data are n (%). Hazard ratios are from Cox proportional hazard model. p values are 2-sided from superiority testing with a Wald test. *Relative risks
were calculated after a continuity correction of 0.5; p values are from 2-sided Fisher exact test.
CI  confidence interval; ST  stent thrombosis; other abbreviations as in Table 1.
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observed no differences with respect to discharge medica-
tions. The sequential enrollment of SES and EES mini-
mizes the potential of confounding by indication because
there was no competition between stent types. Finally, the
number of pairs successfully matched was lower than as-
sumed in the sample size considerations. This resulted in
somewhat lower power and may explain that we formally
missed the pre-specified alpha level for the primary end-
point. However, the consistent findings in clinical outcomes
during long-term follow-up, with robust reductions in MI
Figure 3 Clinical Outcomes According to the Presence or Absence of an Association With Definite ST in a PS-Matched Cohort of Patients
(Left) Cumulative incidence for death (A), MI (C), and TVR (E) associated with definite ST. (Right) Cumulative incidence for death (B), MI (D), and TVR (F)
occurring in the absence of ST. Dotted line  SES, continuous line  EES. Abbreviations as in Figures 1 and 2.
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and ST, make it unlikely that estimates of safety and efficacy
would differ when studied in a larger population.
Clinical implications. The clinical implications of our
study are 3-fold: First, DES efficacy can be further advanced
beyond the level of the previous gold standard of SES
without compromising, but even improving their safety
profile. Second, the phenomenon of very late ST may be less
frequent with EES. Third, our results suggest that the lower
rate of MI was driven at least in part by a lower risk of ST.
This has important implications for the duration of dual
antiplatelet therapy.
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Very Late Coronary Stent Thrombosis of a
Newer-Generation Everolimus-Eluting Stent Compared
With Early-Generation Drug-Eluting Stents
A Prospective Cohort Study
Lorenz Ra¨ber, MD*; Michael Magro, MD*; Giulio G. Stefanini, MD; Bindu Kalesan, MSc;
Ron T. van Domburg, PhD; Yoshinobu Onuma, MD; Peter Wenaweser, MD; Joost Daemen, MD, PhD;
Bernhard Meier, MD; Peter Ju¨ni, MD; Patrick W. Serruys, MD, PhD; Stephan Windecker, MD
Background—Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with
increased risk of very late stent thrombosis occurring 1 year after stent implantation. It is unknown whether the risk
of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES).
Methods and Results—We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of
drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse
probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall
incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9;
hazard ratio, 0.41; 95% confidence interval, 0.27–0.62; P0.0001) and PES (4.4; hazard ratio, 0.33; 95% confidence
interval, 0.23–0.48; P0.0001). The incidence rate per 100 person-years of early (0–30 days), late (31 days–1 year),
and very late stent thrombosis amounted to 0.6, 0.1, and 0.6 among EES-treated patients; 1.0, 0.3, and 1.6 among
SES-treated patients; and 1.3, 0.7, and 2.4 among PES-treated patients. Differences in favor of EES were most
pronounced beyond 1 year, with a hazard ratio of 0.33 (EES versus SES; P0.006) and 0.34 (EES versus PES;
P0.0001). There was a lower risk of cardiac death or myocardial with EES compared with PES (hazard ratio, 0.65;
95% confidence interval, 0.56–0.75; P0.0001), which was directly related to the lower risk of stent thrombosis–
associated events (EES versus PES: hazard ratio, 0.36; 95% confidence interval, 0.23–0.57).
Conclusion—Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with
early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)
Key Words: drug-eluting stents  registries  thrombosis
Stent thrombosis (ST) is a rare but devastating complica-tion after coronary stent implantation; it may lead to
death or myocardial infarction (MI) in up to 90% of cases.1–3
Whereas early ST (0–30 days) and late ST (31–360 days)
occur with similar frequency among patients treated with bare
metal and early-generation drug-eluting stents (DES),4–6 very
late ST (VLST) emerged as a distinct entity complicating the
use of early-generation DES releasing sirolimus (SES) or
paclitaxel (PES) with a steady annual risk of 0.5% to 0.6% up
to 5 years.7,8 Mechanisms leading to VLST are distinct from
those responsible for early or late ST. The persistence of
uncovered struts with evidence of chronic inflammation and
fibrin deposition leading to positive remodeling and strut
malapposition was the hallmarks of thrombosed stent seg-
ments in postmortem and intracoronary imaging studies.7–11
The durable polymer matrix, the dose of the antiproliferative
drug, and its release kinetics have been incriminated as a
likely trigger of delayed healing and chronic inflammation
leading to these late adverse events.12,13
Editorial see p 1078
Clinical Perspective on p 1121
Newer-generation DES have been developed to improve
the safety profile by means of more biocompatible polymers,
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reduced drug dose with adapted release kinetics, and reduced
strut thickness. Newer-generation DES releasing everolimus
(EES) have been shown to improve safety and efficacy
compared with PES in several randomized clinical trials.14,15
Conversely, direct comparison of EES with SES up to 1 year
yielded similar results in terms of safety and efficacy in
several trials,16–21 including the synthesis of these results in a
recently published meta-analysis.22 So far, these studies have
been limited in size with maximal follow-up to only 2 years,
and none of the studies specifically addressed the end point of
VLST in a large patient population with the unrestricted use
of DES. The latter is important because VLST became
apparent mainly in all-comers studies with the inclusion of
complex patient and lesion characteristics, and VLST
constitutes the principal shortcoming of early-generation
DES. We previously reported the incidence of ST in a
cohort of patients treated with the unrestricted use of SES
and PES at 2 academic institutions. For the purpose of the
present study, we extended the cohort to include all
patients treated with EES and compared the incidence of
ST and particularly VLST between the 3 stent types during
follow-up through 4 years.
Methods
Patient Population
Between November 1, 2006, and March 31, 2009, a total of 4212
patients underwent percutaneous coronary intervention (PCI) with
EES (XIENCE V, Abbott Vascular, Santa Clara, CA; or PROMUS,
Boston Scientific, Natick, MA) at 2 academic referral hospitals in the
Netherlands and Switzerland. In the Dutch institution, EES have
been used as a default strategy for PCI as part of the XIENCE Stent
Evaluated at Rotterdam Cardiology Hospital (X-SEARCH) registry
since March 1, 2007, until the end of this study. In the Swiss
institution, EES have been used since November 1, 2006, and
implanted on a daily basis alternating with biolimus-eluting stents
and zotarolimus-eluting stents. Patients who had been treated with
different DES within the same patient were excluded from the
current registry. Between April 16, 2002, and December 31, 2005, a
total of 8146 consecutive patients underwent coronary intervention
with SES or PES, of whom 3882 were treated with SES (Cypher,
Cordis Corp, Johnson & Johnson, Warren, NJ) and 4323 were treated
with PES (TAXUS, Express, or Liberte´, Boston Scientific). The
individual use of both stent types at the 2 centers has been described
in detail elsewhere.23 The study was approved by the local ethics
committee at both institutions and was in accordance with the
Declaration of Helsinki. Written informed consent was obtained
from all patients.
Data Collection
All patients were actively followed up for major adverse cardiac
events by the use of patient-administered postal questionnaires
including questions on rehospitalization and major adverse cardiac
events. This was complemented by a search of hospital databases of
the 2 institutions. In Bern, the last follow-up took place beginning on
February 1, 2007, for patients who had undergone implantation of
SES or PES and beginning on February 1, 2010, for patients with
EES. In Rotterdam, the last follow-up took place beginning on July
1, 2005, for patients with PES; on July 1, 2006, for patients with
SES; and on April 1, 2010, for patients with EES. Vital status was
ascertained from hospital records and municipal civil registries. For
patients with a suspected event, relevant medical records, discharge
letters, and coronary angiography documentation were systemati-
cally collected. All suspected clinical events were adjudicated by
local cardiologists affiliated with the 2 institutions, whereas all ST
events were adjudicated by an independent clinical event committee;
the committee members were unaware of the type of stent implanted.
Baseline clinical and procedural characteristics and all follow-up
data were entered into a dedicated database held at an academic
clinical trials unit (CTU Bern, Bern University Hospital, Switzer-
land) that was responsible for central data audits and maintenance of
the database.
Procedures
EES were available in diameters from 2.25 to 4.0 mm and in
lengths from 8 to 28 mm; SES were available in diameters from
2.25 to 3.5 mm and in lengths from 8 to 33 mm; and PES were
available in diameters from 2.25 to 4.0 mm and in lengths from 8
to 32 mm. The procedure and treatment, including periprocedural
and postprocedural medication regimen, were performed accord-
ing to current practice guidelines. All patients, regardless of stent
type, received a loading dose of clopidogrel 300 to 600 mg during
or immediately after the procedure and were prescribed lifelong
once-daily aspirin. In the Dutch institution, clopidogrel was
administered for at least 3 months to patients with SES and for at
least 6 months if patients had received 3 stents, if the total stent
length was 36 mm, or if a chronic total occlusion or bifurcation
was treated. Dutch patients treated with PES received clopidogrel
for at least 6 months, whereas EES patients were prescribed
clopidogrel for 12 months. In the Swiss institution, all patients
were prescribed clopidogrel for a duration of at least 12 months
regardless of stent type. The use of glycoprotein IIb/IIIa antago-
nists was left to the discretion of the operator.
Definitions
The primary end point was definite ST up to a maximum
follow-up of 4 years. ST was defined according to the Academic
Research Consortium (ARC)24 and reported separately for the
early (0 –30 days), late (31–360 days), and very late (360 days)
time periods. The definition of cardiac death included any deaths
with an immediate cardiac cause, procedure-related deaths, un-
witnessed deaths, and deaths with an unknown cause. The
diagnosis of MI was based on an elevation in creatine kinase to
more than twice the upper limit of normal and an elevation of
creatine kinase-MB to 3 times the upper limit of normal in the
presence of ischemic symptoms or ischemic ECG changes. A
12-lead ECG was obtained before the procedure and within 24
hours after PCI. Additional ECGs were obtained in case of
recurrent signs or symptoms of ischemia. Risk factors and
comorbidities in each patient were determined as classified by the
treating physician. Acute coronary syndrome was defined as acute
myocardial ischemia on the basis of clinical symptoms, ECG
changes, and elevation of cardiac biomarkers and encompasses
acute ST-segment– elevation MI, non–ST-segment– elevation MI,
and unstable angina. Definitions of hypertension, hyperlipidemia,
and renal dysfunction were previously reported.23
Statistical Analysis
Baseline and procedural variables among the 3 stent types are
presented as counts and percentages for dichotomous variables
and as mean and SD for continuous variables. Comparisons
between groups among dichotomous variables were performed
with the Pearson 2 test and the Student t test for continuous
variables. We calculated incidence rates per 100 patient-years as
the number of new events occurring during a specific time period
divided by the total number of patient-years actually observed. In
contrast to crude percentages, incidence rates take into account
differences in the follow-up duration between stent types. Uni-
variable and multivariable Cox proportional hazard regression
models were used to assess hazard ratios (HRs) with 95%
confidence intervals (CIs) for comparing each of the early-
generation DES with EES. For each center, we estimated propen-
sity scores for receiving EES using a logit model that included
age, sex, and pretreatment variables associated with stent selec-
tion at P0.10: family history of coronary artery disease, acute
coronary syndrome, and cardiogenic shock for both centers; body
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mass index and left ventricular ejection fraction as additional
variables for Bern; and arterial hypertension, smoking, diabetes
mellitus, and hyperlipidemia for Rotterdam. Propensity scores
were used to derive the inverse probability of treatment weights,
with the inverse of the propensity score as analytic weights in
EES patients and the inverse of 1 minus the propensity score in
early-generation DES patients. Comparisons between stents were
performed with a Cox proportional hazards model, both crude and
adjusted with the inverse probability of treatment weighting.
Then, we used landmark analyses according to a prespecified
landmark point at 1 year (360 days) and estimated HRs and
cumulative incidence rates separately for events up to 1 year and
beyond. Stratified analyses were performed according to pre-
specified baseline characteristics and accompanied by a 2 test to
assess the interaction between treatment effect and these charac-
teristics. Next, we classified the composite outcome of cardiac
death or MI according to the association of outcome events with
definite ST, accompanied by a test for difference in log HRs of
the composite outcome of cardiac death or MI between outcome
events associated with definite ST and outcome events not
associated with definite ST. Events occurring 7 days before or
after a definite ST were thought to be associated with definite ST
for the purpose of this analysis. Statistical analyses were per-
formed with STATA release 11.1 (Stata Corp, College Station,
TX). All P values are 2 sided.
Results
Between April 16, 2002, and March 31, 2009, 12 339
consecutive patients underwent PCI with EES (4212), SES
(3819), and PES (4308; Figure 1). A total of 11 954
patients (96.9%) completed the last follow-up, with 4101
patients receiving EES (97.4%), 3722 patients receiving
SES (97.5%), and 4131 patients receiving PES (95.9%).
The median follow-up duration among surviving patients
completing the last follow-up was 2.5 years in patients
treated with EES (interquartile range [IQR], 1.8 –3.1
years), 4.0 years in patients treated with SES (IQR,
3.0 – 4.0 years), and 3.0 years in patients treated with PES
(IQR, 2.1–3.6 years) with an accumulated 9519, 12 478,
and 10 795 patient-years, respectively.
Baseline clinical characteristics are summarized in Ta-
ble 1. Patients treated with EES compared with either SES
or PES were older, were more frequently hypertensive,
smoked less frequently, had a lower left ventricular ejec-
tion fraction, and presented more frequently with ST-
segment– elevation MI and cardiogenic shock. Patients
treated with EES compared with those treated with PES
had a higher body mass index, more often had diabetes
mellitus, and were more frequently dyslipidemic. Proce-
dural characteristics are shown in Table 2. Compared with
patients receiving SES and PES, a higher number of
lesions were treated among patients undergoing PCI with
EES. The frequency of multivessel treatment, the total
stent length, and the number of implanted stents were
similar among patients treated with EES and SES but
higher among patients treated with PES. Among patients
receiving EES compared with PES, a higher proportion of
patients underwent revascularization of the left main
coronary artery, and a higher number of saphenous vein
graft interventions were performed.
Stent Thrombosis
Crude and adjusted outcomes for the primary end point of
ARC definite ST and ARC definite or probable ST are shown
Figure 1. Flow of patients according to Consolidated Standards of Reporting Trials (CONSORT). PCI indicates percutaneous coronary
intervention; EES, everolimus-eluting stents; SES, sirolimus-eluting stents; and PES, paclitaxel-eluting stents.
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in Table 3 and Figures 2 and 3. At 4 years, the incidence rate
of ARC definite ST per 100 person-years was lower among
EES-treated patients (1.4) compared with SES-treated pa-
tients (2.9; adjusted HR, 0.41; 95% CI, 0.27–0.62;
P0.0001) and PES-treated patients (4.4; adjusted HR, 0.33;
95% CI, 0.23–0.48; P0.0001) in adjusted analyses. Differ-
ences in terms of ARC definite VLST per 100 person-years
(incidence rate) were particularly pronounced, with an inci-
dence rate of 0.6 in EES, 1.4 in SE, and 2.4 in PES, resulting
in a relative risk reduction of 67% when EES is compared
with SES and 76% when EES is compared with PES. The
annual incidence rate of VLST amounted to 0.8 for PES (95%
CI, 0.2–0.4), 0.5 for SES (95% CI, 0.4–0.7), and 0.2 for EES
(95% CI, 0.1–0.5). The findings of the primary end point of
ARC definite ST were consistent in stratified analyses
across major subgroups including age, sex, diabetes mel-
litus, acute coronary syndromes, left ventricular function,
number of stents, and stent diameter and length (Figure 4).
Similar to the primary outcome measures, incidence rates
were consistently lower for the secondary end point of
ARC definite or probable ST during the overall time period
and beyond 1 year (very late definite or probable ST; Table
3 and Figure 3).
Death and MI
Crude and adjusted outcomes of major ischemic end points,
including death, cardiac death, and MI, are summarized in
Table 4. In crude analyses, the risk of cardiac death was
lowest with SES (unadjusted HR, 1.67; 95% CI, 1.24–2.26;
P0.002) and similar for EES and PES (unadjusted HR,
0.96; 95% CI, 0.81–1.14; P0.65). After adjustment, there
was no difference in the risk of cardiac death for the
comparison of EES with SES (adjusted HR, 1.03; 95% CI,
0.84–1.26; P0.79) but a decreased risk for the comparison
of EES with PES (adjusted HR, 0.79; 95% CI, 0.66–0.94;
P0.007). EES were associated with a lower adjusted risk of
MI compared with SES (adjusted HR, 0.66; 95% CI, 0.51–
0.86; P0.002) and PES (adjusted HR, 0.47; 95% CI,
0.37–0.60; P0.0001). There was a trend toward a lower risk
of cardiac death or MI compared with SES (adjusted HR,
0.86; 95% CI, 0.74–1.02; P0.077) and significantly lower
risk of cardiac death or MI compared with PES (adjusted HR,
0.65; 95% CI, 0.56–0.75; P0.0001).
Figure 5 presents analyses of the composite of cardiac
death or MI and of cardiac death associated with definite ST
(Figure 5A) and not associated with definite ST (Figure 5B)
for the 3 different stent types. Cardiac death or MI associated
with definite ST was less frequent with EES than SES
(adjusted HR, 0.46; 95% CI, 0.26–0.81) and PES (adjusted
HR, 0.36; 95% CI, 0.23–0.57; Figure 5A), whereas there was
little evidence for a difference in cardiac death or MI
occurring in the absence of definite ST between stent types
(EES versus SES: adjusted HR, 1.00; 95% CI, 0.84–1.20; and
EES versus PES: adjusted HR, 0.76; 95% CI, 0.64–0.89;
Table I in the online-only Data Supplement and Figure 5B).
A formal test for differences in the log HRs of the composite
outcome of cardiac death or MI between outcome events
associated with definite ST and outcome events not associ-
ated with definite ST was positive for both crude and adjusted
analyses (P for difference 0.01; see Table I in the online-
only Data Supplement). We observed no difference between
stent types and the risk of cardiac death regardless of the
association with or without definite ST.
Cardiovascular medications at baseline and at latest
follow-up are shown in Table II in the online-only Data
Supplement. The time point of assessment for cardiovas-
Table 1. Baseline Clinical Characteristics
EES SES PES EES vs SES P EES vs PES P SES vs PES P
Total, n 4212 3819 4308
Age, meanSD, y 64.312 62.511.5 62.711.6 0.0001 0.0001 0.3044
Male sex, n (%) 3083 (73.2) 2856 (74.8) 3192 (74.1) 0.11 0.35 0.48
BMI, meanSD, kg/m2 27.24.3 27.24.2 274 0.98 0.02 0.02
Hypertension, n (%) 2384 (56.6) 1966 (51.5) 1778 (41.3) 0.0001 0.0001 0.0001
Family history of CAD, n (%) 1423 (33.8) 1111 (29.1) 1166 (27.1) 0.0001 0.0001 0.04
Current smoking, n (%) 1551 (36.8) 1750 (45.8) 1304 (30.3) 0.0001 0.0001 0.0001
Dyslipidemia, n (%) 2272 (53.9) 2086 (54.6) 1990 (46.2) 0.54 0.0001 0.0001
Diabetes mellitus, n (%) 807 (19.2) 696 (18.2) 618 (14.3) 0.28 0.0001 0.0001
Renal failure (GFR 60 mL/min),* n (%) 182 (11.2) 332 (12) 157 (11.5) 0.46 0.8093 0.66
Renal failure (creatinine 150 mol/L),* n (%) 49 (3) 81 (2.9) 39 (2.9) 0.85 0.79 0.91
Left ventricular ejection fraction 50%,* n (%) 549 (33.8) 744 (26.8) 339 (24.8) 0.0001 0.0001 0.17
Acute coronary syndrome, n (%) 2642 (62.7) 2016 (52.8) 2543 (59) 0.0001 0.0004 0.0001
Unstable angina/non–ST-segment–elevation MI 1105 (41.8) 1042 (56.6) 1151 (45.3)
ST-elevation–elevation MI 1537 (58.2) 874 (43.4) 1388 (54.7)
Cardiogenic shock, n (%) 130 (3.1) 58 (1.5) 66 (1.5) 0.0001 0.0001 0.96
EES indicates everolimus-eluting stent patients; SES, sirolimus-eluting stent patients; PES, paclitaxel-eluting stent patients; BMI, body mass index; CAD, coronary
artery disease; GFR, glomerular filtration rate; and MI, myocardial infarction. Data are presented as meanSD when appropriate. Comparisons between groups among
dichotomous variables were performed with the Pearson 2 test and Student t test for continuous variables.
*Data available only in Bern patients.
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cular medications at the latest follow-up differed among
groups (EES, 2.38 years [IQR, 1.6 –3.0 years]; SES, 3.6
years [IQR, 2.8 – 4.0 years]; PES, 4.0 years [IQR 3.4 – 4.0
years]). The overall number of patients on dual antiplatelet
therapy at the time of latest follow-up was low in all 3
groups (EES, 24,1% at 2.38 years; SES, 16.4% at 3.6
years; PES, 13.7% at 4.0 years). In addition, there were no
differences in the proportion of patients on dual antiplate-
let therapy at the time point of ARC definite ST between
stent types (P0.66), as shown in Table III in the
online-only Data Supplement. The follow-up was not
complete in EES and PES. To test whether the incomplete-
ness of follow-up beyond 2 years influenced results, we
performed a sensitivity analysis limited to patients with
complete follow-up beyond 2 years and found robust
results (Table IV in the online-only Data Supplement).
Table 2. Procedural Characteristics
EES SES PES EES vs SES P EES vs PES P SES vs PES P
Total, n 4212 3819 4308
Multivessel treatment, n (%) 686 (16.3) 653 (17.2) 806 (18.7) 0.29 0.003 0.07
Vessels treated per patient, meanSD, n 1.20.4 1.20.4 1.20.4 0.21 0.66 0.09
Lesions treated per patient, meanSD, n 1.81 1.50.7 1.40.7 0.0001 0.0001 0.45
1, n (%) 821 (50.6) 1777 (64.4) 885 (64.8)
2, n (%) 473 (29.2) 736 (26.7) 381 (27.9)
3, n (%) 218 (13.4) 202 (7.3) 80 (5.9)
4, n (%) 110 (6.8) 38 (1.4) 19 (1.4)
Target vessel, n patients (%)
Left main 179 (4.2) 90 (2.4) 152 (3.5) 0.0001 0.08 0.002
Left anterior descending 2077 (49.3) 1915 (50.3) 2130 (49.4) 0.36 0.90 0.42
Left circumflex 1099 (26.1) 952 (25) 1121 (26) 0.27 0.94 0.31
Right coronary artery 1472 (34.9) 1291 (33.9) 1614 (37.5) 0.34 0.02 0.0009
Arterial bypass graft, n (%) 4 (0.1) 7 (0.2) 6 (0.1) 0.28 0.55 0.61
Saphenous vein graft, n (%) 127 (3) 103 (2.7) 58 (1.3) 0.41 0.0001 0.0001
Stents per patient, meanSD, n 1.91.2 1.91.1 21.3 0.01 0.0004 0.0001
Average stent diameter, meanSD, mm 3.0 (0.4) 2.9 (0.5) 3.0 (0.4) 0.0001 0.03 0.0001
Total stent length per patient, meanSD, mm 33.1 (23.4) 33.7 (22.9) 38.5 (28.2) 0.27 0.0001 0.0001
Glycoprotein IIb/IIIa antagonist, n (%) 895 (21.2) 733 (19.3) 755 (17.7) 0.03 0.0001 0.07
Aspirin at discharge, n (%) 4028 (98.7) 3687 (98.9) 4043 (98.3) 0.36 0.10 0.01
Clopidogrel at discharge, n (%) 4048 (99.2) 3704 (99.8) 4095 (99.4) 0.0003 0.17 0.02
Oral anticoagulation at discharge, n (%) 72 (1.8) 87 (2.3) 130 (3.1) 0.08 0.0001 0.04
EES indicates everolimus-eluting stent patients; SES, sirolimus-eluting stent patients; and PES, paclitaxel-eluting stent patients. Data are presented as meanSD
when appropriate. Comparisons between groups for dichotomous variables were performed with the Pearson 2 test and Student t test for continuous variables. The
number of patients on discharge medication is based on the number of patients alive at discharge.
Table 3. Academic Research Consortium Definite and Definite or Probable Stent Thrombosis Up to 4 Years
Crude Analysis Adjusted Analysis
EES vs SES EES vs PES EES vs SES EES vs PES
EES SES PES HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Definite ST
Early 25 (0.6) 37 (1.0) 54 (1.3) 0.62 (0.38–1.03) 0.07 0.47 (0.29–0.76) 0.002 0.53 (0.30–0.93) 0.03 0.50 (0.31–0.83) 0.006
Late 5 (0.1) 11 (0.3) 27 (0.7) 0.42 (0.15–1.22) 0.11 0.19 (0.07–0.48) 0.0006 0.29 (0.09–0.94) 0.04 0.17 (0.06–0.44) 0.0003
Very late 12 (0.6) 49 (1.6) 53 (2.4) 0.35 (0.18–0.66) 0.001 0.27 (0.15–0.51) 0.0001 0.33 (0.15–0.72) 0.006 0.24 (0.13–0.47) 0.0001
Overall 42 (1.4) 97 (2.9) 134 (4.4) 0.48 (0.33–0.69) 0.0001 0.34 (0.24–0.48) 0.0001 0.41 (0.27–0.62) 0.0001 0.33 (0.23–0.48) 0.0001
Definite/probable ST
Early 162 (3.9) 126 (3.3) 203 (4.8) 1.22 (0.97–1.54) 0.09 0.84 (0.68–1.03) 0.09 0.91 (0.71–1.18) 0.48 0.70 (0.57–0.87) 0.001
Late 16 (0.4) 24 (0.7) 59 (1.5) 0.62 (0.33–1.17) 0.14 0.27 (0.16–0.47) 0.0001 0.46 (0.24–0.89) 0.02 0.24 (0.13–0.41) 0.0001
Very late 36 (2.0) 86 (2.8) 95 (4.0) 0.63 (0.42–0.93) 0.02 0.45 (0.30–0.66) 0.0001 0.63 (0.39–1.01) 0.05 0.40 (0.27–0.61) 0.0001
Overall 214 (6.3) 236 (6.8) 357 (10.1) 0.95 (0.79–1.15) 0.60 0.62 (0.53–0.74) 0.0001 0.78 (0.63–0.95) 0.02 0.55 (0.46–0.65) 0.0001
EES indicates everolimus-eluting stent patients; SES, sirolimus-eluting stent patients; PES, paclitaxel-eluting stent patients; HR, hazard ratio; CI, confidence interval;
and ST, stent thrombosis. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient-years. Crude HRs were calculated with Cox
proportional hazard models. Adjusted risk ratios were calculated with the inverse probability of treatment weights as analytical weighting in Cox proportional hazards
models stratified by center.
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Discussion
In this large, observational cohort study of all-comers patients
treated with the unrestricted use of DES who were followed
up for up to 4 years, newer-generation EES reduced the
overall risk of ARC definite ST by 58% compared with
early-generation SES and by 68% compared with PES. The
benefit in favor of EES was most pronounced during the very
late period (1 year), with a 67% and 76% reduced risk of
definite ST compared with SES and PES, respectively,
resulting in an important reduction of the risk of VLST with
the use of EES.
Our findings are consistent with the 2-year outcomes of the
randomized Comparison of the everolimus eluting XIENCE-V
stent with the paclitaxel eluting TAXUS LIBERTE stent in
all-comers (COMPARE) trial comparing newer-generation
EES with early-generation PES in an all-comers patient
population.25 Compared with PES, the overall risk of definite
ST was lowered by 63% with the use of EES, whereas the risk
of VLST was lowered by 77% between 1 and 2 years of
follow-up. In the randomized Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System in the
Treatment of Subjects With De Novo Native Coronary Artery
Lesions (SPIRIT) IV trial comparing EES with PES, the
overall risk of definite ST at 2 years was also lowered by 64%
in favor of EES, whereas the risk of VLST was nonsignifi-
cantly reduced by 24% during the very late period (1
year).26 The latter observation is most likely related to
differences in patient populations because the phenomenon of
VLST emerged among more complex patients and lesions.
Although the duration of dual antiplatelet therapy was longer
Figure 2. Definite stent thrombosis (ST) in
a cohort of patients who received
everolimus-eluting stents (EES), sirolimus-
eluting stents (SES), or paclitaxel-eluting
stents (PES). The Kaplan-Meier curves
show the cumulative incidence of definite
ST up to 4 years (A) with a landmark
analysis up to 30 days (B), 31 days to 1
year (B), and beyond 1 year (C). P values
and hazard ratios are from Cox propor-
tional hazards models. Confidence inter-
val bars indicated every 6 months. ARC
indicates Academic Research
Consortium.
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in SPIRIT IV compared with COMPARE and may have
influenced outcomes, it remains to be shown whether pro-
longed dual antiplatelet therapy effectively prevents VLST.
The present study adds substantially to the available evidence
of the risk of VLST with newer-generation DES by extending
the follow-up observation to 4 years in the largest patient
population treated with EES so far. Because all consecutive
patients treated with EES, SES, or PES were included in the
present study, this cohort provides a high degree of general-
izability to routine clinical practice in experienced centers.
Moreover, our study is not limited to the comparison of EES
with PES but also provides long-term evidence for the
comparison between EES and SES, demonstrating a similar
reduction in the risk of overall ST and VLST in favor of EES.
Available evidence from randomized trials comparing EES
with SES is still limited and based on 1-year data. In a recent
meta-analysis of data up to 1 year, however, de Waha et al22
reported on the composite of definite or probable ST and
found a 22% relative risk reduction, even though CIs were
wide and overlapped the line of no difference. These midterm
results are in line with our long-term results on the same
outcome, with a 22% relative risk reduction (95% CI,
0.63–0.95). The robustness of the present analysis is further
substantiated by the consistent findings in stratified analyses
across major subgroups for the comparison of EES with SES
and PES.
Although early-generation SES and PES showed the well-
established ongoing risk of VLST with an annual rate of 0.6%
to 0.7%, the risk of VLST associated with EES in the present
study was comparable to published long-term data on bare
Figure 3. Definite or probable stent
thrombosis (ST) in a cohort of patients
who received everolimus-eluting stents
(EES), sirolimus-eluting stents (SES), or
paclitaxel-eluting stents (PES). The
Kaplan-Meier curves show the cumulative
incidence of definite or probable ST up to
4 years (A) with a landmark analysis up to
30 days (B), 31 days to 1 year (B), and
beyond 1 year (C). P values and hazard
ratios are from Cox proportional hazards
models. Confidence interval bars are indi-
cated every 6 months. ARC indicates
Academic Research Consortium.
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metal stents through 4 years.6 The reduction of VLST is
particularly important because the increased risk of VLST
with early-generation DES stirred a debate regarding the need
of prolonged dual antiplatelet therapy.27 Because of the low
rate of VLST observed with EES with a prescription time for
clopidogrel that was limited to 1 year and the relatively low
number of EES patients on dual antiplatelet therapy at the
time of last follow-up (24.1%), it appears unlikely that a
Figure 4. Subgroup analyses of the primary end point. Subgroup analyses are shown, with the relative risks and 95% confidence intervals (CIs), for
the primary end point of Academic Research Consortium definite stent thrombosis throughout 4 years among major subgroups. The P value is for
interaction between subgroups and treatment effects. A, Comparison of everolimus-eluting stents (EES) with sirolimus-eluting stents (SES). B, Com-
parison of EES with paclitaxel-eluting stents (PES). Hazards 1 are in favor of EES. HR indicates hazard ratio; MI, myocardial infarction.
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prolonged regimen of dual antiplatelet therapy in patients
treated with EES can further improve on stent-related out-
comes. This has recently been corroborated by 2 randomized
controlled trials showing no reduction in ischemic end points,
including ST, when dual antiplatelet therapy is prolonged
beyond 6 or 12 months.28,29
In our study, 85% of the 273 patients with definite ST
suffered the composite of cardiac death or MI compared
with a mere 8% of patients without definite ST. The lower
risk of definite ST was therefore bound to translate directly
into a lower risk of cardiac death or MI with newer-
generation EES compared with early-generation SES and
PES. Thus, cardiac death or MI associated with definite ST
was less frequent with EES than SES and PES (Figure 4A),
whereas cardiac death or MI occurring in the absence of
definite ST showed a similar risk for all stent types (Figure
4B), providing a mechanistic explanation for the observed
safety.
Table 4. Clinical Outcomes Up to 4 Years
Crude Analysis Adjusted Analysis
EES vs SES EES vs PES EES vs SES EES vs PES
EES SES PES HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Death
0 to 30 d 135 (3.2) 79 (2.1) 135 (3.1) 1.56 (1.18–2.06) 0.002 1.02 (0.81–1.30) 0.86 1.03 (0.74–1.42) 0.87 0.86 (0.67–1.10) 0.22
30 d to 1 y 108 (2.7) 77 (2.1) 127 (3.1) 1.29 (0.97–1.73) 0.09 0.86 (0.67–1.11) 0.25 1.09 (0.79–1.52) 0.59 0.73 (0.56–0.95) 0.02
1 y to 4 y 141 (6.6) 198 (6.5) 160 (6.5) 1.09 (0.87–1.35) 0.47 1.05 (0.83–1.32) 0.69 0.85 (0.67–1.07) 0.17 0.91 (0.71–1.16) 0.43
0 to 4 y 384 (12.0) 354 (10.3) 422 (12.1) 1.26 (1.09–1.46) 0.002 0.98 (0.85–1.13) 0.79 0.98 (0.83–1.15) 0.77 0.83 (0.72–0.96) 0.01
Cardiac death
0 to 30 d 124 (2.9) 68 (1.8) 122 (2.8) 1.67 (1.24–2.24) 0.0007 1.04 (0.81–1.33) 0.76 1.13 (0.80–1.59) 0.48 0.86 (0.66–1.12) 0.28
30 d to 1 y 61 (1.5) 46 (1.2) 70 (1.7) 1.22 (0.83–1.79) 0.31 0.88 (0.63–1.24) 0.48 1.06 (0.69–1.64) 0.78 0.70 (0.49–0.99) 0.04
1 y to 4 y 70 (3.2) 105 (3.5) 92 (4.0) 1.02 (0.75–1.39) 0.89 0.92 (0.67–1.25) 0.58 0.84 (0.61–1.16) 0.29 0.77 (0.55–1.07) 0.12
0 to 4 y 255 (7.5) 219 (6.4) 284 (8.2) 1.30 (1.08–1.56) 0.005 0.96 (0.81–1.14) 0.65 1.03 (0.84–1.26) 0.79 0.79 (0.66–0.94) 0.007
MI
0 to 30 d 48 (1.2) 57 (1.5) 82 (1.9) 0.77 (0.52–1.13) 0.1748 0.60 (0.42–0.85) 0.0044 0.69 (0.46–1.03) 0.0663 0.58 (0.40–0.84) 0.004
30 d to 1 y 20 (0.5) 24 (0.7) 58 (1.5) 0.76 (0.42–1.38) 0.3758 0.34 (0.21–0.57) 0.0001 0.70 (0.38–1.29) 0.2553 0.32 (0.19–0.54) 0.0001
1 y to 4 y 37 (1.9) 88 (2.9) 88 (3.7) 0.61 (0.41–0.90) 0.0135 0.49 (0.34–0.73) 0.0004 0.63 (0.40–0.99) 0.0461 0.48 (0.32–0.72) 0.0004
0 to 4 y 105 (3.5) 169 (5.0) 228 (7.0) 0.70 (0.55–0.89) 0.0043 0.49 (0.39–0.62) 0.0001 0.66 (0.51–0.86) 0.0023 0.47 (0.37–0.60) 0.0001
Cardiac death/MI
0 to 30 d 165 (3.9) 121 (3.2) 199 (4.6) 1.24 (0.98–1.57) 0.0711 0.84 (0.69–1.04) 0.107 0.94 (0.73–1.21) 0.6322 0.73 (0.59–0.91) 0.005
30 d to 1 y 80 (2.0) 65 (1.8) 119 (3.0) 1.13 (0.81–1.57) 0.4701 0.67 (0.51–0.89) 0.0062 1.01 (0.71–1.44) 0.9521 0.56 (0.42–0.76) 0.0001
1 y to 4 y 101 (4.9) 185 (6.2) 169 (7.4) 0.81 (0.64–1.04) 0.1041 0.71 (0.55–0.91) 0.0066 0.73 (0.56–0.96) 0.0221 0.62 (0.48–0.81) 0.0004
0 to 4 y 346 (10.5) 371 (10.8) 487 (14.2) 1.04 (0.89–1.20) 0.6269 0.76 (0.66–0.87) 0.0001 0.86 (0.74–1.02) 0.0773 0.65 (0.56–0.75) 0.0001
EES indicates everolimus-eluting stent patients; SES, sirolimus-eluting stent patients; PES, paclitaxel-eluting stent patients; HR, hazard ratio; CI, confidence interval;
and MI, myocardial infarction. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient-years. Crude hazard ratios were calculated
with Cox proportional hazard models. Adjusted risk ratios were calculated with the inverse probability of treatment weights as analytical weighting in Cox proportional
hazards models stratified by center.
Figure 5. Clinical outcomes according to the presence or absence of an association with definite stent thrombosis (ST). A, Cumulative
incidence of cardiac death or myocardial infarction (MI) associated with definite ST throughout 4 years. B, Cumulative incidence of car-
diac death or MI not associated with definite ST throughout 4 years. P values shown are derived from unadjusted analysis. Corre-
sponding hazard ratios and P for interaction for adjusted and unadjusted analysis are shown in the Table I in the online-only Data Sup-
plement. Confidence bars are indicated every 6 month. PCI indicates percutaneous coronary intervention; EES, everolimus-eluting
stents; SES, sirolimus-eluting stents; and PES, paclitaxel-eluting stents.
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The mechanisms underlying the lower risk of definite
ST with newer-generation EES remain speculative but may
be related to the different components of the device. First,
the lower strut thickness may result in less arterial injury,
may accelerate reendothelialization owing to the lower
physical height of the mechanical barrier, and may have a
lesser degree of flow disruption, resulting in a lower
thrombogenicity.30,31 Second, it has been suggested that
the properties of the fluoropolymer surface (polyvi-
nylidene fluoride-cohexafluoropropylene) reduce throm-
bogenicity and inflammatory reactions while improving
endothelialization.32 Improved endothelialization has been
shown in a comparative study in rabbit iliac arteries
showing more rapid reendothelialization with EES com-
pared with SES and PES at 14 days.33 Third, drug dose and
release kinetics may play a role because higher doses not
only inhibit endothelialization but also may cause toxic
effects within the vessel wall.34 A nonrandomized study
compared the in vivo healing response between EES and
SES using optical coherence tomography and reported a
lower incidence of uncovered struts (EES, 4.4% versus
10.5%; P0.016) and a lower rate of intracoronary masses
compatible with thrombus (5.0% versus 34.3%;
P0.001).35
Alternative DES platforms such as biodegradable
polymer-based DES and fully bioresorbable devices have
been developed to further improve the clinical safety and
efficacy of PCI. Although it appears difficult to further
improve outcomes in terms of VLST, remaining issues
such as complex patient populations (those with diabetes
mellitus or multivessel disease), lack of vasomotion and
remodeling of the stented segment, side-branch access,
surgical revascularization of previously stented long seg-
ments, and noninvasive imaging will need to be addressed
by future-generation devices.
Limitations
The present study has several limitations. This was not a
randomized comparison between newer- and early-
generation DES; in fact, we observed differences in
baseline clinical and procedural characteristics among the
3 groups. However, analyses were adjusted for these
differences by the use of inverse probability of treatment
weighting, thus minimizing the potential of bias. More-
over, differences in favor of EES were large, consistent
across major subgroups, and plausible in that they relate to
the benefit in reducing the risk of cardiac death or MI for
events associated with ST. The follow-up at 4 years is not
complete in the EES and PES groups; however, a sensi-
tivity analysis limited to patients with complete follow-up
beyond 2 years (Table IV in the online-only Data Supple-
ment) found the results to be even more in favor of EES,
suggesting an important differential in the timing of
individual adverse events (Table IV in the online-only
Data Supplement). Another limitation is the sequential
enrollment period for patients treated with EES compared
with SES and PES. We used postal questionnaires to obtain
information about possible events complemented by a
search of the hospital database at both institutions, which
may be considered inferior to telephone follow-up or
clinical visits. However, event rates observed with early-
generation DES were higher than in many randomized
controlled trials or registries and in view of the similar
methodology applied for all 3 stent groups, and underre-
porting of events appears unlikely. Differences in the
duration of dual antiplatelet therapy within the first year
after DES implantation may have contributed to an im-
proved outcome in patients treated with EES. Although the
prescription time was limited to 1 year in all EES patients,
we cannot exclude that a higher proportion of EES patients
continued the dual antiplatelet therapy beyond 1 year, and
this may improve the outcomes observed with EES.
However, we report the proportion of patients on dual
antiplatelet therapy at the latest follow-up, and the propor-
tions of patients on dual antiplatelet therapy were compa-
rable among the 3 stent types when the different time
points of the latest follow-up at which information about
dual antiplatelet therapy was assessed were taken into
account (24.1% of EES patients on dual antiplatelet
therapy at 2.38 years, 16.4% of SES at 3.6 years, and
13.7% of PES patients at 4.0 years). Finally, recent data
from 2 randomized controlled trials28,29 suggest that a
prolongation of dual antiplatelet therapy beyond 6 months
or 1 year, respectively, does not improve ischemic out-
comes, suggesting that potential differences in dual anti-
platelet therapy beyond 1 year may not have an impact on
the primary outcome measure of ARC definite ST.
We cannot exclude that improvements in interventional
treatment strategies over time such as higher implantation
pressures, more frequently performed postdilatation, and
thrombus aspiration may have contributed to an improved
outcome among EES- compared with SES- and PES-
treated patients. However, these potential improvements in
interventional treatment technique are more likely to affect
stent-related outcomes within the first year after stent
implantation rather than during the very late time period.
Conclusions
Current treatment with EES is associated with a lower risk of
VLST compared with treatment with early-generation DES.
The reduction of the risk of VLST with the unrestricted use of
EES overcomes the principal limitation of early-generation
DES and constitutes an important advance in DES safety.
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CLINICAL PERSPECTIVE
Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with an increased risk of
very late stent thrombosis with an annual incidence of 0.5% to 0.6%. It is unknown whether the risk of very late stent
thrombosis persists with newer-generation everolimus-eluting stents (EES). A total of 12 339 patients undergoing treatment
with either SES, PES, or EES between 2002 and 2009 were followed up for up to 4 years to compare the incidence of stent
thrombosis between stent types with particular focus on very late stent thrombosis. The incidence rate of stent thrombosis
through 4 years was lower among EES-treated patients (1.4%) compared with patients treated with SES (2.9%; P0.0001)
and PES (4.4%; P0.0001). The reduction in stent thrombosis was most prominent during the very late time period (1
year) with a 67% (EES versus SES) and 76% (EES versus PES) risk reduction in favor of EES. The annual incidence rate
of very late stent thrombosis amounted to 0.2% in EES, 0.5% with SES, and 0.8% with PES. The lower risk of cardiac death
or myocardial infarction with EES compared with PES (hazard ratio, 0.67; 95% confidence interval, 0.58–0.77;
P0.0001) was directly related to the lower risk of stent thrombosis–associated events. Newer-generation EES improve
clinical outcome by reducing the risk of stent thrombosis compared with early-generation drug-eluting stents during
long-term follow-up. The important reduction of the risk of very late stent thrombosis with the unrestricted use of EES
overcomes the principal limitation of early-generation drug-eluting stents and constitutes an important advance in
drug-eluting stent safety.
Ra¨ber et al Risk of Stent Thrombosis With Everolimus-Eluting Stents 1121
 at Universitaet Bern on July 29, 2012http://circ.ahajournals.org/Downloaded from 
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Background:Newer generation everolimus-eluting stents (EES) improve clinical outcome compared to early
generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). We investigated whether the
advantage in safety and efficacy also holds among the high-risk population of diabetic patients during long-
term follow-up.
Methods: Between 2002 and 2009, a total of 1963 consecutive diabetic patients treatedwith the unrestricted use
of EES (n= 804), SES (n= 612) and PES (n= 547) were followed throughout three years for the occurrence
of cardiac events at two academic institutions. The primary end point was the occurrence of definite stent
thrombosis.
Results: The primary outcome occurred in 1.0% of EES, 3.7% of SES and 3.8% of PES treated patients ([EES vs. SES]
adjusted HR= 0.58, 95% CI 0.39–0.88; [EES vs. PES] adjusted HR= 0.29, 95% CI 0.13–0.67). Similarly, patients
treated with EES had a lower risk of target-lesion revascularization (TLR) compared to patients treated with SES
and PES ([EES vs. SES], 5.6% vs. 11.5%, adjusted HR=0.68, 95% CI: 0.55–0.83; [EES vs. PES], 5.6% vs. 11.3%, adjusted
HR= 0.51, 95% CI: 0.33–0.77). There were no differences in other safety end points, such as all-cause mortality,
cardiac mortality, myocardial infarction (MI) and MACE.
Conclusion: In diabetic patients, the unrestricted use of EES appears to be associated with improved outcomes,
specifically a significant decrease in the need for TLR and ST compared to early generation SES and PES throughout
3-year follow-up.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Diabetes mellitus (DM) has rapidly grown into a public health
problem in the Western world [1]. Currently, a quarter of the patients
undergoing percutaneous coronary intervention (PCI) have DM, which
has been associated with higher restenosis and major adverse cardiac
event (MACE) rates post-PCI compared to patients without DM [2–4].
Endothelial dysfunction, excessive platelet deposition and the over-
expression of several growth factors, such as insulin-like growth factor-
1, basic fibroblast growth factor and transforming growth factor-beta
are some of the factors contributing to the increased MACE rates [5].
To date, several studies evaluated clinical outcomeof the use of bare-
metal stents (BMS) and early generation drug-eluting stents (DES) in
patients with DM [6–8]. These randomized studies, demonstrated that
sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) reduced
both angiographic and clinical parameters of restenosis compared to BMS
in diabetic patients with no significant difference in the rates of stent
thrombosis [6–8]. Nonetheless, in a real-world setting, the benefit of SES
and PES over BMS seems to be confined to only non-insulin-dependent
diabetic patients [9].
Newer generation everolimus-eluting stents (EES) have thinner
struts, thinner polymer coating and improved biocompatibility of the
polymer layer compared to the early generation DES, theoretically
reducing the risk of in-stent restenosis and thrombosis [10]. A recent
pooled analysis of 4 randomized trials showed that EES significantly
reduced the 2-year risk of mortality, stent thrombosis, myocardial
International Journal of Cardiology 170 (2013) 36–42
Abbreviations: aHR, Adjusted Hazard Ratio; ARC, Academic Research Consortium;
BMS, Bare-Metal Stents; CI, Confidence Interval; DES, Drug-Eluting Stents; DM, Diabetes
Mellitus; ECG, ElectroCardioGraphy; EES, Everolimus-Eluting Stents; IQR, Inter Quartile
Range; MACE, Major Adverse Cardiac Events; MI, Myocardial Infarction; PCI, Percutaneous
Coronary Intervention; PES, Paclitaxel-Eluting Stents; RESEARCH, Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital; SD, Standard Deviation; SES, Sirolimus-
Eluting Stents; ST, Stent Thrombosis; TLR, Target-Lesion Revascularization; TVR, Target-
Vessel Revascularization; T-SEARCH, Taxus–Stent Evaluated At Rotterdam Cardiology
Hospital; X-SEARCH, XIENCE-Stent Evaluated At Rotterdam Cardiology Hospital.
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infarction and target-lesion revascularization compared to paclitaxel-
eluting stents (PES) in patientswithout DM [11]. However, the advantage
of everolimus-eluting stents over paclitaxel-eluting stents was not
reproduced in the general diabetic population [11]. Similar non-
significant findings in short-term clinical efficacy and safety parameters
were shown between EES and SES in diabetic patients [12].
To date, it remains unclear whether there is any long-term clinical
benefit associated with the implantation of EES compared to SES and
PES in a large “all-comer” diabetic population. Therefore, we investigated
the 3-year safety and efficacy profile of the unrestricted use of SES, PES
and EES in diabetic patients of the Bern–Rotterdam study.
2. Methods
2.1. Patient population and study design
Between April 2002 and December 2009, a total of 12,945 consecutive “all-comer” PCI
patients were treated at two academic centers in the Netherlands and Switzerland. All
treated patients were included in the analysiswithout any restrictions to include a patient
population representing the “realworld”. However, patients forming part of a randomized
trial, which required protocol mandated angiographic follow-up, were excluded from the
analysis because of the fact that it is a well-known trigger for coronary revascularization
(n=158). Additionally, patients receiving multiple stent types during the initial procedure
were excluded from analysis (n = 606). The study population consisted of 1963 diabetic
patients (16.1%), of which 804 patients were treatedwith EES (XIENCE V™, Abbott Vascular,
Santa Clara, CA, or PROMUS™, Boston Scientific, Natick, MA, USA), 612 patients with SES
(Cypher™, Cordis Corporation, Johnson and Johnson, Warren, NJ, USA) and 547 patients
with PES (Taxus™, Express2™ or Liberté™, Boston Scientific, Natick, MA, USA) (Fig. 1). A
total of 1100 patients (56.0%) were included in Rotterdam and 863 patients (43.0%) in
Bern (Fig. 3). Since March 2007, EES has been the default strategy in the Thoraxcenter
Rotterdam as part of the XIENCE Stent Evaluated At Rotterdam Cardiology Hospital
(X-SEARCH) registry [10]. The Bern University Hospital has used EES since November
2006 on a daily alternating basis with biolimus-eluting stents and zotarolimus-
eluting stents. The design of the study has been described previously [13].
The procedures were performed according to standard clinical guidelines and every
patient was pre-treated with a loading dose of ≥300mg clopidogrel and lifelong aspirin.
No other thienopyridine or platelet aggregation inhibitor, besides aspirin and clopidogrel,
was used during the study period. At the Thoraxcenter, Rotterdam, SES-patients were
prescribed clopidogrel for a duration of at least 3 months unless one of the following
criteria was present: multiple SES-implantation (≥stents), total stent length 36 mm or
longer, chronic total occlusions and bifurcations, in which case the DAPT were prescribed
for a longer period. DAPT were prescribed for at least 6 months for PES-patients and
12months for EES-patients. At Bern University Hospital, all patients received clopidogrel
for at least 12months irrespective of stent type. Theusage of glycoprotein IIb/IIIa inhibitors
was left at the discretion of the interventional cardiologist.
2.2. Data collection and follow-up
Survival data for all patients were obtained frommunicipal civil registries on a yearly
basis. All living patients received yearly a health-related postal questionnaire, consisting of
queries regarding rehospitalisation and MACE. In Bern, patients who had undergone
implantation of SES or PES had their last follow-up took place beginning on February 1,
2007, and beginning on February 1, 2010, for patients with EES. In Rotterdam, the last
follow-up took place on July 1, 2008, for PES-patients, on July 1, 2008, for SES-patients and
on April 1, 2011, for EES-patients. In case of a patient-reported recurrent rehospitalisation,
the discharge report was screened for a potential cardiac adverse event. Whenever patient
indicated a repeat angiography, the angiography CDs were screened for the type of event
by independent cardiologists. In addition, the hospital database of both hospitals were
screened for repeat angiographies. The total number of reviewed angiograms was 396.
2.3. Definitions and end points
Diabetes was defined as the usage of an oral hypoglycemic agent or insulin. The
predefined primary end point was the occurrence of definite stent thrombosis. Secondary
safety end points included all-cause mortality, myocardial infarction (MI), the composite
of cardiac death/MI, target-lesion revascularization (TLR) and MACE (defined as a
composite of cardiacmortality,MI and TLR).MIwas diagnosed by recurrent typical clinical
symptoms and ischemic electrocardiography changes in combinationwith a CK-MB rise of
three times the upper limit of normal or an elevation of more than two times the upper
limit of normal in CK. TLR was defined as revascularization for a stenosis within the
stent or within 5 mm proximal or distal to the stent. TVR was defined as a repeat PCI in
the same vessel as the index procedure, in the presence of ischemic symptoms or positive
functional ischemia study on the target vessel area and a significant minimal luminal
diameter stenosis of at least 50%.
Stent thrombosis was defined according to the academic research consortium (ARC)
criteria [14]. Stent thrombosis was categorized into early (within 30 days post-stent
implantation), late (between 30 days and 1 year post-stent implantation) and very late
(after 1 year post-stent implantation).
2.4. Statistical analysis
Baseline and procedural variables are presented as mean (±standard deviation (SD)
for continuous variables and as percentages for categorical variables. The Pearson's chi
square test was used to compare categorical variables and Student's t-test for continuous
variables. The estimated cumulative incidence for the pre-specified end points was
generated with the Kaplan–Meier method, and the difference between patients receiving
SES, PES and EES was assessed with the log-rank test. Patients with multiple events were
not censored during the follow-up period.
To adjust for baseline characteristics, a multivariate Cox proportional hazard regression
model (95% confidence interval (CI)) was used. The total number of variables in the final
Cox model was restricted according to generally accepted 10:1 events/degrees-of-freedom
rule. The selection of variables entering themodelwas chosen a priori based on the literature.
Additionally, a stepwise backward deletion of baseline variables was performed to add
variables in the final model for each end point with a p-value≤0.10. The following variables
entered the multivariable Cox proportional hazards model: age, acute coronary syndrome,
number of stents implanted, average stent diameter, prescription time of clopidogrel and
type of stent (Table 3). An interaction term was added to the model to correct for potential
heterogeneity between centers and used stent type. The proportional hazards assumption
of the performed Coxmultivariable analyseswas assessed by the Schoenfeld partial residuals
for all end points. The proportional hazards assumption was not violated for any of the end
points. Patients lost to follow-up were considered at risk until the date of last contact, at
which point they were censored. All reported p-values are two-sided and regarded as
statistically significant if ≤0.05. Statistical analysis was performed with SPSS for Windows
version 15 (SPSS inc., Chicago, Illinois, USA).
3. Results
3.1. Population characteristics
The study population consisted of 1963 consecutive patients
undergoing PCI with EES (n=804), SES (n=612) or PES (n=547). A
total of 1933 patients (98.3%) completed the last follow-up with 788
patients receiving EES (98.0%), 609 patients receiving SES (99.5%) and
536 patients receiving PES (98.0%). The median follow-up duration
among patients treated with EES was 2.1 years (interquartile range
(IQR): 1.4–2.8 years), 3.0years (IQR: 2.0–3.0years) for patients treated
with SES and 2.4years (IQR: 1.4–3.0years) for patients treatedwith PES.
Baseline and procedural characteristics stratified according to stent type
are shown in Table 1. In summary, EES-patients were on average older,
less frequently hypertensive, more often had a family cardiac history,
more often treated with insulin, more often presented with a ST-
elevation myocardial infarction, had a higher average stent diameter
and were more often treated in the left main coronary artery or bypass
graft compared to SES-patients and PES-patients. The duration of
thienopyridine prescription post-stent implantation increased over
time, being significantly longer in the EES-group than the SES-groupFig. 1. The years (x-axis) and the number of stents used (y-axis) of the three stent types.
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and PES-group, respectively (14.4months±11.0 vs. 9.7months±11.2
vs. 7.2months±4.6; pb0.001).
3.2. 3-Year clinical outcome
At 3-year follow-up, the occurrence of definite stent thrombosis was
significantly lower in the EES-group compared to the SES-group and
PES-group (Tables 2 and 4, Fig. 2). The difference in favor of EES was
mainly due to a lower risk of early ST (within the first 30 days after
PCI) and a trend towards a lower risk of very late ST. In addition, EES-
patients had a lower risk of TLR compared to patients treated with SES
and PES The difference in rates of TLR between stent types occurred
during the first year after PCI and was sustained until 3-year follow-
up without evidence of diminished efficacy over time (Fig. 3).
Multivariate Cox regression analysis showed that no difference
between stent types in terms of all-cause mortality, MI and MACE (the
composite end point of cardiac death and/or MI), was significantly
lower in EES-patients compared to PES-patients.
Patients treated with insulin had similar definite stent thrombosis
rates compared to non-insulin dependent DM patients [adjusted
HR = 0.74, 95% CI: 0.36–1.53]. Also, there were no differences in
TLR [adjusted HR=0.82, 95% CI: 0.56–1.21] and TVR rates [adjusted
HR = 0.92, 95% CI: 0.68–1.23]. Insulin-dependent DM patients had
higher all-cause mortality [adjusted HR = 1.51, 95% CI: 1.18–1.95]
and cardiac mortality [adjusted HR= 1.67, 95% CI: 1.23–2.56] rates
compared to those treated without insulin (Table 4).
In both insulin-dependent and non-insulin dependent DM patients,
definite stent thrombosis rates were lower in patients treated with EES
compared to those treated with SES and PES. However, it only reached
statistical significance compared to PES-patients [adjusted HR= 0.39,
95% CI: 0.16–0.98] in the non-insulin dependent DM group. In addition,
TLR rates of non-insulin dependent DM patients treated with EES were
significantly lower compared to those treated with SES [adjusted HR=
0.61, 95% CI: 0.41–0.91], although this effect was attenuated in insulin-
dependent DM-patients [adjusted HR=0.72, 95% CI: 0.45–1.16].
4. Discussion
The main findings of this study show that in a “real world” diabetic
population, implantation of new generation EES is associated with
Table 1
Baseline and procedural characteristics stratified according to stent type.
Number of patients PES EES SES PES p-Value
(n=804) (n=612) (n=547) EES vs. SES EES vs. PES
Demographic characteristics
Age, years (±SD) 66.9 (±10.9) 64.1 (±10.5) 64.3 (±10.9) b0.001 b0.001
Male (%) 70.0 70.4 67.3 0.9 0.3
Risk factors
Current smoking (%) 29.9 39.9 26.5 b0.001 0.2
Hypertension (%) 66.0 74.7 71.1 b0.001 0.1
Hypercholesterolemia (%) 63.6 62.9 70.0 0.8 b0.05
Diabetes – – –
Insulin dependent (%) 28.7 24.0 20.3 b0.05 b0.001
Noninsulin dependent (%) 71.3 76.0 79.7 b0.05 b0.001
Family history (%) 33.3 26.6 29.8 b0.01 0.2
Renal impairment (%) 8.2 7.1 8.5 0.6 0.9
BMI, kg/m2 (±SD) 28.9 (±5.0) 28.8 (±4.9) 28.6 (±4.4) 0.9 0.3
Clinical presentation
Unstable angina/non-STEMI (%) 29.6 27.5 31.1 0.4 0.6
Acute coronary syndrome (%) 53.9 43.2 50.2 b0.001 0.2
ST-elevation MI (%) 24.0 15.7 18.9 b0.001 b0.05
Cardiogenic shock (%) 2.2 1.8 0.4 0.6 b0.01
LVEFa (±SD) 51.5 (±12.4) 53.9 (±12.4) 53.6 (±12.5) b0.01 0.1
Disease severity
Multi-vessel disease (%) 19.5 21.9 17.0 0.3 0.2
Bifurcation (%) 9.6 13.2 13.3 0.2 0.1
Number of stents (±SD) 2.0 (±1.2) 2.0 (±1.1) 2.2 (±1.3) 0.2 0.3
Number of lesions (±SD) 1.8 (±1.0) 1.5 (±0.7) 1.5 (±0.7) b0.001 b0.001
Stent diameter, mm (±SD) 3.0 (±0.4) 2.8 (±0.3) 2.9 (±0.4) b0.001 b0.01
Stent length, mm (±SD) 35.0 (±25.4) 35.9 (±23.7) 42.5 (±29.4) 0.8 b0.001
Treated vessel (%)
RCA 34.8 31.3 35.6 0.2 0.8
LAD 48.1 51.7 48.6 0.2 0.9
LCX 27.2 29.6 28.2 0.3 0.7
LM 5.0 1.6 2.9 b0.001 0.1
Bypass graft 5.7 2.8 1.3 b0.01 b0.001
Medication
Aspirin (%) 96.5 98.3 98.5 b0.05 b0.05
Clopidogrel (%) 97.7 99.0 98.5 0.3 0.1
Clopidogrel duration, months (±SD) 14.4 (±11.0) 9.7 (±11.2) 7.2 (±4.6) b0.001 b0.001
GP IIb/IIIa inhibitor (%) 17.5 16.4 18.9 0.6 0.5
Betablocker (%) 50.4 62.0 64.6 b0.001 b0.001
ACE-inhibitor (%) 35.1 62.3 55.0 b0.001 b0.001
Calcium antagonist (%) 6.3 23.1 29.9 b0.01 b0.001
Statin (%) 84.5 78.1 80.2 b0.05 b0.05
Data are presented as percentages or means (±SD). SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; EES, everolimus-eluting stents; SD, standard deviation; BMI, body mass
index; LVEF, left ventricular ejection fraction;MI, myocardial infarction; RCA, right coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LM,
Left main coronary artery.
a LVEF data is based on the Bern cohort.
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lower rates of definite stent thrombosis as compared to both SES and
PES at 3-year follow-up. This difference emerged during the early period
and showed a trend towards a lower risk during the very late period.
Target lesion revascularization was performed less frequently in the
EES group compared to the SES- and PES-group. The use of EES reduced
the occurrence of TLR by 32% compared to SES and 49% compared to
PES. The advantage in terms of efficacy is largely accrued during the
first year following PCI with maintenance of superiority up to three
years. There appears to be no differences in rates of ST and TLR between
DM-patients on insulin treatment compared to those treated with oral
medication. However, insulin-dependent diabetic patients had higher
all-cause and cardiac mortality rates compared to non-insulin dependent
diabetic patients. These results were consistent with the findings of our
previous paper, where we showed that EES resulted in a lower rate of
definite ST compared to SES [HR = 0.51, 95% CI: 0.34–0.77] and PES
[HR=0.34, 95% CI: 0.23–0.50] in patients without diabetes mellitus [15].
The clinical question of whether the safety and efficacy of EES are
significantly better than SES and PES still needs to be addressed in
Table 2
Crude event rates and multivariate analysis stratified according to different stent types at 3-years.
EES (n=804) SES (n=612) PES (n=547) EES vs. SES EES vs. PES
Number of events (%) Multivariate HR [95% CI]
Mortality
All-cause 122 (17.4%) 91 (12.9%) 76 (14.9%) 1.05 [0.91–1.21] 0.92 [0.69–1.24]
Non-cardiac 38 (5.4%) 32 (4.5%) 27 (5.3%) 1.07 [0.84-1.36] 0.87 [0.52–1.45]
Cardiac 84 (12.0%) 59 (8.4%) 49 (9.6%) 1.04 [0.88–1.23] 0.95 [0.66–1.37]
MI 22 (3.1%) 42 (5.7%) 37 (7.4%) 0.79 [0.60–1.06] 0.72 [0.34–1.54]
CD/MI 102 (14.0%) 97 (14.0%) 83 (16.7%) 0.81 [0.61–1.08] 0.43 [0.22–0.83]
ST
Def/prob 52 (6.8%) 60 (8.7%) 53 (10.2%) 0.89 [0.74–1.08] 0.70 [0.48–1.03]
Definite 8 (1.0%) 23 (3.7%) 20 (3.8%) 0.58 [0.39–0.88] 0.29 [0.13–0.67]
Early 2 (0.2%) 11 (1.8%) 9 (1.7%) 0.40 [0.19–0.85] 0.15 [0.03–0.67]
Late 3 (0.4%) 3 (0.5%) 2 (0.4%) 0.88 [0.39–1.95] 0.97 [0.16–5.88]
Very late 3 (0.4%) 9 (1.4%) 9 (1.7%) 0.66 [0.34–1.29] 0.29 [0.08–1.08]
MACE 133 (18.0%) 144 (21.7%) 112 (20.6%) 0.96 [0.78–1.18] 0.77 [0.47–1.26]
Revascularization
TVR 74 (10.3%) 107 (17.4%) 77 (16.8%) 0.74 [0.64–0.87] 0.62 [0.45–0.87]
TLR 41 (5.6%) 73 (11.5%) 51 (11.3%) 0.68 [0.55–0.83] 0.51 [0.33–0.77]
TLR* 27 (3.5%) 46 (7.2%) 34 (7%) 0.43 [0.26–0.70] 0.68 [0.53–0.87]
TLR** 14 (2.1%) 27 (4.3%) 17 (4.3%) 0.54 [0.26–1.12] 0.80 [0.53–1.20]
IDDM (n=489) NIDDM (n=1474)
EES
(n=231)
SES
(n=147)
PES
(n=111)
EES vs. SES EES vs. PES EES
(n=573)
SES
(n=465)
PES
(n=436)
EES vs. SES EES vs. PES
Number of events (%) Multivariate HR [95% CI] Number of events (%) Multivariate HR [95% CI]
Mortality
All-cause 39 (23.0%) 26 (19.9%) 23 (25.7%) 1.13
[0.84–1.53]
0.85
[0.48–1.53]
83 (19.7%) 65 (15.3%) 53 (15.3%) 1.08 [0.84–1.40] 1.16 [0.77–1.74]
Non-cardiac 13 (10.1%) 5 (4.3%) 7 (8.5%) 4.56
[1.37–15.2]
1.12
[0.36–3.43]
58 (12.9%) 27 (7.0%) 20 (6.2%) 1.40 [0.82–2.39] 1.88 [0.78–4.57]
Cardiac 26 (14.3%) 21 (16.2%) 16 (18.7%) 0.96
[0.68–1.35]
0.77
[0.38–1.57]
25 (7.8%) 38 (8.9%) 33 (9.8%) 1.01 [0.74–1.39] 1.10 [0.68–1.78]
MI 4 (2.0%) 11 (10.2%) 6 (10.0%) 0.57
[0.27–1.18]
0.64
[0.07–5.67]
18 (5.1%) 31 (8.2%) 31 (8.7%) 0.89 [0.50–1.58] 0.90 [0.38–2.13]
CD/MI 30 (14.4%) 30 (23.8%) 22 (27.3%) 0.88
[0.65–1.19]
0.69
[0.37–1.29]
72 (16.8%) 67 (16.1%) 61 (17.1%) 0.96 [0.73–1.26] 0.88 [0.59–1.32]
ST
Def/Prob 12 (7.3%) 15 (13.5%) 9 (14.7%) 0.95
[0.55–1.66]
0.80
[0.32–1.99]
40 (8.8%) 45 (10.9%) 44 (12.3%) 1.08 [0.80–1.43] 0.71 [0.45–1.10]
Definite 1 (0.5%) 6 (4.8%) 2 (4.3%) 0.35
[0.10–1.18]
0.37
[0.03–4.30]
7 (2.0%) 17 (4.3%) 18 (5.6%) 0.95 [0.54–1.69] 0.39 [0.16–0.98]
Early 0 (0%) 4 (2.7%) 0 (0%) – – 2 (0.4%) 7 (1.5%) 9 (2.1%) 0.74 [0.26–2.11] 0.19 [0.04–0.93]
Late 1 (0.5%) 0 (0%) 0 (0%) – – 2 (0.4%) 3 (0.7%) 2 (0.5%) 1.38 [0.35–5.43] 0.74 [0.10–5.44]
Very late 0 (0%) 2 (2.1%) 2 (4.3%) – – 3 (1.2%) 7 (2.1%) 7 (3.0%) 1.39 [0.56–3.47] 0.65 [0.15–2.74]
MACE 39 (22.6%) 37 (29.1%) 27 (33.8%) 0.90
[0.69–1.18]
0.75
[0.43–1.32]
94 (21.3%) 107 (25.2%) 85 (23.9%) 0.84[0.67–1.05] 0.68 [0.43–1.08]
Revascularization
TVR 19 (12.8%) 24 (19.2%) 14 (19.4%) 0.75
[0.52–1.08]
0.66
[0.29–1.50]
55 (14.4%) 83 (20.7%) 63 (19.3%) 0.68 [0.50–0.93] 0.68 [0.45–1.03]
TLR 11 (8.3%) 14 (11.3%) 8 (13.2%) 0.72
[0.45–1.16]
0.78
[0.26–2.33]
30 (8.2%) 59 (14.4%) 43 (12.7%) 0.61 [0.41–0.91] 0.60 [0.35–1.02]
TLR* 7 (3.4%) 8 (5.6%) 4 (4.0%) 0.64
[0.34–1.20]
0.89
[0.16–5.06]
20 (3.8%) 38 (8.6%) 30 (7.4%) 0.63 [0.40–0.98] 0.55 [0.29–1.06]
TLR** 4 (5.1%) 6 (6.0%) 4 (9.4%) 0.82
[0.40–1.68]
0.71
[0.17–3.03]
10 (3.5%) 21 (6.4%) 13 (5.7%) 0.52 [0.20–1.34] 0.71 [0.28–1.82]
CD=cardiac death; CI= confidence interval; Def=definite; EES=everolimus-eluting stent; IDDM= insulin-dependent diabetes mellitus; NIDDM=non-insulin dependent diabetes
mellitus; SES=sirolimus-eluting stent; PES=paclitaxel-eluting stent; Prob=probable; HR=hazard ratio;MACE=Major Adverse Cardiac Events;MI=myocardial infarction; n.a.=not
applicable; ST=stent thrombosis; TLR=target lesion revascularization; TVR=target vessel revascularization. TLR* shows the occurrence of TLR (%) in the period between 0 and 1year.
TLR** shows the occurrence of TLR (%) in the period between 1 and 3 years.
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patients with diabetes mellitus. These patients have worse clinical
outcome when compared to the general population as previously
shown in the pooled COMPARE and SPIRIT trials [11]. In this pooled
analysis the advantage of EES over PES seen in the overall population
failed to emerge in the diabetic population. Treatment with EES was
associated with a reduction in TLR rates among non-insulin dependent
DM patients, whereas a trend towards higher TLR rates was observed
in insulin-dependent DM patients [11]. Moreover, an angiographic
subgroup analysis of the SPIRIT-III trial showed that the differences in
in-stent luminal late loss at 8-months between EES and PES (0.12 vs.
0.27 mm) were less pronounced in the diabetic population (0.18 vs.
0.24 mm) [16]. In our study, the implantation of EES was associated
with lower ST and TLR rates compared to SES and PES in the insulin-
dependent group, although it did not reach statistical significance. The
antiproliferative potency of everolimus has been shown to be non-
inferior to sirolimus, which is reflected in a similar in-stent lumen late
loss in the general population (0.10 vs. 0.05mm) [17]. Similarly, in the
ESSENCE-DIABETES trial, angiographic in-stent late lumen loss was
non-inferior among patients treated with EES compared to those
treated with SES at 8-months (0.23 vs. 0.37 mm) [12]. In this non-
inferiority trial, no significant difference was observed for clinical
safety and efficacy end points.
Our study adds to the increasing evidence of lower risk of ST with
newer generation DES [15,18,19]. We previously described that EES
were associatedwith a lower risk of definite stent thrombosis compared
with early generation drug-eluting stents in a “real-world” setting [15].
A finding was also reproduced in the diabetic population. These initial
observations from crude sub-analysis were intriguing since no previous
Table 3
Hazard ratio and 95% confidence interval for risk factors associated with definite stent
thrombosis during the entire follow-up period frommultivariable Cox regression analysis.
The total number of variables entering the multivariable Cox proportional hazards model
was restricted to 5 (according to the 10:1 events/degrees-of-freedom rule).
Variables Hazard ratio 95% CI
Age 0.98 0.95–1.01
Acute coronary syndrome 3.47 1.62–7.43
Number of stents 1.36 1.11–1.67
Average stent diameter 0.43 0.16–1.18
Prescription time clopidogrel 0.94 0.86–1.02
Fig. 2. Adjusted Kaplan–Meier curves according to stent type for the safety end points. The adverse cardiac event rates with the associated log-rank test for patients treated with SES, PES
and EES: (A) all-causemortality; (B)myocardial infarction; (C) cardiac death/myocardial infarction; (D) definite stent thrombosis. The numbers under thefigures are the “patients at risk”
at that certain time-point of the follow-up.
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study had shown clinical superiority of EES over SES and PES in the
diabetic population. In the present study, we established that EES are
safer and more efficacious than PES and SES in the diabetic population.
In terms of efficacy this effect is more evident in the non-insulin
diabetics compared to the insulin-dependent diabetics.
A comprehensive network meta-analysis of more than 50,000
patients showed not only that patients treated with EES had lower ST
rates compared to earlier generation drug-eluting stents but even
when compared to bare-metal stents at 2-year follow-up [19]. However,
thediabetic populationwas not described in detail in thismeta-analysis,
making it impossible to draw conclusions on the safety and efficacy
parameters of early and new-generation stent types in diabetic patients.
More specifically, the analysis for diabetes populations included in the
pooled meta-analysis by Palmerini et al. was limited to confirmation
of the superiority of EES against other stent types, in terms of definite
stent thrombosis, when this population was excluded. In addition, since
patients in clinical trials, and therefore meta-analysis, are carefully
selected, they do differ from patients in normal clinical practice. As a
result it is important to confirm findings in “real-world” populations.
Third, in view of the phenomenon of very late stent thrombosis, we
not only assessed the incidence at two-years but add data to the
existing literature for longer follow-up to three-years. In the selection
of the stent type, the interventional cardiologist does not only consider
Fig. 3.Adjusted Kaplan–Meier curves according to stent type for the efficacy end points. The adverse cardiac event rateswith the associated log-rank test for patients treatedwith SES, PES
and EES: (A) TVR; (B) TLR; (C) MACE.
Table 4
The usage of antiplatelet medication at the timepoint of definite stent thrombosis.
All EES SES PES p
(n=1963) (n=804) (n=612) (n=547)
ARC definite ST, n 51 8 23 20
Complete data onmedication
At time of ST, n
46 8 20 18
On DAPT at ST, n (%) 21 (45.7) 2 (25.0) 12 (60.0) 7 (38.9) 0.9
Aspirin at ST, n (%) 42 (91.3) 7 (87.5) 17 (85.0) 18 (100.0) 0.2
Clopidogrel at ST, n (%) 21 (45.7) 2 (25.0) 12 (60.0) 7 (38.9) 0.2
On neither antiplatelet at ST,
n (%)
4 (8.7) 1 (12.5) 3 (15.0) 0 (0.0) 0.2
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but also evaluate other performance measures. For this reason, we
additionally provide data on overall performance measures of EES
compared to other stent types. Differences in duration of dual
antiplatelet therapy have been implicated as a main factor contributing
to this, with recent PCI-patients prescribed dual antiplatelet therapy for
at least 12months. However, in our populationwe notice a lower rate of
ST already in the early stages, when dual antiplatelet therapy use is
comparable between the patients.
4.1. Study limitations
“Real-world” registries are a good manner to reflect the complex
health situation of most patients, however there remains several
limitations that needs to be acknowledged and addressed. First of all
this was a non-randomized study resulting in cohorts with differences
in baseline, procedural characteristics, antiplatelet treatment duration
and follow-up duration. Although statistical corrections have been
used to account for these differences, it remains arguable whether this
was sufficient.
Second, the exact duration of clopidogrel use after percutaneous
coronary intervention could not reliably be assessed and therefore the
analysis are based on the prescribed duration of clopidogrel. In addition,
it could be possible that some cases of ST were undetected in our study
despite our attempts of an active surveillance. To avoid underestimation
and overestimation of the occurrence of ST, the composite of definite ST
andprobable STwas provided in addition to the secondary ischemic end
points, such as TLR and cardiac death. Third, the EES group consisted of
804 patients treated with the XIENCE V™ stent (Abbott Vascular, Santa
Clara, CA) or the PROMUS™ stent (Boston Scientific, Natick, MA, USA).
Although both stent have the same antiproliferative drug coating, the
stent platforms have distinct features. Finally, cardiac events could
have beenmissed due to the fact that data collection relied on the ability
of the patient to remember events of the past year.
5. Conclusion
In diabetic patients, the unrestricted use of EES appears to be
associated with improved outcomes, specifically a significant decrease
in the occurrence of ST and in the need for TLR compared to early
generation SES and PES throughout 3-year follow-up. No differences
were observed for the other safety end points. These results should be
interpreted in light of the inherent limitations of registry data.
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Abstract
Aims: Newer-generation everolimus-eluting stents (EES) have been shown to improve clinical outcomes 
compared with early-generation sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in patients under-
going percutaneous coronary intervention (PCI). Whether this benefit is maintained among patients with 
saphenous vein graft (SVG) disease remains controversial.
Methods and results: We assessed cumulative incidence rates (CIR) per 100 patient years after inverse 
probability of treatment weighting to compare clinical outcomes. The pre-specified primary endpoint was the 
composite of cardiac death, myocardial infarction (MI), and target vessel revascularisation (TVR). Out of 
12,339 consecutively treated patients, 288 patients (5.7%) underwent PCI of at least one SVG lesion with 
EES (n=127), SES (n=103) or PES (n=58). Up to four years, CIR of the primary endpoint were 58.7 for EES, 
45.2 for SES and 45.6 for PES with similar adjusted risks between groups (EES vs. SES; HR 0.94, 95% CI: 
0.55-1.60, EES vs. PES; HR 1.07, 95% CI: 0.60-1.91). Adjusted risks showed no significant differences 
between stent types for cardiac death, MI and TVR.
Conclusions: Among patients undergoing PCI for SVG lesions, newer-generation EES have similar safety 
and efficacy to early-generation SES and PES during long-term follow-up to four years.
KEYWORDS
• bypass graft
• drug-eluting stent
• paclitaxel-eluting 
stent
• sirolimus-eluting 
stent
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Abbreviations
ARC Academic Research Consortium
BMS bare metal stent(s)
CIR cumulative incidence rates
DES drug-eluting stent(s)
EES everolimus-eluting stent(s)
HR hazard ratio
IQR interquartile range
MACE major adverse cardiac events
MI myocardial infarction
NSTEMI non-ST-segment elevation myocardial infarction
PCI percutaneous coronary intervention
PES paclitaxel-eluting stent(s)
SD standard deviation
SES sirolimus-eluting stent(s)
ST stent thrombosis
STEMI ST-segment elevation myocardial infarction
SVG saphenous vein graft
TVR target vessel revascularisation
ULN upper limit of normal
Introduction
Approximately 3-6% of percutaneous coronary interventions (PCI) are 
performed among patients with saphenous vein graft (SVG) disease1, 
and this represents the most important revascularisation option for 
patients with graft failure. PCI of SVG lesions is characterised by high 
rates of restenosis and periprocedural myocardial infarction (MI) com-
pared with revascularisation of native coronary arteries. Compared 
with bare metal stents (BMS), drug-eluting stents (DES) have been 
shown to reduce the risk of repeat revascularisation by 50%, related to 
a potent inhibition of neointimal tissue proliferation2 without differ-
ences in terms of cardiac death or MI in the largest randomised trial 
performed to date3,4. However, early-generation DES releasing siroli-
mus (SES) or paclitaxel (PES) from durable polymers were used in two 
thirds of patients enrolled in this study1, and little is known regarding 
the outcomes of newer-generation DES among patients with SVG dis-
ease. The newer-generation everolimus-eluting stent (EES) is a thin-
strut, cobalt-chromium alloy stent, which is coated with a durable, 
fluorinated co-polymer releasing a reduced dose of everolimus com-
pared to the dose used with SES5. EES have been shown to improve 
efficacy and safety compared with early-generation PES6-8 through two 
years and to provide similar efficacy but improved safety compared 
with early-generation SES9,10 in a wide range of patients and lesions. 
However, it is unknown whether the favourable results with the use of 
newer-generation EES remain sustained among patients undergoing 
PCI for SVG disease. We therefore investigated the long-term clinical 
outcomes of patients undergoing PCI of SVG lesions with the use of 
EES compared with SES and PES in a large-scale registry.
Methods
PATIENT POPULATION
The Bern-Rotterdam registry evaluates clinical outcomes of 
patients treated with the unrestricted use of DES enrolled at Bern 
University Hospital, Bern, Switzerland, and the Thoraxcenter, 
Erasmus Medical Center, Rotterdam, The Netherlands.
Primary results with focus on stent thrombosis have been 
reported previously6,7,11. In the Dutch institution, SES had been used 
as a default strategy for PCI as part of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) regis-
try. From the first quarter of 2003, PES became commercially avail-
able and replaced SES as default device and became part of the 
TAXUS Stent Evaluated At Rotterdam Cardiology Hospital 
(T-SEARCH) registry. EES (XIENCE V®; Abbott Vascular, Santa 
Clara, CA, USA, or PROMUS®; Boston Scientific, Natick, MA, 
USA) had been used as a default strategy for PCI as part of the 
XIENCE Stent Evaluated At Rotterdam Cardiology Hospital 
(X-SEARCH) registry since March 1, 2007, until the end of this 
study period. In the Swiss institution, EES had been used since 
November 1, 2006, and were implanted on a daily basis alternating 
with biolimus-eluting stents and zotarolimus-eluting stents. SES 
had been used since April, 2002, and PES since March, 2003. 
Individual patients who had been treated with more than one type of 
DES were excluded from the current registry. The study was 
approved by the local ethics committee at both institutions and was 
in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from all patients.
DATA COLLECTION
All patients were actively followed for major adverse cardiac 
events using patient administered postal questionnaires including 
questions on rehospitalisation and major adverse cardiac events. 
This was complemented by a search of hospital databases at the two 
institutions. In Bern, the last follow-up took place from February 1, 
2007, onwards for patients who had undergone implantation of SES 
or PES and from February 1, 2010, onwards for patients with EES. 
In Rotterdam, the last follow-up took place from July 1, 2005, 
onwards for patients with PES, July 1, 2006, for patients with SES, 
and April 1, 2010, onwards for patients with EES, respectively. For 
patients with a suspected event, relevant medical records, discharge 
letters, and coronary angiography documentation were systemati-
cally collected. All suspected clinical events were adjudicated by 
local cardiologists affiliated with the two institutions, whereas all 
ST events were adjudicated by an independent clinical events com-
mittee whose members were unaware of the type of stent implanted. 
Baseline clinical and procedural characteristics and all follow-up 
data were entered into a dedicated database, held at an academic 
clinical trials unit (CTU Bern, Bern University Hospital, Bern, 
Switzerland) responsible for central data audits and maintenance of 
the database.
PROCEDURES
EES were available in diameters from 2.25 to 4.0 mm and in lengths 
from 8 to 28 mm; SES were available in diameters from 2.25 to 
3.5 mm and in lengths from 8 to 33 mm, and PES were available in 
diameters from 2.25 to 4.0 mm and in lengths from 8 to 32 mm. 
The procedure and treatment including peri- and post-procedural 
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medication regimen were performed according to current practice 
guidelines. All patients irrespective of stent type received a loading 
dose of clopidogrel 300 mg to 600 mg during or immediately after 
the procedure and were prescribed aspirin once daily lifelong. In 
the Dutch institution, clopidogrel was administered to patients with 
SES for at least three months, and for at least six months if patients 
had received three or more stents, the total stent length was >36 mm, 
or a chronic total occlusion or bifurcation was treated. Dutch 
patients treated with EES were prescribed clopidogrel for 
12 months. In the Swiss institution, all patients were prescribed 
clopidogrel for a duration of at least 12 months irrespective of stent 
type. The use of glycoprotein IIb/IIIa antagonists and distal protec-
tion devices was left at the discretion of the operator.
DEFINITIONS
The primary endpoint of this study was major adverse cardiac events 
(MACE) defined as the composite of cardiac death, MI, and target 
vessel revascularisation up to four years. The definition of cardiac 
death included any death due to immediate cardiac cause, procedure-
related deaths, unwitnessed death and death of unknown cause. The 
diagnosis of MI was based on an elevation in CK to more than twice 
the upper limit of normal (ULN) and an elevation of CK-MB to more 
than three times ULN in the presence of ischaemic symptoms or 
ischaemic ECG changes. Target vessel revascularisation (TVR) was 
defined as any repeat percutaneous intervention or surgical bypass of 
any segment within the entire major coronary vessel proximal and 
distal to the target lesion, including upstream and downstream 
branches and the target lesion itself. Target lesion revascularisation 
(TLR) was defined as a repeated revascularisation due to a stenosis 
within the stent or within the 5 mm borders proximal or distal to the 
stent. A 12-lead electrocardiogram was obtained prior to the proce-
dure and within 24 hours after PCI. Additional ECGs were obtained 
in case of recurrent signs or symptoms of ischaemia. Acute coronary 
syndrome was defined as acute myocardial ischaemia based on clini-
cal symptoms, electrocardiographic changes, and elevation of car-
diac biomarkers, and encompassed an acute ST-segment (STEMI) 
and non-ST-segment elevation myocardial infarction (NSTEMI) and 
unstable angina. Definitions of hypertension, hyperlipidaemia and 
renal dysfunction were reported previously7,11. Stent thrombosis was 
defined according to the Academic Research Consortium (ARC)8,9.
STATISTICAL ANALYSIS
Baseline clinical and procedural characteristics of the three stent 
types are presented as counts and percentages for dichotomous 
variables and as mean and standard deviation (SD) for continuous 
variables. Pearson’s chi-square test and Student’s t-test were used 
for comparing dichotomous and continuous variables, respectively. 
Cumulative incidence rates (CIR) per 100 patient years were calcu-
lated for each endpoint, defined as the number of new events occur-
ring during a specific time period divided by the total number of 
patient years observed. In contrast to crude percentages, CIR take 
into account differences in follow-up duration between different 
stent types. Propensity scores for receiving EES were estimated for 
each centre by the use of a logit model including age, gender and 
pre-treatment variables associated with stent selection at p<0.10 
(i.e., family history of coronary artery disease, acute coronary syn-
drome and cardiogenic shock for both centres; body mass index and 
left ventricular ejection fraction as additional variables for Bern; 
arterial hypertension, smoking, diabetes and hyperlipidaemia as 
additional variables for Rotterdam). Propensity scores were used to 
derive inverse probability of treatment weights, with the inverse of 
propensity score as analytical weights in EES-treated patients and 
the inverse of 1 minus the propensity score among early-generation 
DES-treated patients. Comparisons between stent types were per-
formed with a Cox proportional hazards model, crude and adjusted 
using inverse probability of treatment weighting. All statistical 
analyses were performed using STATA release 11.1 (StataCorp, 
College Station, TX, USA). All p-values are two-sided.
Results
Between April 16, 2002, and March 31, 2009, 12,339 consecutive 
patients underwent treatment with the unrestricted use of EES 
(n=4,212), SES (n=3,819) and PES (n=4,308). Out of this cohort, 
288 patients (5.7%) (177 [61.5%] enrolled at Bern University Hospi-
tal, and 111 [38.5%] included at Thoraxcenter, Rotterdam) under-
went PCI of at least one SVG lesion with the use of EES among 
127 patients, SES among 103 patients, and PES among 58 patients. 
Baseline clinical characteristics for all three stent types are summa-
rised in Table 1. Patients treated with EES compared with those 
treated with either SES or PES more frequently had diabetes. 
Patients treated with EES were more frequently hypertensive com-
pared to those treated with PES, and more frequently had dyslipi-
daemia, renal failure and presented with an acute coronary 
syndrome than SES-treated patients. Table 2 shows procedural 
characteristics, which were balanced among the three treatment 
groups with the exception of a larger stent diameter in lesions treated 
with EES compared with those treated with SES. The use of glyco-
protein IIb/IIIa antagonists, aspirin, and proton pump inhibitors was 
more frequent among EES compared with PES-treated patients.
Clinical outcome
The median follow-up duration among surviving patients complet-
ing the last follow-up was 2.5 years in patients treated with EES 
(interquartile range: IQR 1.9 to 3.2 years), four years in patients 
treated with SES (IQR 3.0 to 4.0 years), and 3.5 years in patients 
treated with PES (IQR 2.3 to 4.0 years) with an accumulated 144, 
266, and 302 patient years, respectively.
Clinical outcomes up to four years are summarised in Table 3 
and Table 4.
Up to four years, incidence rates per 100 patient years for the pri-
mary endpoint MACE were similar among patients treated with EES 
(58.7%), SES (45.2%, adjusted HR 0.94, 95% CI: 0.55-1.60) and 
PES (45.6%, adjusted HR 1.07, 95% CI: 0.60.-1.91) in adjusted anal-
yses (Table 3 and Table 4, Figure 1). Similarly, there was no differ-
ence in the risk of cardiac death (EES vs. SES adjusted HR 1.18, 95% 
CI: 0.49-2.84, EES vs. PES adjusted HR 0.81, 95% CI: 0.30-2.17), 
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Table 1. Baseline clinical characteristics.
Stent type p-value
EES (A) SES (B) PES (C) A vs. B A vs. C
Number of patients 127 103 58
Age (yr) 69.2 (9.6) 67.5 (10.5) 68.3 (8.8) 0.19 0.54
Male gender 104 (81.9) 86 (83.5) 53 (91.4) 0.75 0.09
Body mass index (kg/m2) 27.7 (3.6) 27.2 (3.7) 27.4 (3.8) 0.27 0.64
Hypertension 89 (70.1) 67 (65.0) 28 (48.3) 0.42 0.004
Family history of CAD 44 (34.6) 33 (32.0) 18 (31) 0.68 0.63
Smoking at baseline 43 (33.9) 47 (45.6) 24 (41.4) 0.07 0.32
Dyslipidaemia 101 (79.5) 69 (67.0) 39 (67.2) 0.031 0.07
Diabetes mellitus 46 (36.2) 18 (17.5) 11 (19) 0.002 0.018
Renal failure (GFR <60 ml/min)* 12 (21.4) 11 (13.4) 8 (20.5) 0.21 0.91
Renal failure (creatinine >150 μmol/l)* 4 (7.1) 0 (0) 2 (5.1) 0.014 0.69
Left ventricular ejection fraction, <30% 3 (6.3) 6 (7.8) 3 (8.8) 0.75 0.66
Acute coronary syndrome 74 (58.3) 39 (37.9) 26 (44.8) 0.002 0.09
Unstable angina/non-ST-elevation MI 57 (77.0) 34 (87.2) 23 (88.5) 0.20 0.21
ST-elevation MI 17 (23.0) 5 (12.8) 3 (11.5) – –
Cardiogenic shock 1 (0.8) 0 (0) 0 (0) 0.37 0.50
Values are n (%) or mean±SD. *data only available in Bern patients. Comparisons between groups among dichotomous variables were performed using 
Pearson’s chi-square test and Student’s t-test for continuous variables.  CAD: coronary artery disease; EES: everolimus-eluting stent; GFR: glomerular 
filtration rate; MI: myocardial infarction; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
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Figure 1. Cumulative event curves for the primary endpoint of major adverse cardiac events (MACE) (A), cardiac death (B), myocardial 
infarction (MI) (C), and target vessel revascularisation (TVR) (D) up to 48 months. *Crude hazard ratio is shown, as adjusted model did not 
converge. EES: everolimus-eluting stents; PES: paclitaxel-eluting stents; SES: sirolimus-eluting stents 
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MI (EES vs. SES adjusted HR 0.84, 95% CI: 0.25-2.83, EES vs. PES 
crude HR 4.14, 95% CI: 0.51-33.44), and TVR (EES vs. SES adjusted 
HR 0.92, 95% CI: 0.49-1.75, EES vs. PES adjusted HR 1.17, 95% 
CI: 0.58-2.36) in adjusted analyses. The incidence rates per 100 
patient years for definite ST and definite or probable ST showed no 
differences among stent types at any time point (Table 5).
Table 2. Baseline procedural characteristics.
Stent type p-value
EES (A) SES (B) PES (C) A vs. B A vs. C
Total (n) 127 103 58
Multivessel treatment 20 (15.7) 22 (21.4) 11 (19.0) 0.27 0.59
Number of vessels treated per patient 1.2 (0.4) 1.2 (0.6) 1.2 (0.4) 0.29 0.80
Number of lesions treated per patient 1.4 (0.6) 1.4 (0.8) 1.3 (0.5) 0.68 0.34
1 lesion 40 (71.4) 55 (67.1) 30 (76.9) – –
2 lesions 11 (19.6) 19 (23.2) 8 (20.5) – –
3 lesions 5 (8.9) 4 (4.9) 1 (2.6) – –
Number of stents per patient 1.9 (1.1) 2.1 (1.2) 1.8 (1.0) 0.33 0.41
Average stent diameter 3.2 (0.5) 3 (0.3) 3.2 (0.5) 0.0002 0.35
Total stent length per patient 32.4 (23.0) 37.6 (24.4) 33.1 (26.5) 0.10 0.86
Glycoprotein IIb/IIIa antagonist 26 (20.5) 14 (13.6) 2 (3.4) 0.17 0.003
Medication at discharge
Aspirin 123 (100) 99 (98.0) 56 (96.6) 0.12 0.038
Clopidogrel 123 (100) 99 (99.0) 57 (98.3) 0.27 0.14
Oral anticoagulation 7 (5.7) 6 (5.9) 7 (12.1) 0.94 0.13
Beta-blocker 37 (66.1) 54 (67.5) 25 (64.1) 0.86 0.84
ACE inhibitor 23 (41.1) 39 (48.8) 18 (46.2) 0.38 0.62
AT II inhibitor 10 (17.9) 17 (21.3) 4 (10.3) 0.63 0.30
Calcium antagonist 12 (21.4) 18 (22.5) 11 (28.2) 0.88 0.45
Statin 52 (92.9) 69 (86.3) 33 (84.6) 0.23 0.20
Oral antidiabetic 8 (14.3) 12 (15.0) 2 (5.1) 0.91 0.15
Insulin 5 (8.9) 3 (3.8) 5 (12.8) 0.21 0.54
Diuretics 18 (32.1) 20 (25.0) 13 (33.3) 0.36 0.90
Proton pump inhibitor 21 (37.5) 20 (25.0) 6 (15.4) 0.12 0.019
Values are n (%) or mean±SD. Comparisons between groups among dichotomous variables were performed using Pearson’s chi-square test and Student’s 
t-test for continuous variables. Number of patients on discharge medication is based on the number of patients alive at discharge. EES: everolimus-
eluting stent; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
Table 3. Clinical outcome at 1 year.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
All-cause death 13 (10.4) 3 (2.9) 4 (7.0) 3.71 (1.06-13.03)* 0.04* 1.50 (0.49-4.60)* 0.48*
Cardiac death 7 (5.8) 3 (2.9) 3 (5.3) 1.18 (0.20-7.05) 0.85 0.89 (0.21-3.81) 0.87
MI 4 (3.4) 3 (2.9) 1 (1.8) 0.70 (0.13-3.73) 0.68 0.47 (0.03-7.40) 0.59
TLR 7 (6.1) 11 (10.8) 3 (5.6) 0.43 (0.12-1.50) 0.18 0.73 (0.17-3.16) 0.68
TVR 10 (8.6) 17 (16.7) 5 (9.3) 0.34 (0.10-1.13) 0.08 0.55 (0.17-1.80) 0.32
Cardiac death/MI 11 (9.0) 5 (4.9) 4 (7.0) 1.46 (0.43-5.01) 0.55 0.93 (0.26-3.33) 0.91
Cardiac death/MI/TLR 15 (12.3) 15 (14.6) 7 (12.3) 0.71 (0.30-1.70) 0.45 0.75 (0.28-1.99) 0.56
Cardiac death/MI/TVR 17 (13.9) 21 (20.4) 9 (15.8) 0.53 (0.23-1.23) 0.14 0.63 (0.26-1.50) 0.29
Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were calculated using inverse 
probability of treatment weights as analytical weighting in Cox proportional hazard models. *Crude rates are shown, as adjusted model did not converge. 
CI: confidence interval; EES: everolimus-eluting stent; HR: hazard ratio; MI: myocardial infarction; PES: paclitaxel-eluting stent; SES: sirolimus-eluting 
stent; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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The duration of dual antiplatelet therapy differed between the 
two institutions. In order to analyse potential site-specific differ-
ences in outcomes comparing EES with early-generation DES, we 
performed a sensitivity analysis for the primary outcome and found 
hazards to be similar for both institutions regarding the primary 
endpoint (Bern EES vs. early-generation DES: HR 0.94, 95% CI: 
0.55-1.60, p=0.82; Rotterdam EES vs. early-generation DES: HR 
1.07, 95% CI: 0.60-1.01, p=0.82).
Discussion
This is the first report comparing newer-generation EES with early-
generation SES and PES during long-term follow-up among 
patients undergoing PCI for SVG disease. The main findings of our 
study are: 1) the use of EES resulted in similar safety and efficacy 
compared to the use of early-generation SES and PES among 
patients with SVG lesions; 2) event rates for restenosis and recur-
rent ischaemia were exceedingly high during follow-up through 
four years regardless of the type of DES implanted.
Limited data are available on the treatment of SVG lesions with 
coronary artery stents.
A comparison of DES with BMS in SVG lesions in a total of 
5,543 patients followed for at least one year yielded similar results 
to those observed in other patient populations, namely a substantial 
improvement in the need for repeat revascularisation of the target 
vessel without differences in terms of MI or stent thrombosis. 
Differences in cardiac death were not recorded when taking into 
account only randomised trials12. However, conflicting results were 
observed among the few studies investigating outcomes beyond 
one year. The randomised Extended Duration of the Reduction of 
Restenosis In Saphenous vein grafts with Cypher stent (DELAYED 
RRISC) study suggested an increased risk of cardiac death and 
numerically lower rates of MI with SES compared with BMS as 
well as a loss of the initially observed lower risk of TVR during 
long-term follow-up. Conversely, the long-term results of the 
Stenting of Saphenous Vein Grafts (SOS) trial suggested a similar 
risk of cardiac death but a lower risk of MI as well as sustained effi-
cacy in terms of repeat revascularisation among PES compared 
with BMS-treated patients with SVG disease during long-term 
follow-up.
Newer-generation DES have been designed to improve upon 
the limitations of early-generation DES by reducing stent strut 
thickness, increasing the biocompatibility of polymers and modi-
fying drug content. Several randomised clinical trials as well as 
large-scale registries confirmed improved safety and efficacy of 
Table 5. Definite or definite/probable stent thrombosis up to 4 years.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
Definite stent thrombosis 4 (4.0) 3 (3.1) 1 (2.2) 1.28 (0.29-5.74)* 0.74* 0.88 (0.10-8.03) 0.91
Definite or probable stent thrombosis 9 (10.1) 9 (9.5) 3 (5.7) 0.79 (0.24-2.61) 0.69 0.90 (0.22-3.64) 0.89
Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were calculated using inverse probability 
of treatment weights as analytical weighting in Cox proportional hazard models stratified by centre. *Crude rates are shown, as adjusted model did not 
converge. CI: confidence interval; HR: hazard ratio; EES: everolimus-eluting stent; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
Table 4. Clinical outcome up to 4 years.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
All-cause death 22 (21.5) 19 (19.5) 11 (24.8) 1.01 (0.52-1.97) 0.98 0.94 (0.41-2.14) 0.88
Cardiac death 14 (15.3) 12 (13.2) 9 (21.8) 1.18 (0.49-2.84) 0.71 0.81 (0.30-2.17) 0.67
MI 8 (9.1) 8 (8.5) 1 (1.8) 0.84 (0.25-2.83) 0.77 4.14 (0.51-33.44)* 0.18*
TLR 19 (25.8) 26 (27.6) 6 (12.6) 0.73 (0.35-1.53) 0.40 1.58 (0.57-4.35) 0.38
TVR 28 (52.0) 34 (35.5) 14 (31.0) 0.92 (0.49-1.75) 0.81 1.17 (0.58-2.36) 0.67
Cardiac death/MI 21 (21.8) 19 (20.3) 10 (23.2) 1.01 (0.48-2.10) 0.99 0.95 (0.38-2.41) 0.92
Cardiac death/MI/TLR 34 (37.9) 36 (37.6) 15 (32.0) 0.87 (0.49-1.56) 0.65 1.16 (0.59-2.31) 0.66
Cardiac death/MI/TVR¶ 40 (58.7) 44 (45.2) 22 (45.6) 0.94 (0.55-1.60) 0.82 1.07 (0.60-1.91) 0.81
¶Composite primary endpoint. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were 
calculated using inverse probability of treatment weights as analytical weighting in Cox proportional hazard models. *Crude rates are shown, as adjusted 
model did not converge. CI: confidence interval; EES: everolimus-eluting stent; HR: hazard ratio; MI: myocardial infarction; PES: paclitaxel-eluting 
stent; SES: sirolimus-eluting stent; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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newer-generation EES compared with PES and SES in a wide 
range of patient and lesion subsets. To date, only one study has 
compared early-generation DES with a newer-generation stent 
releasing sirolimus from a biodegradable polymer among patients 
undergoing treatment of SVG lesions and observed no difference in 
terms of the primary endpoint including cardiac death, MI, and 
repeat revascularisation13. As it relates to long-term results, no data 
are available at this point in time.
Our study is the first to compare newer-generation EES with 
early-generation SES and PES among patients undergoing PCI of 
SVG lesions during long-term follow-up through four years, and is 
of particular interest due to the unselected, consecutive patient pop-
ulation undergoing PCI with the unrestricted use of DES. Similar to 
outcomes in ISAR-CABG, outcomes for the primary endpoint and 
its individual components were similar for newer-generation DES 
compared with early-generation SES and PES. Even when consid-
ering device-specific endpoints such as cardiac death, MI and TLR 
as well as stent thrombosis, no differences were noted among these 
devices throughout the entire follow-up period.
Irrespective of stent type, adverse events were much more fre-
quent among patients undergoing PCI of SVG lesions compared to 
those undergoing PCI of native coronary arteries. Specifically, rates 
of MACE at four years in the present study (46%) were similar to 
those reported among PES-treated patients in the randomised 
Stenting of Saphenous Vein Grafts (SOS) trial at 35 months of fol-
low-up (54%)14. Similarly, in the Extended Duration of the 
Reduction of Restenosis In Saphenous vein grafts with Cypher 
stent (DELAYED RRISC) study15, rates of MACE amounted to 
58% among SES-treated patients at a median follow-up of 
32 months. These figures contrast with rates of MACE in the range 
of 20% among unselected patients enrolled in all-comers studies 
with the predominant treatment of native coronary artery lesions16-18. 
Of note, clinical outcomes were driven by high rates of death, reste-
nosis of the target lesion as well as disease progression within the 
target vessel, reflecting the advanced stage of coronary artery dis-
ease in this patient population.
Potential explanations for the lack of benefit with newer-genera-
tion EES compared with early-generation DES in the specific sub-
set of SVG lesions may have been the small patient population. 
However, considering the high event rates and the long-term fol-
low-up, hazards would be expected to favour EES, assuming simi-
lar benefits in terms of relative risk reduction observed in pivotal 
trials and all-comer patient populations. Differences between SVG 
lesions and native coronary arteries in terms of periprocedural treat-
ment characteristics, atherosclerotic disease burden as well as the 
interaction with revascularisation by means of drug-eluting stents 
may be of relevance. Brilakis and colleagues reported an increased 
risk for in-hospital mortality among patients undergoing PCI for 
treatment of SVG compared to native coronary artery lesions (HR 
1.22, 95% CI: 1.12-1.32, p<0.001). This was related to differences 
in patient and lesion risk profile and a higher incidence of acute 
complications such as no reflow19. SVG failure remote from the 
stented lesion (TVR without TLR) occurs in 30-50% of all repeat 
revascularisation procedures. This proportion is certainly higher 
compared with lesions involving native coronary arteries20,21, sug-
gesting that non-stented disease progression remains an important 
adverse event among patients with SVG disease. Although rates of 
target lesion revascularisation during the first year in the present 
study were very much comparable to those observed following 
treatment of native coronary artery lesions, recurrent ischaemia 
related to the stented segment became increasingly apparent at 
a later time, suggesting a considerable lack of long-term efficacy. 
Specifically, annual rates of TLR between the first and fourth year 
of follow-up were 50 to 70% higher compared with annual rates 
previously reported in the context of native coronary artery dis-
ease16. Therefore, SVG lesions continue to represent an important 
lesion subset with inadequate efficacy following the use of newer-
generation DES.
Pathological analyses and experimental animal models have con-
tributed to our understanding of accelerated atherosclerosis in SVG 
lesions22. Mechanical stress induced by a substantial change in 
haemodynamics from a venous to an arterial circulation has been 
identified as an important source of saphenous vein graft wall thick-
ening, largely related to gene expression of adhesion molecules, 
which evoke inflammatory processes and signal pathways resulting 
in proliferative cell growth. Neointimal formation is followed by 
macrophage infiltration and eventually necrotic core formation, 
resulting in vulnerable plaque formation. Stent implantation of 
SVG lesions more often lead to strut penetration into the necrotic 
core, which may delay healing and perpetuate inflammation, com-
pared with stents implanted into native coronary artery lesions 
resulting in an increased risk for thrombotic occlusions23. In addi-
tion, neoatherosclerotic changes have been observed as early as one 
year after stent implantation in SVG lesions, which is more prema-
ture than observed in native coronary artery lesions. Although the 
prevalence of neoatherosclerosis within DES-treated SVG lesions 
has not been assessed to date, pathology studies suggest that neo-
atherosclerosis is an important mechanism contributing to resteno-
sis during long-term follow-up, providing a potential explanation 
for the high TLR rates observed in this study beyond one year.
Very late stent thrombosis is one of the major concerns with the 
use of early-generation DES; however, the use of EES was associated 
with a substantial reduction in an all-comers patient population9,10. In 
the present study, there were no differences among the three stent 
platforms. However, event rates and patient population were small, 
precluding further exploration of differences among devices.
Limitations
The present study has to be interpreted in view of the following limi-
tations. First, this study was not specially designed to compare the 
safety and efficacy of newer-generation EES with early-generation 
DES in SVG lesions. The data are derived from a non-randomised, 
observational cohort. Second, we lack information regarding the 
diameter of SVG lesions, the use of distal protection devices, and the 
age of SVGs at the time point of the intervention. Third, patients were 
enrolled during different time periods and advances in interventional 
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techniques (e.g., more frequent post-dilatation) may have impacted 
on results. In addition, the follow-up period differed among the three 
treatment groups. However, we employed statistical methodologies 
to present adjusted analyses by employing inverse probability of 
treatment weights and the reporting of cumulative incidence rates. 
Finally, the sample size of this study is small; larger patient popula-
tions are needed to address more definitively the value of newer-
generation DES in SVG lesions.
Conclusions
Among patients undergoing PCI for SVG lesions, newer-genera-
tion EES provide similar safety and efficacy compared to early-
generation SES and PES during long-term follow-up. The high 
rates of adverse events among patients with SVG disease are related 
to disease progression of treated and untreated SVG segments.
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7 NEw GENErATioN DES  iN STEmi PATiENTS
7.1 New generation metallic DES using a biodegradable surface polymer for drug release in patients with ST-
elevation myocardial infarction
Effect of biolimus-eluting stents 
with biodegradable polymer versus 
bare metal stents on cardiovascular 
events among patients with 
acute myocardial infarction. The 
COMFORTABLE AMI Randomized 
Trial.
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Investigators
PRIMARY PERCUTANEOUS CORO-nary intervention (PCI) is thereperfusion therapy of choiceamong patients with ST-
segment elevation myocardial infarc-
tion (STEMI) owing to a lower risk of re-
infarction and improved survival
compared with fibrinolysis.1,2 Bare-
metal stents minimize the risk of in-
farct vessel reocclusion and reinfarc-
tion comparedwith balloon angioplasty,
but are associatedwith restenosis due to
neointimal hyperplasia.3,4 Early genera-
tion drug-eluting stents releasing siroli-
mus or paclitaxel from durable poly-
mers reduce the need for repeat
revascularization compared with bare-
metal stents.5-7 However, vessel healing
is delayed with evidence of chronic in-
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Context The efficacy and safety of drug-eluting stents compared with bare-metal
stents remains controversial in patients with ST-segment elevation myocardial infarc-
tion (STEMI) undergoing primary percutaneous coronary intervention (PCI).
Objective To compare stents eluting biolimus from a biodegradable polymer with
bare-metal stents in primary PCI.
Design, Setting, and Patients A prospective, randomized, single-blinded, con-
trolled trial of 1161 patients presenting with STEMI at 11 sites in Europe and Israel
between September 19, 2009, and January 25, 2011. Clinical follow-up was per-
formed at 1 and 12 months.
Intervention Patients were randomized 1:1 to receive the biolimus-eluting stent
(n=575) or the bare-metal stent (n=582).
Main Outcome Measures Primary end point was the rate of major adverse car-
diac events, a composite of cardiac death, target vessel–related reinfarction, and ischemia-
driven target-lesion revascularization at 1 year.
Results Major adverse cardiac events at 1 year occurred in 24 patients (4.3%) re-
ceiving biolimus-eluting stents with biodegradable polymer and 49 patients (8.7%)
receiving bare-metal stents (hazard ratio [HR], 0.49; 95%CI, 0.30-0.80; P=.004). The
difference was driven by a lower risk of target vessel–related reinfarction (3 [0.5%] vs
15 [2.7%]; HR, 0.20; 95% CI, 0.06-0.69; P=.01) and ischemia-driven target-lesion
revascularization (9 [1.6%] vs 32 [5.7%]; HR, 0.28; 95% CI, 0.13-0.59; P .001) in
patients receiving biolimus-eluting stents compared with those receiving bare-metal
stents. Rates of cardiac death were not significantly different (16 [2.9%] vs 20 [3.5%],
P=.53). Definite stent thrombosis occurred in 5 patients (0.9%) treated with biolimus-
eluting stents and 12 patients (2.1%; HR, 0.42; 95% CI, 0.15-1.19; P=.10) treated
with bare-metal stents.
Conclusion Compared with a bare-metal stent, the use of biolimus-eluting stents
with a biodegradable polymer resulted in a lower rate of the composite of major ad-
verse cardiac events at 1 year among patients with STEMI undergoing primary PCI.
Trial Registration clinicaltrials.gov Identifier: NCT00962416
JAMA. 2012;308(8):777-787 www.jama.com
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flammation related at least in part to the
persistence of durable polymer compo-
nents in patients with acute STEMI.8
In addition, acute myocardial infarc-
tion (MI) is a predictor of thrombotic
stent complications occurring late after
drug-eluting stent implantation, particu-
larly in the presence of a high thrombus
burden, raising concerns regarding the
balance of risks and benefits of these de-
vices in this clinical setting.9,10 Two
meta-analyses in patients with acuteMI
confirmed a lower risk of repeat revas-
cularizationwith early generation drug-
eluting stents compared with bare-
metal stents, however, at the expense of
a 2-fold increased risk of very late stent
thrombosis.11,12
Newer-generationdrug-eluting stents
with biodegradable polymers provide
controlled drug release with subse-
quent degradation of the polymer ren-
dering the stent surface more closely to
a bare-metal stent after the period of bio-
degradation. The unrestricted use of
stents elutingbiolimus, an equipotent si-
rolimus analogue, from biodegradable
polylactic acid was noninferior and po-
tentially better than sirolimus-eluting
stents in terms ofmajor adverse clinical
events in a large clinical trial with fol-
low-upof 4 years,with a substantially re-
duced risk (80%)of stent thrombosis oc-
curring beyond 1 year.13,14 A stratified
analysis suggested a particularly pro-
nounced benefit among patients with
acute STEMI.We therefore performed a
multicenter, randomized trial to com-
pare the efficacy and safety of stents elut-
ing biolimus froma biodegradable poly-
merwith bare-metal stents of otherwise
identical design.
METHODS
Study Design
The COMFORTABLEAMI trial (Com-
parison of Biolimus Eluted From an
Erodible Stent CoatingWith BareMetal
Stents in Acute ST-Elevation Myocar-
dial Infarction) was amulticenter, ran-
domized, assessor-blinded, superior-
ity trial in patients presenting with
STEMI undergoing primary PCI. The
full study design was reported else-
where.15 The study complied with the
Declaration of Helsinki and was ap-
proved by all institutional ethics com-
mittees. All patients provided written
informed consent.
Patient Population
Patients aged 18 years or older with
symptomonsetwithin 24hours and ST-
segment elevation of at least 1 mm in
2 or more contiguous leads, true pos-
terior MI, or new left bundle branch
block were eligible for randomization
in the presence of at least 1 culprit le-
sionwithin the infarct vessel. Therewas
no limit regarding thenumber of treated
lesions, vessels, or complexity. Exclu-
sion criteria were presence ofmechani-
cal complications of acute MI, known
allergy to any studymedication, use of
vitamin K antagonists, planned sur-
gery unless dual antiplatelet therapy
could be maintained throughout the
perisurgical period, history of bleed-
ing diathesis or known coagulopathy,
pregnancy, participation in another trial
before reaching the primary end point,
inability to provide informed consent,
and noncardiac comorbid conditions
with life expectancy of less than 1 year.
Patients were recruited between Sep-
tember 19, 2009, and January 25, 2011,
in 11 centers throughout Europe and
Israel (Denmark [n=1], Israel [n=1],
the Netherlands [n=1], Serbia [n=1],
Switzerland [n=6], and the United
Kingdom [n=1]).
Procedures
Randomization was performed via a
web-based system after diagnostic an-
giography. The allocation sequencewas
computer generated in randomly vary-
ing blocks of 2, 4, and 6, and stratified
by center. Patients were randomly al-
located on a 1:1 basis to treatment with
stents eluting biolimus from a biode-
gradable polylactic acid polymer (Bio-
Matrix, Biosensors Europe SA) or bare-
metal stents of otherwise identical
design (Gazelle, Biosensors Europe SA).
Both stent types were available in di-
ameters of 2.25, 2.50, 2.75, 3.00, 3.50,
and 4.00 mm and in lengths of 8, 11,
18, 24, and 28 mm. Before stent im-
plantation, thrombus aspiration was
recommended in all patients when-
ever aspiration was deemed techni-
cally feasible. Predilation of the cul-
prit lesion was left to the discretion of
the operator. Complete revasculariza-
tion of all lesionswithin the infarct ves-
sel had to be performed with the ran-
domly allocated study stent.Nonculprit
vessels were treated by default with bio-
limus-eluting stents at baseline anddur-
ing follow-up and did not contribute to
the primary end point. Staged proce-
dures for the treatment of nonculprit
vesselswere permittedwithin 3months
with the uniform use of biolimus-
eluting stent in all lesions.
Acetylsalicylic acid (250 mg) was
administered before the procedure. In
centers where prasugrel was available,
an initial dose of 60 mg (including pa-
tients preloaded with clopidogrel) was
administered followed up with a daily
dose of 10 mg. If prasugrel was not
available or contraindicated, clopido-
grel was administered at a loading dose
of 600 mg, followed up with a dose of
75 mg twice daily for 7 days, followed
up with a maintenance dose of 75 mg
once daily. Dual antiplatelet therapy
was prescribed for the duration of at
least 1 year in all patients. Unfraction-
ated heparin was routinely adminis-
tered with a minimal dose of 5000 IE
or a dose of 70 to 100 IU/kg to main-
tain an activated clotting time of 250
seconds. Bivalirudin was adminis-
tered at a dose of 0.75 mg/kg intrave-
nously followed upwith an infusion of
1.75 mg/kg per hour during the dura-
tion of the procedure. The use of gly-
coprotein IIb/IIIa inhibitors was left to
the discretion of the operator.
We assessed creatinine kinase, cre-
atinin kinase-MB, and troponin at ad-
mission and thereafter every 8 hours
until the peak creatinine kinase had
been reached. A 12-lead electrocardio-
gram was performed before the proce-
dure, within 24 hours after the proce-
dure, before discharge, and in case of
recurrent signs of ischemia.
Data Management
Independent study monitors verified
source data according to a prespeci-
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fiedmonitoring plan.15 Datawere stored
in a central database (Cardiobase, Clini-
cal Trials Unit, andDepartment of Car-
diology, BernUniversityHospital, Swit-
zerland, and 2mT, Ulm, Germany).
Follow-up appointments were sched-
uled at 30 days and 1 year, and pa-
tients were questioned about the oc-
currence of angina, any adverse events,
hospitalization, and cardiovascular
medication intake. All serious adverse
eventswere submitted toClinical Trials
Unit, University of Bern, Bern, Swit-
zerland, in a blinded fashion.Anydeath,
reinfarction, revascularization, stent
thrombosis, cerebrovascular accident,
and bleeding event was indepen-
dently adjudicated by a blinded clini-
cal event committee. An independent
data and safety monitoring board
blinded to treatment groups periodi-
cally reviewed all event information and
compared safety outcomes between
groups.
Angiograms were centrally assessed
by the core laboratory at Bern Univer-
sity Hospital by blinded personnel. The
bare-metal stent and biodegradable
polymer-based drug-eluting stent were
indistinguishable on angiography. The
core laboratory assessment encom-
passed quantitative coronary angiog-
raphy using dedicated software (XAan-
gio XA 7.1, Medis) and the assessment
of the SYNTAXMI score,16 and throm-
bolysis in MI (TIMI) flow grade.
Study End Points
The prespecified primary end pointwas
the device-oriented composite of car-
diac death, target vessel–related rein-
farction, and ischemia-driven target-
lesion revascularization at 1 year.
Secondary end points included the pa-
tient-oriented composite of death, any
reinfarction, and any revasculariza-
tion, as well as target vessel–related re-
infarction and any revascularization
(percutaneous and surgical proce-
dures), cardiac death, all-cause mor-
tality, Q-wave and non–Q-wave rein-
farction, stroke, stent thrombosis
according to the definitions of the Aca-
demic Research Consortium, and de-
vice and lesion success. Detailed defi-
nitions of all primary and secondary end
points were reported elsewhere.15
Target-lesion revascularization was
defined as a repeated revasculariza-
tion due to a stenosis within the stent
or within the 5-mm borders proximal
or distal to the stent. Target-vessel re-
vascularization was defined as any re-
peat PCI or surgical bypass of any seg-
ment within the entire major coronary
vessel proximal and distal to a target le-
Figure 1. Trial Profile and Flow of Patients
575 Included in primary analysis
15 Censored at time point of refusal or
lost to follow-up
582 Included in primary analysis
16 Censored at time point of refusal or
lost to follow-up
2575 Patients with STEMI were treated at 11
centers during study inclusion period
575 Randomized to receive biolimus-eluting stent (629 lesions)
570 Received ≥1 biolimus-eluting stent (624 lesions)
3 Did not receive biolimus-eluting stent (3 lesions)
2 Had PCI but did not receive a stent (2 lesions)
1 Received study bare-metal stent only (1 lesion)
2 Received nonstudy bare-metal stent only (2 lesions)
568 Received biolimus-eluting stent only (621 lesions)
1 Received biolimus-eluting stent (1 lesion) and
nonstudy drug-eluting stent (1 lesion)
1 Received biolimus-eluting stent and nonstudy
bare-metal stent in same lesion (1 lesion)
578 Randomized to receive biolimus-eluting stent
3 Provided preliminary consent but refused definite
consent after randomization
583 Randomized to receive bare-metal stent
1 Provided preliminary consent but refused definite
consent after randomization
582 Randomized to receive bare-metal stent (648 lesions)
572 Received ≥1 bare-metal stent (638 lesions)
6 Did not receive bare-metal stent (6 lesions)
3 Had PCI but did not receive a stent (3 lesions)
1 Had no PCI (1 lesion assumed) b
2 Received study biolimus-eluting stent only (2 lesions)
2 Received nonstudy drug-eluting stent only (2 lesions)
2 Received nonstudy bare-metal stent only (2 lesions)
563 Received bare-metal stent only (621 lesions)
9 Received bare-metal stent and biolimus-eluting
stent (17 lesions)
11 Lost to follow-up before 1 year
4 Refused follow-up
542 Alive
18 Died
560 Follow-up for primary clinical end point
available up to 1 year
11 Lost to follow-up before 1 year
5 Refused follow-up
543 Alive
23 Died
566 Follow-up for primary clinical end point
available up to 1 year
1414 Excluded a
1161 Randomized
STEMI indicates ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention.
aA total of 2575 patients underwent primary PCI for treatment of STEMI at 11 international sites during the inclusion period. No reliable data for patients assessed for
eligibility are available.
bOne patient treated with bare-metal stent did not undergo PCI and was assumed to have 1 lesion.
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sion, including upstream and down-
stream branches and the target lesion
itself. A revascularization was consid-
ered ischemia-driven if the diameter ste-
nosis of the treated lesion was at least
50% on the basis of quantitative coro-
nary angiography in the presence of is-
chemic signs or symptoms, or if there
was a diameter stenosis of at least 70%
irrespective of the presence of ische-
mic signs or symptoms.
Statistical Analysis
Our trialwas powered for superiority on
the primary clinical end point at 1 year.
On the basis of theHORIZON-AMI6 and
LEADERS trials,13 we assumed an inci-
dence ofmajor adverse cardiac events of
14%within1year in thebare-metal stent
group and a 40% relative risk reduction
associated with the biolimus-eluting
stent, corresponding to a rate of major
adverse cardiac events of 8.4%. Enroll-
ment of 1064 patients would therefore
provide 80% power to detect a relative
risk of 0.60 with 2-sided =.05.
All analyses were performed accord-
ing to the intention-to-treat principle,
with inclusion of all randomized pa-
tients in the analysis according to the
group they were originally allocated.
Cox proportional hazards regression
models were used to compare clinical
outcomes between the groups, with pa-
tients censored at the time of their last
known contact. Correspondingly, we
constructed time-to-event curves using
Kaplan-Meier estimates and the pro-
portional hazards assumption was
tested and met in each case.
Categorical variables are reported as
numbers and percentages, and groups
are compared using 2 or Fisher exact
tests (low counts). Continuous vari-
ables are reported as means ±standard
deviations, and groups are compared
using unpaired t tests. Times are re-
ported asmedians (interquartile ranges
[IQRs]), and groups are compared
using Wilcoxon Mann-Whitney rank
sum test.
We prespecified stratified analyses of
the primary end point at 1 year accord-
ing to age, sex, diabetes, renal failure, le-
sion length, and vessel size. In addition,
we performed post hoc analyses strati-
fied according to left ventricular ejec-
tion fraction, left anterior descending ar-
tery lesion localization, preprocedural
TIMI flow, time from pain onset to bal-
loon time, thrombusaspiration, andmul-
tivessel treatment. All stratified analy-
ses were accompanied by tests for
Table 1. Baseline Clinical Characteristics of Patients Receiving Either Biolimus-Eluting Stents
or Bare-Metal Stentsa
Characteristics
Biolimus-Eluting Stents
(n = 575)
Bare-Metal Stents
(n = 582)
Patients
Age, mean (SD), y 60.7 (11.6) 60.4 (11.9)
Male sex 463 (80.5) 455 (78.2)
BMI, mean (SD) 27.3 (4.5) 27.2 (4.0)
Cardiovascular risk factors
Diabetes 84 (14.6) 90 (15.5)
Hypertension 279 (48.5) 265 (45.5)
Hyperlipidemia 324 (56.6) 328 (56.7)
Current smoker 272 (47.9) 301 (52.3)
Family history of CAD 193 (34.3) 179 (31.3)
Renal failure 79 (14.1) 86 (15.1)
Previous MI 31 (5.4) 32 (5.5)
Previous PCI 19 (3.3) 27 (4.6)
Previous CABG surgery 10 (1.7) 4 (0.7)
Laboratory findings
Anemia 87 (15.6) 79 (13.9)
Thrombocytopenia 22 (4.0) 30 (5.3)
Clinical presentation
Time to balloon inflation, median (IQR), min
From symptom onset 232 (164-380) 236 (163-400)
0-6 421 (73.2) 421 (72.6)
6-12 109 (19.0) 100 (17.2)
12-24 45 (7.8) 59 (10.2)
From hospital admission 44 (32-70) 44 (32-74)
Killip class II, III, or IV, No./total No. (%) 40 (7.0) 37 (6.4)
Resuscitation before hospital arrival 16 (2.8) 9 (1.5)
LVEF, mean (SD), %b 49 (11) 50 (10)
Electrocardiographic localization of MI
Anterior 211 (36.9) 213 (36.9)
Lateral 18 (3.1) 13 (2.2)
Inferior 236 (41.3) 249 (43.1)
Posterior 29 (5.1) 23 (4.0)
Inferior and posterior 78 (13.6) 80 (13.8)
Right ventricular MI 52 (9.1) 55 (9.5)
Lesion complexityc
Bifurcation lesion 52 (9.0) 49 (8.4)
Small vessel 74 (12.9) 79 (13.7)
Long lesion 204 (35.7) 183 (31.7)
SYNTAX MI score, mean (SD)d 15.1 (8.2) 14.8 (8.1)
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index, calculated as weight in kilograms divided
by height in meters squared; CABG, coronary artery bypass graft; CAD, coronary artery disease; IQR, interquartile
range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
aData are expressed as No. (%) unless otherwise specified. Anemia was defined as a hemoglobin concentration of
less than 120 g/L for women and less than 130 g/L for men, according to the definition of the World Health Orga-
nization. Thrombocytopenia was defined as less than 150 000 platelets/µL. Renal failure was defined as glomerular
filtration rate of less than 60 mL/min.
bLeft ventricular function as assessed by angiography or by echocardiography, in case angiography was not available.
cSmall vessel indicates reference vessel diameter of 2.5 mm or less and long lesion is a lesion length of 20 mm or
more.
dSYNTAX score was assessed before recanalization according to Magro et al.16 The SYNTAX score provides a nu-
merical score summarizing a comprehensive angiographic assessment of the entire coronary artery tree, with higher
scores indicating increasing complexity of CAD. In the absence of significant CAD (absence of a stenosis 50% in
a vessel with a reference diameter1.5 mm), the score amounts to 0. The score increases with more complex CAD.
The highest score as reported in the SYNTAX trial amounted to 84.17
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interaction between stent type and sub-
group. Therewere positive treatment
patient characteristics interactions for age
and sex. In view of a correlation be-
tween age and sex (P .001), we ex-
plored treatmentage interactions sepa-
rately in men and women. All analyses
were performed with STATA version
12.1 (StataCorp) and2-sidedP.05was
considered statistically significant.
RESULTS
A total of 1161 patients were ran-
domly assigned to receive biolimus-
eluting stents with biodegradable poly-
mer (578 patients) or bare-metal stents
(583 patients). Three patients allo-
cated to the biolimus-eluting stent and
1 patient allocated to the bare-metal
stent did not confirm their initial writ-
ten consent and had to be excluded, re-
sulting in 575 patientswith 629 infarct-
vessel lesions randomly assigned to
biolimus-eluting stents and 582 pa-
tients with 648 infarct-vessel lesions
randomly assigned to bare-metal stents
for final analyses (FIGURE 1). A total of
31 patients refused or were lost to fol-
low-up at a median of 31 days in the
biolimus-eluting stent group and 32
days in the bare-metal stent group.
Baselinemedications and clinical, an-
giographic, and procedural character-
istics were similar in both groups
(TABLE 1, TABLE 2, and TABLE 3). The
mean (SD) age of patients was 60.6
(11.8) years and 79% were men. The
median (IQR) time from symptom
onset to balloon inflationwas 234 (164-
386)minutes and fromhospital admis-
sion to balloon inflation was 44 (32-
72)minutes. Thrombus aspirationwas
performed in 62% of patients and 47%
received a glycoprotein IIb/IIIa antago-
nist during the procedure. No differ-
enceswere observed in lesion complex-
ity between both groups including the
SYNTAX MI score (mean, 15; SD, 8).
At discharge, 43% of patients received
prasugrel and 57% of patients re-
ceived clopidogrel. The use of dual an-
tiplatelet therapy was high and bal-
anced in both treatment groups
throughout the entire follow-up pe-
riod up to 1 year (Table 2).
Clinical outcomes during follow-up
are shown inTABLE 4. At 1 year, the pri-
mary end point of major adverse car-
diac events (cardiac death, target vessel–
related reinfarction, and ischemia-
driven target-lesion revascularization)
occurred in 4.3% of patients receiving
biolimus-eluting stents and 8.7% of pa-
tients receiving bare-metal stents (haz-
ard ratio [HR], 0.49; 95% CI, 0.30-
0.80; P=.004) (FIGURE 2A). For cardiac
death alone, the percentages were
smaller (2.9% of patients received bio-
limus-eluting stents and 3.5% of pa-
tients received bare-metal stents; HR,
0.81; 95% CI, 0.42-1.56; P = .53)
(Figure 2B). The treatment effect in fa-
vor of patients receiving biolimus-
eluting stents was attributable to both
a lower risk of target vessel–related re-
infarction (0.5%vs 2.7%;HR, 0.20; 95%
CI, 0.06-0.69; P=.01) (Figure 2C) and
ischemia-driven target-lesion revascu-
larization (1.6% vs 5.7%;HR, 0.28; 95%
CI, 0.13-0.59; P .001) (Figure 2D).
Differences between stent typeswith re-
spect to the primary outcome emerged
early and continued throughout the
study period.
Among patients treated with bioli-
mus-eluting stents, 3 target vessel–
related reinfarctions resulted fromdefi-
Table 2. Medication Use Among Patients Receiving Either Biolimus-Eluting Stents or
Bare-Metal Stentsa
Medications
Biolimus-Eluting Stents
(n = 575)
Bare-Metal Stents
(n = 582)
During primary PCI
Unfractionated heparin 510 (88.7) 523 (89.9)
Bivalirudin 74 (12.9) 67 (11.5)
Low molecular weight heparin 19 (3.3) 19 (3.3)
Glycoprotein IIb/IIIa antagonists 276 (48.0) 266 (45.7)
Loading dose of clopidogrel and prasugrel
None 2 (0.3) 6 (1.0)
Clopidogrel only (600 mg) 320 (55.8) 330 (57.0)
Prasugrel only (60 mg) 104 (18.2) 110 (19.0)
Both 126 (22.0) 128 (22.1)
At discharge
Acetylsalicylic acid 568 (99.8) 576 (99.7)
Clopidogrel 323 (56.8) 327 (56.6)
Prasugrel 245 (43.1) 248 (42.9)
Any dual antiplatelet therapy 567 (99.6) 574 (99.3)
-Blockers 491 (86.3) 476 (82.4)
ACE inhibitors or receptor blockers 410 (72.1) 411 (71.1)
Statins 559 (98.2) 571 (98.8)
At 30 d
Acetylsalicylic acid 555 (99.3) 565 (99.1)
Clopidogrel 323 (57.6) 322 (56.5)
Prasugrel 241 (43.0) 245 (43.0)
Any dual antiplatelet therapy 554 (98.9) 559 (98.1)
-Blockers 487 (87.0) 482 (84.6)
ACE inhibitors or receptor blockers 396 (70.7) 401 (70.4)
Statins 534 (95.5) 550 (96.5)
At 1 y
Acetylsalicylic acid 529 (97.6) 524 (96.3)
Clopidogrel 284 (52.4) 266 (48.9)
Prasugrel 214 (39.6) 222 (40.8)
Any dual antiplatelet therapy 488 (90.0) 478 (87.9)
-Blockers 435 (80.4) 428 (78.8)
ACE inhibitors or receptor blockers 330 (61.0) 338 (62.2)
Statins 496 (91.7) 506 (93.2)
Abbreviations: ACE, angiotensin-converting enzyme; PCI, percutaneous coronary intervention.
aData are expressed as No. (%). Two-sided P values were calculated using 2 or Fisher exact texts (all P .07).
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nite stent thrombosis in 2 patients and
restenosis in 1 patient. Among pa-
tients treatedwith bare-metal stents, 15
target vessel–related reinfarctions re-
sulted from definite stent thrombosis
in 10 patients, restenosis in 4 patients,
and spontaneous MI in 1 patient. The
risk of target vessel–related reinfarc-
tion associated with stent thrombosis
or restenosis was lower among pa-
tients treated with biolimus-eluting
stents vs bare-metal stents (HR, 0.22;
95% CI, 0.06-0.75; P=.02).
The findings for the primary end
point were consistent across stratified
analyses for diabetes, renal failure, left
ventricular ejection fraction, left ante-
rior descending artery, thrombus aspi-
ration, time from pain onset to bal-
loon inflation, multivessel treatment,
small vessel disease, and lesion length
(FIGURE 3). A significant interaction
with stent typewas observed for age and
sex. Men were on average 6.5 years
younger than women. In exploratory
analyses, we foundHRs below the point
estimate of the primary end point in the
overall cohort (HR=0.49) in women
younger than 65 years (HR, 0.40; 95%
CI, 0.80-1.95), inmen younger than 65
years (HR, 0.25; 95% CI, 0.10-0.61),
and inmen 65 years or older (HR, 0.43;
95% CI, 0.16-1.11), but not in women
65 years or older (HR, 1.89; 95% CI,
0.65-5.54).
At 1 year, rates of definite stent throm-
bosis amounted to 0.9% among pa-
tients receiving biolimus-eluting stents
and2.1%amongpatients receiving bare-
metal stents (HR, 0.42; 95% CI, 0.15-
1.19; P=.10). Five patients treated with
biolimus-eluting stents experienceddefi-
nite stent thrombosis while receiving
dual antiplatelet therapy,whereas 12pa-
tients treated with bare-metal stents ex-
perienceddefinite stent thrombosiswith
11 patients receiving dual antiplatelet
therapy and 1 patient not taking acetyl-
salicylic acid and clopidogrel. We ob-
servednodifferences inall-causeandcar-
diac mortality between the groups at 1
year. In addition to the device-oriented
primary outcome measure, we re-
corded a lower risk of the comprehen-
sivepatient-oriented composite of death,
Table 3. Angiographic and Procedural Characteristics of Patients Receiving Either
Biolimus-Eluting Stents or Bare-Metal Stentsa
Characteristics
Biolimus-Eluting Stents
(n = 629)
Bare-Metal Stents
(n = 648)
P
Value
Lesions
Treated in infarct vessel, No. 629 648b
Treated per patient, mean (SD) 1.1 (0.3) 1.1 (0.4) .61
2 treated in infarct vessel 49 (8.5) 59 (10.1) .34
Infarct vessel localization
Left main coronary artery 2 (0.3) 1 (0.2)
Left anterior descending artery 226 (39.3) 230 (39.6)
Left circumflex artery 82 (14.3) 90 (15.5) .74
Right coronary artery 264 (45.9) 259 (44.6)
Saphenous vein graft 1 (0.2) 1 (0.2)
Baseline TIMI flow
0 or 1 437 (69.6) 423 (65.6)
2 81 (12.9) 95 (14.7) .31
3 110 (17.5) 127 (19.7)
Baseline quantitative coronary angiographic data
Reference vessel diameter, mm
Mean (SD) 3.04 (0.47) 3.01 (0.46) .17
Median (IQR) 3.02 (2.72-3.33) 2.97 (2.67-3.29) .17
Minimum lumen diameter, mm
Mean (SD) 0.42 (0.59) 0.44 (0.57) .47
Median (IQR) 0 (0-0.80) 0 (0-0.88) .41
Diameter stenosis, %
Mean (SD) 86.44 (18.37) 85.24 (18.37) .25
Median (IQR) 100.0 (72.6-100.0) 100.0 (70.4-100.0) .21
Lesion length, mm
Mean (SD) 18.19 (9.73) 17.77 (9.57) .44
Median (IQR) 15.46 (11.79-21.97) 15.63 (11.52-21.30) .46
Primary PCI procedure
No. of stents per lesion, mean (SD) 1.32 (0.61) 1.26 (0.60) .16
Type of stentc
Study biolimus-eluting 623 (99.4) 12 (1.9) .001
Other drug-eluting 0 2 (0.3) .50
Study bare-metal 1 (0.2) 633 (98.3) .001
Other bare-metal 4 (0.6) 2 (0.3) .44
No stent implanted 2 (0.3) 4 (0.6) .69
Stent length per lesion, mean (SD), mm 25.2 (12.7) 24.1 (12.3) .10
Stent diameter per lesion, mean (SD), mm 3.2 (0.4) 3.2 (1.1) .42
Direct stenting 236 (37.6) 240 (37.3) .89
Maximal balloon pressure, mean (SD), atm 15.2 (3.5) 15.1 (3.4) .50
Overlapping stents 148 (23.6) 120 (18.7) .03
Thrombus aspiration 350 (60.9) 374 (64.4) .22
Intraaortic balloon counterpulsation 14 (2.4) 15 (2.6) .88
Intravenous vasopressors 18 (3.1) 19 (3.3) .90
TIMI flow
0 or 1 3 (0.5) 3 (0.5)
2 25 (4.0) 32 (5.0) .70
3 601 (95.5) 611 (94.6)
Postprocedural QCA, mean (SD)
Reference vessel diameter, mm 3.06 (0.50) 3.02 (0.48) .07
Minimum lumen diameter, mm 2.59 (0.50) 2.56 (0.48) .19
Diameter stenosis, % 15.53 (8.35) 15.22 (7.81) .49
Abbreviations: IQR, interquartile range; PCI, percutaneous coronary intervention; QCA, quantitative coronary angiography;
TIMI, thrombolysis in myocardial infarction.
aData are expressed as No. (%) unless otherwise specified. Two-sided P values were calculated using a 2 test for cat-
egorical variables and using t test for continuous variables.
b Includes 1 patient randomly allocated to bare-metal stents who had no PCI and where 1 lesion was assumed; 2 patients
randomly allocated to biolimus-eluting stents and 1 patient randomly allocated to bare-metal stents did not have QCA
due to missing angiography cardiovascular disease.
c In 1 patient who was randomly allocated to the biolimus-eluting stent group, a biolimus-eluting stent and a bare-metal
stent were implanted within the same lesion; and in 5 patients who were randomly allocated to the bare-metal stent
group, a biolimus-eluting stent and a bare-metal stent were implanted within the same lesion.
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any reinfarction, and any revasculariza-
tion in favor of biolimus-eluting stents
(8.4%vs 12.2%;HR, 0.68; 95%CI, 0.47-
0.98; P=.04).
Staged procedures were performed
after a median duration of 12.0 days
(IQR, 4.0-41.5 days) among patients
treatedwith biolimus-eluting stents and
after amedian duration of 6 days (IQR,
3-33 days;P=.25). A total of 1 ischemia-
driven target-lesion revascularization
was associated with a staged proce-
dure in the biolimus-eluting stent group
compared with 2 ischemia-driven tar-
get-lesion revascularization events in
the bare-metal stent group.
COMMENT
In this randomized, multicenter, asses-
sor-blinded trial in patientswith STEMI,
compared with the use of bare-metal
stents, the use of biolimus-eluting stents
with a biodegradable polymer was as-
sociated with a significant 4.4% abso-
lute reduction and 51% relative reduc-
tion in the risk ofmajor adverse cardiac
events at 1 year, which prevents 42
events per 1000 patients treated with
biolimus-eluting stents comparedwith
bare-metal stents at 1 year. Findings
were also robust for the more compre-
hensive patient-oriented composite of
any death, reinfarction, or revascular-
ization. Accordingly, our results sug-
gest better clinical outcomes in terms
of major adverse cardiac events of a
stent releasing biolimus from a biode-
gradable polymer compared with a
bare-metal stent for the treatment of pa-
tients with STEMI.
In the single largest trial enrolling pa-
tients with STEMI,6 paclitaxel-eluting
stents resulted in a 41% lower risk of
target-lesion revascularization com-
pared with bare-metal stents. In our
trial, biolimus-eluting stents were as-
sociated with a 4.9% absolute reduc-
tion and a 72% relative reduction in the
risk of ischemia-driven target-lesion re-
vascularization compared with bare-
metal stents. This risk reduction is no-
table as repeat revascularizations were
due to recurrent ischemia in the ab-
sence of protocol-mandated angio-
graphic follow-up before assessment of
the primary end point at 1 year. Rates
of revascularization with the biolimus-
eluting stent in our study were lower
than in the LEADERS trial,13 which en-
rolled patients with a broad spectrum
of indications and lesions. Explana-
tions for this finding include the larger
reference vessel diameter in vessels
causing acute MI (3.0 vs 2.6 mm) and
the lack of routine angiographic follow-
up, as well as less ischemia in vessels
subtending previously infarcted myo-
cardium.13
Despite a similar risk profile and
mortality in our study compared with
patients with STEMI enrolled into pre-
vious large-scale randomized trials,5,6we
observed a lower absolute rate of re-
peat revascularization in both treat-
ment groups. This observation is con-
sistent with a recent trial comparing
newer-generation everolimus-eluting
stentswith bare-metal stents among pa-
tients with STEMI18 and is potentially
related to improved lesion prepara-
tion due to thrombus aspiration19 and
more potent antithrombotic medica-
tions, such as prasugrel,20 reducing the
risk of stent thrombosis–related revas-
cularization. Notwithstanding, the ab-
solute risk reduction of 4.1% in our trial
means that 24 patients need to be
treated with biolimus-eluting stents to
prevent 1 major adverse cardiac event.
Differences in favor of biolimus-
eluting stents over bare-metal stents in
our study with respect to the primary
end point were not limited to efficacy
but also driven by an 80% lower risk
of target vessel–related reinfarction.
This difference in safety has not been
observed in previous randomized trials
comparing drug-eluting and bare-
metal stents among patients with
STEMI,5,6,21-26 but is consistent with the
findings of a recent meta-analysis12 re-
porting a lower risk of reinfarction dur-
ing the first year with a number needed
Table 4. Clinical Outcomes at 1 Year of Patients Receiving Either Biolimus-Eluting Stents or
Bare-Metal Stentsa
Clinical Outcomes
No. (%) of Patients
Hazard Ratio
(95% CI)
P
Value
Biolimus-Eluting
Stents
(n = 575)
Bare-Metal
Stents
(n = 582)
Death 18 (3.2) 23 (4.1) 0.79 (0.43-1.47) .46
Cardiac death 16 (2.9) 20 (3.5) 0.81 (0.42-1.56) .53
Reinfarction 11 (2.0) 21 (3.7) 0.53 (0.25-1.09) .08
Q-wave 2 (0.4) 7 (1.2) 0.29 (0.06-1.39) .12
Non–Q-wave 9 (1.6) 14 (2.5) 0.65 (0.28-1.50) .31
Target vessel–related reinfarction 3 (0.5) 15 (2.7) 0.20 (0.06-0.69) .01
Q-wave 1 (0.2) 7 (1.2) 0.14 (0.02-1.17) .07
Non–Q-wave 2 (0.4) 8 (1.4) 0.25 (0.05-1.19) .08
Cardiac death or target vessel–related
reinfarction
19 (3.4) 32 (5.7) 0.60 (0.34-1.05) .07
Any target-lesion revascularization 9 (1.6) 34 (6.0) 0.26 (0.13-0.55) .001
Ischemia-driven target-lesion
revascularization
9 (1.6) 32 (5.7) 0.28 (0.13-0.59) .001
Any target-vessel revascularization 11 (2.0) 37 (6.5) 0.30 (0.15-0.58) .001
Ischemia-driven target-vessel
revascularization
11 (2.0) 35 (6.2) 0.31 (0.16-0.62) .001
Major adverse cardiac eventsb 24 (4.3) 49 (8.7) 0.49 (0.30-0.80) .004
Death, any reinfarction, any
revascularization
47 (8.4) 69 (12.2) 0.68 (0.47-0.98) .04
Stroke 6 (1.1) 4 (0.7) 1.52 (0.43-5.40) .51
Stent thrombosis
Definite 5 (0.9) 12 (2.1) 0.42 (0.15-1.19) .10
Definite or probable 14 (2.5) 21 (3.7) 0.67 (0.34-1.32) .25
aHazard ratios are derived from Cox proportional hazard regression models. P values are 2-sided from superiority testing
with a 2 test.
bComposite of cardiac death, target vessel–related reinfarction, and ischemia-driven target-lesion revascularization.
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to treat of 79 compared with 45 in our
study.
In exploring the mechanism for the
lower risk of target vessel–related rein-
farction, we observed that the device-
related adverse events definite stent
thrombosis or target-lesion revascular-
ization due to restenosis were respon-
sible for target vessel–related reinfarc-
tion in 17 of 18 cases and were less
common among patients receiving bio-
limus-eluting stents than patients re-
ceiving bare-metal stents (3 vs 14, re-
spectively;P=.01). In contrastwithmost
previous trials among patients with
STEMI,dual antiplatelet therapywasbal-
anced between patients receiving bioli-
mus-eluting stents and those receiving
bare-metal stents throughout the en-
tire study period rendering differences
in antiplatelet therapy unlikely as an ex-
planation for the differential in target
vessel–related reinfarction.
We found positive interactions be-
tween stent type and age and sex. Be-
cause age and sex were correlated, we
further explored these interactions and
found estimated HRs below the point
estimate of the primary end point for
the overall cohort (HR = 0.49) in
younger women and men irrespective
of age, but not in women aged 65 years
or older. It is unclear whether our re-
sults reflect a lack of benefit in women
or in those aged 65 years or older, or
in the subgroup of elderly women only.
We are unaware of biological mecha-
nisms that might explain interactions
with age or sex, and in view of the lack
of mechanisms and the large number
of stratified analyzes, chance should also
be considered as an explanation of our
findings.
A numerically lower rate of definite
stent thrombosis was observed (0.9%
vs 2.1%, P=.10) with the use of bioli-
mus-eluting stents vs bare-metal stents
at 1 year, with most events occurring
during the peri-interventional period.
Although this finding has to be inter-
preted cautiously, a similar statisti-
cally nonsignificant reduction at up to
1 year among patients with STEMI has
been observed in a recent meta-
Figure 2. Kaplan-Meier Curves for Major Adverse Cardiac Events, Cardiac Death, Target Vessel–Related Reinfarction, and Ischemia-Driven
Target-Lesion Revascularization Among Patients Randomized to Receive Either the Biolimus-Eluting Stent or the Bare-Metal Stent
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Major adverse cardiac events included a composite of cardiac death, target vessel–related reinfarction, and ischemia-driven target-lesion revascularization. P values are
2-sided from Cox proportional hazards regression models 2 test. HR indicates hazard ratio.
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analysis12 comparing early generation
drug-eluting stents with bare-metal
stents. Moreover, a significant reduc-
tion in the risk of stent thrombosis has
been reported in the EXAMINATION
trial18 comparing newer-generation
everolimus-eluting stents with bare-
metal stents (0.5% vs 1.9%, P=.01). Ex-
perimental data indicate lower throm-
bogenicity of drug-eluting stents
compared with bare-metal stents sug-
gesting a possible thromboresistant ef-
fect of polymer coatings during the im-
mediate peri-interventional period.27
The latter may be particularly impor-
tant among patients with STEMI who
carry a higher baseline risk of stent
thrombosis due to a large thrombus
burden9 and increased platelet activa-
tion.28
In addition, biolimus is the limus
analogue with the highest lipophilic-
ity used for drug elution on currently
available stent platforms.29 Among pa-
tients with STEMI, the acute coronary
lesions predominantly consist of lipid-
rich, ruptured plaques with large ne-
crotic cores.30 Theoretically, the in-
creased lipophilicity of the drug
biolimusmay provide amore rapid and
homogeneous drug distribution, po-
tentially leading to a more potent anti-
inflammatory and antithrombotic lo-
cal effect. However, this hypothesis
requires validation in dedicated stud-
ies assessing the properties of various
drugs used for elution on drug-
eluting stents in the presence of lipid-
rich plaques.
Figure 3. Subgroup Analyses of the 1-Year Rates of Major Adverse Cardiac Events Among Patients Randomized to Receive Either the
Biolimus-Eluting Stent or the Bare-Metal Stent
Favors
Biolimus-Eluting
Stents
Favors
Bare-Metal
Stents
0.05 41.00.1
Hazard Ratio (95% CI)
Major Adverse Cardiac
Events, No.
Biolimus-Eluting
Stents
Bare-Metal
Stents
Major Adverse Cardiac
Events,  Total No.
Biolimus-Eluting
Stents
Bare-Metal
Stents P Value
Hazard Ratio
(95% CI)
P for
Interaction
Age, y
8 30 370 381<65 .0010.27 (0.12-0.59)
16 19 205 201≥65 .580.83 (0.43-1.61)
.03
BMI
18 30 447 441<30 .070.58 (0.33-1.05)
5 17 122 136≥30 .030.32 (0.12-0.87)
.31
LVEF, %
17 22 248 215<50 .220.67 (0.36-1.26)
6 21 290 322≥50 .010.31 (0.13-0.77)
.17
Reference vessel diameter, mm
5 8 74 79≤2.50 .500.68 (0.22-2.07)
19 41 498 501>2.50 .0050.46 (0.27-0.79)
.53
Lesion length, mm
10 19 204 184≥20 .040.46 (0.21-0.98)
14 30 368 396<20 .030.50 (0.27-0.95)
.85
Sex
12 37 463 455Male <.0010.31 (0.16-0.60)
12 12 112 127Female .741.14 (0.51-2.55)
.01
Diabetes
8 9 84 90Yes .920.95 (0.37-2.47)
16 40 491 492No .0020.39 (0.22-0.70)
.13
Infarct lesion in left anterior descending artery
12 24 238 239Yes .0480.50 (0.25-0.99)
12 25 337 342No .040.48 (0.24-0.96)
.95
Thrombus aspiration
13 34 350 374Yes .0050.40 (0.21-0.76)
11 15 225 207No .310.67 (0.31-1.46)
.32
Multivessel treatment
2 5 32 35Yes .280.41 (0.08-2.10)
22 44 543 546No .0070.50 (0.30-0.83)
.83
Preprocedural TIMI flow
20 33 430 4070-1 .0470.57 (0.33-0.99)
4 16 144 1722-3 .030.29 (0.10-0.86)
.28
Pain onset to balloon, h
21 41 530 5210-12 .0090.50 (0.29-0.84)
3 8 45 5912-24 .310.50 (0.13-1.89)
.99
Renal failure
2 7 79 86Yes .140.30 (0.06-1.46)
21 42 483 483No .0080.49 (0.29-0.83)
.56
BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); LVEF, left ventricular ejection fraction; TIMI, thrombolysis in
myocardial infarction. Two patients randomized to receive the biolimus-eluting stent and 1 patient randomized to receive the bare-metal stent could not be included
in the stratified analyses for lesion characteristics (reference vessel diameter and lesion length) due to missing angiography.
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Our results have to be interpreted in
view of the following limitations. First,
the trial indicated superiority on the pri-
mary composite outcome but was not
powered to address individual compo-
nents of efficacy or safety. Moreover,
observed event rates were lower than
anticipated. In view of the size of the
observed treatment effect and results of
previous trials, we consider it unlikely
that estimates of efficacy would sub-
stantially differ in a larger patient co-
hort. The inclusion of safety out-
comes in the primary composite
outcome ismeaningful as cardiac death
or target vessel–related reinfarctionmay
be device related. Event rates of car-
diac death or target vessel–related re-
infarctionwere of similarmagnitude as
ischemia-driven target-lesion revascu-
larization in our trial providing a simi-
lar weight of efficacy and safety param-
eters within the composite end point.
Second, the biolimus-eluting stent
used in our study is currently not ap-
proved by the US Federal Drug Admin-
istration and not considered as stan-
dard of care in the United States. The
biolimus-eluting stent has been shown
to be noninferior comparedwith the si-
rolimus-elutingCYPHER stent in a ran-
domized trial of 1707 all-comer pa-
tients for the composite clinical end
point of major adverse events at 9
months and 4 years.13,14 On the basis of
these data, the biolimus-eluting stent
is recommended as one of a few drug-
eluting stents for clinical use in the Eu-
ropean guidelines on myocardial re-
vascularization.31 It remains to be
determinedhow this stent platformper-
forms compared with newer-genera-
tion durable polymer-based drug-
eluting stents. Similarly, the optimal
duration of dual antiplatelet therapy af-
ter implantation of biolimus-eluting
stentswith a biodegradable polymer has
not been established.
Third, althoughour trial had very few
exclusion criteria, the results apply only
to patients with characteristics similar
to those enrolled. Patientswhowere un-
able to provide written informed con-
sent before the procedure had to be ex-
cluded from participation in this trial
introducing an element of selectionbias.
Because no reliable data for reasons
leading to patient exclusion were col-
lected, we cannot determine the pro-
portion of patients excludeddue to poor
clinical condition and those refusing
participation in the trial.
Fourth, the P2Y12 inhibitor prasu-
grel was administered instead of clopi-
dogrel in 40% of patients andmay have
contributed to the low overall event
rates in our study. Although the use of
prasugrel was higher than in previous
trials comparing drug-eluting stents
with bare-metal stents among patients
with STEMI, it conforms to the recom-
mendations of the American College of
Cardiology/American Heart Associa-
tion guidelines for the management of
STEMI and reflects contemporary prac-
tice.
Fifth, our study does not address late
events beyond 1 year. However, in a
previous study,14 biolimus-eluting
stents were shown to reduce the risk of
stent thrombosis beyond 1 year by 80%
compared with early generation siro-
limus-eluting stents providing sup-
port for the improved long-term bio-
compatibility of drug-eluting stentswith
biodegradable polymer coatings.
In conclusion, comparedwith a bare-
metal stent, the use of a biolimus-
eluting stentwith a biodegradable poly-
mer resulted in a lower rate of the
composite of major adverse cardiac
events at 1 year among patients with
STEMI undergoing primary PCI.
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7.2 New generation DES in patients with ST-elevation myocardial infarction:  A pooled analysis
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Objectives This study sought to study the efficacy and safety of newer-generation drug-eluting stents
(DES) compared with bare-metal stents (BMS) in an appropriately powered population of patients with
ST-segment elevation myocardial infarction (STEMI).
Background Among patients with STEMI, early generation DES improved efficacy but not safety
compared with BMS. Newer-generation DES, everolimus-eluting stents, and biolimus A9-eluting stents,
have been shown to improve clinical outcomes compared with early generation DES.
Methods Individual patient data for 2,665 STEMI patients enrolled in 2 large-scale randomized
clinical trials comparing newer-generation DES with BMS were pooled: 1,326 patients received
a newer-generation DES (everolimus-eluting stent or biolimus A9-eluting stent), whereas the
remaining 1,329 patients received a BMS. Random-effects models were used to assess differences
between the 2 groups for the device-oriented composite endpoint of cardiac death, target-vessel
reinfarction, and target-lesion revascularization and the patient-oriented composite endpoint of
all-cause death, any infarction, and any revascularization at 1 year.
Results Newer-generation DES substantially reduce the risk of the device-oriented composite
endpoint compared with BMS at 1 year (relative risk [RR]: 0.58; 95% confidence interval [CI]: 0.43
to 0.79; p ¼ 0.0004). Similarly, the risk of the patient-oriented composite endpoint was lower with
newer-generation DES than BMS (RR: 0.78; 95% CI: 0.63 to 0.96; p ¼ 0.02). Differences in favor of newer-
generation DES were driven by both a lower risk of repeat revascularization of the target lesion (RR:
0.33; 95% CI: 0.20 to 0.52; p < 0.0001) and a lower risk of target-vessel infarction (RR: 0.36; 95% CI: 0.14
to 0.92; p ¼ 0.03). Newer-generation DES also reduced the risk of definite stent thrombosis (RR: 0.35;
95% CI: 0.16 to 0.75; p ¼ 0.006) compared with BMS.
Conclusions Among patients with STEMI, newer-generation DES improve safety and efficacy
compared with BMS throughout 1 year. It remains to be determined whether the differences in favor
of newer-generation DES are sustained during long-term follow-up. (J Am Coll Cardiol Intv
2014;7:55–63) ª 2014 by the American College of Cardiology Foundation
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262  Chapter 7.2
Early generation drug-eluting stents (DES), namely,
sirolimus-eluting stents and paclitaxel-eluting stents, have
been compared with bare-metal stents (BMS) in the clinical
setting of ST-segment elevation myocardial infarction
(STEMI) in several randomized controlled trials and
consistently showed a reduction in major adverse cardiac
events mainly related to a lower risk of repeat revasculari-
zation procedures (1–6).
Notwithstanding, concerns regarding the safety of DES in
STEMI patients have been repeatedly raised: pathological
analysis of autopsy specimens have revealed more inflam-
mation, fibrin deposition, and uncovered struts among lesions
treated with early generation DES in patients with acute
myocardial infarction compared with those with stable
lesions, suggesting a differential healing response depending
on the underlying plaque morphology (7). Intracoronary in
vivo imaging studies have further substantiated these find-
ings, highlighting an impaired
healing process of DES im-
planted in thrombotic compared
with stable lesions (8).
Newer-generation devices with
drug release from durable or
biodegradable polymer surface
coating may provide the basis for
improved biocompatibility and
vascular healing (9). The EXAM-
INATION (clinical Evaluation
of the Xience-V stent in Acute
Myocardial INfArcTION) and
COMFORTABLE-AMI (Com-
parison of Biolimus Eluted From
an Erodible Stent Coating With
Bare Metal Stents in Acute
ST-Elevation Myocardial Infarc-
tion) trials have tested the efficacy
of everolimus eluted fromdurable polymer (everolimus-eluting
stent [EES]) and of biolimus A9 eluted from biodegradable
polymer (biolimusA8–eluting stent [BES]) stents versusBMS,
respectively, in an all-comer STEMI population (10–13).
Whereas the EXAMINATION trial showed a significant
reduction in stent thrombosis with the EES (0.9% vs. 2.5%,
p ¼ 0.019), the COMFORTABLE-AMI trial demon-
strated a significant reduction in major adverse cardiac
events with the BES (4.3% vs. 8.7%, p ¼ 0.004) compared
with BMS. Nevertheless, neither of these 2 trials had a
sample size sufficiently powered to achieve all the safety and
efficacy endpoints.
We sought, therefore, to determine whether the benefits
of newer DES translate into improved safety compared with
BMS among patients with STEMI in an appropriately
powered patient population.
Methods
Patient population. We performed a patient-level pooled
analysis of the 2 largest multicenter, randomized clinical
trials comparing newer-generation DES, with either dura-
ble or biodegradable polymer, with BMS (Multilink
Vision, Abbott, Santa Clara, California; the Gazelle stent,
Biosensors Europe SA, Morges, Switzerland) in STEMI:
the EXAMINATION and the COMFORTABLE-AMI
trials. Detailed descriptions relating to the design of the 2
trials were reported elsewhere (12,13).
Procedural medications. During the procedure, all patients
received unfractionated heparin or bivalirudin, whereas
the use of glycoprotein IIb/IIIa antagonists was left at the
discretion of the operators. In the EXAMINATION trial,
all patients received aspirin (loading dose of 250 to 500 mg
and maintenance dose of 100 mg/day) and clopidogrel
(loading dose of at least 300 mg and maintenance dose of 75
mg/day). Neither prasugrel nor ticagrelol was approved
during the recruitment period. In the COMFORTABLE-
AMI, in the centers where prasugrel was available, an initial
dose of 60 mg (including patients pre-loaded with clopi-
dogrel) was administered followed by a daily dose of 10 mg.
If prasugrel was not available or contraindicated, clopidogrel
was administered at a loading dose of 600 mg, followed by
a dose of 75 mg twice daily for 7 days, and a maintenance
dose of 75 mg once daily thereafter. Dual antiplatelet
therapy was prescribed in both trials for at least 1 year in all
patients.
Endpoints and definitions. Pre-specified endpoints of this
analysis were the device-oriented composite endpoint
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Abbreviations
and Acronyms
BES = biolimus A9–eluting
stent(s)
BMS = bare-metal stent(s)
CI = confidence interval
DES = drug-eluting stent(s)
DOCE = device-oriented
composite endpoint
EES = everolimus-eluting
stent(s)
HR = hazard ratio
POCE = patient-oriented
composite endpoint
RR = relative risk
STEMI = ST-segment
elevation myocardial
infarction
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(DOCE) of cardiac death, target vessel reinfarction and
ischemia-driven target lesion revascularization, and the
patient-oriented endpoint (POCE) of all-cause death, any
myocardial infarction, and any revascularization.
Cardiac death was defined as death because of immediate
cardiac causes or complications related to the procedure,
as well as any death in which a cardiac cause could not
be excluded. Myocardial infarction was defined according
to the World Health Organization extended definition
(14). Target lesion revascularization was defined as any
clinically indicated repeat revascularization (percutaneous
or surgical) of the target lesions. Additional endpoints
analyzed were the single components of the above-
mentioned endpoints. Stent thrombosis was defined
according to the Academic Research Consortium criteria
(15).
Both trials used identical endpoint definitions, and the
chairman of the clinical event committee was the same, en-
suring a similar event adjudication process. All the endpoints
were evaluated at 1-year follow-up.
Statistical analysis. Continuous data are presented as mean
� SD or median (interquartile range). Categorical data are
presented as count and percentage. Comparison between
groups was done by a Student t test or chi-square test, as
appropriate. Meta-analysis was performed on individual
patient data according to intention to treat. Random-effects
models were used to assess differences in clinical outcomes
between newer generation DES and BMS for the pre-
specified DOCE of cardiac death, target-vessel infarction,
and target-lesion revascularization and the POCE of all-
cause death, any infarction, and any revascularization at
1 year. A 2-sided p value <0.05 was considered as statisti-
cally significant. Statistical analysis was performed using the
Table 1. Baseline and Procedural Characteristics
Drug-Eluting Stents
(N ¼ 1,326)
Bare-Metal Stents
(N ¼ 1,329) p Value
Age, yrs 60.77 � 11.96 61.09 � 12.29 0.502
Male 1,097 (82.73) 1,065 (80.14) 0.090
Body mass index, kg/m2 27.25 � 4.09 27.32 � 3.95 0.656
Cardiovascular risk factors
Diabetes mellitus 221 (16.68) 211 (15.88) 0.599
Hypertension 626 (47.25) 643 (48.38) 0.560
Hypercholesterolemia 678 (51.29) 629 (47.47) 0.052
Current smoker 644 (48.86) 687 (51.93) 0.120
Family history of
coronary artery disease
327 (25.83) 298 (23.63) 0.213
Previous cardiac events
Myocardial infarction 64 (4.83) 79 (5.94) 0.229
PCI 48 (3.62) 59 (4.44) 0.324
CABG 13 (0.98) 11 (0.83) 0.688
Clinical presentation
Primary PCI (<12 h) 1,160 (87.48) 1,159 (87.41) 1.000
Killip class II, III, or IV 120 (9.06) 113 (8.52) 0.632
Left ventricular ejection
fraction
49.98 � 10.95 50.36 � 9.93 0.405
Site of infarct-related artery 0.947
Left main 3 (0.23) 3 (0.23) 1.000
LAD 549 (41.40) 535 (40.29) 0.580
Left circumflex 184 (13.88) 197 (14.83) 0.507
Right circumflex 586 (44.19) 588 (44.28) 0.969
Saphenous vein graft 4 (0.30) 5 (0.38) 1.000
Angiographic and procedural
characteristics
TIMI flow 0 to 2 before PCI 1,089 (82.38) 1,099 (83.26) 0.571
Thrombus aspiration 845 (63.73) 855 (64.38) 0.746
No. of vessels treated at
procedure
0.664
1 1,266 (95.48) 1,277 (96.16) 0.385
2 57 (4.30) 48 (3.61) 0.372
3 3 (0.23) 3 (0.23) 1.000
Treatment of LAD 566 (42.68) 547 (41.19) 0.455
Lesions and stenting
No. of lesions treated 1.18 � 0.44 1.18 � 0.44 0.907
Total stent length, mm 28.21 � 14.72 27.54 � 14.66 0.241
Maximum stent
diameter, mm
3.24 � 0.46 3.24 � 0.87 0.799
No. of stents implanted 1.44 � 0.70 1.43 � 0.75 0.683
Direct stenting 686 (52.25) 663 (50.69) 0.435
Overlapping stents 347 (26.19) 327 (24.70) 0.397
Values are mean � SD or n (%).
CABG ¼ coronary artery bypass graft; LAD ¼ left anterior descending artery; PCI ¼ percu-
taneous coronary interventions; TIMI ¼ Thrombolysis In Myocardial Infarction.
Table 2. Medication Used at Procedure, Discharge, and Follow-up
Drug-Eluting
Stents
(N ¼ 1,326)
Bare-Metal
Stents
(N ¼ 1,329) p Value
During primary PCI
Aspirin* 1,265 (95.47) 1,271 (95.71) 0.778
Clopidogrel* 1,183 (89.28) 1,177 (88.56) 0.578
Prasugrel* 231 (17.42) 238 (17.90) 0.857
Any DAPT*y 679 (90.41) 675 (90.36) 1.000
Unfractionated heparin 1,109 (83.63) 1,113 (83.75) 0.958
Low molecular weight heparin 81 (6.11) 90 (6.77) 0.527
Bivalirudin 123 (9.28) 123 (9.26) 1.000
Glycoprotein IIb/IIIa antagonists 566 (42.68) 545 (41.01) 0.387
At discharge
Aspirin 1,309 (99.47) 1,313 (99.47) 1.000
Any DAPT 1,306 (99.32) 1,310 (99.32) 1.000
At 30 days
Aspirin 1,230 (98.80) 1,247 (99.13) 0.437
Any DAPT 1,223 (98.15) 1,237 (98.41) 0.647
At 1 yr
Aspirin 1,187 (97.53) 1,185 (97.45) 0.898
Any DAPT 1,138 (93.43) 1,073 (88.24) <0.001
Values are n (%). *Loading dose or already taking for aspirin, clopidogrel, and prasugrel. yDAPT
was aspirin with clopidogrel in the EXAMINATION trial and aspirin with clopidogrel or prasugrel
in the COMFORTABLE-AMI trial.
DAPT ¼ dual antiplatelet therapy; PCI ¼ percutaneous coronary intervention.
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STATA software version 12.1 (StataCorp, College Station,
Texas).
Results
Patient population. A total of 2,665 patients were included
in the present analysis; the EXAMINATION trial randomly
(1:1) assigned 1,504 patients to treatment with EES or
BMS, and the COMFORTABLE-AMI trial randomly
(1:1) assigned 1,161 patients to treatment with BES or
BMS. All patients were stratified according to the type of
stent implanted at the index procedure: 1,326 patients
received a newer-generation DES with either durable or
degradable polymer, whereas the remaining 1,329 patients
received a BMS.
Table 1 summarizes the baseline clinical characteristics of
the 2 groups. Male sex and hypercholesterolemia tended to
be higher in the DES compared with the BMS group. No
other differences in clinical or procedural characteristics were
observed. Table 2 shows the medication used during the
procedure, at discharge, and at follow-up: no differences
were found between the 2 groups up to 30-day follow-up.
Of note is that at 1 year, dual antiplatelet therapy was
frequently used in DES compared with BMS group (93.4%
vs. 88.2%, p < 0.001).
Clinical outcomes. Clinical outcomes of the 2 trials at 1 year
are summarized in Online Table 1 no relevant heterogeneity
across the trials was observed in the analyses of all endpoints.
DES reduced DOCE by 42% compared with BMS
(hazard ratio [HR]: 0.58; 95% confidence interval [CI]: 0.43
to 0.79; p < 0.001). Similarly, POCE was significantly
reduced with DES (HR: 0.76; 95% CI: 0.61 to 0.96;
p ¼ 0.02) (Fig. 1). Figures 2 and 3 show the Kaplan-Meier
curves for DOCE, POCE, and their single components in
the 2 groups. Differences in favor of newer-generation DES
were driven by both a lower risk of repeat revasculariza-
tion of the target lesion (HR: 0.32; 95% CI: 0.20 to 0.52;
p < 0.001) and a lower risk of target-vessel infarction
(HR: 0.36; 95% CI: 0.14 to 0.91; p ¼ 0.032) (Fig. 4). No
differences were found between groups in terms of all-cause
mortality (HR: 0.90; 95% CI: 0.60 to 1.35; p ¼ 0.613) or
cardiac mortality (HR: 0.98; 95%CI: 0.63 to 1.51; p¼ 0.921).
The risk of either definite or definite/probable stent
thrombosis was lower among patients treated with DES
than BMS (HR: 0.35; 95% CI: 0.16 to 0.75; p < 0.01; HR:
0.53; 95% CI: 0.29 to 0.95; p ¼ 0.03, respectively) (Fig. 5).
Figure 1. Clinical Endpoints at 1 Year
Forrest plot with hazard ratios of each endpoint for individual trials and the pooled population. BMS ¼ bare-metal stent(s); CI ¼ confidence interval; DES ¼ drug-eluting
stent(s); DOCE ¼ device-oriented primary composite endpoint (cardiac death, target vessel reinfarction, target lesion revascularization); HR ¼ hazard ratio;
POCE ¼ patient-oriented composite endpoint (all-cause death, any myocardial infarction, any revascularization); TLR ¼ target lesion revascularization;
TV ¼ target vessel; TVR ¼ target vessel revascularization.
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The benefit was particularly evident within the first 30 days
after implantation (Table 3).
The benefit in terms of the primary endpoint of DES
over BMS was consistent across stratified analyses including
body mass index, left anterior descending artery, Throm-
bolysis In Myocardial Infarction flow, thrombus aspiration,
multivessel treatment, lesion length, and vessel diameter.
An interaction with stent type was found for age (older than
65 vs. younger than 65 years of age), whereas a tendency
for association was observed for diabetes in the DOCE.
Interestingly, for definite/probable stent thrombosis, an
association with stent type was found with diabetes (Online
Figs. 1 to 3).
Discussion
This pooled analysis shows that new-generation DES, with
either durable or biodegradable polymer, improve safety and
efficacy compared with BMS in appropriately powered
STEMI populations.
Early generation DES have been associated with a
reduced risk of restenosis compared with BMS (16,17). For
this reason, they have quickly replaced BMS for many
clinical indications and are progressively used in more
complex coronary lesion subsets including off-label settings
(18,19). However, the early enthusiasm was dampened by
concerns related to the safety profile of DES. In particular,
STEMI has been identified as an independent predictor
of stent thrombosis after DES implantation (20). It was
therefore postulated that although early generation DES
were associated with a lower risk of repeat revascularization,
this benefit was offset by an increased risk of very late
(>1 year) stent thrombosis (18,19,21–23).
Biodegradable polymer DES and DES with more
biocompatible durable polymers have been developed with
the aim to reduce these adverse effects, related to the persis-
tence of a durable polymer or to a nonbiocompatible durable
polymer in the arterial wall (24–26). Recent experimental data
indicate a lower thrombogenicity of these DES compared
with BMS, suggesting a possible thromboresistant effect of
Figure 2. One-Year Patient-Oriented Composite Outcome
Kaplan-Meier curves for the patient-oriented composite endpoint (A) and its individual component, all cause-death (B), any infarction (C), and any revascularization
(D) in each of the stent groups. Abbreviations as in Figure 1.
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polymer coatings during the early period (27). This may be
particularly important in patients with STEMI who carry
a higher baseline risk of early stent thrombosis because of
a large thrombus burden (28) and increased platelet activation
(29). In particular, the thromboresistance of biodegradable
polymer-based stents may be related to the presence of
biolimus A9, which is the limus analogue with the highest
lipophilicity used for DES (9). As the acute coronary lesions
predominantly consist of lipid-rich, ruptured plaques with
large necrotic cores (30), it may be hypothesized that the
increased lipophilicity of biolimus A9 may provide a more
rapid and homogeneous drug distribution, potentially leading
Figure 3. One-Year Device-Oriented Composite Endpoint
Kaplan-Meier curves for the device-oriented composite endpoint (A) and its individual component, cardiac death (B), target vessel infarction (C), and ischemia-driven
target lesion revascularization (D) in each of the stent groups. Abbreviations as in Figure 1.
Figure 4. Outcomes According to Target Vessel Reinfarction
Forrest plot with hazard ratios of revascularization and stent thrombosis according to their association with target vessel reinfarction for the 2 stent groups. A single
outcome is considered associated if it occurred in the �7 to þ 7 days from the target vessel reinfarction. Abbreviations as in Figure 1.
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to a more potent anti-inflammatory and antithrombotic local
effects. This hypothesis requires, however, validation in
dedicated studies. In addition, the safety profile of these
newer-generation DES appears to go beyond 1 year, with
a very low rate of stent thrombosis at long-term follow-up
(31–33).
The EXAMINATION and COMFORTABLE-AMI
trials recently individually tested the safety and efficacy of
newer generation DES compared with BMS in STEMI at 1
year of follow-up. However, the power of the individual
trials to detect differences in rarely occurring adverse safety
endpoints, such as stent thrombosis, was inadequate and one
of the reasons to undertake the present analysis. The recently
published PROTECT trial is to date the first study de-
signed to detect differences in stent thrombosis between
zotarolimus-eluting and sirolimus-eluting stents. However,
the trial failed to show differences in terms of the safety
endpoint despite a large patient population, which may have
been related at least in part to the inclusion of lower-risk
patients. Thus, only 9% of patients presented with STEMI,
the clinical condition with the highest risk of stent throm-
bosis and ischemic endpoints (34).
Our meta-analysis shows in an appropriately powered
STEMI population that second-generation DES are safe
and efficacious compared with BMS in terms of a reduced
rate of either device- and patient-oriented endpoints or stent
thrombosis during the first year of follow-up. The findings
of the current analysis may be regarded as novel and
important for at least 2 reasons.
First, with respect to safety, our findings show for the first
time a significant and clinically important risk reduction for
definite stent thrombosis in favor of newer-generation DES
Figure 5. One-Year Stent Thrombosis
Kaplan-Meier curves for the definite (A) and definite/probable stent thrombosis (B) in each of the stent groups. Abbreviations as in Figure 1.
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compared with BMS during the first year after stent
implantation in a thrombotic milieu such as STEMI. This
observation corroborates the above-mentioned experimental
and clinical data suggesting a thromboresistant role of the
respective polymer-drug combination (27,33).
Second, the target vessel myocardial infarction was less
frequent with newer-generation DES than BMS. This
difference in safety was not observed in previous randomized
trials comparing early generation DES with BMS among
patients with STEMI, (1–3,5) but is consistent with the
findings of a recent meta-analysis reporting a lower risk of
reinfarction during the first year (35). It is interesting to note
that a reduction in acute/subacute stent thrombosis was able
to reduce target vessel reinfarction but not cardiac mortality.
Although the former is strictly dependent on the type of
stent implanted, the latter is multifactorial in a STEMI
population.
Taken together, these findings may be regarded as an
important step to change the treatment paradigm of STEMI
patients, suggesting not only a more effective but also safer
outcome after DES compared with BMS implantation.
It is unclear whether our results reflect a lack of benefit in
diabetic patients. We are unaware of biological mechanisms
that might explain interactions with diabetes, and in view of
the lack of mechanisms and the large number of stratified
analyses, chance should also be considered as an explanation
of our findings.
Study limitations. First, this was not a randomized clinical
trial, but a pooled analysis of individual patient data from 2
different randomized clinical trials. However, the trials
primarily intended to investigate newer-generation DES
compared with BMS, consistent with the aim of the present
analysis. Moreover, our analysis showed no evidence of
heterogeneity across the trials, and pooled individual data
revealed no significant and clinically important differences
between the 2 groups compared at baseline.
Longer follow-up is needed to confirm that the safety
profile, achieved during the first year after implantation, is
sustained with persistence of the antirestenotic efficacy and
without an increase in very late stent thrombosis. However, in
previous studies and meta-analyses BES and EES have been
shown to reduce the risk of stent thrombosis beyond 1 year
compared, for example, with early generation sirolimus-eluting
stents, providing support for the improved long-term bio-
compatibility of newer-generation DES (31,32).
Conclusions
In patients with STEMI, newer-generation DES improved
safety and efficacy compared with BMS throughout 1 year.
It remains to be determined whether these differences in
favor of newer-generation DES continue during long-term
follow-up.
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7.3 New generation DES using a biodegradable polymer in patients with ST-elevation myocardial 
infarction after dual antiplatelet 
therapy cessation
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Primary percutaneous coronary intervention (PCI) is the reperfusion therapy of choice for patients with acute 
ST-segment–elevation myocardial infarction (STEMI).1,2 
Early-generation drug-eluting stents (DES) have been shown 
more effective than bare-metal stents (BMS), but they were 
associated with an increased risk of very late stent thrombo-
sis (ST).3 Polymers components applied to the stent surface 
to enable delayed drug release have been implicated in the 
pathogenesis of delayed arterial healing and vessel remodeling 
owing to chronic inflammation. More recently, new-genera-
tion DESs with more biocompatible durable and biodegrad-
able polymers have largely overcome this limitation, although 
the long-term safety profile of these devices particularly 
among patients with STEMI has not been established to date.
Biolimus-eluting stents (BES) are new-generation DES with 
biodegradable polymer for drug release, which is resorbed 
Background—This study sought to determine whether the 1-year differences in major adverse cardiac event between a stent 
eluting biolimus from a biodegradable polymer and bare-metal stents (BMSs) in the COMFORTABLE trial (Comparison 
of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) 
were sustained during long-term follow-up.
Methods and Results—A total of 1161 patients were randomly assigned to biolimus-eluting stent (BES) and BMS at 11 
centers, and follow-up rates at 2 years were 96.3%. A subgroup of 103 patients underwent angiography at 13 months. 
At 2 years, differences in the primary end point of cardiac death, target-vessel myocardial infarction, and target lesion 
revascularization continued to diverge in favor of BES-treated patients (5.8%) compared with BMS-treated patients 
(11.9%; hazard ratio=0.48; 95% confidence interval, 0.31–0.72; P<0.001) with a significant risk reduction during the 
second year of follow-up (hazard ratio 1–2 years=0.45; 95% confidence interval, 0.20–1.00; P=0.049). Differences in the 
primary end point were driven by a reduction in target lesion revascularization (3.1% versus 8.2%; P<0.001) and target-
vessel reinfarction (1.3% versus 3.4%; P=0.023). The composite of death, any reinfarction and revascularization (14.5% 
versus 19.3%; P=0.03), and cardiac death or target-vessel myocardial infarction (4.2% versus 7.2%; P=0.036) were less 
frequent among BES-treated patients compared with BMS-treated patients. The 13-month angiographic in-stent percent 
diameter stenosis amounted to 12.0±7.2 in BES- and 39.6±25.2 in BMS-treated lesions (P<0.001).
Conclusions—Among patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary 
intervention, BES continued to improve cardiovascular events compared with BMS beyond 1 year.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NTC00962416.   
(Circ Cardiovasc Interv. 2014;7:355-364.)
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during a period of 6 to 9 months. In an all comers trial,4 a sig-
nificant reduction of very late ST vis-à-vis a durable polymer–
based early-generation sirolimus-eluting stent was observed 
during long-term follow-up. A dedicated randomized trial in 
patients with STEMI comparing BES with BMS of otherwise 
identical design showed a reduction in major adverse cardiac 
events (MACEs) at 1 year owing to a lower risk of target-
lesion revascularization and target-vessel myocardial infarc-
tion.5 Whether the clinical benefits of BES over BMS remain 
sustained during long-term follow-up is unknown. The pur-
pose of this study is to report the long-term clinical outcome 
of patients included in Comparison of Biolimus Eluted from 
an Erodible Stent Coating with Bare-Metal Stents in Acute 
ST-Elevation Myocardial Infarction (COMFORTABLE AMI) 
trial throughout 2 years and the results of the angiographic 
substudy performed 13 months after stent implantation (see 
the Data Supplement for a list of investigators).
Methods
Study Design
The study design of COMFORTABLE AMI trial has been reported 
elsewhere.5,6 Briefly, this is a multicenter, randomized, assessor-blind, 
superiority trial in patients with STEMI undergoing primary PCI reg-
istered at ClinicalTrials.gov (NTC00962416). Consecutive patients 
≥18 years with acute ST-segment elevation of ≥1 mm in ≥2 contigu-
ous leads, true posterior myocardial infarction, or new left bundle 
branch block were eligible for randomization in the presence of ≥1 
culprit lesion within the infarct vessel. There was no limit about the 
number of treated lesions, vessels, or complexity. Exclusion crite-
ria were presence of mechanical complications of acute myocardial 
infarction, known allergy to any study medication, use of vitamin 
K-antagonists, planned surgery unless dual antiplatelet therapy could 
be maintained throughout the perisurgical period, history of bleeding 
diathesis or known coagulopathy, pregnancy, participation in another 
trial before reaching the primary end point, inability to provide in-
formed consent, and noncardiac comorbid conditions with life ex-
pectancy below 1 year. The study complied with the declaration of 
Helsinki and was approved by all institutional ethics committees. All 
patients provided written, informed consent.
Procedures
Randomization was performed via a Web-based system after diag-
nostic angiography. Patients were randomly assigned 1:1 to treatment 
with stents eluting biolimus from a biodegradable polylactic acid 
polymer (BioMatrix; Biosensors Europe SA, Morges, Switzerland) 
or BMSs of otherwise identical design (Gazelle; Biosensors Europe 
SA, Morges, Switzerland). Before stent implantation, thrombus aspira-
tion was recommended whenever aspiration was deemed technically 
feasible. Predilatation of the culprit lesion was left to the discretion 
of the operator. Complete revascularization of all lesions within the 
infarct vessel had to be performed with the randomly allocated study 
stent. Acetylsalicylic acid (≥250 mg) was given before the procedure. 
In centers where prasugrel was available, an initial dose of 60 mg (in-
cluding patients preloaded with clopidogrel) was given followed by a 
daily dose of 10 mg. If prasugrel was not available or contraindicated, 
clopidogrel was administered at a loading dose of 600 mg, followed by 
a dose of 75 mg twice daily for 7 days followed by a maintenance dose 
of 75 mg once daily. Dual antiplatelet therapy was prescribed for the 
duration of ≥1 year in all patients. During the procedure, unfraction-
ated heparin was given at a dose of at least 5000 international units or 
70 to 100 international units/kg or alternatively bivalirudin. The use of 
glycoprotein IIb/IIIa inhibitors was left to the discretion of the operator.
Data Management and Clinical End Points
Independent study monitors verified source data according to a pre-
specified monitoring plan.5 Data were stored in a central database 
(Cardiobase, Clinical Trials Unit and Department of Cardiology, 
Bern University Hospital, Switzerland and 2mT, Ulm, Germany). 
Follow-ups were scheduled at 30 days and 1 and 2 years, and patients 
were questioned about the occurrence of angina, any adverse events, 
recurrent hospitalizations, and cardiovascular medication intake. Any 
death, reinfarction, revascularization, ST, cerebrovascular accident, 
and bleeding event were independently adjudicated by a blinded 
clinical event committee. The prespecified primary end point was the 
device-oriented composite of cardiac death, target-vessel reinfarc-
tion, and ischemia-driven target-lesion revascularization within 12 
months. Detailed definitions of all primary and secondary end points 
were reported elsewhere.7
Angiographic Substudy
Five participating centers were selected as intracoronary imaging 
centers and recruited patients into the formal angiographic and intra-
coronary imaging substudy (Bern, Copenhagen, Geneva, Lugano, 
and Zurich). Patients enrolled in the COMFORTABLE AMI study 
were eligible for participating the angiographic substudy when the 
following criteria were fulfilled: age <90 years, hemodynamic stabil-
ity, preserved renal function (glomerular filtration rate >30 mL/min), 
thrombolysis in myocardial infarction flow ≥II of the infarct-related 
artery at the end of the intervention, coronary anatomy suitable for in-
tracoronary imaging, and agreement to undergo angiographic and intra-
coronary imaging follow-up at 13 months. All patients were scheduled 
for repeat angiography of the culprit lesion at 13 months after record-
ing of the primary clinical outcome. Coronary angiograms were re-
corded at baseline immediately after the procedure and at 13 months 
and were assessed at the core laboratory of Bern University Hospital. 
Patients received nitroglycerin before angiography, and measurements 
were performed on cineangiograms. The contrast-filled, untapered tip 
of the catheter was used for calibration. Quantitative measurements in-
cluded reference vessel diameter, minimal lumen diameter, and percent 
diameter stenosis. Digital angiograms were analyzed with the use of the 
software (QAngio XA Version 7.1; Medis, Leiden, The Netherlands). 
Quantitative coronary angiograms from patients returning for repeat an-
giography in the setting of ST were not included during the first 30 days.
WHAT IS KNOWN
•	Among patients with ST-elevation myocardial in-
farction undergoing primary percutaneous coronary 
intervention, biodegradable polymer biolimus-elut-
ing stents reduce major cardiovascular events com-
pared with bare-metal stents at 1 year.
•	The clinical effect of newer generation biodegrad-
able drug-eluting stent beyond 1 year after primary 
percutaneous coronary intervention is unknown.
WHAT THE STUDY ADDS
•	Biolimus-eluting stent is associated with a continued 
reduction of major cardiovascular events during the 
second year of follow-up.
•	Clinical differences were not only driven by a dif-
ference in efficacy but also by ischemic end points 
including cardiac death or target-vessel myocardial 
infarction.
•	Although 60% patients discontinued dual antiplate-
let therapy at 1 year, no difference in very late stent 
thrombosis was observed between biodegradable 
drug-eluting stent and bare-metal stents.
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Statistical Analysis
COMFORTABLE AMI trial was powered for superiority on the prima-
ry clinical end point at 1 year. All analyses were performed according 
to the intention-to-treat principle, with inclusion of all 1161 random-
ized patients in the analysis according to the originally allocated stent 
type. Medication intake at discharge and follow-up was reported as 
counts and percentages, and groups were compared using Fisher exact 
tests. Cox proportional hazards models were used to compare clinical 
outcomes between the allocated stents, with patients censored at the 
time of their last valid contact. Landmark Cox proportional hazards 
models were used to compare clinical outcomes between the allocated 
stents in different periods since PCI; the P value for the interaction 
compares the period before (eg, 30 days or 1 year) to the period after 
the landmark (eg, beyond 30 days or 1 year) using robust variance 
estimators. Analyses for MACE were repeated excluding the subgroup 
of patients enrolled in the COMFORTABLE Imaging substudy. All 
P values are 2-sided, and all analyses were performed with Stata 12.1. 
The sample size of the imaging subgroup was calculated to show supe-
riority of BES over BMS in terms of neointimal thickness as assessed 
by optical coherence tomography (not reported here).
Table 1.  Baseline and Procedural Characteristics
Patients
Biolimus-Eluting  
Stents (n=575)
Bare-Metal  
Stents (n=582)
P  
Value
Age, y 60.7±11.6 60.4±11.9
Male sex, n (%) 463 (80.5) 455 (78.2)
Body mass index, kg/m2 27.3±4.5 27.2±4.0
Cardiovascular risk factors
 Diabetes mellitus, n (%) 84 (14.6) 90 (15.5)
 Hypertension, n (%) 279 (48.5) 265 (45.5)
 Hyperlipidemia, n (%) 324 (56.6) 328 (56.7)
 Current smoker, n (%) 272 (47.9) 301 (52.3)
 Family history of CAD, n (%) 193 (34.3) 179 (31.3)
Clinical presentation
 Time from symptom onset to balloon inflation, min (IQR) 232 (164–380) 236 (163–400)
  0–6 h 421 (73.2) 421 (72.6)
  6–12 h 109 (19.0) 100 (17.2)
  12–24 h 45 (7.8) 59 (10.2)
 Time from hospital admission to balloon inflation, min (IQR) 44 (32–70) 44 (32–74)
 Killip class II, III, or IV, n/total n (%) 40 (7.0) 37 (6.4)
 Left ventricular ejection fraction, % 49±11 50±10
Lesion complexity
 Bifurcation lesion, n (%) 52 (9.0) 49 (8.4)
 Small vessel (reference vessel diameter ≤2.5 mm) 74 (12.9) 79 (13.7)
 Long lesion (lesion length ≥20 mm) 204 (35.7) 183 (31.7)
 SYNTAX MI score 15.1±8.2 14.8±8.1
 Lesions treated in infarct vessel, n 629 648
 Lesions treated per patient 1.1±0.3 1.1±0.4 0.61
 Baseline TIMI flow, n (%) 0.31
  0 or 1 437 (69.6) 423 (65.6)
  2 81 (12.9) 95 (14.7)
  3 110 (17.5) 127 (19.7)
 Primary PCI procedure
  No. of stents per lesion 1.32±0.61 1.26±0.60 0.16
  Stent length per lesion, mm 25.2±12.7 24.1±12.3 0.10
  Stent diameter per lesion, mm 3.2±0.4 3.2±1.1 0.42
  Direct stenting, n (%) 236 (37.6) 240 (37.3) 0.89
  Maximal balloon pressure, atm 15.2±3.5 15.1±3.4 0.50
  Thrombus aspiration, n (%) 350 (60.9) 374 (64.4) 0.22
 Final TIMI flow, n (%)
  0 or 1 3 (0.5) 3 (0.5) 0.70
  2 25 (4.0) 32 (5.0)
  3 601 (95.5) 611 (94.6)
CAD indicates coronary artery disease; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; and 
TIMI, thrombolysis in myocardial infarction.
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Results
A total of 1161 patients were randomly assigned to receive 
BES with biodegradable polymer (578 patients) or BMS 
(583 patients). Follow-up at 2 years was available in 96.7% 
of BES-treated patients and 95.9% of BMS-treated patients. 
Baseline clinical and procedural characteristics were well bal-
anced in both stent groups (Table 1). Compliance with recom-
mended durations of dual antiplatelet therapy is summarized 
in Table 2. Per protocol, dual antiplatelet therapy with either 
clopidogrel or prasugrel was recommended for ≥1 year. We 
observed no differences in dual antiplatelet therapy compli-
ance at any time point, and ≈18% of patients in both groups 
remained on thienopyridines throughout 2 years. No differ-
ences about the type of thienopyridine were noted between 
groups at any time point.
Clinical Outcomes During Long-Term Clinical 
Follow-Up
Long-term clinical outcomes are summarized in Table 3. At 
2 years, the primary end point of MACEs (cardiac death, 
target-vessel reinfarction, and ischemia-driven target-lesion 
revascularization) occurred in 5.8% of patients receiv-
ing BES and 11.9% of patients receiving BMS (hazard 
ratio [HR], 0.48; 95% confidence interval [CI], 0.31–0.72; 
P<0.001) (Figure 1A). Individual components of the pri-
mary end point showed significant differences in favor 
of BES for target-vessel reinfarction (1.3% versus 3.4%; 
HR, 0.37; 95% CI, 0.15–0.87; P=0.023) and ischemia-
driven target-lesion revascularization (3.1% versus 8.2%; 
HR, 0.36; 95% CI, 0.21–0.63; P<0.001) (Figure 1B–1D). 
The patient-oriented composite end point of all-cause death, 
any reinfarction, and any revascularization was observed in 
14.5% among BES-treated patients with STEMI and 19.3% of 
BMS-treated patients with STEMI (HR, 0.73; 95% CI, 0.55–
0.97; P=0.03). Cardiac death or target-vessel reinfarction was 
lower among patients receiving BES (4.2%) compared with 
patients receiving BMS (7.2%; HR, 0.58; 95% CI, 0.35–0.97; 
P=0.036) at 2 years. Rates of definite or definite and probable 
ST are shown in Figure 2 and were numerically but not statis-
tically lower with BES compared with BMS at 2 years.
Clinical Outcomes Beyond 1 Year of Follow-Up
Clinical outcomes between 1 and 2 years are summarized in 
Table 2 and Figure 3. The landmark analysis at 1 year shows 
that differences between stent types in terms of the primary 
end point MACE continued to favor patients treated with BES 
(1.7% versus 3.7%; HR, 0.45; 95% CI, 0.20–1.00; P=0.049) 
without evidence of interaction between the 2 time periods 
(Pinteraction=0.88). A sensitivity analysis excluding patients 
undergoing repeat angiography at 13 months showed a con-
sistent benefit of BES over BMS during the second year of 
follow-up (HR1-2 years, 0.45; 95% CI, 0.20–1.0; P=0.049). Dif-
ferences between stent types were not significant for cardiac 
death, target-vessel reinfarction, and ischemia-driven target-
lesion revascularization, although event rates were numeri-
cally lower for BES than BMS between 1 and 2 years. There 
were no differences in rates of very late definite (BES 0.6% 
versus BMS 0.4%; HR, 1.47; 95% CI, 0.25–8.83; P=0.67) 
and very late definite or probable ST (BES 0.8% versus BMS 
0.8%; HR, 0.98; 95% CI, 0.25–3.93; P=0.98).
Angiographic Results
A total of 103 patients were included into the angiographic sub-
study, and the results are shown in Table 4. Only few patients 
Table 2. Dual Antiplatelet Therapy Intake Throughout 2 Years
Biolimus-Eluting Stents (n=575) Bare-Metal Stents (n=582) P Value
At discharge, n (%) n=569 n=578
 Acetylsalicylic acid 568 (99.8%) 576 (99.7%) 1.00
 Clopidogrel 323 (56.8%) 327 (56.6%) 0.95
 Prasugrel 245 (43.1%) 248 (42.9%) 1.00
 Any dual antiplatelet therapy 567 (99.6%) 574 (99.3%) 0.69
At 30 d, n (%) n=560 n=570
 Acetylsalicylic acid 556 (99.3%) 565 (99.1%) 1.00
 Clopidogrel 323 (57.6%) 322 (56.5%) 0.72
 Prasugrel 240 (42.9%) 245 (43.0%) 1.00
 Any dual antiplatelet therapy 554 (98.9%) 559 (98.1%) 0.33
At 1 y, n (%) n=543 n=545
 Acetylsalicylic acid 530 (97.6%) 525 (96.3%) 0.29
 Clopidogrel 287 (52.9%) 266 (48.8%) 0.18
 Prasugrel 213 (39.2%) 223 (40.9%) 0.58
 Any dual antiplatelet therapy 490 (90.2%) 479 (87.9%) 0.24
At 2 y, n (%) n=530 n=525
 Acetylsalicylic acid 511 (96.4%) 498 (94.9%) 0.23
 Clopidogrel 71 (13.4%) 59 (11.2%) 0.30
 Prasugrel 29 (5.5%) 40 (7.6%) 0.17
 Any dual antiplatelet therapy 93 (17.5%) 93 (17.7%) 1.00
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of the angiographic cohort did not undergo protocol-mandated 
follow-up angiography at 13 months (13.2% for BES- and 
10% for BMS-treated patients). Reference vessel diameter 
and minimal lumen diameter were comparable in both groups 
after the procedure. At 13-month follow-up, percent diameter 
stenosis (in-stent, 12.02±7.23 versus 39.60±25.21; in-seg-
ment, 21.55±8.70 versus 41.29±24.10 mm) and in-segment 
(0.10±0.30 versus 0.71±0.75 mm; P<0.001) and in-stent late 
lumen loss (0.10±0.24 versus 0.97±0.75 mm, P<0.001) were 
lower in BES-treated lesion compared with BMS-treated 
lesions. As a result, there was a large difference in in-segment 
binary restenosis (0% versus 25.9%; P<0.001). The cumula-
tive distribution of % diameter stenosis stratified by stent type 
is shown in Figure 4.
Discussion
This study reports long-term clinical outcomes of new-gener-
ation DES with biodegradable polymer compared with BMS 
Table 3. Clinical Outcomes at 2 Years and Between 1 and 2 Years
Biolimus-Eluting Stents (n=575) Bare-Metal Stents (n=582) Hazard Ratio (95% CI) P Value
All events at 2 y
 Death 28 (4.9%) 32 (5.6%) 0.79 (0.53–1.46) 0.62
 Cardiac death 17 (3.0%) 25 (4.4%) 0.69 (0.37–1.27) 0.23
 Reinfarction 18 (3.3%) 28 (5.0%) 0.64 (0.35–1.16) 0.14
  Q-wave 6 (1.1%) 9 (1.6%) 0.67 (0.24–1.88) 0.45
  Non–Q-wave 12 (2.2%) 19 (3.4%) 0.63 (0.31–1.30) 0.21
 Target-vessel reinfarction 7 (1.3%) 19 (3.4%) 0.37 (0.15–0.87) 0.023
  Q-wave 4 (0.7%) 8 (1.4%) 0.50 (0.15–1.67) 0.26
  Non–Q-wave 3 (0.6%) 11 (2.0%) 0.27 (0.08–0.98) 0.046
 Cardiac death or target-vessel reinfarction 24 (4.2%) 41 (7.2%) 0.58 (0.35–0.97) 0.036
 Any TLR 19 (3.5%) 53 (9.5%) 0.35 (0.21–0.59) <0.001
 Ischemia-driven TLR 17 (3.1%) 46 (8.2%) 0.36 (0.21–0.63) <0.001
 Any TVR 26 (4.7%) 58 (10.4%) 0.44 (0.27–0.69) <0.001
 Ischemia-driven TVR 23 (4.2%) 51 (9.1%) 0.44 (0.27–0.72) 0.001
 Major adverse cardiac events* 33 (5.8%) 68 (11.9%) 0.48 (0.31–0.72) <0.001
 Death, any reinfarction, any revascularization 82 (14.5%) 110 (19.3%) 0.73 (0.55–0.97) 0.03
 Stroke 6 (1.6%) 4 (1.1%) 1.51 (0.54–4.25) 0.43
 Definite stent thrombosis 8 (1.4) 15 (2.6) 0.53 (0.23–1.26) 0.15
 Definite or probable stent thrombosis 18 (3.2%) 25 (4.4%) 0.72 (0.39–1.32) 0.29
All events between 1 and 2 y
 Death 10 (1.9%) 9 (1.7%) 1.11 (0.45–2.73) 0.82
 Cardiac death 1 (0.2%) 5 (0.9%) 0.20 (0.02–1.71) 0.14
 Reinfarction 7 (1.3%) 7 (1.4%) 0.99 (0.35–2.82) 0.98
  Q-wave 4 (0.7%) 2 (0.4%) 1.99 (0.36–10.87) 0.43
  Non–Q-wave 3 (0.6%) 5 (1.0%) 0.59 (0.14–2.48) 0.48
 Target-vessel reinfarction 4 (0.8%) 4 (0.8%) 0.98 (0.25–3.92) 0.98
  Q-wave 3 (0.6%) 1 (0.2%) 2.98 (0.31–28.64) 0.35
  Non–Q-wave 1 (0.2%) 3 (0.6%) 0.33 (0.03–3.15) 0.33
 Cardiac death or target-vessel reinfarction 5 (0.9%) 9 (1.7%) 0.55 (0.18–1.63) 0.28
 Any TLR 24 (4.7%) 31 (6.3) 0.74 (0.44–1.27) 0.27
 Ischemia-driven TLR 8 (1.5%) 14 (2.7) 0.55 (0.23–1.30) 0.17
 Any TVR 15 (2.9%) 21 (4.1) 0.68 (0.35–1.32) 0.25
 Ischemia-driven TVR 12 (2.3%) 16 (3.1) 0.72 (0.34–1.52) 0.39
 Major adverse cardiac events* 9 (1.7%) 19 (3.7%) 0.45 (0.20–1.00) 0.049
 Death, any reinfarction, any revascularization 35 (6.9%) 41 (8.3%) 0.82 (0.52–1.29) 0.39
 Stroke 3 (0.6%) 2 (0.4%) 1.51 (0.25–9.02) 0.65
 Definite stent thrombosis 3 (0.6%) 2 (0.4%) 1.47 (0.25–8.83) 0.67
 Definite or probable stent thrombosis 4 (0.8%) 4 (0.8%) 0.98 (0.25–3.93) 0.98
Data are number of patients (%). Hazard ratios are derived from Cox proportional hazard models. P values are 2-sided from superiority testing with a χ2 test. CI 
indicates confidence interval; TLR, target lesion revascularization; and TVR, target vessel revascularization.
*It is a composite of cardiac death, target-vessel reinfarction, and ischemia-driven target-lesion revascularization.
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among patients with STEMI undergoing primary PCI with the 
following principal findings:
1. At 2 years, BES significantly reduced the risk of the device-
oriented composite of cardiac death, target-vessel myocar-
dial infarction (TV-MI), ischemia-driven target lesion re-
vascularization (TLR), and the patient-oriented composite 
of death, any reinfarction, and any repeat revascularization.
2. The benefit of BES over BMS in terms of major cardiovas-
cular events was not only sustained but also continued to 
accrue beyond 1 year of clinical follow-up.
3. At 2 years, BES was associated with a significantly reduced 
risk of cardiac death or TV-MI and a reduced risk for the 
individual components of the primary end point including 
TV-MI and ischemia-driven TLR.
4. Very late ST occurred with similar frequency among BES- 
and BMS-treated patients beyond 1 year.
5. Compared with BMS, BES potently suppressed neointimal 
hyperplasia resulting in a lower risk of restenosis.
A key finding of this study is the continued benefit of DES 
over BMS in the prevention of MACEs during the time period 
beyond 1 year. Indeed, the clinical benefit of BES over BMS 
estimated as numbers needed to treat to prevent 1 MACE 
amounted to 24 at 1 year but further decreased to 13 at 2 
years of follow-up suggesting continued clinical benefit. Of 
note, the improved outcomes at 2 years in terms of the com-
posite primary end point of MACEs were not only driven by 
expected differences in efficacy but also extended to ischemic 
end points including a lower risk for the composite of cardiac 
death or TV-MI as well as TV-MI, a finding which has not 
been previously observed in STEMI trials comparing early-
generation DES with BMS.8,9
The continued reduction in major cardiovascular events 
between the first and second of follow-up in favor of BES 
warrants discussion because the biodegradable polymer–
based DES should theoretically have turned into a metallic 
bare stent with similar properties as BMS. The performance 
of a repeat angiography in 8% of the overall study popula-
tion did not significantly impact the outcome as evidenced in 
a sensitivity analysis. Although data from angiographic fol-
low-up studies indicate that most restenotic events leading to 
repeat revascularization occur between 6 and 12 months with 
BMS, the numerically higher event rate in terms of TLR in 
this study speaks to the fact that delayed restenosis beyond 1 
year may be more pronounced with BMS than BES. However, 
it remains speculative why the reduced risk of TLR beyond 1 
year was accompanied by numerically lower events rates for 
cardiac death and myocardial infarction because there were no 
differences in terms of definite or probable ST.
Figure 1. Time-to-event curves for the primary end point of major adverse cardiac events (composite of cardiac death, target-vessel–
related reinfarction, and ischemia-driven target-lesion revascularization) throughout 2 years (A), cardiac death (B), target-vessel–related 
reinfarction (C), and ischemia-driven target-lesion revascularization (D) for patients receiving biolimus-eluting stents with biodegradable 
polymer and patients receiving bare-metal stents. P values are 2-sided from Cox regression models χ2 test. CI indicates confidence inter-
val; and HR, hazard ratio.
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BES was also associated with a lower risk of the primary 
end point MACE (a composite of cardiac death, myocardial 
infarction, and clinically indicated TLR) compared with siroli-
mus-eluting stent–treated patients (BES 6.7% versus sirolimus-
eluting stent 15.7%; HR, 0.40; 95% CI, 0.18–0.87; P=0.02) in 
the STEMI subgroup of patients enrolled into the BES With 
Biodegradable Polymer Versus Sirolimus-Eluting Stent With 
Durable Polymer for Coronary Revascularization (LEADERS) 
trial. The favorable treatment effect of BES over sirolimus-elut-
ing stent observed in the STEMI subgroup of the LEADERS 
Figure 3. Time-to-event curves for the primary end point of major adverse cardiac events throughout 2 years with landmark analysis at 
1 year (A), cardiac death (B), target-vessel–related reinfarction (C), and ischemia-driven target-lesion revascularization (D) for patients 
receiving biolimus-eluting stents with biodegradable polymer and patients receiving bare-metal stents. P values for interaction are for dif-
ferences in hazard ratios between 0 to 1 and 1 to 2 years. HR indicates hazard ratio.
Figure 2. Time-to-event curves for definite (A) and definite or probable (B) stent thrombosis throughout 2 years. CI indicates confidence 
interval; and HR, hazard ratio.
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trial provides further support for the clinical benefit observed 
with BES in our trial. Extended follow-up beyond 1 year 
among patients with STEMI undergoing primary PCI is clini-
cally important to assess the long-term safety profile of DES 
particularly at the time after discontinuation of the routinely 
recommended 12-month duration of dual antiplatelet therapy. 
Previous studies did suggest an increased risk of very late ST 
and TV-MI beyond 1 year in patients treated with early-gener-
ation DES.8,9 We, therefore, performed detailed analyses using 
landmark techniques set at 1 year to gain insights into the risk 
profile and potential mechanisms of action of biodegradable 
polymer DES compared with BMS. Although there were no dif-
ferences in cardiac death, BES showed a significant interaction 
with time in terms of TV-MI, namely a reduced risk of TV-MI, 
compared with BMS during the first year risk reduction=80%) 
followed by a similar risk (risk reduction=2%) during the 
subsequent year of follow-up. The similar rather than increased 
risk of TV-MI associated with BES compared with BMS 
beyond 1 year is noteworthy because it differs from the previous 
experience with early-generation DES. It is explained at least 
in part by the optimized polymer-drug profile characterized by 
early drug release followed by biodegradation of the polylactid 
acid polymer resulting in a surface similar to a BMS platform 
after a period of 6 to 9 months. In addition, the antiproliferative 
drug does not only suppress neointimal proliferation thereby 
preventing TV-MI due to restenosis but may also exert an anti-
thrombotic effect in concert with the polymer,10 which is hypo-
thetically more relevant in the hypercoagulable milieu of patients 
with STEMI.11
Similar to the risk of TV-MI, we observed a trend toward a 
lower rate of ST with BES during the first year, followed by 
the absence of differences in very late definite and definite or 
Table 4. Angiographic Results
Biolimus-Eluting Stents BMS Difference (95% CI)* P Value†
No. of patients 53 50
No. of lesions 62 59
Preprocedural
 Reference vessel diameter, mm 3.05±0.51 3.00±0.44 0.05 (–0.12 to 0.22) 0.57
 Minimal lumen diameter, mm 0.52±0.57 0.48±0.59 0.04 (–0.17 to 0.25) 0.70
 Lesion length, mm 15.59±7.99 17.19±9.54 –1.60 (–4.76 to 1.57) 0.32
 Diameter stenosis, % 82.78±18.64 83.75±19.76 –0.97 (–7.88 to 5.94) 0.78
Postprocedural
 Reference vessel diameter, mm 3.08±0.57 3.06±0.48 0.02 (–0.17 to 0.21) 0.85
 Minimal lumen diameter, mm
  In-stent 2.83±0.53 2.77±0.39 0.07 (–0.10 to 0.23) 0.43
  In-segment 2.48±0.48 2.43±0.50 0.05 (–0.12 to 0.23) 0.55
 Diameter stenosis, %
  In-stent 9.04±4.61 10.30±5.03 –1.26 (–3.00 to 0.47) 0.15
  In-segment 18.39±9.11 20.48±10.80 –2.08 (–5.68 to 1.51) 0.25
13-mo follow-up‡
 No. of patients FUP 46 45
 No. of lesions FUP 54 54
 Reference vessel diameter, mm 3.07±0.61 2.92±0.52 0.15 (–0.06 to 0.37) 0.16
 Minimal lumen diameter, mm
  In-stent 2.73±0.57 1.79±0.83 0.94 (0.67 to 1.21) <0.001
  In-segment 2.37±0.47 1.75±0.80 0.62 (0.37 to 0.87) <0.001
 Diameter stenosis, %
  In-stent 12.02±7.23 39.60±25.21 –27.58 (–34.65 to –20.52) <0.001
  In-segment 21.55±8.70 41.29±24.10 –19.74 (–26.65 to –12.84) <0.001
 Binary stenosis, %
  In-stent 0 (0.00%) 14 (25.93%) –25.93 (–37.84 to –14.01) <0.001§
  In-segment 0 (0.00%) 14 (25.93%) –25.93 (–37.84 to –14.01) <0.001§
 Late loss, mm
  In-stent 0.11±0.24 0.97±0.75 –0.87 (–1.08 to –0.65) <0.001
  In-segment 0.10±0.30 0.71±0.75 –0.61 (–0.83 to –0.39) <0.001
BMS indicates bare-metal stent; CI, confidence interval; and FUP, follow-up.
*Crude difference biolimus-eluting stent (BES) vs BMS overall across all lesions (95% CI).
†Mixed model P values accounting for lesions nested within patient identifier.
‡Two patients (n=1 BES; n=1 BMS) who presented with definite stent thrombosis within 30 d were excluded from the follow-up 13-mo quantitative coronary analysis.
§All BES lesions without binary stenosis: Fisher test on culprit lesion only.
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probable ST beyond 1 year. Nevertheless, very late ST was 
not eliminated as indicated by a residual rate of 0.6% for 
BES-treated patients and 0.4% for BMS-treated patients dur-
ing the second year of follow-up. In Harmonizing Outcomes 
With Revascularization and Stents in Acute Myocardial 
Infarction (HORIZON AMI) trial,12 the rate of very late ST 
was 1.1% among paclitaxel-eluting stents and 0.6% among 
BMS-treated patients during the second year of follow-up. 
The 2-year results of the everolimus-eluting stent (EES) ver-
sus BMS in ST-segment–elevation myocardial infarction 
(EXAMINATION)13 trial comparing EES with BMS in patients 
with STEMI are consistent with this study, specifically, there 
was no difference in very late ST (EES 0.3% versus BMS 0.3%). 
Although EES in the setting of STEMI did not result in a lower 
risk of TV-MI, they were associated with a significant reduction 
in definite ST at 2 years (EES 0.8% versus BMS 2.1%; P=0.03). 
Although in the EXAMINATION trial, BMS-treated patients 
showed a significantly higher discontinuation of dual antiplate-
let therapy at 1 year (90%) compared with EES-treated patients 
(98%, P<0.001), numbers were comparable between treatment 
arms at 2 years (EES and BMS 18%) in both trials.
The similar safety profile of BES and BMS beyond 1 year 
is supported by the fact that ≈60% of patients in both treat-
ment groups discontinued routine dual antiplatelet therapy 
at 13 months and 82% at 2 years. Although observational in 
nature, the results of this study suggest that discontinuation of 
P2Y12 inhibitors at 1 year may be reasonable among patients 
with STEMI.
Compared with BMS, BES reduced the risk of TLR by 72% 
during the first year, whereas no significant reduction was 
observed during the second year. The angiographic results 
obtained at 13 months in the subgroup of 103 patients revealed 
a late lumen loss, which was similar to the one observed in 
the angiographic substudy of the biolimus-eluting stent with 
biodegradable polymer versus sirolimus-eluting stent with 
durable polymer for coronary revascularization (LEADERS)4 
trial assessed at 9 months (BES in-segment 0.08±0.45 mm; 
in-stent 0.13±0.46 mm). Although the time interval between 
9 and 13 months may be too short to ascertain relevant dif-
ferences in terms of late catch-up, the results reassuringly 
confirm the potent and sustained suppression of neointimal 
hyperplasia by the antiproliferative agent biolimus with a late 
lumen loss lower than with any early-generation DES in the 
setting of STEMI.12,14,15 The long-term efficacy outcome of 
BES is also in line with previous reports comparing BES with 
sirolimus-eluting stent in an all comers trial with a continued 
benefit of BES throughout 5 years.4 Conversely, late lumen 
loss observed with BMS used in this study was comparable 
to the one recorded in the paclitaxel-eluting stents versus 
BMSs in acute myocardial infarction (HORIZON AMI) trial12 
(in-segment/in-stent late loss BMS COMFORTABLE AMI, 
0.71±0.75 mm/0.97±0.75 mm versus BMS HORIZON AMI, 
0.59±0.64 mm/0.82±0.70 mm).
Limitation
Our results have to be interpreted in view of the following 
limitations. The trial indicated superiority on the primary 
composite outcome but was not powered to address individual 
components of efficacy or safety. Moreover, observed event 
rates were lower than anticipated. In view of the size of the 
observed treatment effect and results of previous trials, we 
consider it unlikely that estimates of efficacy would substan-
tially differ in a larger patient cohort.
The inclusion of safety outcomes in the primary composite 
outcome is meaningful because cardiac death or TV-MI may 
be device related. Event rates of cardiac death or TV-MI were 
of similar magnitude as ischemia-driven target-lesion revas-
cularization in our trial providing a similar weight of efficacy 
and safety parameters within the composite end point.
Conclusions
Our findings suggest that the use of BESs with biodegradable 
polymer in patients with STEMI is associated with continued 
clinical benefit in terms of MACEs beyond 1 year following 
routine discontinuation of dual antiplatelet therapy. Apart from 
the expected sustainability of a superior efficacy, BES was asso-
ciated with a favorable safety profile as evidenced by lower rates 
of the composite of cardiac death or TV-MI as well as TV-MI 
throughout 2 years. The latter finding is hypothesis generating 
and requires validation in appropriately designed studies.
Figure 4. Cumulative distribution curve for angio-
graphic percent diameter stenosis comparing bio-
limus-eluting stents vs bare-metal stents at 13-mo 
follow-up.
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SummAry AND coNcluSioNS
This thesis addresses the safety and efficacy of early and new generation DES in routine 
clinical practise and how the assessment of the arterial healing response following 
DES implantation assists in the interpretation of DES related cardiovascular outcomes. 
Specifically, the following topics were addressed:
PArT A
1. clinical and angiographic evaluation of the long-term efficacy and safety of 
early generation DES
chapter 1 adresses the clinical and angiographic long-term findings following coronary 
revascularisation using early generation SES and PES. The SIRTAX LATE trial had the 
following clinical implications: first, the superiority of SES over PES in terms of MACE 
was no longer present after five years of follow-up, suggesting an interaction by time 
in the clinical performance of these two early generation DES devices. The risk of repeat 
revascularization with early generation DES is low despite evidence of an angiographic 
catch-up phenomenon and second, very late stent thrombosis remains an important 
limitation of early generation DES and accounts for more than half of all myocardial 
infarctions between 1 and 5 years. Finally, the continued increase in late loss in conjunc-
tion with the ongoing risk of VLST suggested that vascular healing remains incomplete 
up to 5 years after implantation of first generation DES.
2. High resolution intravascular imaging evaluation of adverse healing 
responses following early generation DES implantation
Arterial healing following early generation SES versus PES
As angiography does not allow a precise assessment of the vascular healing following 
stent implantation, a subgroup of patients of the SIRTAX trial underwent intracoronary 
imaging with high-resolution optical coherence tomography (OCT) at five years (chap-
ter 2.1). The healing response was assessed by analysing stent strut coverage, malap-
position and protrusion. For the first time, coronary evaginations were symstematically 
assessed a distinct morphological finding referring to aneurysm like outward bulges 
of the vessel wall between stent struts. In addition, geographical maps to visualize the 
healing pattern of each lesion were computed. This facilitated a statistical cluster analy-
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sis of the long-term healing response. The main findings of the study were an overall 
low frequency of uncovered, malapposed and protruding struts at five years. By means 
of geographical lesion maps, however, a few patients were identified with a high degree 
of these characteristics, suggesting a heterogeneous healing pattern. Coronary evagina-
tions were found to be associated with SES rather than PES, confirming a differences 
in the healing pattern between the two devices. Of particular interest was that during 
extended clinical follow-up, two patients suffered from very late stent thrombosis. In 
these patients, a high degree high degree of malappostion, protrusion and coronary 
evagination was observed at the time of OCT investigation, suggesting that patients at 
risk for future thrombotic events may be identified by the use of OCT. 
Differential healing response attributable to clinical presentation
Whether the clinical indication at the time point of stent implantation impacts on the 
arterial healing response over a long-term time course was not previously investigated. 
We speculated that the composition of the underlying lesion impacts on the healing 
response and that differences persist throughout the long-term follow-up. (chapter 
2.2). Indeed,  uncovered, malapposed, and protruding stent struts as well as clusters of 
adverse healing were observed to be more frequent in culprit lesion of acute coronary 
syndrome patients compared to stable coronary artery disease patients, suggesting a 
differential healing response attributable to lesion characteristics of patients with acute 
coronary syndrome compared with stable coronary artery disease.
Coronary evaginations as a marker of adverse arterial healing following DES implantation 
As mentioned above, we systematically analyzed evaginations in the setting of the 
SIRTAX LATE study and found a different frequency in SES versus PES. We further ex-
tended the analysis to a pooled OCT database to allow a comparison between early and 
newgeneration DES and to investigate specific mechanisms behind this morphological 
finding (chapter 2.3). We found that OCT-detected major evaginations are a specific 
morphological footprint of early-generation SES and are nearly absent in newer-gen-
eration ZES and EES. Evaginations appear to be related to vessel injury at baseline, are 
associated with positive vessel remodeling by means of serial IVUS investigations, and 
correlate with uncovered or malapposed stent struts, and thrombus at follow-up.
Neoatherosclerosis as cause for late stent failures 
The frequency and dynamics of neoatherosclerosis remains poorly described. On the 
basis of two clinical cases (chapter 2.4), we demonstrated that the presence of a fa-
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vorable long-term angiographic long-term result does not necessarily exclude a future 
neoatherosclerosis-related ischemic event. The conduction of large observational and 
long-term intracoronary imaging studies thus may be required to further elucidate this 
new disease entity.
In a long-term angiographic and OCT study we assessed the association between 
neoatherosclerosis and native atherosclerosis and observed that the formation of 
in-stent neoatherosclerosis is closely associated with progression of native coronary 
atherosclerosis, suggesting similarities in the pathophysiologic mechanisms of these 
two entities. These findings may have important clinical implications for the develop-
ment and implementation of strategies to prevent neoatherosclerosis among patients 
undergoing PCI (chapter 2.5).
3. clinical and angiographic relevance of stent overlap
The effect of DES overlap was investigated by OCT on the basis of a pooled database 
of 42 overlapping segments compared to the non-overlapping zone of the same stent. 
(chapter 3.1). The effect of overlapping DES on neointimal inhibition was markedly 
heterogeneous: on average, DES overlap is associated with more incomplete and thin-
ner coverage, but in some cases, the overlap elicits an exaggerated neointimal reaction, 
thicker than in the corresponding non-overlapping segments. These results might help 
to understand why overlapping DES is associated with worse clinical outcomes, both in 
terms of thrombotic phenomena and in terms of restenosis and revascularization.
To assess the clinical consequences,  the clinical impact of early generation DES overlap 
in patients included in the SIRTAX trial was investigated (chapter 3.2). DES overlap was 
observed in 10% of patients undergoing PCI in routine clinical practice. DES overlap was 
associated associated with an impaired angiographic and long-term clinical outcome, 
including death or myocardial infarction.
4. Safety and efficacy of early generation DES in important clinical subgroups
Diabetic patients
The effect of different DES types on cardiovascular outcomes may vary depending on 
the particular clinical and lesion characteristics. Diabetes mellitus patients represent a 
relevant clinical subgroup given their higher risk for stent-related failures and coronary 
artery disease progression. In a long-term evaluation of the SIRTAX LATE study, we found 
diabetic patients at increased risk for all cause death after revascularization indepen-
dent of the type of early generation DES (chapter 4.1). Conversely, diabetes mellitus 
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was not associated with an increased risk of clinical and angiographic restenosis. This 
is notable as diabetes used to be an independent predictor of restenosis in the bal-
loon angioplasty and bare-metal stent era. Angiographic and ultrasonic studies have 
shown more neointimal hyperplasia in diabetic than non-diabetic patients in response 
to stent-mediated arterial injury. Early generation DES results in a profound suppression 
of neointimal hyperplasia and appears to overcome the more profound proliferative 
vascular response in diabetic patients.
Early generation DES in STEMI patients
STEMI patients are at an increased risk of stent thrombosis compared to stable CAD pa-
tients and therefore represent a common high risk patient group of interest. We aimed 
to investigate the long-term safety and effectiveness of early generation DES compared 
with BMS and to determine whether relative risks and benefits of DES vs. BMS varied 
over time. In a meta-analysis  of 15 randomized controlled trials enrolling a total of 7867 
STEMI patients, a benefit of early generation DES as compared with BMS was observed 
within the first year consisting of a reduction in TVR and a trend towards less definite ST. 
The latter, however, was offset during the subsequent years of follow-up by an increased 
risk of very late ST (chapter 4.2).
PArT B
5. clinical outcomes with the unrestricted use of a new generation everolimus-
eluting stents
Unrestricted use of new generation EES versus SES
Randomized controlled trials have suggested improved cardiovascular outcomes fol-
lowing implantation of EES as compared with PES. Whether similar benefits are  pres-
ent following EES versus SES (the previous gold standard) implantation was unkown. 
unknown. We therefore investigated clinical outcomes following the unrestricted use of 
EES versus SES in daily clinical routine based on the Bern PCI registry (chapter 5.1). We 
found that the unrestricted use of EES appeared to be associated with improved clinical 
long-term outcomes compared with SES and differences were driven in part by a lower 
risk of MI associated with stent thrombosis.
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Very late stent thrombosis with a new generation everolimus eluting stent versus early 
generation SES and PES 
The increased risk of very late stent thrombosis observed following early generation DES 
compared as opposed to BMS mainly appeared in all comers patient populations under 
the inclusion of high risk patients, a a patient group which was previously excluded from 
stent trials. Accordingly, we hypothesized that with the use of a new generation EES, the 
incidence of very late stent thrombosis can be reduced in a patient population reflect-
ing daily clinical routine. In a two center registry including more than 12’000 patients, 
we found the treatment with EES to be associated with a lower risk of VLST compared 
with early-generation DES. The reduction of the risk of VLST with the unrestricted use 
of EES overcomes the principal limitation of early-generation DES and constitutes an 
important advance in DES safety (chapter 5.2).
6. New generation DES in important clinical subgroups
Efficacy and safety of new generation EES in diabetic patients
Whether there is heterogeneity in the safety and efficacy of EES versus early generation 
DES according to the presence or absence of diabetes is a relevant clinical question 
given the high proportion of diabetic patients in daily clinical routine and based on 
a higher risk for restenosis and stent thrombosis. We therefore compared clinical out-
comes of diabetic patients enrolled in the Bern Rotterdam registry study and found that 
the unrestricted use of EES appears to be associated with improved outcomes, specifi-
cally a significant decrease in the occurrence of ST and in the need for TLR compared 
to both early generation SES and PES throughout a 3-year follow-up. No differences, 
however, were observed in terms of myocardial infarction and death. The results have to 
be interpreted with caution given the observational nature of the obtained data.
Saphenous vein grafts and new generation DES: „piece de resistance“?
Data on clinical outcomes following early versus new generation DES implantation in 
saphenous vein graft patients were not available. It is against this background that we 
were investigating whether the beneficial clinical results obtained in the overall Bern 
Rotterdam patient cohort could be translated to patients undergoing saphenous vein 
graft interventions. New generation EES showed a similar safety and efficacy to early-
generation SES and PES during long-term follow-up throughout four years. The results 
have to be interpreted with caution given the observational nature and the limited 
sample size, nevertheless, they suggest that improvements are required in the treat-
ment of this specific subgroup of coronary artery disease patients
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7. New generation DES for primary Pci
New generation DES using a biodegradable polymer in patients with ST-elevation myocardial 
infarction
New generation DES with biodegradable polymers (BES) provide controlled drug release 
with subsequent degradation of the polymer rendering the stent surface more closely 
to a bare metal stent upon the period of biodegradation. The unrestricted use of stents 
eluting biolimus, an equipotent sirolimus analogue, from biodegradable polylactic acid 
was non-inferior and potentially superior to SES in terms of major adverse clinical events 
in a large clinical trial with follow-up to four years, with a significant reduction in very 
late stent thrombosis. A stratified analysis suggested a particularly pronounced ben-
efit among patients with STEMI. Against this background, we conducted a multicenter 
randomized controlled trial (COMFORTABLE AMI) investigating the efficacy and safety 
of a BES versus BMS at one year in terms of MACE, defined as the composite of cardiac 
death, target vessel myocardial infarction and target lesion revascularization (chapter 
7.1). The use of BES  resulted in a lower rate of the composite of MACE at 1 year among 
patients with STEMI undergoing primary PCI. Differences were driven by both, an im-
proved efficacy (TLR) but also a lower rate of target vessel myocardial infarction. 
As the trial was not powered for safety endpoints, we pooled our data with another 
primary PCI trial comparing a durable polymer new generation DES with a BMS (EX-
AMINATION) and with respect to safety, our findings show for the first time a significant 
and clinically important risk reduction for definite stent thrombosis in favor of new-
generation DES compared with BMS during the first year after stent implantation in a 
thrombotic milieu such as STEMI (chapter 7.2). Second, target vessel myocardial infarc-
tion was less frequent with new-generation DES than BMS. This difference in safety was 
not observed in previous randomized trials comparing early generation DES with BMS 
among patients with STEMI. Taken together, these findings may be regarded as an im-
portant step to change the treatment paradigm of STEMI patients, suggesting not only 
a more effective but also safer outcome after DES compared with BMS implantation.
The extension of the follow-up to two years is of clinical interest as the duration of 
dual antiplatelet therapy was limited to one year per protocol, so that the safety hazards 
between stent types eventually change in the absence of a potent second thrombocyte 
inhibitor. Biolimus-eluting stent was associated with a continued reduction of major 
cardiovascular events during the second year of follow-up (chapter 7.3). Clinical differ-
ences were not only driven by a difference in efficacy but also by ischemic end points 
including cardiac death or target-vessel myocardial infarction. Although 60% patients 
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discontinued dual antiplatelet therapy at 1 year, no differences in very late stent throm-
bosis were observed between biodegradable drug-eluting stent and bare-metal stents.
coNcluSioNS
In conclusion, Part A of this thesis addresses the timing, frequency and clinical impact 
of limitations inherent to early generation DES and unravels the underlying pathophysi-
ological mechanisms by coronary angiography and optical coherence tomography. The 
latter emerged as the optimal technique to characterize arterial healing following DES 
implantation.
Part B of this thesis provides evidence how advances in coronary stent design directly 
translated into further improvement of clinical outcomes particularly among patients 
at highest risk. Based on the clinical data of this thesis, new generation metallic drug-
eluting stents (DES) should represent the standard of care for the percutaneous coronary 
revascularization of all patient and lesion subsets.
SAmENVATTiNG EN coNcluSiES
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 SAmENVATTiNG EN coNcluSiES
Dit proefschrift behandelt de veiligheid en effectiviteit van vroege- en nieuwe gene-
ratie DES in de dagelijkse klinische praktijk. Tevens wordt uitgelegd op welke wijze de 
beoordeling van de arteriële genezingsrespons na DES-implantatie de interpretatie van 
DES-gerelateerde cardiovasculaire uitkomsten ondersteunt. Met name de volgende 
onderwerpen worden behandeld:
DEEl A
1. Klinische en angiografische evaluatie van de effectiviteit en veiligheid op de 
lange termijn van vroege generatie DES
Hoofdstuk 1 gaat over de klinische en angiografische langetermijnbevindingen na co-
ronaire revascularisatie met vroege generatie SES en PES. De SIRTAX LATE trial kende de 
volgende klinische implicaties: ten eerste was de superioriteit van SES ten opzichte van 
PES wat betreft MACE gedurende de langetermijnfollow-up niet langer aanwezig, wij-
zend op een interactie met tijd in de klinische prestatie van deze twee vroege generatie 
DES-instrumenten. Het risico van herhaalde revascularisatie met vroege generatie DES is 
laag, ondanks bewijs voor een angiografisch catch-up fenomeen. Ten tweede blijft een 
zeer late stenttrombose (very late stent thrombosis- VLST) een belangrijke beperkende 
factor voor vroege generatie DES en is deze verantwoordelijk voor meer dan de helft 
van alle myocardinfarcten tussen 1 en 5 jaar. Tot slot wees de voortgezette stijging van 
laat verlies in samenhang met het voortdurende risico van VLST er op dat vasculaire 
genezing tot 5 jaar na implantatie van eerste generatie DES onvolledig blijft. 
2. Evaluatie met high resolution intravasculaire beeldvorming van slechte 
genezingsrespons na vroege generatie DES-implantatie
Arteriële genezing na vroege generatie SES versus PES
Omdat met angiografie geen exacte beoordeling van de vasculaire genezing na sten-
timplantatie mogelijk is, onderging een subgroep patiënten van de SIRTAX trial na vijf 
jaar  intracoronaire beeldvorming met high-resolution optical-coherence tomografie 
(OCT) (Hoofdstuk 2.1). De genezingsrespons werd beoordeeld aan de hand van stent-
strutbedekking, malappositie en protrusie. Wij beoordeelden voor het eerst systema-
tisch coronaire evaginaties, een duidelijke morfologische bevinding met aneurysma-
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achtige uitstulpingen van de vaatwand tussen de stentstruts. Daarnaast werden met 
de computer geografische kaarten ter visualisatie van het genezingspatroon van elke 
laesie vervaardigd. Hiermee werd een statistische clusteranalyse van de langetermijn-
genezingsreactie mogelijk. De belangrijkste bevindingen van de studie waren een 
in het algemeen lage frequentie van onbedekte struts, malappositie van de struts en 
protruderende struts na 5 jaar. Door middel van geografische laesiekaarten werd echter 
een aantal patiënten met een hoog aantal van deze kenmerken geïdentificeerd, wat kan 
wijzen op een heterogeen genezingspatroon. Coronaire evaginaties bleken vaker geas-
socieerd te zijn met SES dan met PES, en hiermee werd een differentieel in de genezings-
respons van de twee hulpmiddelen bevestigd. Van bijzonder belang was dat tijdens de 
verlengde follow-up bij twee patiënten een zeer late stenttrombose optrad waarbij 
tijdens het OCT-onderzoek clusters van een hoge mate van malappositie, protrusie en 
coronaire evaginatie werden gezien. Dit kan erop wijzen dat patiënten met een risico 
op toekomstige trombotische voorvallen middels OCT kunnen worden geïdentificeerd.
Differentiële genezingsrespons toe te schrijven aan klinische presentatie
Nog niet eerder was onderzocht of de klinische indicatie op het moment van stentimplan-
tatie invloed heeft op de langetermijn arteriële genezingsrespons na DES-implantatie. 
Onze theorie was dat de samenstelling van de onderliggende laesie een wisselwerking 
heeft met de genezingsrespons en dat verschillen in genezing nog steeds aanwezig zijn 
tijdens langetermijnfollow-up (Hoofdstuk 2.2). Inderdaad werden vaker onbedekte, 
gemalappositioneerde en protruderende stentstruts alsmede clusters van vertraagde 
genezing waargenomen in de verantwoordelijke laesie bij patiënten met acuut coronair 
syndroom dan bij patiënten met stabiele coronaire arteriële ziekte, duidend op een 
differentiële genezingsrespons die toe te schrijven is aan de laesiekenmerken van pati-
enten met acuut coronair syndroom ten opzichte van stabiele coronaire arteriële ziekte.
Coronaire evaginaties als marker voor slechte arteriële genezing na DES-implantatie 
Zoals hierboven gemeld, analyseerden wij systematisch evaginaties in de setting van 
de SIRTAX LATE studie en vonden daar een verschillende frequentie bij SES ten opzichte 
van PES. Wij breidden de analyse verder uit naar een gepoolde OCT-database voor een 
vergelijking tussen vroege- en nieuwere generatie DES en om het specifieke mecha-
nisme achter deze morfologische bevinding te onderzoeken (Hoofdstuk 2.3). Wij von-
den dat door OCT-gedetecteerde ME‘s een specifieke morfologische voetafdruk vormen 
van vroege generatie SES en vrijwel afwezig zijn in de nieuwere generatie ZES en EES. 
Evaginaties lijken gerelateerd te zijn aan vaatletsel op de baseline; ze zijn geassocieerd 
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met positieve vaatremodellering volgens seriële IVUS-onderzoeken en correleren met 
onbedekte of gemalappositoneerde stentstruts, en trombus bij follow-up.
Neoatherosclerose als oorzaak voor late-stentfalen. 
De frequentie en dynamiek van neoatherose blijft slechts summier beschreven. Op basis 
van twee klinische gevallen (Hoofdstuk 2.4) toonden wij aan dat de aanwezigheid van 
een gunstig resultaat van angiografie op de lange termijn een toekomstig neoatherose-
gerelateerd ischemisch voorval niet noodzakelijk uitsluit.  Grote observationele en 
langetermijn intracoronaire beeldvormende studies kunnen dus nodig zijn om deze 
nieuwe ziektevorm op te helderen.
In een langetermijn angiografische en OCT-studie bepaalden wij het verband tussen 
neoatherosclerose en native atherosclerose en zagen we dat de vorming van in-stent 
neoatherosclerose nauw geassocieerd is met progressie van native coronaire atheros-
clerose, wijzend op overeenkomsten in de fysiopathologische mechanismen van deze 
twee ziektevormen. Deze bevindingen kunnen belangrijke klinische implicaties hebben 
voor de ontwikkeling en implementatie van strategieën ter preventie van neoatheros-
clerose bij patiënten die PCI ondergaan (Hoofdstuk 2.5).
3. Klinische en angiografische relevantie van stent-overlap
Het effect van DES overlap volgens OCT-bevindingen werd onderzocht in een gepoolde 
database op een totaal van 42 overlappende gebieden met niet-overlappende regio 
(Hoofdstuk 3.1). Het effect van overlappende DES op neointimale remming is duidelijk 
heterogeen: gemiddeld wordt DES geassocieerd met meer onvolledige en dunnere 
bedekking, maar in enkele gevallen brengt de overlap een overdreven neointimale re-
actie teweeg, dikker dan in de corresponderende niet-overlappende segmenten. Deze 
resultaten helpen ons te begrijpen waarom overlappende DES geassocieerd is met 
slechtere klinische uitkomsten, zowel wat betreft trombotische fenomenen als wat 
betreft restenose en revascularisatie.
Om de klinische gevolgen te bepalen, werd de klinische impact van vroege generatie 
DES overlap bij patiënten in de SIRTAX-trial onderzocht (Hoofdstuk 3.2). DES-overlap 
werd bij 10% van de patiënten die in de dagelijkse klinische praktijk een PCI ondergingen 
waargenomen. We zagen dat DES-overlap geassocieerd was met een slechtere angio-
grafische en langetermijn klinische uitkomst, waaronder overlijden of myocardinfarct. 
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4. Veiligheid en effectiviteit van vroege generatie DES in belangrijke klinische 
subgroepen
Diabetespatiënten
Het effect van verschillende DES-types op cardiovasculaire uitkomsten kan variëren, 
afhankelijk van de speciale klinische kenmerken. Diabetespatiënten vertegenwoordi-
gen een relevante klinische subgroep vanwege hun hogere risico op stentgerelateerd 
falen en progressie van de kransslagaderaandoening. In een langetermijnevaluatie van 
de SIRTAX LATE-studie, zagen wij dat diabetespatiënten een verhoogd risico hebben 
op mortaliteit na revascularisatie, onafhankelijk van het type vroege generatie DES 
(Hoofdstuk 4.1). Omgekeerd was diabetes niet gerelateerd aan een verhoogd risico 
op klinische en angiografische restenose. Dit is opmerkelijk omdat diabetes een onaf-
hankelijke predictor was van restenose in de ballonangioplastiek en bare metal stents-
periode. Angiografische en ultrasone studies toonden meer neointimale hyperplasie 
bij diabetespatiënten dan bij niet-diabetespatiënten als reactie op stentgemedieerd 
arterieel letsel. Vroege generatie DES heeft een duidelijke suppressie van neointimale 
hyperplasie tot gevolg en lijkt de duidelijker proliferatieve vasculaire respons bij diabe-
tespatiënten te ondervangen.
Vroege generatie DES bij STEMI patiënten
STEMI-patiënten op zich hebben een speciaal verhoogd risico op stenttrombose in 
vergelijking met stabiele CAD-patiënten en vertegenwoordigen daarom een andere 
belangrijke hoogrisico-patiëntengroep. Wij wilden de veiligheid en effectiviteit op de 
lange termijn van vroege generatie DES ten opzichte van BMS onderzoeken en bepa-
len of relatieve risico‘s en voordelen van DES versus BMS in de tijd varieerden. In een 
meta-analyse van 15 gerandomiseerde gecontroleerde trials met in totaal 7867 STEMI-
patiënten, werd een voordeel van vroege generatie DES ten opzichte van BMS waar-
genomen binnen het eerste jaar, bestaande uit een daling van TVR en een trend naar 
minder definitieve ST. Het laatste werd echter in de daaropvolgende follow-up jaren 
teniet gedaan door een verhoogd risico op zeer late ST (Hoofdstuk 4.2).
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DEEl B
5. Klinische uitkomsten bij het onbeperkte gebruik van een nieuwere generatie 
everolimus-eluerende stents.
Onbeperkt gebruik van nieuwere generatie EES versus SES.
Gerandomiseerde, gecontroleerde trials leken te wijzen op betere cardiovasculaire 
uitkomsten na implantatie van EES in vergelijking met PES. Of dergelijke voordelen ook 
aanwezig zijn na EES versus de voorgaande „gouden standaard“ vroege generatie SES 
was onbekend. Om die reden onderzochten wij klinische uitkomsten na het onbeperkte 
gebruik van EES versus SES in de dagelijkse klinische praktijk op basis van het Bern PCI 
register (Hoofdstuk 5.1). Wij zagen dat het onbeperkte gebruik van EES geassocieerd 
bleek te zijn met betere klinische langetermijnuitkomsten ten opzichte van SES. De 
verschillen waren voor een deel toe te schrijven aan een lager risico van MI in verband 
met stenttrombose.
De Achilleshiel van vroege generatie DES: Zeer late stenttrombose met een nieuwere 
generatie everolimus-eluerende stent versus vroege generatie SES en PES
Het hogere risico op zeer late stenttrombose in vroege generatie DES in vergelijking met 
BMS bleek voornamelijk in „all comers“ patiëntpopulaties onder de inclusie van hoog-
risicopatiënten, een groep die voorheen uitgesloten werd van stenttrials. Dienovereen-
komstig was onze hypothese dat met het gebruik van een nieuwere generatie EES, de 
incidentie van zeer late stenttrombose verminderd kan worden in een patiëntpopulatie 
die de dagelijkse klinische praktijk weerspiegelt. In een twee-centrumregister met meer 
dan 12000 patiënten, zagen wij dat de behandeling met EES geassocieerd was met een 
lager risico op VLST ten opzichte van behandeling met vroege generatie DES. De daling 
van het risico van VLST bij het onbeperkte gebruik van EES ondervangt de voornaamste 
beperking van vroege generatie DES en betekent een belangrijke vooruitgang in de 
veiligheid van DES (Hoofdstuk 5.2).
6. Nieuwe generatie DES in belangrijke klinische subgroepen
Effectiviteit en veiligheid van nieuwe generatie EES bij diabetespatiënten
Of er heterogeniteit bestaat in de veiligheid en effectiviteit van EES versus vroege 
generatie DES afhankelijk van de aanwezigheid of afwezigheid van diabetes is een 
relevante klinische vraag gezien het hoge aandeel diabetespatiënten in de dagelijkse 
klinische praktijk en op basis van de eerder opgemerkte hogere risico‘s voor restenose 
302 Sammenvatting & conclusies
en stenttrombose in deze subgroep. Wij vergeleken daarom klinische resultaten van 
diabetespatiënten die deelnamen aan de Bern-Rotterdam registerstudie en zagen dat 
het onbeperkte gebruik van EES geassocieerd bleek met betere uitkomsten, meer spe-
cifiek met een significante daling in het optreden van ST en in de behoefte voor TLR in 
vergelijking met zowel vroege generatie SES en PES in 3 jaar follow up. Geen verschillen 
werden echter waargenomen wat betreft myocardinfarct en overlijden. De resultaten 
moeten voorzichtig worden geïnterpreteerd vanwege de observationele aard van de 
verkregen data.
Vena saphena grafts en nieuwe generatie DES: „pièce de resistance“?
Data over klinische uitkomsten na vroege- versus nieuwe generatie DES-implantatie in 
vena saphena graft-patiënten waren niet beschikbaar. Het is tegen deze achtergrond 
dat we onderzochten of de gunstige klinische resultaten verkregen in het totale Bern- 
Rotterdam patiëntencohort vertaald kunnen worden naar patiënten die vena saphena 
graft-interventies ondergaan. Nieuwe generatie EES toonde een gelijke veiligheid en 
effectiviteit als vroege generatie SES en PES tijdens langetermijn follow-up tot vier jaar. 
De resultaten dienen voorzichtig te worden geïnterpreteerd gezien de observationele 
aard en de beperkte steekproefgrootte; ze lijken er echter op te wijzen dat er verbeterin-
gen nodig zijn in de behandeling van deze specifieke subgroep van kransslagaderaan-
doeningpatiënten.
7. Nieuwe generatie DES voor primaire Pci
Nieuwe generatie DES die gebruik maken van een biologisch afbreekbaar polymeer bij 
patiënten met ST-elevatie myocardinfarct (STEMI).
Nieuwe generatie DES met biologisch afbreekbare polymeren (BES) bieden een gere-
guleerde vrijgifte van geneesmiddel met daaropvolgende afbraak van het polymeer, 
waardoor de stent op een metalen stent lijkt na de periode van afbraak. Het onbeperkte 
gebruik van stents die biolimus elueren, een equipotente sirolimus-analoog, van biolo-
gisch afbreekbaar polylactaatzuur was niet-inferieur en potentieel superieur aan SES wat 
betreft belangrijke klinische bijwerkingen in een grote klinische trial met follow-up tot 
vier jaar, met een significante daling van zeer late stenttrombose. Een gestratificeerde 
analyse leek te wijzen op een met name gunstig effect onder patiënten met STEMI. Te-
gen deze achtergrond voerden wij een multicenter-, gerandomiseerde, gecontroleerde 
trial uit (COMFORTABLE AMI) waarbij de effectiviteit en veiligheid van  BES versus BMS 
werd onderzocht na 1 jaar wat betreft MACE, gedefinieerd als composiet van cardiale 
Progress with DES technology 303
dood, target vessel myocardinfarct en target laesion revascularisatie (Hoofdstuk 7.1). 
Het gebruik van BES leidde tot een lagere frequentie van het composiet MACE na 1 jaar 
onder patiënten met STEMI die primaire PCI ondergingen. De verschillen waren het 
gevolg van zowel een verbeterde effectiviteit (TLR) als een lagere incidentie van target 
vessel myocardinfarct. 
Omdat de trial niet het vermogen had voor eindpunten, poolden wij onze data met 
een andere primaire PCI trial waarbij een duurzaam polymeer nieuwe generatie DES 
met een BMS (EXAMINATION) werd vergeleken. Met betrekking tot veiligheid, toonden 
onze bevindingen voor de eerste maal een significante en klinisch belangrijke risicofac-
tordaling voor definitieve stenttrombose ten gunste van de nieuwe generatie DES in 
vergelijking met BMS gedurende het eerste jaar na stentimplantatie in een trombotisch 
milieu zoals STEMI (Hoofdstuk 7.2). Ten tweede was target vessel myocardinfarctie 
minder frequent bij de nieuwe generatie DES dan bij BMS. Dit verschil in veiligheid werd 
niet waargenomen in voorgaande gerandomiseerde trials waarbij de vroege generatie 
DES werd vergeleken met BMS onder patiënten met STEMI. Samengevat kunnen deze 
bevindingen worden gezien als een belangrijke stap in het wijzigen van het behande-
lingsschema van STEMI patiënten, waarbij niet alleen een meer effectieve maar ook 
veiligere uitkomst na DES lijkt te verwachten vergeleken met BMS implantatie.
De uitbreiding van de follow-up naar twee jaar is van klinisch belang omdat de duur 
van duale antiplaatjestherapie beperkt was tot een jaar, volgens protocol, zodat de 
veiligheidsrisico‘s tussen stenttypes uiteindelijk wijzigen in afwezigheid van een po-
tente tweede trombocytenremmer. Biolimus-eluerende stent was geassocieerd met een 
voortgezette daling van ernstige cardiovasculaire voorvallen gedurende het tweede 
jaar van follow up (Hoofdstuk 7.3). Klinische verschillen werden niet alleen bepaald 
door een verschil in effectiviteit maar tevens door ischemische eindpunten waaronder 
cardiale dood of target vessel myocardinfarctie. Hoewel 60% van de patiënten na 1 jaar 
stopten met antiplaatjestherapie, werden geen verschillen waargenomen wat betreft 
zeer late stenttrombose tussen bioafbreekbare medicijn-eluerende stents en bare metal 
stents.
coNcluSiES
Concluderend behandelt Deel A van dit proefschrift de timing, frequentie en klinische 
impact van beperkingen die inherent zijn aan vroege generatie DES en beschrijft de 
onderliggende fysiopathologische mechanismen van coronaire angiografie en optische 
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coherentietomografie. De laatste kwam naar voren als de optimale techniek om arteriële 
genezing na DES-implantatie te karakteriseren.
Deel B van dit proefschrift levert bewijs dat vooruitgang in coronaire stentontwerpen 
zich rechtstreeks vertaalt naar verdere verbetering van klinische uitkomsten, met name 
onder patiënten met het hoogste risico. Op basis van de klinische data van dit proef-
schrift, zouden nieuwe generatie metalen medicijn-eluerende stents (DES) de standaard 
zorg moeten vormen voor de percutane coronaire revascularisatie van alle patiënten en 
laesie-subsets.
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